Selegiline	B-Chemical
-	O
induced	O
postural	O
hypotension	T-obl
in	O
Parkinson	O
'	O
s	O
disease	O
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

Selegiline	T-amod
-	O
induced	O
postural	B-Disease
hypotension	I-Disease
in	T-nmod
Parkinson	T-nmod
'	O
s	T-nmod
disease	O
:	O
a	T-dep
longitudinal	T-dep
study	O
on	O
the	O
effects	T-dep
of	O
drug	O
withdrawal	O
.	O

Selegiline	O
-	O
induced	T-nmod
postural	T-nmod
hypotension	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	T-nmod
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	T-compound
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	T-compound
Group	O
(	O
UKPDRG	T-compound
)	O
trial	T-compound
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	T-nmod
in	T-nmod
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	T-dep
with	T-dep
Parkinson	T-dep
'	O
s	T-dep
disease	O
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	T-obj
to	T-obj
receive	O
10	T-compound
mg	O
selegiline	B-Chemical
per	O
day	T-obj
and	O
L	O
-	O
dopa	O
compared	T-obj
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	T-conj
10	O
mg	O
selegiline	O
per	T-conj
day	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	T-obj
taking	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-nsubj:pass
with	T-nsubj:pass
selegiline	B-Chemical
and	T-conj
L	T-conj
-	O
dopa	O
was	T-nsubj:pass
associated	O
with	O
selective	O
systolic	O
orthostatic	O
hypotension	T-nsubj:pass
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	O
associated	T-conj
with	O
selective	O
systolic	O
orthostatic	O
hypotension	O
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-obl
with	T-obl
selegiline	T-obl
and	O
L	O
-	O
dopa	O
was	T-obl
associated	O
with	O
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	T-acl:relcl
was	T-acl:relcl
abolished	O
by	O
withdrawal	T-acl:relcl
of	O
selegiline	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	O
and	O
L	O
-	O
dopa	O
was	O
associated	O
with	O
selective	O
systolic	O
orthostatic	O
hypotension	O
which	O
was	O
abolished	T-nmod
by	T-nmod
withdrawal	O
of	O
selegiline	B-Chemical
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	T-nmod
of	T-nmod
the	T-nmod
cardiovascular	T-nmod
consequences	O
of	O
stopping	O
selegiline	B-Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	O
hypotension	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	O
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	T-obj
by	O
which	T-obj
the	O
drug	T-obj
causes	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	T-compound
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	T-compound
PD	B-Disease
patients	O
receiving	T-compound
selegiline	O
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	O
patients	T-obj
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

RESULTS	T-obj
:	O
Head	O
-	O
up	O
tilt	T-obj
caused	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	T-acl:relcl
was	T-acl:relcl
marked	O
in	O
six	O
of	O
20	O
PD	O
patients	T-acl:relcl
on	O
selegiline	O
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	O
orthostatic	O
hypotension	O
which	O
was	O
marked	T-compound
in	T-compound
six	O
of	O
20	T-compound
PD	B-Disease
patients	O
on	O
selegiline	T-compound
,	O
one	T-compound
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	O
orthostatic	O
hypotension	O
which	O
was	O
marked	T-nmod
in	T-nmod
six	O
of	O
20	T-nmod
PD	T-nmod
patients	O
on	O
selegiline	B-Chemical
,	O
one	T-nmod
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	T-nmod
lesser	T-nmod
degree	O
of	O
orthostatic	B-Disease
hypotension	I-Disease
occurred	T-nmod
with	O
standing	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	T-nsubj:pass
ameliorated	O
4	O
days	T-nsubj:pass
after	O
withdrawal	T-nsubj:pass
of	O
selegiline	O
and	O
totally	O
abolished	T-nsubj:pass
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Orthostatic	O
hypotension	O
was	O
ameliorated	T-nmod
4	O
days	O
after	T-nmod
withdrawal	O
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Stopping	O
selegiline	B-Chemical
also	T-nsubj
significantly	T-nsubj
reduced	O
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	T-nsubj
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

Stopping	T-nsubj
selegiline	O
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	T-amod
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	T-nsubj:pass
that	T-nsubj:pass
selegiline	B-Chemical
in	T-nmod
combination	O
with	O
L	O
-	O
dopa	T-nmod
is	T-nsubj:pass
associated	O
with	O
selective	O
orthostatic	O
hypotension	T-nsubj:pass
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	T-nmod
in	T-nmod
combination	O
with	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
is	O
associated	O
with	O
selective	O
orthostatic	O
hypotension	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	T-obl
that	T-obl
selegiline	T-obl
in	O
combination	O
with	O
L	O
-	O
dopa	O
is	T-obl
associated	O
with	O
selective	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	T-conj
of	T-conj
monoamine	T-conj
oxidase	O
or	O
of	O
amphetamine	B-Chemical
and	O
metamphetamine	T-conj
are	O
discussed	O
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	T-conj
of	T-conj
monoamine	T-conj
oxidase	O
or	O
of	O
amphetamine	T-conj
and	O
metamphetamine	B-Chemical
are	O
discussed	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	T-dep
degradation	T-dep
product	O
p	B-Chemical
-	I-Chemical
choloroaniline	I-Chemical
is	O
not	O
a	O
significant	O
factor	T-dep
in	O
chlorhexidine	O
-	O
digluconate	O
associated	O
erosive	O
cystitis	O
.	O

The	O
results	O
have	O
shown	T-nmod
that	T-nmod
the	O
degradation	O
product	T-nmod
p	O
-	O
choloroaniline	O
is	T-nmod
not	T-nmod
a	T-nmod
significant	T-nmod
factor	O
in	O
chlorhexidine	B-Chemical
-	I-Chemical
digluconate	I-Chemical
associated	T-dep
erosive	T-dep
cystitis	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	O
factor	T-dep
in	T-dep
chlorhexidine	T-dep
-	O
digluconate	O
associated	O
erosive	O
cystitis	B-Disease
.	O

A	O
high	O
percentage	O
of	O
kanamycin	B-Chemical
-	O
colistin	O
and	O
povidone	O
-	O
iodine	T-compound
irrigations	T-compound
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

A	O
high	O
percentage	T-compound
of	T-compound
kanamycin	O
-	O
colistin	B-Chemical
and	T-conj
povidone	T-conj
-	O
iodine	O
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

A	O
high	O
percentage	O
of	O
kanamycin	T-conj
-	O
colistin	O
and	O
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	T-conj
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

A	O
high	O
percentage	T-obl
of	O
kanamycin	O
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	T-obl
associated	O
with	O
erosive	O
cystitis	B-Disease
and	O
suggested	T-obl
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	B-Chemical
irrigations	O
appeared	T-compound
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	O
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Picloxydine	O
irrigations	O
appeared	O
to	O
have	T-nmod
a	T-nmod
lower	T-nmod
incidence	O
of	O
erosive	O
cystitis	B-Disease
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	T-nmod
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Effects	O
of	O
tetrandrine	B-Chemical
and	T-conj
fangchinoline	O
on	O
experimental	O
thrombosis	T-nmod
in	O
mice	T-nmod
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-conj
of	T-conj
tetrandrine	O
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	O
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	O
of	O
tetrandrine	T-nmod
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	B-Disease
in	O
mice	T-nmod
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-conj
of	O
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	O
in	T-conj
mice	O
and	O
human	O
platelet	B-Disease
aggregation	I-Disease
.	O

Tetrandrine	B-Chemical
(	O
TET	O
)	O
and	T-conj
fangchinoline	O
(	O
FAN	T-conj
)	O
are	T-nsubj
two	T-nsubj
naturally	O
occurring	T-nsubj
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	T-nsubj
.	O

Tetrandrine	O
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	T-appos
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	T-appos
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	T-conj
)	O
and	O
fangchinoline	B-Chemical
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	T-conj
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	T-appos
(	O
TET	O
)	O
and	T-appos
fangchinoline	O
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	T-compound
with	T-compound
a	T-compound
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	T-nmod
effects	O
of	O
TET	B-Chemical
and	T-conj
FAN	O
on	O
the	O
experimental	O
thrombosis	T-nmod
induced	T-nmod
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	T-conj
of	T-conj
TET	O
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	O
induced	O
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	T-nmod
effects	O
of	O
TET	T-nmod
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	B-Disease
induced	T-nmod
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	O
by	O
collagen	T-dep
plus	T-dep
epinephrine	B-Chemical
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-conj
by	T-conj
collagen	O
plus	O
epinephrine	O
(	O
EP	B-Chemical
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-compound
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	T-compound
platelet	B-Disease
aggregation	I-Disease
and	T-conj
blood	T-conj
coagulation	O
in	T-compound
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	O
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	T-conj
aggregation	O
and	O
blood	B-Disease
coagulation	I-Disease
in	O
vitro	T-conj
.	O

In	T-nsubj
the	T-nsubj
vitro	T-nsubj
human	O
platelet	B-Disease
aggregations	I-Disease
induced	O
by	O
the	O
agonists	T-nsubj
used	O
in	O
tests	O
,	O
TET	O
and	O
FAN	O
showed	T-nsubj
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
the	O
vitro	O
human	O
platelet	O
aggregations	O
induced	O
by	O
the	O
agonists	O
used	T-conj
in	T-conj
tests	O
,	O
TET	B-Chemical
and	O
FAN	T-conj
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
the	O
vitro	O
human	O
platelet	O
aggregations	O
induced	O
by	O
the	O
agonists	O
used	T-conj
in	T-conj
tests	O
,	O
TET	T-conj
and	O
FAN	B-Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
addition	T-nsubj
,	O
neither	O
TET	B-Chemical
nor	T-conj
FAN	O
showed	O
any	O
anticoagulation	O
activities	T-nsubj
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	T-nsubj
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

In	O
addition	O
,	O
neither	T-conj
TET	O
nor	O
FAN	B-Chemical
showed	T-conj
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	T-conj
FAN	O
in	O
mice	T-nmod
may	O
be	O
mainly	O
related	T-nmod
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	T-conj
of	T-conj
TET	O
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Angioedema	B-Disease
due	T-nmod
to	O
ACE	T-nmod
inhibitors	O
:	O
common	T-nmod
and	O
inadequately	O
diagnosed	O
.	O

Angioedema	O
due	O
to	T-case
ACE	B-Chemical
inhibitors	I-Chemical
:	O
common	O
and	O
inadequately	O
diagnosed	T-amod
.	O

The	T-nmod
estimated	T-nmod
incidence	O
of	O
angioedema	B-Disease
during	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	T-nmod
.	O

The	O
estimated	O
incidence	T-obl
of	O
angioedema	O
during	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitor	I-Chemical
treatment	T-obl
is	T-obl
between	O
1	O
and	O
7	O
per	O
thousand	T-obl
patients	T-compound
.	O

Cocaine	B-Chemical
-	O
induced	O
mood	O
disorder	T-obl
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	T-amod
-	O
induced	O
mood	B-Disease
disorder	I-Disease
:	O
prevalence	T-dep
rates	O
and	O
psychiatric	O
symptoms	T-dep
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	T-dep
.	O

Cocaine	O
-	O
induced	O
mood	O
disorder	O
:	O
prevalence	O
rates	T-amod
and	T-amod
psychiatric	B-Disease
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	O
-	O
induced	O
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	B-Chemical
-	O
dependent	O
sample	T-obl:npmod
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	T-conj
substance	T-conj
-	O
induced	O
and	O
other	O
mood	B-Disease
disorders	I-Disease
.	O

243	O
cocaine	B-Chemical
-	O
dependent	O
outpatients	T-obl:npmod
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	B-Chemical
-	O
induced	O
mood	O
disorder	T-obl
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	T-nmod
cocaine	O
-	O
dependent	T-nmod
outpatients	O
with	O
cocaine	T-amod
-	O
induced	O
mood	B-Disease
disorder	I-Disease
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	T-nmod
,	O
or	O
no	O
mood	O
disorder	T-nmod
were	O
compared	T-nmod
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	T-appos
with	T-appos
cocaine	O
-	O
induced	T-appos
mood	T-appos
disorder	O
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	T-conj
cocaine	O
-	O
dependent	T-conj
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	T-conj
(	O
CIMD	O
)	O
,	O
other	O
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	O
disorder	T-conj
were	O
compared	T-conj
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	T-conj
cocaine	O
-	O
dependent	T-conj
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	T-conj
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	T-conj
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	T-conj
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	T-amod
of	T-amod
psychiatric	B-Disease
symptoms	O
.	O

Introduction	T-nmod
of	T-nmod
the	T-nmod
DSM	O
-	O
IV	T-nmod
diagnosis	O
of	O
CIMD	B-Disease
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	O
disorders	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	O
did	O
not	O
substantially	O
affect	T-nmod
rates	O
of	O
the	O
other	O
depressive	B-Disease
disorders	I-Disease
.	O

Patients	O
with	O
CIMD	B-Disease
had	T-nmod
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	O
disorder	O
.	O

Patients	O
with	O
CIMD	O
had	O
symptom	O
severity	O
levels	O
between	O
those	T-nmod
of	T-nmod
patients	O
with	O
and	O
without	T-case
a	O
mood	B-Disease
disorder	I-Disease
.	O

These	O
findings	O
suggest	O
some	O
validity	T-nmod
for	T-nmod
the	T-nmod
new	T-nmod
DSM	O
-	O
IV	T-nmod
diagnosis	O
of	O
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Effect	T-amod
of	T-amod
fucoidan	B-Chemical
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	O
hemorrhage	O
in	O
rats	O
.	O

Effect	O
of	O
fucoidan	O
treatment	T-nmod
on	O
collagenase	T-amod
-	O
induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
rats	T-nmod
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	T-nmod
some	O
of	O
the	O
brain	B-Disease
damage	I-Disease
following	T-nmod
ischemic	T-nmod
stroke	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	T-nmod
of	T-nmod
the	T-nmod
brain	T-nmod
damage	O
following	O
ischemic	B-Disease
stroke	I-Disease
.	O

Intracerebral	B-Disease
hemorrhage	I-Disease
is	T-nsubj:pass
associated	O
with	O
more	O
inflammation	T-nsubj:pass
than	O
ischemic	O
stroke	O
.	O

Intracerebral	O
hemorrhage	T-obl
is	T-obl
associated	O
with	O
more	O
inflammation	B-Disease
than	T-nmod
ischemic	T-nmod
stroke	O
.	O

Intracerebral	O
hemorrhage	O
is	O
associated	T-nmod
with	T-nmod
more	T-nmod
inflammation	O
than	O
ischemic	B-Disease
stroke	I-Disease
.	O

We	T-obj
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	B-Chemical
,	O
which	T-acl:relcl
has	T-acl:relcl
been	T-acl:relcl
reported	O
to	O
reduce	T-acl:relcl
inflammatory	O
brain	O
damage	O
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	O
hemorrhage	O
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	T-obj
to	T-obj
reduce	O
inflammatory	O
brain	B-Disease
damage	I-Disease
,	O
in	O
a	O
rat	O
model	T-obj
of	O
intracerebral	O
hemorrhage	O
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	T-nmod
inflammatory	O
brain	O
damage	O
,	O
in	T-nmod
a	T-nmod
rat	T-nmod
model	O
of	O
intracerebral	B-Disease
hemorrhage	I-Disease
induced	O
by	O
injection	T-amod
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	T-nmod
.	O

Rats	O
were	O
treated	T-nmod
with	T-nmod
seven	O
day	T-nmod
intravenous	T-nmod
infusion	O
of	O
fucoidan	B-Chemical
(	O
30	O
micrograms	T-appos
h	O
-	O
1	T-appos
)	O
or	T-conj
vehicle	O
.	O

The	O
hematoma	B-Disease
was	T-nsubj:pass
assessed	O
in	O
vivo	T-nsubj:pass
by	O
magnetic	O
resonance	O
imaging	T-nsubj:pass
.	O

Fucoidan	B-Chemical
-	O
treated	O
rats	T-obl
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-nmod
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	T-conj
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	T-conj
of	T-conj
impaired	T-conj
blood	T-conj
clotting	O
and	O
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-obj
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	T-obj
to	T-obj
have	O
less	O
inflammation	B-Disease
in	O
the	O
vicinity	T-obj
of	O
the	O
hematoma	O
after	O
three	O
days	T-obj
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	T-nmod
less	O
inflammation	O
in	T-nmod
the	T-nmod
vicinity	O
of	O
the	O
hematoma	B-Disease
after	O
three	O
days	O
.	O

They	T-obl
showed	O
significantly	O
more	O
rapid	O
improvement	T-obl
of	O
motor	O
function	O
in	O
the	O
first	O
week	T-obl
following	O
hemorrhage	B-Disease
and	T-conj
better	T-conj
memory	T-conj
retention	O
in	T-nmod
the	T-nmod
passive	T-nmod
avoidance	T-nmod
test	O
.	O

Acute	O
white	B-Disease
matter	I-Disease
edema	I-Disease
and	T-conj
eventual	T-conj
neuronal	T-conj
loss	O
in	T-nmod
the	T-nmod
striatum	O
adjacent	T-nmod
to	O
the	O
hematoma	O
did	T-nsubj
not	T-nsubj
differ	O
between	O
the	O
two	O
groups	T-nsubj
.	O

Acute	T-conj
white	O
matter	T-conj
edema	O
and	O
eventual	O
neuronal	B-Disease
loss	I-Disease
in	O
the	O
striatum	T-conj
adjacent	O
to	O
the	O
hematoma	O
did	O
not	O
differ	T-conj
between	O
the	O
two	O
groups	O
.	O

Acute	O
white	O
matter	O
edema	O
and	O
eventual	O
neuronal	O
loss	O
in	O
the	O
striatum	T-obl
adjacent	O
to	O
the	O
hematoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	T-obl
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	T-obl
warranted	O
in	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O

Accumulation	O
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	T-nmod
led	T-nmod
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	O
respiratory	B-Disease
arrest	I-Disease
with	T-nmod
severe	T-nmod
desaturation	O
and	O
bradycardia	T-nmod
occurred	O
.	O

A	T-nmod
respiratory	T-nmod
arrest	O
with	O
severe	O
desaturation	B-Disease
and	T-conj
bradycardia	O
occurred	T-nmod
.	O

A	O
respiratory	O
arrest	T-conj
with	T-conj
severe	T-conj
desaturation	O
and	O
bradycardia	B-Disease
occurred	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	T-obj
enabling	O
a	O
neuromuscular	B-Disease
blockade	I-Disease
to	O
occur	T-obj
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

The	T-nmod
haemodynamic	T-nmod
effects	O
of	O
propofol	B-Chemical
in	O
combination	T-nmod
with	O
ephedrine	O
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
haemodynamic	O
effects	T-nmod
of	O
propofol	O
in	T-nmod
combination	O
with	O
ephedrine	B-Chemical
in	T-nmod
elderly	T-nmod
patients	O
(	O
ASA	O
groups	T-nmod
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	T-nmod
and	T-nmod
negative	T-nmod
inotropic	T-nmod
effects	O
of	O
propofol	B-Chemical
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	T-nmod
and	O
efficacy	O
of	T-nmod
adding	T-nmod
different	T-nmod
doses	O
of	O
ephedrine	B-Chemical
to	O
propofol	O
in	O
order	O
to	O
obtund	O
the	O
hypotensive	O
response	O
.	O

We	T-obl
investigated	O
the	O
safety	T-obl
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	O
to	O
propofol	B-Chemical
in	O
order	O
to	O
obtund	T-obl
the	O
hypotensive	O
response	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	O
to	O
propofol	O
in	O
order	O
to	O
obtund	T-amod
the	T-amod
hypotensive	B-Disease
response	O
.	O

The	O
haemodynamic	O
effects	T-nmod
of	T-nmod
adding	T-nmod
15	T-nmod
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	B-Chemical
to	O
200	O
mg	O
of	O
propofol	O
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
haemodynamic	O
effects	T-nmod
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	O
to	T-nmod
200	T-nmod
mg	O
of	O
propofol	B-Chemical
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	T-nmod
addition	O
of	O
ephedrine	B-Chemical
to	T-nmod
propofol	O
appears	T-nmod
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

The	O
addition	T-nmod
of	T-nmod
ephedrine	O
to	O
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	T-amod
the	T-amod
hypotensive	B-Disease
response	O
to	O
propofol	T-amod
at	O
all	O
doses	T-amod
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	T-nmod
the	T-nmod
hypotensive	T-nmod
response	O
to	O
propofol	B-Chemical
at	O
all	O
doses	T-nmod
used	O
in	O
this	O
study	O
.	O

However	T-nsubj
,	O
marked	O
tachycardia	B-Disease
associated	O
with	O
the	O
use	T-amod
of	O
ephedrine	O
in	O
combination	O
with	O
propofol	O
occurred	O
in	O
the	O
majority	T-nsubj
of	O
patients	O
,	O
occasionally	O
reaching	T-nsubj
high	O
levels	O
in	O
individual	O
patients	O
.	O

However	O
,	O
marked	O
tachycardia	O
associated	T-nmod
with	T-nmod
the	T-nmod
use	O
of	O
ephedrine	B-Chemical
in	O
combination	T-nmod
with	O
propofol	O
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

However	O
,	O
marked	O
tachycardia	O
associated	O
with	O
the	O
use	T-nmod
of	O
ephedrine	O
in	T-nmod
combination	O
with	O
propofol	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	T-nmod
to	O
the	T-nmod
risk	O
of	O
this	O
tachycardia	B-Disease
inducing	O
myocardial	O
ischemia	T-acl
,	O
we	O
would	O
not	O
recommend	T-nmod
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	T-obj
inducing	O
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	O
myocardial	O
ischemia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	T-compound
of	T-compound
the	T-compound
ephedrine	B-Chemical
/	O
propofol	T-compound
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	O
myocardial	O
ischemia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	T-compound
of	T-compound
the	T-compound
ephedrine	T-compound
/	O
propofol	B-Chemical
/	O
mixtures	O
studied	O
.	O

Gemcitabine	B-Chemical
plus	T-conj
vinorelbine	O
in	T-nmod
nonsmall	T-nmod
cell	O
lung	O
carcinoma	T-nmod
patients	O
age	T-nmod
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	O
.	O

Gemcitabine	O
plus	O
vinorelbine	B-Chemical
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
patients	T-conj
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	O
.	O

Gemcitabine	T-compound
plus	O
vinorelbine	O
in	T-compound
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
patients	O
age	T-compound
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	O
.	O

Gemcitabine	O
plus	O
vinorelbine	O
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
patients	O
age	T-acl:relcl
70	O
years	O
or	O
older	O
or	T-acl:relcl
patients	O
who	O
cannot	O
receive	O
cisplatin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
the	T-nmod
prevalence	O
of	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	O
)	O
is	O
high	T-nmod
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	O
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	T-dep
of	T-dep
nonsmall	T-dep
cell	O
lung	T-dep
carcinoma	O
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	O
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	T-conj
regarding	T-conj
the	T-conj
efficacy	O
and	O
toxicity	B-Disease
of	O
chemotherapy	T-conj
in	O
this	O
group	T-conj
of	O
patients	O
.	O

In	O
the	O
current	O
study	O
the	T-conj
efficacy	O
and	O
toxicity	B-Disease
of	O
the	O
combination	T-conj
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	T-conj
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	T-conj
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	T-nmod
and	O
toxicity	O
of	T-nmod
the	T-nmod
combination	O
of	O
GEM	B-Chemical
and	T-conj
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	T-conj
of	T-conj
GEM	O
and	O
VNB	B-Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	T-nmod
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	T-nmod
elderly	T-nmod
patients	O
with	O
advanced	O
NSCLC	B-Disease
or	T-conj
those	O
with	O
some	O
contraindication	T-conj
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	T-nmod
with	T-nmod
some	T-nmod
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	T-nmod
patients	O
with	O
advanced	O
NSCLC	B-Disease
were	O
included	T-nmod
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	O
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	T-nmod
some	T-nmod
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
.	O

All	O
patients	O
were	O
evaluable	T-conj
for	T-conj
response	O
and	O
toxicity	B-Disease
.	O

Treatment	T-obl
was	T-obl
comprised	O
of	O
VNB	B-Chemical
,	O
25	T-conj
mg	O
/	O
m	T-conj
(	O
2	T-conj
)	O
,	O
plus	T-conj
GEM	O
,	O
1000	T-conj
mg	O
/	O
m	T-conj
(	O
2	T-conj
)	O
,	O
both	T-appos
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	T-appos
28	T-appos
days	O
.	O

Treatment	O
was	O
comprised	T-conj
of	T-conj
VNB	O
,	O
25	O
mg	T-conj
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	T-conj
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	T-conj
.	O

Toxicity	B-Disease
was	T-nsubj
mild	O
.	O

The	O
median	O
age	O
of	O
those	O
patients	T-obj
developing	O
Grade	O
3	T-nummod
-	T-nummod
4	O
neutropenia	B-Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O
72	O
years	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	T-nmod
combination	O
of	O
GEM	B-Chemical
and	T-conj
VNB	O
is	O
moderately	O
active	T-nmod
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-conj
of	T-conj
GEM	O
and	O
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	T-nmod
an	T-nmod
increased	T-nmod
risk	O
of	O
myelosuppression	B-Disease
.	O

New	O
chemotherapy	O
combinations	T-conj
with	T-conj
higher	T-conj
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	O
are	O
needed	T-nmod
for	T-nmod
elderly	T-nmod
patients	O
with	O
advanced	O
NSCLC	B-Disease
.	O

A	O
selective	O
dopamine	B-Chemical
D4	O
receptor	T-compound
antagonist	O
,	O
NRA0160	O
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

A	T-appos
selective	T-appos
dopamine	O
D4	O
receptor	T-appos
antagonist	O
,	O
NRA0160	B-Chemical
:	O
a	O
preclinical	O
neuropharmacological	O
profile	T-appos
.	O

NRA0160	B-Chemical
,	T-conj
5	T-nummod
-	T-nummod
[	O
2	T-nummod
-	O
(	O
4	O
-	O
(	O
3	O
-	O
fluorobenzylidene	O
)	O
piperidin	T-appos
-	O
1	O
-	O
yl	O
)	O
ethyl	T-appos
]	O
-	O
4	O
-	O
(	O
4	O
-	O
fluorophenyl	O
)	O
thiazole	O
-	O
2	O
-	O
carboxamide	T-parataxis
,	O
has	O
a	O
high	O
affinity	T-parataxis
for	O
human	O
cloned	O
dopamine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	T-nsubj
,	T-appos
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
thiazole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
,	O
has	T-appos
a	O
high	O
affinity	T-nsubj
for	O
human	O
cloned	O
dopamine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	O
,	O
5	O
-	O
[	O
2	O
-	O
(	O
4	O
-	O
(	O
3	O
-	O
fluorobenzylidene	O
)	O
piperidin	O
-	O
1	O
-	O
yl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
(	O
4	O
-	O
fluorophenyl	O
)	O
thiazole	O
-	O
2	O
-	O
carboxamide	O
,	O
has	O
a	O
high	O
affinity	T-compound
for	T-compound
human	O
cloned	T-compound
dopamine	B-Chemical
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	T-nsubj
over	T-nsubj
20	T-nummod
,	O
000fold	T-nsubj
more	O
potent	O
at	O
the	T-nummod
dopamine	O
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	O
D2L	O
receptor	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	T-compound
at	T-compound
the	T-compound
dopamine	B-Chemical
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	O
D2L	O
receptor	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamine	O
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D2L	O
receptor	O
.	O

NRA0160	B-Chemical
has	O
negligible	O
affinity	T-nsubj
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	O
receptor	T-compound
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	O
affinity	T-compound
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5	T-dep
-	T-dep
HT	O
)	O
2A	T-compound
receptors	O
(	O
Ki	O
=	O
180	O
nM	T-compound
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	T-dep
serotonin	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
receptors	T-dep
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	T-conj
clozapine	O
antagonized	O
locomotor	O
hyperactivity	T-nsubj
induced	O
by	O
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	O
and	O
clozapine	B-Chemical
antagonized	T-conj
locomotor	O
hyperactivity	O
induced	O
by	O
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	T-obj
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
methamphetamine	T-acl
(	O
MAP	O
)	O
in	O
mice	T-acl
.	O

NRA0160	O
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	T-obl
induced	O
by	O
methamphetamine	B-Chemical
(	O
MAP	O
)	O
in	O
mice	T-obl
.	O

NRA0160	O
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	O
induced	T-appos
by	T-appos
methamphetamine	O
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O

NRA0160	B-Chemical
and	T-conj
clozapine	O
significantly	T-nsubj
reversed	O
the	O
disruption	T-nsubj
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	O
.	O

NRA0160	O
and	O
clozapine	B-Chemical
significantly	O
reversed	T-conj
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	T-obl
produced	O
by	O
apomorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	T-conj
clozapine	O
significantly	T-nsubj
shortened	O
the	O
phencyclidine	T-nsubj
(	O
PCP	O
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0160	O
and	O
clozapine	B-Chemical
significantly	O
shortened	T-conj
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0160	T-iobj
and	O
clozapine	O
significantly	T-iobj
shortened	O
the	O
phencyclidine	B-Chemical
(	O
PCP	O
)	O
-	O
induced	T-dep
prolonged	T-dep
swimming	T-dep
latency	O
in	O
rats	T-dep
in	O
a	O
water	O
maze	O
task	T-dep
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
shortened	T-dep
the	T-dep
phencyclidine	O
(	O
PCP	B-Chemical
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	T-dep
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	O
suggest	T-nsubj
that	T-nsubj
NRA0160	B-Chemical
may	T-nsubj
have	O
unique	O
antipsychotic	O
activities	T-nsubj
without	O
the	O
liability	T-nsubj
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O

Warfarin	B-Chemical
-	O
induced	O
artery	O
calcification	T-obl
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	O
D	O
.	O

Warfarin	T-amod
-	O
induced	O
artery	B-Disease
calcification	I-Disease
is	T-nsubj:pass
accelerated	O
by	O
growth	T-nsubj:pass
and	O
vitamin	O
D	O
.	O

Warfarin	O
-	O
induced	O
artery	O
calcification	O
is	O
accelerated	T-conj
by	T-conj
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	T-conj
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	T-nmod
the	T-nmod
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	T-nmod
given	T-nmod
sufficient	T-nmod
doses	O
of	O
Warfarin	B-Chemical
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	T-compound
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	T-compound
calcification	B-Disease
inhibitor	O
known	T-compound
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	T-nmod
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-Disease
calcification	I-Disease
in	O
Warfarin	O
-	O
treated	O
rats	T-nmod
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	O
calcification	O
in	O
Warfarin	B-Chemical
-	O
treated	O
rats	T-obl
.	O

Treatment	O
for	O
2	O
weeks	T-nmod
with	O
Warfarin	B-Chemical
caused	T-nmod
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	O
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

Treatment	T-obj
for	O
2	O
weeks	O
with	O
Warfarin	O
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	T-obj
and	O
less	O
extensive	O
focal	O
calcification	O
in	O
42	O
-	O
day	O
-	O
old	O
rats	T-obj
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	O
caused	T-conj
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	T-conj
20	O
-	O
day	O
-	O
old	T-conj
rats	O
and	O
less	T-amod
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

In	O
contrast	T-nsubj:pass
,	O
no	O
artery	B-Disease
calcification	I-Disease
could	T-nsubj:pass
be	T-nsubj:pass
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	T-nsubj:pass
even	O
after	O
4	O
weeks	T-nsubj:pass
of	O
Warfarin	O
treatment	O
.	O

In	O
contrast	O
,	O
no	O
artery	O
calcification	O
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	T-compound
of	T-compound
Warfarin	B-Chemical
treatment	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	O
calcification	T-obl
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

To	O
directly	O
examine	T-nmod
the	T-nmod
importance	O
of	O
growth	T-nmod
to	O
Warfarin	T-amod
-	O
induced	O
artery	B-Disease
calcification	I-Disease
in	O
animals	T-nmod
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	T-nmod
of	T-nmod
both	T-nmod
dietary	T-nmod
groups	O
with	O
Warfarin	B-Chemical
produced	O
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	O
calcification	O
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Concurrent	O
treatment	T-obj
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	O
produced	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	T-nmod
the	T-nmod
ad	O
libitum	O
-	O
fed	T-nmod
rats	O
but	T-conj
no	T-conj
detectable	T-conj
artery	T-conj
calcification	O
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	T-conj
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	O
produced	T-conj
massive	T-conj
focal	T-conj
calcification	O
of	O
the	O
artery	O
media	T-conj
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	T-conj
but	O
no	O
detectable	O
artery	B-Disease
calcification	I-Disease
in	T-nmod
the	T-nmod
restricted	O
-	O
diet	T-nmod
,	O
growth	O
-	O
inhibited	T-nmod
group	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	O
calcification	T-obl
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	O
levels	O
.	O

This	O
observation	O
suggests	O
that	O
increased	T-nmod
susceptibility	O
to	O
Warfarin	T-amod
-	O
induced	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
related	T-nmod
to	O
higher	O
serum	O
phosphate	O
levels	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	O
-	O
induced	O
artery	O
calcification	O
could	O
be	O
related	T-compound
to	T-compound
higher	T-compound
serum	O
phosphate	B-Chemical
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	T-nmod
the	T-nmod
possible	T-nmod
synergy	O
between	O
vitamin	B-Chemical
D	I-Chemical
and	T-conj
Warfarin	O
in	O
artery	O
calcification	T-nmod
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	T-conj
between	T-conj
vitamin	T-conj
D	O
and	O
Warfarin	B-Chemical
in	O
artery	O
calcification	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	T-nmod
the	T-nmod
possible	T-nmod
synergy	O
between	O
vitamin	O
D	T-nmod
and	O
Warfarin	O
in	O
artery	B-Disease
calcification	I-Disease
.	O

High	T-nmod
doses	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
known	T-nmod
to	O
cause	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
vitamin	O
D	O
are	O
known	T-obj
to	T-obj
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	T-obj
.	O

High	O
doses	O
of	O
the	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	T-compound
are	O
also	O
known	O
to	O
cause	O
calcification	O
of	O
the	O
artery	O
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

High	T-nmod
doses	O
of	O
the	O
vitamin	O
K	T-compound
antagonist	O
Warfarin	B-Chemical
are	O
also	O
known	T-nmod
to	O
cause	O
calcification	O
of	O
the	O
artery	O
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

High	O
doses	O
of	O
the	O
vitamin	O
K	O
antagonist	O
Warfarin	O
are	O
also	O
known	T-obj
to	T-obj
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	T-compound
Warfarin	B-Chemical
administration	O
dramatically	O
increased	T-compound
the	O
extent	O
of	O
calcification	O
in	O
the	O
media	O
of	O
vitamin	O
D	O
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	O
administration	O
dramatically	O
increased	T-nmod
the	T-nmod
extent	O
of	O
calcification	B-Disease
in	O
the	O
media	T-nmod
of	O
vitamin	O
D	O
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	O
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	O
in	O
the	O
media	O
of	O
vitamin	B-Chemical
D	I-Chemical
-	O
treated	O
rats	T-obl
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-compound
of	T-compound
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	T-nmod
between	T-nmod
the	T-nmod
effect	O
of	O
vitamin	O
D	O
dose	T-nmod
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	T-nmod
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-compound
of	T-compound
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-nmod
of	O
vitamin	O
D	O
dose	O
on	T-nmod
the	T-nmod
elevation	O
of	O
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-nsubj
that	T-nsubj
vitamin	B-Chemical
D	I-Chemical
may	T-nsubj
induce	O
artery	O
calcification	T-nsubj
through	O
its	O
effect	T-nsubj
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-obj
that	T-obj
vitamin	O
D	T-obj
may	T-obj
induce	O
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	T-obj
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	T-nmod
artery	O
calcification	O
through	T-nmod
its	T-nmod
effect	O
on	O
serum	O
calcium	B-Chemical
.	O

Because	O
Warfarin	B-Chemical
treatment	O
had	T-compound
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	T-nmod
on	T-nmod
the	T-nmod
elevation	O
in	O
serum	O
calcium	B-Chemical
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	T-obl
no	O
effect	T-obl
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	T-nmod
synergy	O
between	O
Warfarin	B-Chemical
and	T-conj
vitamin	T-conj
D	O
is	O
probably	O
best	O
explained	T-nmod
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	T-conj
between	T-conj
Warfarin	O
and	O
vitamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	T-nsubj
that	T-nsubj
Warfarin	B-Chemical
inhibits	O
the	O
activity	T-nsubj
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	T-nsubj
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	T-compound
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	T-compound
a	T-compound
calcification	B-Disease
inhibitor	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	T-nmod
at	T-nmod
sites	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	O
with	O
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	T-obl
treated	O
with	O
vitamin	B-Chemical
D	I-Chemical
plus	T-conj
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	T-conj
with	T-conj
vitamin	T-conj
D	O
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	O
with	O
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	O
that	T-acl:relcl
the	T-acl:relcl
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carboxylated	I-Chemical
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	T-compound
gamma	B-Chemical
-	I-Chemical
carboxyglutamate	I-Chemical
residues	O
of	O
matrix	O
Gla	O
protein	T-compound
are	O
apparently	O
required	T-compound
for	O
its	O
function	O
as	O
a	O
calcification	O
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	O
sites	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	T-compound
for	O
its	O
function	O
as	T-compound
a	T-compound
calcification	B-Disease
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	O
sites	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	O
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	T-compound
at	T-compound
calcification	B-Disease
sites	O
.	O

Apomorphine	B-Chemical
,	O
a	T-appos
nonselective	T-appos
dopamine	T-appos
agonist	O
,	O
was	T-nsubj:pass
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	T-nsubj:pass
,	O
its	O
ability	T-nsubj:pass
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	T-nsubj:pass
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	O
selected	T-appos
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	T-obj
to	T-obj
induce	O
hypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	T-compound
to	T-compound
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
activity	T-obl
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
hyperactivity	T-obl
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	T-amod
-	O
induced	O
hyperactivity	B-Disease
was	O
facilitated	T-nmod
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	T-nmod
upon	T-nmod
other	T-nmod
physiological	T-nmod
responses	O
to	O
apomorphine	B-Chemical
such	T-nmod
as	O
drug	O
-	O
induced	T-nmod
hypothermia	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	T-nmod
to	T-nmod
apomorphine	O
such	O
as	T-case
drug	T-amod
-	O
induced	O
hypothermia	B-Disease
.	O

In	O
mice	T-nsubj
,	O
apomorphine	B-Chemical
produced	O
qualitatively	O
different	O
responses	T-nsubj
under	O
novel	O
conditions	O
when	T-nsubj
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

By	O
contrast	O
,	O
apomorphine	B-Chemical
-	O
induced	O
locomotion	T-obl
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	B-Chemical
turnover	O
ratios	T-compound
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	T-appos
ratios	O
(	O
DOPAC	B-Chemical
:	O
DA	O
and	O
HVA	T-dep
:	O
DA	T-dep
)	O
were	O
found	T-appos
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	T-dep
(	O
DOPAC	O
:	O
DA	B-Chemical
and	T-conj
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	T-conj
:	O
DA	O
and	O
HVA	B-Chemical
:	O
DA	T-conj
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	T-dep
:	O
DA	O
and	O
HVA	T-dep
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine	B-Chemical
-	O
induced	O
reductions	T-obl
in	O
striatal	O
dopamine	O
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

However	O
,	O
apomorphine	O
-	O
induced	O
reductions	T-compound
in	T-compound
striatal	T-compound
dopamine	B-Chemical
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

Hemolysis	B-Disease
of	T-nmod
human	T-nmod
erythrocytes	O
induced	O
by	O
tamoxifen	T-nsubj
is	O
related	T-nsubj
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Hemolysis	T-obl
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	T-obl
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	B-Chemical
(	O
TAM	O
)	O
,	O
the	T-appos
antiestrogenic	T-appos
drug	O
most	O
widely	O
prescribed	T-appos
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	O
changes	T-nsubj
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	O
(	O
TAM	B-Chemical
)	O
,	O
the	O
antiestrogenic	O
drug	T-appos
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	T-appos
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	T-nmod
in	T-nmod
the	T-nmod
chemotherapy	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	T-conj
of	T-conj
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

This	O
work	O
evaluates	T-nmod
the	T-nmod
effects	O
of	O
TAM	B-Chemical
on	O
isolated	O
human	O
erythrocytes	T-nmod
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	O
-	O
induced	O
hemolytic	O
anemia	O
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	B-Chemical
-	O
induced	O
hemolytic	O
anemia	T-obl
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	T-nmod
the	T-nmod
underlying	T-nmod
mechanisms	O
on	O
TAM	T-amod
-	O
induced	O
hemolytic	B-Disease
anemia	I-Disease
and	O
the	O
involvement	T-nmod
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	B-Chemical
induces	O
hemolysis	T-nsubj
of	O
erythrocytes	O
as	O
a	O
function	T-nsubj
of	O
concentration	O
.	O

TAM	T-obj
induces	O
hemolysis	B-Disease
of	T-nmod
erythrocytes	O
as	O
a	O
function	T-obj
of	O
concentration	O
.	O

The	T-nsubj
extension	T-obj
of	T-nmod
hemolysis	B-Disease
is	T-obj
variable	T-nmod
with	O
erythrocyte	O
samples	T-obj
,	T-obj
but	O
12	T-obj
.	O
5	O
microM	O
TAM	O
induces	O
total	O
hemolysis	O
of	O
all	O
tested	O
suspensions	O
.	O

The	O
extension	O
of	O
hemolysis	O
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
induces	O
total	O
hemolysis	O
of	O
all	O
tested	O
suspensions	O
.	O

The	O
extension	O
of	O
hemolysis	O
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
induces	O
total	O
hemolysis	B-Disease
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	T-nsubj
,	O
TAM	B-Chemical
does	T-nsubj
not	T-nsubj
shift	O
the	O
osmotic	O
fragility	O
curves	T-nsubj
of	O
erythrocytes	O
.	O

The	T-amod
hemolytic	B-Disease
effect	O
of	O
TAM	T-amod
is	O
prevented	T-amod
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	T-nmod
hemolytic	T-nmod
effect	O
of	O
TAM	B-Chemical
is	O
prevented	T-nmod
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	O
alpha	T-dep
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	T-dep
(	O
alpha	O
-	O
TAc	T-dep
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	T-dep
-	O
tocopherol	O
(	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	T-conj
alpha	O
-	O
tocopherol	T-conj
acetate	O
(	O
alpha	T-dep
-	O
TAc	O
)	O
(	O
inactivated	T-dep
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	T-conj
(	O
alpha	T-conj
-	O
T	O
)	O
and	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
acetate	I-Chemical
(	O
alpha	O
-	O
TAc	T-conj
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	T-dep
(	O
alpha	T-dep
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	T-dep
(	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	O
inactivated	O
functional	O
hydroxyl	T-dep
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	T-nmod
by	T-nmod
low	T-nmod
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	T-amod
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	B-Chemical
-	O
induced	O
hemolysis	T-obl
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	T-nsubj:pass
that	T-nsubj:pass
TAM	T-amod
-	O
induced	O
hemolysis	B-Disease
is	T-nsubj:pass
not	T-nsubj:pass
related	O
to	O
oxidative	O
membrane	O
damage	T-nsubj:pass
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	T-compound
of	T-compound
oxygen	B-Chemical
consumption	O
and	O
hemoglobin	O
oxidation	T-compound
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induced	O
hemolysis	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	O
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	B-Chemical
-	O
induced	O
hemolysis	T-obl
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	O
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	T-nmod
in	T-nmod
parallel	O
with	O
TAM	T-amod
-	O
induced	O
hemolysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	T-nsubj
that	T-nsubj
TAM	B-Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	T-nsubj
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhibits	T-obl
the	O
peroxidation	T-obl
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	B-Chemical
,	O
thus	O
ruling	T-obl
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
induced	O
cell	O
oxidative	O
stress	T-obl
.	O

Hemolysis	B-Disease
caused	O
by	O
TAM	T-nsubj
was	O
not	O
preceded	T-nsubj
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O

Hemolysis	T-obl
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	T-obl
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	O
preceded	T-nmod
by	T-nmod
the	T-nmod
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	T-nmod
from	T-nmod
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O

However	T-nsubj
,	O
TAM	B-Chemical
induces	O
release	T-nsubj
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
or	T-conj
alpha	O
-	O
TAc	T-conj
increases	T-conj
membrane	O
packing	O
and	O
prevents	T-compound
TAM	O
partition	T-compound
into	O
model	O
membranes	O
.	O

Either	O
alpha	O
-	O
T	T-compound
or	T-compound
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
increases	T-compound
membrane	O
packing	O
and	O
prevents	O
TAM	O
partition	O
into	O
model	O
membranes	O
.	O

Either	O
alpha	O
-	O
T	O
or	O
alpha	O
-	O
TAc	O
increases	O
membrane	O
packing	T-compound
and	O
prevents	O
TAM	B-Chemical
partition	O
into	O
model	O
membranes	T-compound
.	O

These	O
effects	O
suggest	O
that	O
the	T-nmod
protection	O
from	O
hemolysis	B-Disease
by	O
tocopherols	T-nmod
is	O
related	T-nmod
to	O
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

These	O
effects	O
suggest	O
that	O
the	T-nmod
protection	O
from	O
hemolysis	T-nmod
by	O
tocopherols	B-Chemical
is	O
related	T-nmod
to	O
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	O
by	O
tocopherols	O
is	O
related	T-compound
to	T-compound
a	T-compound
decreased	T-compound
TAM	B-Chemical
incorporation	O
in	O
condensed	O
membranes	T-compound
and	O
the	O
structural	O
damage	T-compound
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	B-Chemical
-	O
induced	O
hemolysis	O
results	T-obl
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

Therefore	O
,	O
TAM	O
-	O
induced	T-compound
hemolysis	B-Disease
results	O
from	O
a	O
structural	O
perturbation	T-compound
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	T-compound
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	T-obl
the	O
abnormal	O
erythrocyte	O
shape	O
and	T-obl
decreased	O
mechanical	O
stability	T-obl
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	O
anemia	T-acl
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	T-obl
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	T-nmod
disruption	O
of	O
the	O
structural	O
characteristics	T-nmod
of	O
biomembranes	O
by	O
TAM	B-Chemical
may	O
contribute	T-nmod
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	T-compound
of	T-compound
sodium	B-Chemical
and	T-conj
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	T-compound
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	B-Chemical
affinities	T-conj
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	T-compound
of	T-compound
the	T-compound
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	T-dep
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	T-dep
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	B-Chemical
oxide	I-Chemical
deficient	O
hypertension	T-obl:npmod
.	O

Changes	T-conj
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	T-amod
deficient	O
hypertension	B-Disease
.	O

In	O
the	O
cardiovascular	O
system	T-nsubj:pass
,	O
NO	B-Chemical
is	T-nsubj:pass
involved	O
in	O
the	O
regulation	T-nsubj:pass
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	T-det
of	T-det
NO	B-Chemical
synthesis	O
induces	O
sustained	O
hypertension	O
.	O

Inhibition	T-obj
of	O
NO	O
synthesis	O
induces	O
sustained	O
hypertension	B-Disease
.	O

In	T-nmod
several	T-nmod
models	O
of	O
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	O
level	O
was	O
documented	T-nmod
in	O
cardiac	O
tissue	O
.	O

In	O
several	O
models	O
of	O
hypertension	O
,	O
elevation	T-compound
of	T-compound
intracellular	T-compound
sodium	B-Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	T-nmod
in	T-nmod
transmembraneous	T-nmod
transport	O
of	O
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	T-acl
studied	T-acl
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	T-acl
ATPase	O
to	O
NO	O
-	O
deficient	T-acl
hypertension	B-Disease
induced	T-obl
in	O
rats	T-obl
by	O
NO	O
-	T-obl
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	T-obl
ester	O
(	O
L	O
-	O
NAME	O
)	T-obl
for	O
4	T-obl
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	B-Chemical
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	T-nmod
induced	O
in	O
rats	T-nmod
by	O
NO	O
-	T-nmod
synthase	O
inhibition	O
with	T-compound
40	O
mg	O
/	O
kg	O
/	T-compound
day	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	T-appos
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	T-appos
inhibition	T-appos
with	O
40	T-appos
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	T-appos
arginine	T-appos
methyl	O
ester	O
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
4	O
four	O
weeks	O

When	O
activating	O
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	T-compound
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	T-compound
the	T-compound
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	T-obl
activating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	T-obl
with	O
its	O
substrate	O
ATP	B-Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	T-obl
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	T-amod
.	O

After	T-nmod
recovery	O
from	O
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	T-nmod
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	T-compound
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	T-dep
of	T-dep
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	B-Chemical
-	O
binding	O
site	T-obl
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	T-nmod
from	T-nmod
the	T-nmod
lowered	T-nmod
Km	T-nmod
value	O
for	O
ATP	B-Chemical
.	O

The	O
K	B-Chemical
(	O
Na	O
)	O
value	T-dep
for	O
Na	O
+	O
returned	O
to	O
control	O
value	O

The	T-compound
K	O
(	O
Na	B-Chemical
)	O
value	O
for	O
Na	T-compound
+	T-compound
returned	O
to	O
control	O
value	O

The	T-nmod
K	O
(	O
Na	T-nmod
)	O
value	O
for	O
Na	B-Chemical
+	T-nmod
returned	O
to	O
control	O
value	O

Inhibition	T-amod
of	T-amod
NO	B-Chemical
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O

Inhibition	T-obj
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	B-Disease
accompanied	O
by	O
depressed	O
Na	O
+	O
-	T-acl
extrusion	O
from	O
cardiac	T-acl
cells	O
as	O
a	T-obj
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	T-compound
by	T-compound
depressed	B-Disease
Na	B-Chemical
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	B-Chemical
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	T-compound
binding	T-compound
properties	T-compound
of	O
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	T-nmod
extrusion	O
of	O
Na	B-Chemical
+	T-nmod
from	T-nmod
cardiac	O
cells	O
was	T-nmod
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
activity	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	O
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
activity	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	O
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
activity	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	T-nmod
with	O
isoproterenol	B-Chemical
on	T-nmod
bromocriptine	O
-	O
induced	T-nmod
tachycardia	O
in	T-nmod
conscious	T-nmod
rats	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	O
on	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	T-obl
in	O
conscious	O
rats	O
.	O

Effects	T-nmod
of	O
long	O
-	O
term	O
pretreatment	O
with	T-nmod
isoproterenol	O
on	O
bromocriptine	T-amod
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	T-nmod
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	T-obl
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	T-dep
that	O
bromocriptine	T-amod
-	O
induced	O
tachycardia	B-Disease
,	O
which	T-dep
persisted	O
after	O
adrenalectomy	T-dep
,	O
is	O
(	O
i	O
)	O
mediated	T-dep
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	T-dep
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	B-Chemical
D2	O
receptor	T-compound
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	T-compound
by	T-compound
5	O
-	O
day	T-compound
isoproterenol	B-Chemical
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	T-nmod
pretreatment	O
with	O
isoproterenol	B-Chemical
could	O
abolish	T-nmod
bromocriptine	O
-	O
induced	O
tachycardia	O
in	O
conscious	O
rats	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	O
could	O
abolish	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	T-obl
in	O
conscious	O
rats	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	T-obj
whether	T-obj
prolonged	O
pretreatment	T-obj
with	O
isoproterenol	O
could	T-obj
abolish	O
bromocriptine	T-amod
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	T-obj
.	O

Isoproterenol	B-Chemical
pretreatment	O
for	O
15	O
days	T-compound
caused	T-compound
cardiac	O
hypertrophy	O
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Isoproterenol	O
pretreatment	T-obj
for	O
15	O
days	O
caused	O
cardiac	B-Disease
hypertrophy	I-Disease
without	T-obj
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	T-nsubj
,	O
intravenous	O
bromocriptine	B-Chemical
(	O
150	T-dep
microg	O
/	O
kg	T-dep
)	O
induced	O
significant	O
hypotension	T-nsubj
and	O
tachycardia	O
.	O

In	O
control	O
rats	T-obj
,	O
intravenous	O
bromocriptine	T-obj
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	B-Disease
and	T-conj
tachycardia	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	O
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	T-conj
significant	T-conj
hypotension	O
and	O
tachycardia	B-Disease
.	O

Bromocriptine	B-Chemical
-	O
induced	O
hypotension	T-nummod
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	T-nmod
-	O
induced	O
hypotension	B-Disease
was	T-nsubj
unaffected	O
by	O
isoproterenol	O
pretreatment	T-nsubj
,	O
while	O
tachycardia	O
was	O
reversed	T-nsubj
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	T-compound
by	T-compound
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	T-nsubj:pass
by	O
isoproterenol	O
pretreatment	O
,	O
while	T-nsubj:pass
tachycardia	B-Disease
was	T-nsubj:pass
reversed	O
to	O
significant	O
bradycardia	T-nsubj:pass
,	O
an	O
effect	T-nsubj:pass
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	T-obl
by	O
isoproterenol	O
pretreatment	O
,	O
while	T-obl
tachycardia	T-obl
was	T-obl
reversed	O
to	O
significant	O
bradycardia	B-Disease
,	O
an	O
effect	T-obl
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	T-compound
by	T-compound
isoproterenol	B-Chemical
pretreatment	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	B-Chemical
-	O
pretreated	O
rats	T-obl
,	O
the	O
isoproterenol	O
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	O
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	O
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
maximal	O
increase	T-obl
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	O
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	O
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	O
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
increase	T-obl
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	T-compound
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	T-compound
but	O
reversed	O
bromocriptine	O
-	O
induced	O
tachycardia	O
to	O
bradycardia	O
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	T-obl
to	O
bradycardia	O
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	T-obj
but	T-obj
reversed	O
bromocriptine	T-amod
-	O
induced	O
tachycardia	B-Disease
to	O
bradycardia	T-obj
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	T-obl
but	T-obl
reversed	O
bromocriptine	O
-	O
induced	O
tachycardia	T-obl
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	T-nsubj
that	T-nsubj
,	O
in	O
normal	O
conscious	O
rats	T-nsubj
,	O
the	O
central	O
tachycardia	B-Disease
of	T-nmod
bromocriptine	O
appears	O
to	O
predominate	T-nsubj
and	O
to	O
mask	O
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	T-nmod
central	T-nmod
tachycardia	O
of	O
bromocriptine	B-Chemical
appears	T-nmod
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	O
to	O
predominate	T-obj
and	T-obj
to	T-obj
mask	O
the	O
bradycardia	B-Disease
of	T-nmod
this	T-nmod
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	T-obj
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-Chemical
D2	O
receptors	T-compound
.	O

A	O
developmental	O
analysis	T-nmod:poss
of	T-nmod:poss
clonidine	B-Chemical
'	O
s	O
effects	O
on	O
cardiac	O
rate	T-nmod:poss
and	O
ultrasound	O
production	O
in	O
infant	O
rats	T-nmod:poss
.	O

Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	T-appos
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	T-appos
agonist	O
,	O
clonidine	B-Chemical
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	T-nmod
response	O
to	O
clonidine	B-Chemical
,	O
ultrasound	O
production	O
increases	T-nmod
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	T-nsubj
that	T-nsubj
clonidine	B-Chemical
induces	O
sympathetic	O
withdrawal	T-nsubj
and	O
bradycardia	O
,	O
we	O
hypothesized	O
that	O
clonidine	O
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	O
induces	T-conj
sympathetic	T-conj
withdrawal	O
and	O
bradycardia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonidine	O
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	O
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	O
,	O
we	O
hypothesized	O
that	O
clonidine	B-Chemical
'	O
s	O
developmental	T-nmod:poss
effects	O
on	O
cardiac	O
rate	T-nmod:poss
and	O
ultrasound	O
production	O
would	O
mirror	T-nmod:poss
each	O
other	O
.	O

Therefore	O
,	T-conj
in	O
the	O
present	O
experiment	T-conj
,	T-conj
the	T-cc
effects	T-conj
of	T-compound
clonidine	B-Chemical
administration	T-compound
(	T-compound
0	T-compound
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	B-Chemical
-	O
induced	O
bradycardia	T-obl
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	T-conj
in	O
cardiovascular	O
variables	O
,	O
including	T-conj
baseline	T-conj
cardiac	T-conj
rate	O
and	O
clonidine	T-amod
-	O
induced	O
bradycardia	B-Disease
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	T-obl
that	T-obl
compensates	O
for	O
clonidine	B-Chemical
'	O
s	O
detrimental	T-dep
effects	O
on	O
cardiovascular	O
function	T-dep
.	O

Recurrent	T-nmod
use	O
of	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
and	T-conj
the	T-conj
risk	O
of	O
venous	O
thromboembolism	T-conj
.	O

Recurrent	O
use	O
of	O
newer	O
oral	O
contraceptives	T-nmod
and	T-nmod
the	T-nmod
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	T-nmod
the	T-nmod
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	T-acl
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	T-dep
of	T-dep
venous	T-dep
thromboembolism	O
(	O
VTE	B-Disease
)	O
associated	T-dep
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	T-obl
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-dep
with	T-dep
newer	T-dep
oral	T-dep
contraceptives	O
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	T-compound
of	T-compound
OC	B-Chemical
use	O
,	O
namely	O
first	O
-	O
time	O
users	T-compound
,	O
repeaters	T-compound
and	O
switchers	T-compound
.	O

Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	T-nmod
the	T-nmod
risk	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
patterns	T-nmod
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	T-nmod
cases	O
of	O
VTE	B-Disease
were	O
identified	T-nmod
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	T-nmod
with	T-nmod
equivalent	T-nmod
risks	O
of	O
VTE	B-Disease
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	T-obl
that	T-obl
the	O
higher	O
risk	T-obl
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	T-nmod
other	T-nmod
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Differential	T-nmod
effects	O
of	O
systemically	T-amod
administered	O
ketamine	B-Chemical
and	T-conj
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	T-nmod
induced	T-nmod
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	O
effects	T-conj
of	T-conj
systemically	O
administered	T-conj
ketamine	O
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	O
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	T-nmod
effects	O
of	O
systemically	O
administered	O
ketamine	T-nmod
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	T-amod
hyperalgesia	B-Disease
induced	T-nmod
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	O
effects	T-obl
of	O
systemically	O
administered	O
ketamine	O
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	O
by	O
intradermal	O
capsaicin	B-Chemical
in	O
humans	T-obl
.	O

We	O
have	O
examined	O
the	O
effect	T-nmod
of	T-nmod
systemic	T-nmod
administration	O
of	O
ketamine	B-Chemical
and	T-conj
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	O
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	T-conj
of	T-conj
ketamine	O
and	O
lidocaine	B-Chemical
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	O
by	O
capsaicin	O
.	O

We	T-obl
have	T-obl
examined	O
the	O
effect	T-obl
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	T-amod
-	O
evoked	O
(	O
dynamic	O
)	O
pain	B-Disease
and	T-conj
punctate	T-conj
-	O
evoked	O
(	O
static	T-conj
)	O
hyperalgesia	T-acl
induced	O
by	O
capsaicin	T-acl
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	T-dep
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	O
by	O
capsaicin	T-dep
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	T-obl
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	T-obl
induced	O
by	O
capsaicin	B-Chemical
.	O

Capsaicin	B-Chemical
100	T-nmod
micrograms	T-nummod
was	O
injected	T-nmod
intradermally	O
on	O
the	T-nummod
volar	T-nummod
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	O
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Capsaicin	O
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	T-nummod
by	T-nummod
an	O
i	T-nummod
.	T-nummod
v	O
.	O
infusion	O
of	O
ketamine	B-Chemical
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Capsaicin	O
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	O
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	T-nmod
after	O
injection	O
of	O
capsaicin	B-Chemical
.	O

The	T-dep
following	O
were	T-dep
measured	O
:	O
spontaneous	O
pain	B-Disease
,	O
pain	T-conj
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	T-conj
(	O
VAS	O
)	O
,	O
and	T-conj
areas	O
of	T-conj
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	T-nsubj
,	O
pain	B-Disease
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	T-nsubj
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	O
,	O
pain	O
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	T-conj
brush	T-conj
-	O
evoked	O
and	O
punctate	T-amod
-	O
evoked	O
hyperalgesia	B-Disease
.	O

Ketamine	B-Chemical
reduced	O
both	O
the	O
area	T-nsubj
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	O
.	O

Ketamine	O
reduced	O
both	O
the	O
area	O
of	T-conj
brush	T-conj
-	O
evoked	O
and	O
punctate	T-amod
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
and	O
it	O
tended	T-conj
to	O
reduce	O
brush	O
-	O
evoked	O
pain	O
.	O

Ketamine	O
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
significantly	O
and	O
it	O
tended	T-obj
to	T-obj
reduce	O
brush	T-amod
-	O
evoked	O
pain	B-Disease
.	O

Lidocaine	B-Chemical
reduced	O
the	O
area	T-nsubj
of	O
punctate	O
-	O
evoked	O
hyperalgesia	O
significantly	T-nsubj
.	O

Lidocaine	O
reduced	T-nmod
the	T-nmod
area	O
of	O
punctate	T-amod
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
reduce	T-nmod
VAS	T-nmod
scores	O
of	O
spontaneous	O
pain	B-Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	O
but	O
had	T-nmod
no	T-nmod
effect	O
on	O
evoked	O
pain	B-Disease
.	O

The	T-nmod
differential	T-nmod
effects	O
of	O
ketamine	B-Chemical
and	T-conj
lidocaine	O
on	O
static	T-nmod
and	O
dynamic	O
hyperalgesia	O
suggest	T-nmod
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	T-conj
of	T-conj
ketamine	O
and	O
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	T-conj
of	O
ketamine	O
and	O
lidocaine	O
on	T-conj
static	O
and	O
dynamic	O
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	T-nmod
two	T-nmod
types	O
of	O
hyperalgesia	B-Disease
are	O
mediated	T-nmod
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	O
behavior	T-obl
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

Development	O
of	O
apomorphine	T-amod
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
:	O
comparison	T-nmod
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	T-amod
development	T-amod
of	O
apomorphine	B-Chemical
-	T-compound
induced	O
(	O
1	T-dep
.	O
0	O
mg	O
/	T-amod
kg	T-amod
s	O
.	O
c	O
.	O
once	O
daily	T-amod
)	O
aggressive	O
behavior	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

The	O
development	O
of	O
apomorphine	O
-	O
induced	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	T-amod
)	T-amod
aggressive	B-Disease
behavior	I-Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	T-compound
apomorphine	B-Chemical
treatment	O
induced	T-compound
a	O
gradual	O
development	O
of	O
aggressive	O
behavior	O
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	O
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	O
induced	T-nmod
a	T-nmod
gradual	T-nmod
development	O
of	O
aggressive	B-Disease
behavior	I-Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	O
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	O
behavior	O
as	O
evidenced	T-nmod
by	T-nmod
the	T-nmod
increased	T-nmod
intensity	O
of	O
aggressiveness	B-Disease
and	O
shortened	O
latency	T-nmod
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	T-nmod
a	T-nmod
weak	T-nmod
tendency	O
toward	O
aggressiveness	B-Disease
was	O
found	T-nmod
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	O
behavior	T-obl
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	T-nmod
in	T-nmod
the	T-nmod
development	O
of	O
the	O
apomorphine	T-amod
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
and	T-conj
cocaine	T-conj
abuse	O
:	O
analysis	O
of	O
prognostic	O
indicators	T-dep
.	O

Intracranial	T-conj
aneurysms	O
and	O
cocaine	B-Disease
abuse	I-Disease
:	O
analysis	T-conj
of	O
prognostic	O
indicators	O
.	O

OBJECTIVE	O
:	O
The	T-nmod
outcome	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	T-nmod
with	O
cocaine	O
abuse	O
is	O
reportedly	O
poor	T-nmod
.	O

OBJECTIVE	O
:	O
The	O
outcome	T-obl
of	O
subarachnoid	O
hemorrhage	O
associated	O
with	O
cocaine	B-Disease
abuse	I-Disease
is	O
reportedly	O
poor	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	T-obl
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	T-nmod
14	T-nmod
patients	O
with	O
cocaine	T-amod
-	O
related	O
aneurysms	B-Disease
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	T-nmod
of	T-nmod
135	T-nmod
patients	O
with	O
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	O
abuse	O
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	T-nmod
of	O
135	O
patients	O
with	O
ruptured	O
aneurysms	O
and	T-nmod
no	T-nmod
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
.	O

Age	O
at	O
presentation	T-nmod
,	O
time	T-nmod
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	T-nmod
and	O
Hess	O
grade	T-nmod
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
size	O
of	O
the	O
aneurysm	T-appos
,	O
location	O
of	O
the	O
aneurysm	T-appos
,	O
and	T-conj
the	T-conj
Glasgow	O
Outcome	O
Scale	T-conj
score	O
were	O
assessed	T-nmod
and	O
compared	O
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	O
hemorrhage	T-nmod
,	O
size	O
of	O
the	O
aneurysm	B-Disease
,	O
location	O
of	O
the	O
aneurysm	O
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	O
hemorrhage	T-nmod
,	O
size	O
of	O
the	O
aneurysm	O
,	O
location	O
of	O
the	O
aneurysm	B-Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

In	O
patients	T-nsubj:pass
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B-Disease
were	T-nsubj:pass
located	O
in	O
the	O
anterior	O
circulation	T-nsubj:pass
.	O

The	T-nmod
majority	T-dep
of	T-dep
these	T-dep
aneurysms	B-Disease
were	T-dep
smaller	T-dep
than	O
those	T-dep
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	O
-	O
related	O
aneurysms	B-Disease
.	O

CONCLUSION	T-nsubj
:	O
Cocaine	B-Chemical
use	O
predisposed	O
aneurysmal	O
rupture	T-nsubj
at	O
a	O
significantly	O
earlier	O
age	T-nsubj
and	O
in	O
much	O
smaller	O
aneurysms	T-nsubj
.	O

CONCLUSION	T-obj
:	O
Cocaine	T-obj
use	O
predisposed	O
aneurysmal	B-Disease
rupture	I-Disease
at	O
a	O
significantly	O
earlier	O
age	T-obj
and	O
in	O
much	O
smaller	O
aneurysms	T-obj
.	O

CONCLUSION	T-conj
:	O
Cocaine	T-conj
use	O
predisposed	O
aneurysmal	O
rupture	T-conj
at	O
a	O
significantly	O
earlier	O
age	T-conj
and	O
in	O
much	T-amod
smaller	O
aneurysms	B-Disease
.	O

Effect	O
of	O
intravenous	O
nimodipine	B-Chemical
on	O
blood	O
pressure	T-nmod
and	O
outcome	O
after	O
acute	O
stroke	T-nmod
.	O

Effect	O
of	O
intravenous	O
nimodipine	T-nmod
on	O
blood	O
pressure	T-nmod
and	O
outcome	O
after	O
acute	B-Disease
stroke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	T-compound
Intravenous	T-compound
Nimodipine	B-Chemical
West	T-compound
European	T-compound
Stroke	T-compound
Trial	O
(	O
INWEST	T-compound
)	O
found	T-compound
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	T-compound
Intravenous	T-compound
Nimodipine	T-compound
West	T-compound
European	T-compound
Stroke	B-Disease
Trial	O
(	O
INWEST	T-compound
)	O
found	T-compound
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	B-Chemical
-	O
induced	O
reduction	T-obl
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	T-nmod
a	T-nmod
correlation	O
between	O
nimodipine	T-amod
-	O
induced	O
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	T-conj
an	T-conj
unfavorable	T-conj
outcome	O
in	O
acute	O
stroke	T-conj
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	T-nmod
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	T-nmod
an	T-nmod
unfavorable	T-nmod
outcome	O
in	O
acute	B-Disease
stroke	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	T-nmod
with	T-nmod
increasing	T-nmod
levels	O
of	O
BP	B-Disease
reduction	I-Disease
.	O

METHODS	O
:	O
Patients	T-nmod
with	T-nmod
a	T-nmod
clinical	T-nmod
diagnosis	O
of	O
ischemic	B-Disease
stroke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
94	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	O
stroke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	T-compound
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	T-compound
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	T-dep
=	T-dep
101	O
)	O
,	O
or	T-conj
2	T-conj
mg	O
/	O
h	T-conj
(	O
high	O
-	O
dose	T-conj
)	O
nimodipine	O
(	O
n	O
=	O
94	T-compound
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	O
stroke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	T-obj
to	T-obj
receive	O
placebo	T-obj
(	O
n	O
=	O
100	T-obj
)	O
,	O
1	T-compound
mg	O
/	O
h	T-compound
(	O
low	O
-	O
dose	T-compound
)	O
nimodipine	O
(	O
n	O
=	O
101	T-compound
)	O
,	O
or	O
2	O
mg	T-compound
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	T-dep
=	T-dep
94	O
)	O
.	O

Nimodipine	B-Chemical
treatment	O
resulted	T-compound
in	O
a	O
statistically	O
significant	O
reduction	O
in	O
systolic	O
BP	O
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

Nimodipine	O
treatment	T-obl
resulted	O
in	O
a	O
statistically	T-amod
significant	O
reduction	B-Disease
in	I-Disease
systolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	T-conj
diastolic	T-conj
BP	O
(	O
DBP	T-conj
)	O
from	O
baseline	T-conj
compared	T-nmod
with	T-nmod
placebo	O
during	T-nmod
the	T-nmod
first	T-nmod
few	T-nmod
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	T-nmod
significant	T-nmod
correlation	O
between	O
DBP	B-Disease
reduction	I-Disease
and	T-conj
worsening	O
of	O
the	O
neurological	O
score	T-conj
was	O
found	T-nmod
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	T-nmod
after	T-nmod
the	T-nmod
intravenous	T-nmod
administration	O
of	O
high	T-compound
-	O
dose	O
nimodipine	B-Chemical
after	O
acute	O
stroke	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	T-obl
with	T-obl
neurological	T-obl
worsening	O
after	O
the	O
intravenous	O
administration	T-obl
of	O
high	O
-	O
dose	O
nimodipine	O
after	O
acute	B-Disease
stroke	I-Disease
.	O

For	O
low	T-compound
-	O
dose	O
nimodipine	B-Chemical
,	O
the	O
results	T-obl
were	T-obl
not	T-obl
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	T-nmod
or	O
exclude	O
a	T-nmod
neuroprotective	T-nmod
property	O
of	O
nimodipine	B-Chemical
.	O

Neonatal	O
pyridoxine	B-Chemical
responsive	T-compound
convulsions	O
due	O
to	O
isoniazid	O
therapy	T-compound
.	O

Neonatal	T-compound
pyridoxine	O
responsive	O
convulsions	B-Disease
due	T-nmod
to	O
isoniazid	T-nmod
therapy	O
.	O

Neonatal	O
pyridoxine	O
responsive	O
convulsions	T-compound
due	T-compound
to	O
isoniazid	B-Chemical
therapy	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	T-compound
on	T-compound
isoniazid	B-Chemical
therapy	O
13	O
mg	T-compound
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	O
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	O
fits	O
.	O

A	T-nmod
17	O
-	O
day	O
-	O
old	T-nmod
infant	O
on	O
isoniazid	O
therapy	T-nmod
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	T-case
maternal	O
tuberculosis	B-Disease
was	O
admitted	T-nmod
after	O
4	O
days	O
of	O
clonic	O
fits	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	O
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	O
was	O
admitted	T-nmod
after	T-nmod
4	T-nmod
days	O
of	O
clonic	B-Disease
fits	I-Disease
.	O

The	O
fits	B-Disease
ceased	O
within	O
4	O
hours	T-nsubj
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	T-nsubj
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	T-nmod
within	T-nmod
4	T-nmod
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	T-compound
of	T-compound
pyridoxine	B-Chemical
deficiency	O
secondary	T-compound
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	T-compound
to	T-compound
isoniazid	B-Chemical
medication	O
.	O

Ketamine	B-Chemical
sedation	O
for	O
the	O
reduction	T-compound
of	O
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
.	O

Ketamine	O
sedation	T-nmod
for	T-nmod
the	T-nmod
reduction	O
of	O
children	O
'	T-nmod:poss
s	T-nmod:poss
fractures	B-Disease
in	O
the	O
emergency	O
department	T-nmod
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	T-nmod
in	T-nmod
the	T-nmod
utilization	O
of	O
ketamine	B-Chemical
,	O
a	O
unique	O
anesthetic	T-nmod
,	O
for	O
emergency	O
-	O
department	O
procedures	T-nmod
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	T-nmod
the	T-nmod
safety	O
and	O
efficacy	T-nmod
of	O
ketamine	B-Chemical
for	O
sedation	T-nmod
in	O
the	O
treatment	O
of	O
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	O
for	O
sedation	T-nmod
in	T-nmod
the	T-nmod
treatment	O
of	O
children	O
'	T-nmod:poss
s	T-nmod:poss
fractures	B-Disease
in	T-nmod
the	T-nmod
emergency	T-nmod
department	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	T-obl
3	O
years	T-obl
;	O
range	O
,	T-obl
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	T-compound
of	O
an	O
isolated	O
fracture	B-Disease
or	O
dislocation	O
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O

METHODS	O
:	T-advmod
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	O
or	T-advmod
dislocation	B-Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	O
or	O
dislocation	O
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	B-Chemical
hydrochloride	I-Chemical
was	T-nsubj:pass
administered	O
intravenously	T-nsubj:pass
(	O
at	O
a	O
dose	T-nsubj:pass
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	T-nsubj:pass
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	T-nsubj:pass
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	T-nsubj:pass
.	O

Any	O
pain	B-Disease
during	T-nmod
the	T-nmod
reduction	O
was	T-nsubj:pass
rated	O
by	O
the	O
orthopaedic	O
surgeon	T-nsubj:pass
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	T-nsubj:pass
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
(	O
CHEOPS	O
)	O
.	O

Any	O
pain	O
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	T-compound
of	T-compound
Eastern	O
Ontario	T-compound
Pain	B-Disease
Scale	O
(	O
CHEOPS	T-compound
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	T-nmod
from	T-nmod
intravenous	T-nmod
administration	O
of	O
ketamine	B-Chemical
to	O
manipulation	O
of	O
the	O
fracture	O
or	O
dislocation	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	T-nmod
from	O
intravenous	O
administration	O
of	O
ketamine	O
to	T-nmod
manipulation	O
of	O
the	O
fracture	B-Disease
or	T-conj
dislocation	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	O
to	O
manipulation	T-conj
of	T-conj
the	T-conj
fracture	O
or	O
dislocation	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	T-compound
of	T-compound
Eastern	O
Ontario	T-cc
Pain	B-Disease
Scale	T-cc
was	T-compound
6	T-cc
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	O
during	O
fracture	O
reduction	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B-Disease
during	O
fracture	O
reduction	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	O
during	O
fracture	B-Disease
reduction	O
.	O

Adequate	T-compound
fracture	B-Disease
reduction	O
was	O
obtained	T-compound
in	O
111	O
of	O
the	O
children	O
.	O

Minor	O
side	O
effects	T-obj
included	O
nausea	B-Disease
(	O
thirteen	T-appos
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	T-conj
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	T-conj
dysphoric	T-conj
reaction	O
(	O
one	O
patient	T-conj
)	O
.	O

Minor	O
side	O
effects	O
included	T-conj
nausea	O
(	O
thirteen	O
patients	T-conj
)	O
,	O
emesis	B-Disease
(	O
eight	T-dep
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	T-dep
(	O
evident	O
as	O
ataxic	O
movements	T-dep
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-conj
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	T-nmod
of	T-nmod
the	T-nmod
thirteen	T-nmod
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	O
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	T-dep
(	O
eight	T-dep
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	B-Disease
(	O
evident	O
as	O
ataxic	O
movements	T-dep
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	O
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	T-obl
(	O
eight	T-obl
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	T-obl
(	O
evident	O
as	O
ataxic	B-Disease
movements	I-Disease
in	T-nmod
ten	T-nmod
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	O
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	T-conj
nausea	O
(	O
thirteen	O
patients	T-conj
)	O
,	O
emesis	T-conj
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	O
one	T-appos
patient	O
)	O
.	O

No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	T-obj
,	O
and	T-obj
no	O
patients	T-obj
had	O
hallucinations	B-Disease
or	T-conj
nightmares	O
.	O

CONCLUSIONS	T-nsubj
:	O
Ketamine	B-Chemical
reliably	T-nsubj
,	O
safely	T-nsubj
,	O
and	T-nsubj
quickly	T-nsubj
provided	O
adequate	O
sedation	T-nsubj
to	O
effectively	O
facilitate	T-nsubj
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

CONCLUSIONS	O
:	O
Ketamine	O
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	T-nmod
the	T-nmod
reduction	O
of	O
children	O
'	T-nmod:poss
s	T-nmod:poss
fractures	B-Disease
in	O
the	O
emergency	O
department	T-nmod
at	O
our	O
institution	T-nmod
.	O

Ketamine	B-Chemical
should	T-nsubj:pass
only	T-nsubj:pass
be	T-nsubj:pass
used	O
in	O
an	O
environment	T-nsubj:pass
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Cyclosporine	B-Chemical
and	T-conj
tacrolimus	O
-	O
associated	T-conj
thrombotic	T-conj
microangiopathy	O
.	O

Cyclosporine	O
and	O
tacrolimus	B-Chemical
-	O
associated	O
thrombotic	O
microangiopathy	T-obl
.	O

Cyclosporine	O
and	O
tacrolimus	T-amod
-	O
associated	O
thrombotic	B-Disease
microangiopathy	I-Disease
.	O

The	T-nmod
development	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
TMA	O
)	O
associated	T-nmod
with	O
the	O
use	O
of	O
cyclosporine	O
has	O
been	O
well	O
documented	O
.	O

The	O
development	T-dep
of	T-dep
thrombotic	T-dep
microangiopathy	O
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	O
has	O
been	O
well	O
documented	O
.	O

The	O
development	O
of	O
thrombotic	O
microangiopathy	O
(	O
TMA	O
)	O
associated	T-nmod
with	T-nmod
the	T-nmod
use	O
of	O
cyclosporine	B-Chemical
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	T-compound
or	O
reduction	O
of	T-compound
cyclosporine	B-Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

The	O
last	O
decade	O
has	O
seen	T-nmod
the	T-nmod
emergence	O
of	O
tacrolimus	B-Chemical
as	O
a	O
potent	O
immunosuppressive	O
agent	T-nmod
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	O
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	T-nmod
to	T-nmod
those	O
of	O
cyclosporine	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	B-Chemical
has	O
been	O
reported	T-obl
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	O
-	O
induced	O
TMA	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	O
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	T-obl
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	O
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	T-nmod
in	T-nmod
the	T-nmod
setting	O
of	O
cyclosporine	T-amod
-	O
induced	O
TMA	B-Disease
.	O

With	T-nmod
the	T-nmod
more	O
widespread	T-nmod
application	O
of	O
tacrolimus	B-Chemical
in	O
organ	O
transplantation	T-nmod
,	O
tacrolimus	O
-	O
associated	O
TMA	O
has	O
also	O
been	O
recognized	T-nmod
.	O

With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	O
in	O
organ	O
transplantation	O
,	O
tacrolimus	B-Chemical
-	O
associated	O
TMA	T-obl
has	O
also	O
been	O
recognized	O
.	O

With	O
the	O
more	O
widespread	O
application	T-nsubj:pass
of	O
tacrolimus	O
in	O
organ	O
transplantation	O
,	O
tacrolimus	T-amod
-	O
associated	O
TMA	B-Disease
has	T-nsubj:pass
also	T-nsubj:pass
been	T-nsubj:pass
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	T-nmod
of	T-nmod
the	T-nmod
recurrence	O
of	O
TMA	B-Disease
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	O
and	O
tacrolimus	O
is	O
limited	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	O
in	O
patients	T-obl
exposed	O
sequentially	T-obl
to	O
cyclosporine	B-Chemical
and	O
tacrolimus	O
is	O
limited	O
.	O

However	O
,	O
literature	T-conj
regarding	T-conj
the	T-conj
incidence	O
of	O
the	O
recurrence	T-conj
of	O
TMA	O
in	O
patients	T-conj
exposed	O
sequentially	O
to	O
cyclosporine	O
and	O
tacrolimus	B-Chemical
is	O
limited	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	T-obl
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	O
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	T-obj
who	T-obj
developed	O
cyclosporine	T-amod
-	O
induced	O
TMA	B-Disease
that	T-acl:relcl
responded	O
to	O
the	O
withdrawal	T-acl:relcl
of	O
cyclosporine	O
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	O
-	O
induced	O
TMA	O
that	O
responded	T-nmod
to	T-nmod
the	T-nmod
withdrawal	O
of	O
cyclosporine	B-Chemical
in	O
conjunction	T-nmod
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	O
of	O
tacrolimus	B-Chemical
as	O
an	O
alternative	O
immunosuppressive	O
agent	T-nmod
resulted	T-nmod
in	O
the	O
recurrence	O
of	O
TMA	O
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Introduction	O
of	O
tacrolimus	O
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	T-nmod
in	T-nmod
the	T-nmod
recurrence	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
loss	T-nmod
of	O
the	O
renal	O
allograft	O
.	O

Patients	T-obl
who	T-obl
are	T-obl
switched	O
from	O
cyclosporine	B-Chemical
to	O
tacrolimus	T-obl
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	O
.	O

Patients	T-obl
who	T-obl
are	T-obl
switched	O
from	O
cyclosporine	T-obl
to	O
tacrolimus	B-Chemical
or	T-conj
vice	T-conj
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	O
to	O
tacrolimus	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	T-nmod
for	T-nmod
the	T-nmod
signs	O
and	O
symptoms	T-nmod
of	O
recurrent	O
TMA	B-Disease
.	O

Analgesic	T-nmod
effect	O
of	O
intravenous	O
ketamine	B-Chemical
in	O
cancer	O
patients	T-nmod
on	O
morphine	O
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	T-nmod
.	O

Analgesic	O
effect	T-compound
of	O
intravenous	O
ketamine	O
in	T-compound
cancer	B-Disease
patients	O
on	O
morphine	O
therapy	T-compound
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	O
in	O
cancer	O
patients	T-compound
on	T-compound
morphine	B-Chemical
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
not	T-amod
responsive	O
to	O
morphine	T-amod
is	T-nsubj
often	T-nsubj
problematic	O
.	O

Pain	T-obl
not	T-obl
responsive	O
to	O
morphine	B-Chemical
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	O
)	O
antagonists	T-dep
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	T-dep
-	O
methyl	T-dep
-	O
D	T-dep
-	O
aspartate	O
(	O
NMDA	B-Chemical
)	O
antagonists	O
,	O
such	O
as	O
ketamine	T-compound
,	O
may	O
be	O
effective	T-compound
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	T-nmod
)	O
antagonists	O
,	O
such	O
as	T-case
ketamine	B-Chemical
,	O
may	O
be	O
effective	T-nmod
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	T-compound
in	O
improving	O
opioid	O
analgesia	O
in	T-compound
difficult	T-compound
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	T-compound
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	T-nmod
in	O
improving	O
opioid	O
analgesia	O
in	T-nmod
difficult	T-nmod
pain	T-nmod
syndromes	O
,	O
such	O
as	T-case
neuropathic	B-Disease
pain	I-Disease
.	O

A	O
slow	T-nmod
bolus	T-nmod
of	T-nmod
subhypnotic	T-nmod
doses	T-case
of	T-case
ketamine	B-Chemical
(	T-case
0	T-case
.	T-case
25	O
mg	O
/	O
kg	T-case
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-Disease
patients	O
whose	O
pain	T-amod
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	T-obl
25	O
mg	T-obl
/	T-obl
kg	O
or	O
0	T-obl
.	O
50	O
mg	O
/	O
kg	T-amod
)	O
was	O
given	O
to	O
10	O
cancer	T-dep
patients	O
whose	O
pain	B-Disease
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
intensity	O
on	T-compound
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	T-dep
to	T-dep
10	T-dep
numerical	T-dep
scale	O
;	O
nausea	B-Disease
and	T-conj
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	T-conj
dry	T-conj
mouth	O
,	O
using	O
a	O
scale	T-acl
from	T-acl
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	T-conj
;	O
nausea	O
and	O
vomiting	B-Disease
,	O
drowsiness	T-conj
,	O
confusion	T-conj
,	O
and	O
dry	O
mouth	T-conj
,	O
using	T-conj
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	T-conj
;	O
nausea	O
and	O
vomiting	T-conj
,	O
drowsiness	T-conj
,	O
confusion	B-Disease
,	O
and	O
dry	O
mouth	T-conj
,	O
using	T-conj
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	T-conj
;	O
nausea	O
and	O
vomiting	T-conj
,	O
drowsiness	T-conj
,	O
confusion	T-conj
,	O
and	O
dry	B-Disease
mouth	I-Disease
,	O
using	T-conj
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Ketamine	B-Chemical
,	O
but	O
not	T-conj
saline	T-conj
solution	O
,	O
significantly	T-nsubj
reduced	O
the	O
pain	O
intensity	T-nsubj
in	O
almost	O
all	O
the	O
patients	T-nsubj
at	O
both	O
doses	T-nsubj
.	O

Ketamine	O
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	T-compound
the	T-compound
pain	B-Disease
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

Hallucinations	B-Disease
occurred	O
in	O
4	O
patients	T-nsubj
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
"	O
empty	O
head	O
"	O
)	O
was	O
also	O
reported	T-nsubj
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	T-nmod
after	T-nmod
the	T-nmod
administration	O
of	O
diazepam	B-Chemical
1	T-dep
mg	O
intravenously	T-dep
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	T-obl
treated	O
with	O
ketamine	B-Chemical
in	T-nmod
both	T-nmod
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	O
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	T-obl
in	O
patients	O
treated	O
with	O
ketamine	O
in	O
both	O
groups	O
and	T-obl
were	T-obl
more	T-obl
marked	O
with	O
ketamine	B-Chemical
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O

Ketamine	B-Chemical
can	T-nsubj
improve	O
morphine	O
analgesia	T-nsubj
in	O
difficult	O
pain	O
syndromes	T-nsubj
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	O
improve	T-compound
morphine	B-Chemical
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	O
improve	T-compound
morphine	O
analgesia	O
in	T-compound
difficult	T-compound
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	T-compound
.	O

Ketamine	O
can	O
improve	T-nmod
morphine	O
analgesia	O
in	T-nmod
difficult	T-nmod
pain	T-nmod
syndromes	O
,	O
such	O
as	T-case
neuropathic	B-Disease
pain	I-Disease
.	O

This	O
observation	O
should	O
be	O
tested	O
in	O
studies	T-compound
of	T-compound
prolonged	T-compound
ketamine	B-Chemical
administration	O
.	O

Paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	T-conj
gemcitabine	O
combination	T-compound
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-compound
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	T-conj
combination	O
chemotherapy	T-conj
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	T-conj
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	T-conj
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	T-nmod
within	T-nmod
a	T-nmod
multidisciplinary	T-nmod
therapeutic	T-nmod
approach	O
in	O
metastatic	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
-	O
based	O
chemotherapy	O
combinations	T-obl
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O

BACKGROUND	T-obl
:	O
Cisplatin	O
-	O
based	O
chemotherapy	O
combinations	T-obl
improve	O
quality	T-obl
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
-	O
based	O
chemotherapy	O
combinations	O
improve	T-dep
quality	O
of	O
life	O
and	O
survival	O
in	T-dep
advanced	T-dep
nonsmall	T-dep
cell	O
lung	T-dep
carcinoma	O
(	O
NSCLC	B-Disease
)	O
.	O

METHODS	T-conj
:	O
The	O
objective	T-conj
of	O
this	O
study	O
was	T-conj
to	T-conj
determine	O
the	O
feasibility	T-conj
,	O
response	O
rate	T-conj
,	O
and	O
toxicity	B-Disease
of	T-nmod
a	T-nmod
paclitaxel	O
,	O
cisplatin	T-nmod
,	O
and	O
gemcitabine	T-nmod
combination	O
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	T-nmod
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	T-nmod
toxicity	O
of	O
a	O
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	T-conj
gemcitabine	O
combination	T-conj
to	O
treat	T-conj
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	T-conj
of	T-conj
a	T-conj
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	T-conj
combination	O
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	T-conj
of	T-conj
a	T-conj
paclitaxel	O
,	O
cisplatin	T-conj
,	O
and	O
gemcitabine	B-Chemical
combination	O
to	T-xcomp
treat	O
metastatic	O
NSCLC	T-xcomp
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	T-obj
combination	O
to	T-obj
treat	O
metastatic	O
NSCLC	B-Disease
.	O

Thirty	O
-	O
five	T-nmod
consecutive	T-nmod
chemotherapy	O
-	O
naive	T-nmod
patients	O
with	O
Stage	O
IV	O
NSCLC	B-Disease
and	T-conj
an	T-conj
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	T-conj
status	O
of	O
0	O
-	O
2	T-conj
were	O
treated	T-nmod
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	T-nmod
with	T-nmod
a	T-nmod
combination	O
of	O
paclitaxel	B-Chemical
(	O
135	T-dep
mg	O
/	O
m	T-dep
(	O
2	T-dep
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	T-appos
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	T-appos
Day	O
1	T-appos
,	O
cisplatin	B-Chemical
(	O
120	T-dep
mg	O
/	O
m	T-dep
(	O
2	T-dep
)	O
given	T-nmod
intravenously	T-nmod
in	T-nmod
6	T-nmod
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	T-nsubj
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	T-nsubj
gemcitabine	B-Chemical
(	O
800	T-dep
mg	O
/	O
m	T-dep
(	O
2	T-dep
)	O
given	O
intravenously	T-nsubj
in	O
30	O
minutes	T-nsubj
)	O
on	O
Days	T-nsubj
1	O
and	O
8	O
,	O
every	O
4	O
weeks	T-nsubj
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	B-Disease
rates	O
reported	T-compound
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

RESULTS	T-obl
:	O
All	O
the	O
patients	T-obl
were	T-obl
examined	O
for	O
toxicity	B-Disease
;	O
34	O
were	O
examinable	T-obl
for	O
response	O
.	O

There	T-nsubj
was	O
one	O
treatment	T-amod
-	O
related	O
death	B-Disease
.	O

Nonhematologic	O
toxicities	B-Disease
were	T-nsubj
mild	O
.	O

CONCLUSIONS	O
:	O
The	T-nmod
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	T-conj
gemcitabine	O
is	O
well	O
tolerated	T-nmod
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-conj
of	T-conj
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	T-conj
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-conj
of	T-conj
paclitaxel	O
,	O
cisplatin	T-conj
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	T-obl
:	O
The	O
combination	T-obl
of	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	T-obl
well	T-obl
tolerated	O
and	O
shows	T-obl
high	O
activity	T-obl
in	O
metastatic	O
NSCLC	B-Disease
.	O

This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	B-Chemical
-	O
based	O
regimens	T-obl
.	O

Serotonergic	B-Chemical
antidepressants	I-Chemical
and	T-conj
urinary	T-conj
incontinence	O
.	O

Serotonergic	T-conj
antidepressants	O
and	O
urinary	B-Disease
incontinence	I-Disease
.	O

Many	O
new	O
serotonergic	B-Chemical
antidepressants	I-Chemical
have	T-nsubj:pass
been	T-nsubj:pass
introduced	O
over	O
the	O
past	O
decade	T-nsubj:pass
.	O

Although	T-nsubj:pass
urinary	B-Disease
incontinence	I-Disease
is	T-nsubj:pass
listed	O
as	O
one	O
side	O
effect	T-nsubj:pass
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	T-nsubj:pass
there	O
is	T-nsubj:pass
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	T-obj
who	T-obj
experienced	O
incontinence	B-Disease
while	O
taking	T-obj
venlafaxine	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	T-obj
incontinence	O
while	T-obj
taking	O
venlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	T-obj
who	T-obj
developed	O
incontinence	B-Disease
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	T-amod
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	T-obj
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	T-compound
to	T-compound
the	T-compound
selective	T-compound
serotonin	B-Chemical
reuptake	T-compound
inhibitors	O
paroxetine	T-compound
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	T-dep
to	T-dep
the	T-dep
selective	T-dep
serotonin	T-dep
reuptake	T-dep
inhibitors	O
paroxetine	B-Chemical
and	T-conj
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	T-conj
paroxetine	O
and	O
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	T-obl
who	T-obl
developed	O
this	O
side	O
effect	T-obl
on	O
venlafaxine	B-Chemical
.	O

In	O
2	T-obj
of	O
the	O
3	O
cases	O
the	O
patients	T-obj
were	T-obj
also	T-obj
taking	O
lithium	B-Chemical
carbonate	I-Chemical
and	T-conj
beta	T-conj
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	T-obj
to	O
the	O
incontinence	O
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	T-obl
lithium	O
carbonate	O
and	O
beta	O
-	O
blockers	O
,	O
both	T-obl
of	O
which	O
could	T-obl
have	T-obl
contributed	O
to	O
the	O
incontinence	B-Disease
.	O

Animal	O
studies	O
suggest	T-nsubj:pass
that	T-nsubj:pass
incontinence	B-Disease
secondary	O
to	O
serotonergic	O
antidepressants	T-amod
could	T-nsubj:pass
be	T-nsubj:pass
mediated	O
by	O
the	O
5HT4	O
receptors	T-nsubj:pass
found	O
on	O
the	O
bladder	O
.	O

Animal	O
studies	O
suggest	O
that	O
incontinence	T-obl
secondary	O
to	O
serotonergic	B-Chemical
antidepressants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O

Acute	O
cocaine	B-Chemical
-	O
induced	O
seizures	T-obl
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Acute	O
cocaine	T-amod
-	O
induced	O
seizures	B-Disease
:	O
differential	T-dep
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	T-dep
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	T-nmod
for	T-nmod
susceptibility	O
to	O
behavioral	O
seizures	B-Disease
induced	T-nmod
by	O
a	O
single	O
injection	O
of	O
cocaine	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	O
induced	T-nmod
by	T-nmod
a	T-nmod
single	T-nmod
injection	O
of	O
cocaine	B-Chemical
.	O

Cocaine	B-Chemical
was	T-nsubj:pass
injected	O
ip	T-nsubj:pass
over	O
a	O
range	T-nsubj:pass
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	T-nsubj:pass
for	O
20	O
minutes	O
.	O

Seizure	B-Disease
end	O
points	T-compound
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	O
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	O
.	O

Seizure	O
end	O
points	O
included	O
latency	T-nmod
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B-Disease
and	T-conj
latency	O
to	O
jumping	O
bouncing	O
seizure	T-conj
.	O

Seizure	O
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	T-nmod
and	T-nmod
latency	O
to	O
jumping	O
bouncing	O
seizure	B-Disease
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	B-Chemical
determined	T-nmod
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	B-Chemical
-	O
induced	O
seizures	T-obl
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	T-nmod
genetic	T-nmod
influences	O
on	O
cocaine	T-amod
-	O
induced	O
seizures	B-Disease
.	O

Hypotension	B-Disease
following	T-nmod
the	T-nmod
initiation	O
of	O
tizanidine	T-nmod
in	O
a	O
patient	T-nmod
treated	T-nmod
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	T-nmod
following	T-nmod
the	T-nmod
initiation	O
of	O
tizanidine	B-Chemical
in	O
a	O
patient	T-nmod
treated	T-nmod
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-compound
with	T-compound
an	T-compound
angiotensin	B-Chemical
converting	T-compound
enzyme	T-compound
inhibitor	O
for	O
chronic	O
hypertension	T-compound
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-nmod
with	T-nmod
an	T-nmod
angiotensin	T-nmod
converting	T-nmod
enzyme	T-nmod
inhibitor	O
for	O
chronic	O
hypertension	B-Disease
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	T-nmod
in	T-nmod
the	T-nmod
treatment	O
of	O
spasticity	B-Disease
related	T-nmod
to	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	T-obl
of	O
spasticity	O
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

In	O
addition	T-nmod
to	T-nmod
their	T-nmod
effects	O
on	O
spasticity	B-Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	T-nsubj
with	T-nsubj
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitors	T-nsubj
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	O
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
may	O
have	T-obl
a	O
limited	O
ability	O
to	T-obl
respond	O
to	O
hypotension	B-Disease
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	T-obl
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	T-obl
chronically	T-obl
treated	O
with	O
lisinopril	B-Chemical
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	T-compound
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	T-compound
angiotensin	B-Chemical
converting	T-compound
enzyme	T-compound
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	T-obj
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	T-obj
control	O
hypertension	B-Disease
who	T-acl:relcl
developed	O
hypotension	T-acl:relcl
following	O
the	O
addition	T-acl:relcl
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	T-obj
who	T-obj
developed	O
hypotension	B-Disease
following	O
the	O
addition	T-obj
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	T-nmod
hypotension	O
following	T-nmod
the	T-nmod
addition	O
of	O
tizanidine	B-Chemical
,	O
an	T-appos
alpha	T-appos
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	T-nmod
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	T-nmod
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	T-nmod
the	T-nmod
treatment	O
of	O
spasticity	B-Disease
.	O

The	T-nmod
possible	T-nmod
interaction	O
of	O
tizanidine	B-Chemical
and	T-conj
other	T-conj
antihypertensive	T-conj
agents	O
should	O
be	O
kept	T-nmod
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	O
or	O
spasticity	O
in	O
such	O
patients	O
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	T-obj
in	O
mind	O
when	T-obj
prescribing	O
therapy	T-obj
to	T-obj
treat	O
either	O
hypertension	B-Disease
or	T-conj
spasticity	O
in	O
such	O
patients	T-obj
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	T-conj
either	T-conj
hypertension	O
or	O
spasticity	B-Disease
in	O
such	O
patients	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
-	O
induced	O
seizures	T-obl
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
selected	T-nmod
for	T-nmod
differential	T-nmod
sensitivities	O
to	O
beta	O
-	O
carboline	T-amod
-	O
induced	O
seizures	B-Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	O
-	O
carboline	O
-	O
induced	O
seizures	O
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
ligands	T-dep
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	T-nmod
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	T-nmod
resistance	O
(	O
BR	O
line	T-nmod
)	O
to	O
seizures	B-Disease
induced	T-nmod
by	O
a	O
single	O
i	T-dep
.	T-dep
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	B-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	T-dep
.	O

We	O
measured	O
diazepam	B-Chemical
-	O
induced	O
anxiolysis	T-obl
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-Chemical
-	O
induced	O
sedation	T-obl
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	T-compound
the	O
vigilance	O
states	O
,	O
and	T-compound
picrotoxin	B-Chemical
-	O
and	O
pentylenetetrazol	T-compound
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	T-conj
the	O
vigilance	O
states	O
,	O
and	T-conj
picrotoxin	T-conj
-	O
and	O
pentylenetetrazol	B-Chemical
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	T-nmod
,	O
diazepam	O
-	O
induced	T-nmod
sedation	O
by	O
recording	T-amod
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	B-Disease
after	O
i	T-nmod
.	O
p	O
.	O
injections	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	T-nmod
differential	T-nmod
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	T-nmod
to	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extended	T-nmod
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	T-obl
that	T-obl
the	O
differential	O
sensitivities	T-obl
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	T-obl
be	T-obl
extended	O
to	O
diazepam	B-Chemical
,	O
picrotoxin	O
,	O
and	T-conj
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	T-acl
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	T-conj
to	T-conj
diazepam	O
,	O
picrotoxin	B-Chemical
,	O
and	O
pentylenetetrazol	T-conj
,	O
suggesting	T-conj
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	T-conj
to	T-conj
diazepam	O
,	O
picrotoxin	T-conj
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	T-conj
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	T-dep
.	O

Propylthiouracil	B-Chemical
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	T-obl
in	O
conjunction	O
with	O
pericarditis	O
.	O

Propylthiouracil	T-amod
-	O
induced	O
perinuclear	T-compound
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	T-amod
-	O
positive	O
vasculitis	B-Disease
in	T-nmod
conjunction	O
with	O
pericarditis	T-nmod
.	O

Propylthiouracil	O
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	T-nmod
in	T-nmod
conjunction	O
with	O
pericarditis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	B-Chemical
-	O
induced	O
vasculitis	T-obl
manifesting	O
with	O
pericarditis	O
.	O

OBJECTIVE	O
:	O
To	O
describe	T-nmod
a	T-nmod
case	O
of	O
propylthiouracil	T-amod
-	O
induced	O
vasculitis	B-Disease
manifesting	O
with	O
pericarditis	T-acl
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	O
-	O
induced	O
vasculitis	T-obl
manifesting	O
with	O
pericarditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	T-nmod
of	T-nmod
a	T-nmod
woman	O
with	O
hyperthyroidism	B-Disease
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	T-obl
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	B-Chemical
in	O
whom	T-acl:relcl
a	O
syndrome	T-acl:relcl
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	T-nmod
syndrome	O
of	O
pericarditis	B-Disease
,	O
fever	O
,	O
and	T-conj
glomerulonephritis	O
developed	T-nmod
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-conj
of	T-conj
pericarditis	O
,	O
fever	B-Disease
,	O
and	O
glomerulonephritis	T-conj
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-conj
of	T-conj
pericarditis	O
,	O
fever	T-conj
,	O
and	O
glomerulonephritis	B-Disease
developed	O
.	O

RESULTS	O
:	O
A	T-nmod
25	O
-	O
year	O
-	O
old	T-nmod
woman	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
had	T-nmod
a	O
febrile	O
illness	O
and	O
evidence	O
of	O
pericarditis	O
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

RESULTS	T-obj
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	T-obj
with	O
Graves	O
'	O
disease	O
had	O
a	O
febrile	B-Disease
illness	I-Disease
and	T-conj
evidence	O
of	O
pericarditis	T-conj
,	O
which	O
was	O
confirmed	T-obj
by	O
biopsy	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	O
'	O
disease	O
had	O
a	O
febrile	O
illness	T-nmod
and	T-nmod
evidence	O
of	O
pericarditis	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

Propylthiouracil	B-Chemical
therapy	O
was	O
withdrawn	T-compound
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	O
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

Propylthiouracil	O
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	T-nmod
with	T-nmod
a	T-nmod
1	O
-	O
month	T-nmod
course	O
of	O
prednisone	B-Chemical
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	T-nmod
no	T-nmod
prior	T-nmod
reports	O
of	O
pericarditis	B-Disease
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	T-nmod
associated	T-nmod
with	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

A	O
literature	O
review	O
revealed	T-nmod
no	T-nmod
prior	T-nmod
reports	O
of	O
pericarditis	T-nmod
in	O
anti	T-compound
-	O
MPO	O
pANCA	T-amod
-	O
positive	O
vasculitis	B-Disease
associated	T-nmod
with	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	O
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	O
associated	T-compound
with	T-compound
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O

CONCLUSION	T-nsubj
:	O
Pericarditis	B-Disease
may	T-nsubj
be	T-nsubj
the	T-nsubj
initial	T-nsubj
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	T-nsubj
attributable	O
to	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

CONCLUSION	T-nmod
:	O
Pericarditis	T-nmod
may	T-nmod
be	T-nmod
the	T-nmod
initial	T-nmod
manifestation	O
of	O
drug	T-amod
-	O
induced	O
vasculitis	B-Disease
attributable	O
to	O
propylthio	O
-	O
uracil	O
therapy	T-amod
.	O

CONCLUSION	O
:	O
Pericarditis	O
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	O
attributable	T-compound
to	T-compound
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O

Repeated	O
transient	O
anuria	B-Disease
following	T-nmod
losartan	T-nmod
administration	O
in	T-nmod
a	T-nmod
patient	O
with	O
a	O
solitary	O
kidney	T-nmod
.	O

Repeated	O
transient	O
anuria	T-compound
following	T-compound
losartan	B-Chemical
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	T-amod
of	T-amod
a	T-amod
70	O
-	O
year	O
-	O
old	T-amod
hypertensive	B-Disease
man	O
with	O
a	O
solitary	O
kidney	T-amod
and	O
chronic	O
renal	O
insufficiency	O
who	O
developed	T-amod
two	O
episodes	O
of	O
transient	O
anuria	O
after	O
losartan	O
administration	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	T-conj
with	T-conj
a	T-conj
solitary	T-conj
kidney	O
and	O
chronic	B-Disease
renal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	O
after	O
losartan	O
administration	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	O
renal	O
insufficiency	O
who	O
developed	T-nmod
two	T-nmod
episodes	O
of	O
transient	O
anuria	B-Disease
after	O
losartan	O
administration	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	O
renal	O
insufficiency	O
who	O
developed	T-compound
two	O
episodes	O
of	O
transient	O
anuria	O
after	T-compound
losartan	B-Chemical
administration	O
.	O

He	T-obl
was	T-obl
hospitalized	O
for	O
a	O
myocardial	B-Disease
infarction	I-Disease
with	T-nmod
pulmonary	T-nmod
edema	O
,	O
treated	T-obl
with	O
high	O
-	O
dose	O
diuretics	O
.	O

He	O
was	O
hospitalized	T-nmod
for	T-nmod
a	T-nmod
myocardial	T-nmod
infarction	O
with	O
pulmonary	B-Disease
edema	I-Disease
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

Due	O
to	T-case
severe	O
systolic	B-Disease
dysfunction	I-Disease
losartan	B-Chemical
was	T-obl
prescribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	T-nmod
of	T-nmod
50	T-nmod
mg	O
of	O
losartan	B-Chemical
resulted	O
in	O
a	O
sudden	O
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

Surprisingly	T-obl
,	O
the	O
first	O
dose	T-obl
of	O
50	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	O
anuria	B-Disease
,	O
which	T-acl:relcl
lasted	O
eight	O
hours	T-acl:relcl
despite	O
high	O
-	O
dose	O
furosemide	T-acl:relcl
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	O
anuria	T-obl
,	O
which	T-obl
lasted	O
eight	O
hours	T-obl
despite	O
high	T-compound
-	O
dose	O
furosemide	B-Chemical
and	T-conj
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	O
anuria	O
,	O
which	O
lasted	T-conj
eight	O
hours	O
despite	T-conj
high	O
-	O
dose	T-conj
furosemide	O
and	O
amine	B-Chemical
infusion	T-conj
.	O

One	O
week	O
later	T-nsubj:pass
,	O
by	O
mistake	T-nsubj:pass
,	O
losartan	B-Chemical
was	T-nsubj:pass
prescribed	O
again	T-nsubj:pass
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	T-nsubj:pass
a	O
second	O
episode	O
of	O
transient	O
anuria	O
lasting	O
10	O
hours	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	O
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	T-nmod
a	T-nmod
second	T-nmod
episode	O
of	O
transient	O
anuria	B-Disease
lasting	T-nmod
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	T-nsubj:pass
but	T-nsubj:pass
no	O
severe	O
hypotension	B-Disease
was	T-nsubj:pass
noted	O
.	O

In	O
this	O
patient	T-nsubj
,	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
combined	O
with	O
heart	O
failure	T-nsubj
and	O
diuretic	O
therapy	O
certainly	O
resulted	T-nsubj
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O

In	O
this	O
patient	T-obl
,	O
renal	O
artery	O
stenosis	T-obl
combined	O
with	O
heart	B-Disease
failure	I-Disease
and	T-conj
diuretic	T-conj
therapy	O
certainly	O
resulted	T-obl
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O

In	O
this	O
patient	O
,	O
renal	O
artery	O
stenosis	O
combined	O
with	O
heart	O
failure	O
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	T-compound
of	T-compound
the	T-compound
renin	O
-	O
angiotensin	B-Chemical
system	O
(	O
RAS	T-compound
)	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	B-Chemical
II	I-Chemical
receptor	T-compound
blockade	O
by	O
losartan	T-compound
probably	O
induced	T-compound
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	T-nmod
II	O
receptor	T-nmod
blockade	O
by	O
losartan	B-Chemical
probably	O
induced	T-nmod
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	T-compound
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	T-compound
losartan	O
can	O
cause	T-compound
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	O
disease	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	T-nsubj
that	T-nsubj
the	O
angiotensin	O
II	T-compound
receptor	T-compound
antagonist	O
losartan	B-Chemical
can	T-nsubj
cause	O
serious	O
unexpected	O
complications	T-nsubj
in	O
patients	O
with	O
renovascular	O
disease	O
and	O
should	O
be	O
used	T-nsubj
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
losartan	O
can	O
cause	O
serious	O
unexpected	O
complications	T-nmod
in	T-nmod
patients	O
with	O
renovascular	B-Disease
disease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	T-compound
pain	B-Disease
syndrome	O
(	O
CIPS	T-compound
)	O
:	O
a	O
severe	O
disabling	O
complication	T-compound
after	O
organ	O
transplantation	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	T-dep
pain	T-dep
syndrome	O
(	O
CIPS	B-Disease
)	O
:	O
a	O
severe	O
disabling	O
complication	T-dep
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	B-Disease
after	T-nmod
transplantation	O
is	T-nsubj
a	T-nsubj
frequent	T-nsubj
complication	O
that	O
can	O
be	O
caused	T-nsubj
by	O
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	T-nmod
on	T-nmod
the	T-nmod
correct	T-nmod
diagnosis	O
of	O
the	O
pain	B-Disease
.	O

Nine	T-nmod
patients	O
with	O
severe	O
pain	B-Disease
in	O
their	O
feet	T-nmod
,	O
which	O
was	O
registered	T-nmod
after	O
transplantation	O
,	O
were	O
investigated	T-nmod
.	O

Magnetic	O
resonance	O
imaging	T-obj
demonstrated	O
bone	B-Disease
marrow	I-Disease
oedema	I-Disease
in	O
the	O
painful	O
bones	T-obj
.	O

Pain	B-Disease
was	T-nsubj:pass
not	T-nsubj:pass
explained	O
by	O
other	O
diseases	T-nsubj:pass
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-obj
causing	O
foot	O
pain	B-Disease
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-nmod
by	T-nmod
other	T-nmod
diseases	O
causing	T-nmod
foot	O
pain	O
,	O
like	O
reflex	B-Disease
sympathetic	I-Disease
dystrophy	I-Disease
,	O
polyneuropathy	O
,	O
Morton	T-conj
'	O
s	T-conj
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	T-conj
necrosis	O
,	O
intermittent	T-conj
claudication	O
,	O
orthopaedic	T-conj
foot	T-conj
deformities	O
,	O
stress	T-conj
fractures	O
,	O
and	T-conj
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	B-Disease
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	B-Disease
'	I-Disease
s	I-Disease
neuralgia	I-Disease
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	B-Disease
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	B-Disease
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	B-Disease
necrosis	I-Disease
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	B-Disease
claudication	I-Disease
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	B-Disease
deformities	I-Disease
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	B-Disease
fractures	I-Disease
,	O
and	O
hyperparathyroidism	T-conj
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-conj
causing	O
foot	O
pain	O
,	O
like	T-conj
reflex	T-conj
sympathetic	T-conj
dystrophy	O
,	O
polyneuropathy	T-conj
,	O
Morton	O
'	O
s	O
neuralgia	T-conj
,	O
gout	T-conj
,	O
osteoporosis	T-conj
,	O
avascular	O
necrosis	T-conj
,	O
intermittent	O
claudication	T-conj
,	O
orthopaedic	O
foot	O
deformities	T-conj
,	O
stress	O
fractures	T-conj
,	O
and	O
hyperparathyroidism	B-Disease
.	O

The	O
reduction	O
of	O
cyclosporine	B-Chemical
-	O
or	O
tacrolimus	T-compound
trough	O
levels	T-compound
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
reduction	O
of	O
cyclosporine	T-conj
-	O
or	O
tacrolimus	B-Chemical
trough	O
levels	T-conj
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	B-Chemical
channel	O
blockers	T-compound
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	T-nmod
to	T-nmod
relief	O
of	O
pain	B-Disease
.	O

The	T-compound
Calcineurin	O
-	O
inhibitor	T-compound
Induced	T-compound
Pain	B-Disease
Syndrome	O
(	O
CIPS	T-compound
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	T-compound
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	T-dep
Calcineurin	O
-	O
inhibitor	T-dep
Induced	T-dep
Pain	T-dep
Syndrome	O
(	O
CIPS	B-Disease
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	T-dep
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	O
Syndrome	T-nmod
(	O
CIPS	O
)	O
is	T-nmod
a	T-nmod
rare	T-nmod
but	O
severe	O
side	T-nmod
effect	O
of	O
cyclosporine	B-Chemical
or	T-conj
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	T-nmod
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	T-conj
of	T-conj
cyclosporine	O
or	O
tacrolimus	B-Chemical
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	T-obl
suffering	O
from	O
CIPS	B-Disease
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	T-obl
.	O

Brain	O
natriuretic	O
peptide	T-nmod
is	T-nmod
a	T-nmod
predictor	O
of	O
anthracycline	T-amod
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Anthracyclines	B-Chemical
are	T-nsubj
effective	T-nsubj
antineoplastic	T-nsubj
drugs	O
,	O
but	O
they	O
frequently	O
cause	T-nsubj
dose	O
-	O
related	O
cardiotoxicity	O
.	O

Anthracyclines	O
are	O
effective	O
antineoplastic	O
drugs	T-obj
,	O
but	T-obj
they	T-obj
frequently	T-obj
cause	O
dose	T-amod
-	O
related	O
cardiotoxicity	B-Disease
.	O

The	O
cardiotoxicity	B-Disease
of	T-nmod
conventional	T-nmod
anthracycline	T-nmod
therapy	O
highlights	O
a	O
need	T-nsubj
to	O
search	T-nsubj
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	O
dysfunction	O
.	O

The	O
cardiotoxicity	T-compound
of	T-compound
conventional	T-compound
anthracycline	B-Chemical
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	O
dysfunction	O
.	O

The	O
cardiotoxicity	O
of	O
conventional	O
anthracycline	O
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	T-obl
and	T-obl
capable	O
of	O
predicting	O
cardiac	B-Disease
dysfunction	I-Disease
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	T-obl
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	T-nmod
as	T-nmod
a	T-nmod
simple	T-nmod
diagnostic	T-nmod
indicator	O
of	O
anthracycline	T-amod
-	O
induced	O
cardiotoxicity	B-Disease
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	T-nmod
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	T-nmod
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
treated	T-nmod
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	B-Chemical
(	O
DNR	O
)	O
-	O
containing	T-dep
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	B-Chemical
)	O
-	O
containing	O
regimen	T-dep
.	O

Thirteen	T-nmod
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
were	O
treated	T-nmod
with	O
a	O
DNR	O
-	O
containing	O
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	O
leukemia	O
were	O
treated	O
with	O
a	O
DNR	B-Chemical
-	O
containing	O
regimen	T-obl
.	O

Three	O
patients	T-obj
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	T-obj
of	O
chemotherapy	O
.	O

Five	O
patients	T-obl
were	T-obl
diagnosed	O
as	O
having	O
subclinical	O
heart	B-Disease
failure	I-Disease
after	O
the	O
completion	T-obl
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	T-nmod
of	O
BNP	O
in	T-nmod
all	T-nmod
the	T-nmod
patients	O
with	O
clinical	O
and	O
subclinical	T-amod
heart	B-Disease
failure	I-Disease
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	O
failure	O
by	O
radionuclide	O
angiography	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	O
failure	O
increased	T-nmod
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	T-nmod
the	T-nmod
detection	O
of	O
clinical	O
or	O
subclinical	T-amod
heart	B-Disease
failure	I-Disease
by	O
radionuclide	O
angiography	T-nmod
.	O

On	O
the	O
other	O
hand	T-obl
,	O
BNP	T-obl
did	T-obl
not	T-obl
increase	O
in	O
the	O
patients	T-obl
without	O
heart	B-Disease
failure	I-Disease
given	T-nmod
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	T-obl
/	O
m	O
(	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	T-nmod
in	O
the	O
patients	O
without	T-nmod
heart	T-nmod
failure	O
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	T-nmod
in	T-nmod
all	T-nmod
the	T-nmod
patients	O
with	O
clinical	O
and	O
subclinical	T-amod
heart	B-Disease
failure	I-Disease
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	T-obl
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	T-nmod
as	T-nmod
an	T-nmod
early	T-nmod
and	O
sensitive	O
indicator	O
of	O
anthracycline	T-amod
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Nephrotoxicity	B-Disease
of	T-nmod
combined	T-nmod
cephalothin	O
-	O
gentamicin	T-nmod
regimen	O
.	O

Nephrotoxicity	O
of	O
combined	O
cephalothin	B-Chemical
-	O
gentamicin	O
regimen	T-compound
.	O

Nephrotoxicity	T-compound
of	T-compound
combined	T-compound
cephalothin	O
-	O
gentamicin	B-Chemical
regimen	O
.	O

Two	O
patients	T-obj
developed	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	T-obj
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	T-obj
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	O
.	O

Two	O
patients	O
developed	T-obl
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	T-obl
by	O
acute	O
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	O
.	O

Two	O
patients	O
developed	O
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	T-nmod
a	T-nmod
combination	O
of	O
cephalothin	B-Chemical
sodium	I-Chemical
and	T-conj
gentamicin	T-conj
sulfate	O
therapy	O
.	O

Two	O
patients	O
developed	O
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	T-conj
of	T-conj
cephalothin	T-conj
sodium	O
and	O
gentamicin	B-Chemical
sulfate	I-Chemical
therapy	T-conj
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	T-nmod
very	O
carefully	O
for	T-nmod
early	T-nmod
signs	O
of	O
nephrotoxicity	B-Disease
.	O

Patients	O
with	O
renal	B-Disease
insufficiency	I-Disease
should	O
not	O
be	O
given	T-nmod
this	O
regimen	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B-Disease
cell	O
deaths	T-conj
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	B-Chemical
-	O
induced	O
nephrotoxicity	T-obl
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	T-nmod
associated	T-nmod
apoptotic	T-nmod
and	O
necrotic	O
cell	T-nmod
deaths	O
during	O
acetaminophen	T-amod
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	O
-	O
induced	T-conj
lung	T-conj
toxicity	O
and	T-conj
doxorubicin	O
-	O
induced	T-conj
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	T-nmod
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	B-Chemical
-	O
induced	O
lung	O
toxicity	T-obl
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	T-conj
during	T-conj
acetaminophen	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
amiodarone	T-amod
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	T-conj
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	T-obl
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	T-conj
during	T-conj
acetaminophen	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	T-conj
and	O
doxorubicin	T-amod
-	O
induced	O
cardiotoxicity	B-Disease
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	T-nmod
associated	T-nmod
apoptotic	T-nmod
and	O
necrotic	O
cell	T-nmod
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	T-nmod
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O

Grape	B-Chemical
seed	I-Chemical
extract	I-Chemical
,	O
primarily	T-appos
a	T-appos
mixture	O
of	O
proanthocyanidins	T-appos
,	O
has	T-nsubj:pass
been	T-nsubj:pass
shown	O
to	O
modulate	T-nsubj:pass
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

Grape	O
seed	O
extract	T-nmod
,	O
primarily	T-nmod
a	T-nmod
mixture	O
of	O
proanthocyanidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	T-nmod
the	T-nmod
ability	O
of	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-dep
of	T-dep
IH636	O
grape	O
seed	T-dep
proanthocyanidin	T-dep
extract	O
(	O
GSPE	B-Chemical
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	B-Chemical
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	T-obl
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	B-Chemical
)	O
-	O
induced	T-appos
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	T-amod
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-conj
lung	T-conj
toxicity	O
,	O
and	T-conj
doxorubicin	O
(	O
DOX	T-conj
)	O
-	O
induced	O
cardiotoxicity	T-obl
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	B-Chemical
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	T-obl
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	B-Chemical
)	O
-	O
induced	T-appos
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
amiodarone	T-amod
(	O
AMI	O
)	O
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	T-conj
(	O
DOX	O
)	O
-	O
induced	T-conj
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	T-conj
,	O
and	O
doxorubicin	B-Chemical
(	O
DOX	O
)	O
-	O
induced	T-conj
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	T-appos
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	T-appos
doxorubicin	O
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	T-obj
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-obj
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	T-amod
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	T-obj
.	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	T-appos
:	O
control	O
(	O
vehicle	T-appos
alone	O
)	O
,	O
GSPE	B-Chemical
alone	O
,	O
drug	O
alone	T-conj
and	T-conj
GSPE	T-conj
+	O
drug	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	T-amod
alone	O
,	O
drug	O
alone	O
and	T-amod
GSPE	B-Chemical
+	O
drug	O

For	O
the	O
cytoprotection	O
study	T-obj
,	O
animals	T-obj
were	T-obj
orally	T-obj
gavaged	O
100	T-compound
mg	T-case
/	O
Kg	T-compound
GSPE	B-Chemical
for	T-case
7	T-compound
-	O
10	T-case
days	T-obj
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	T-dep
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	B-Chemical
:	T-nmod
500	O
mg	T-nmod
/	T-nmod
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	O
prior	O
to	O
AAP	T-compound
,	O
AMI	O
and	O
DOX	O
,	O
provided	T-compound
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	T-nmod
preexposure	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	O
and	T-conj
DOX	O
,	O
provided	T-nmod
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-conj
prior	T-conj
to	T-conj
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	T-conj
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-conj
prior	T-conj
to	T-conj
AAP	O
,	O
AMI	T-conj
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	T-obl
moderate	O
to	O
massive	O
tissue	B-Disease
damage	I-Disease
with	T-nmod
a	T-nmod
variety	O
of	O
morphological	O
aberrations	T-nmod
by	O
all	O
the	O
three	O
drugs	T-nmod
in	O
the	O
absence	T-nmod
of	O
GSPE	O
preexposure	O
than	O
in	O
its	O
presence	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	O
damage	O
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	T-compound
of	T-compound
GSPE	B-Chemical
preexposure	O
than	O
in	O
its	O
presence	O
.	O

GSPE	B-Chemical
+	O
drug	O
exposed	T-compound
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O

Interestingly	O
,	O
all	O
the	O
drugs	T-nsubj
,	O
such	T-nsubj
as	O
,	O
AAP	B-Chemical
,	O
AMI	O
and	T-conj
DOX	O
induced	O
apoptotic	O
death	T-nsubj
in	O
addition	T-nsubj
to	O
necrosis	O
in	O
the	O
respective	O
organs	T-nsubj
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	T-conj
induced	T-conj
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	T-conj
and	O
DOX	B-Chemical
induced	T-conj
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	T-nmod
apoptotic	O
death	O
in	T-nmod
addition	O
to	O
necrosis	B-Disease
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	T-obl
which	T-obl
was	T-obl
very	O
effectively	T-obl
blocked	O
by	O
GSPE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	O
AMI	T-obl
and	O
DOX	O
undergo	O
biotransformation	T-obl
and	O
are	O
known	T-obl
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	T-obl
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	T-nsubj
,	O
AMI	B-Chemical
and	T-conj
DOX	O
undergo	O
biotransformation	T-nsubj
and	O
are	O
known	T-nsubj
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	T-nsubj
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
undergo	T-conj
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	T-nmod
protection	O
by	O
GSPE	B-Chemical
may	O
be	O
linked	T-nmod
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	B-Chemical
-	O
induced	O
apoptotic	O
death	T-obl
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	T-nmod:poss
GSPE	B-Chemical
'	O
s	O
abundant	T-nmod:poss
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Antidepressant	B-Chemical
-	O
induced	O
mania	T-obl
in	O
bipolar	O
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

Antidepressant	T-amod
-	O
induced	O
mania	B-Disease
in	T-nmod
bipolar	T-nmod
patients	O
:	O
identification	O
of	O
risk	O
factors	T-dep
.	O

Antidepressant	O
-	O
induced	O
mania	T-amod
in	T-amod
bipolar	B-Disease
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	T-obl
of	T-obl
switching	O
to	O
mania	B-Disease
associated	O
with	O
antidepressants	O
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	O
depression	O
.	O

BACKGROUND	O
:	O
Concerns	T-obl
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	O
associated	O
with	O
antidepressants	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	O
depression	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	O
associated	O
with	O
antidepressants	O
continue	O
to	O
interfere	O
with	O
the	O
establishment	T-nmod
of	T-nmod
an	T-nmod
optimal	T-nmod
treatment	T-nmod
paradigm	O
for	O
bipolar	B-Disease
depression	I-Disease
.	O

METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	T-obl
meeting	O
DSM	O
-	O
IV	O
criteria	T-obl
for	O
bipolar	B-Disease
disorder	I-Disease
to	O
naturalistic	O
treatment	T-obl
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	O
who	T-conj
experienced	T-nmod
a	T-nmod
manic	B-Disease
or	T-nmod
hypomanic	T-nmod
switch	T-cc
were	T-nmod
compared	T-conj
with	T-nmod
those	O
who	T-advmod
did	O
not	T-nmod
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	T-conj
who	O
experienced	T-det
a	T-det
manic	T-det
or	T-det
hypomanic	B-Disease
switch	T-amod
were	T-det
compared	T-amod
with	T-det
those	O
who	T-cc
did	O
not	T-amod
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	T-nmod
not	T-nmod
on	T-nmod
several	T-nmod
variables	T-det
including	T-nmod
age	T-dep
,	T-amod
sex	T-dep
,	O
diagnosis	T-compound
(	T-dep
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-Chemical
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	B-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	B-Chemical
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Sex	T-conj
,	T-aux
age	O
,	O
diagnosis	O
(	O
bipolar	B-Disease
I	I-Disease
vs	T-aux
.	T-conj
bipolar	O
II	T-aux
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

Sex	O
,	T-obj
age	O
,	O
diagnosis	O
(	O
bipolar	O
I	T-obj
vs	T-obj
.	O
bipolar	B-Disease
II	I-Disease
)	T-nmod
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

The	O
number	T-amod
of	T-amod
previous	T-amod
manic	B-Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	T-compound
with	T-compound
acute	T-compound
antidepressant	B-Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	O
therapy	O
may	O
be	O
reduced	T-compound
by	T-compound
lithium	B-Chemical
treatment	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	T-conj
in	T-conj
allografts	O
and	O
native	O
kidney	B-Disease
disease	I-Disease
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	T-obl
:	O
An	O
association	T-obl
has	T-obl
been	T-obl
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	O
)	O
and	T-conj
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	T-conj
(	O
PTCR	T-conj
)	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	T-dep
between	T-dep
transplant	T-dep
glomerulopathy	O
(	O
TG	B-Disease
)	O
and	O
reduplication	T-dep
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

In	O
addition	T-nmod
to	T-nmod
renal	T-nmod
allografts	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	O
,	O
chronic	O
allograft	O
nephropathy	O
and	O
stable	O
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	O
,	O
we	O
also	O
examined	T-conj
grafts	O
with	T-conj
acute	T-conj
rejection	O
,	O
recurrent	O
glomerulonephritis	B-Disease
,	O
chronic	O
allograft	O
nephropathy	T-conj
and	O
stable	O
grafts	T-conj
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	O
,	O
we	O
also	O
examined	T-conj
grafts	O
with	T-conj
acute	T-conj
rejection	O
,	O
recurrent	O
glomerulonephritis	T-conj
,	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
and	O
stable	O
grafts	T-conj
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	T-nmod
a	T-nmod
wide	T-nmod
range	O
of	O
glomerulopathies	B-Disease
as	O
well	O
as	O
cases	T-nmod
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	T-nmod
of	O
glomerulopathies	O
as	T-nmod
well	O
as	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	T-conj
hypertension	O
,	O
acute	T-conj
interstitial	T-conj
nephritis	O
,	O
and	T-conj
acute	T-conj
tubular	T-conj
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-conj
of	T-conj
thrombotic	T-conj
microangiopathy	O
,	O
malignant	B-Disease
hypertension	I-Disease
,	O
acute	O
interstitial	O
nephritis	T-conj
,	O
and	O
acute	O
tubular	O
necrosis	T-conj
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-conj
of	T-conj
thrombotic	T-conj
microangiopathy	O
,	O
malignant	O
hypertension	T-conj
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	O
tubular	O
necrosis	T-conj
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-conj
of	T-conj
thrombotic	T-conj
microangiopathy	O
,	O
malignant	O
hypertension	T-conj
,	O
acute	O
interstitial	O
nephritis	T-conj
,	O
and	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O

RESULTS	O
:	O
We	O
found	T-nmod
PTCR	O
in	T-nmod
14	O
of	O
15	T-nmod
cases	O
of	O
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	O
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

RESULTS	O
:	O
We	O
found	T-nmod
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	O
,	O
in	T-nmod
7	O
transplant	T-nmod
biopsy	T-nmod
specimens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	T-nmod
cases	O
of	O
malignant	B-Disease
hypertension	I-Disease
,	O
thrombotic	T-conj
microangiopathy	O
,	O
lupus	T-conj
nephritis	O
,	O
Henoch	O
-	O
Schonlein	T-conj
nephritis	O
,	O
crescentic	T-conj
glomerulonephritis	O
,	O
and	T-conj
cocaine	O
-	O
related	T-conj
acute	T-conj
renal	T-conj
failure	O
.	O

These	O
13	O
included	O
cases	T-conj
of	T-conj
malignant	T-conj
hypertension	O
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
lupus	O
nephritis	T-conj
,	O
Henoch	O
-	O
Schonlein	O
nephritis	T-conj
,	O
crescentic	O
glomerulonephritis	T-conj
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	T-conj
.	O

These	O
13	O
included	O
cases	T-conj
of	T-conj
malignant	T-conj
hypertension	O
,	O
thrombotic	O
microangiopathy	T-conj
,	O
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch	O
-	O
Schonlein	O
nephritis	T-conj
,	O
crescentic	O
glomerulonephritis	T-conj
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	T-conj
.	O

These	O
13	O
included	O
cases	T-conj
of	T-conj
malignant	T-conj
hypertension	O
,	O
thrombotic	O
microangiopathy	T-conj
,	O
lupus	O
nephritis	T-conj
,	O
Henoch	B-Disease
-	I-Disease
Schonlein	I-Disease
nephritis	I-Disease
,	O
crescentic	O
glomerulonephritis	T-conj
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	T-conj
.	O

These	O
13	O
included	O
cases	T-conj
of	T-conj
malignant	T-conj
hypertension	O
,	O
thrombotic	O
microangiopathy	T-conj
,	O
lupus	O
nephritis	T-conj
,	O
Henoch	O
-	O
Schonlein	O
nephritis	T-conj
,	O
crescentic	O
glomerulonephritis	B-Disease
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	T-conj
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	B-Chemical
-	O
related	O
acute	O
renal	O
failure	T-obl
.	O

These	O
13	O
included	O
cases	T-conj
of	T-conj
malignant	T-conj
hypertension	O
,	O
thrombotic	O
microangiopathy	T-conj
,	O
lupus	O
nephritis	T-conj
,	O
Henoch	O
-	O
Schonlein	O
nephritis	T-conj
,	O
crescentic	O
glomerulonephritis	T-conj
,	O
and	O
cocaine	T-amod
-	O
related	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Mild	T-nmod
PTCR	O
in	O
allografts	T-nmod
without	O
TG	B-Disease
did	O
not	O
predict	T-nmod
renal	O
failure	O
or	O
significant	O
proteinuria	O
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

Mild	O
PTCR	T-obj
in	O
allografts	O
without	O
TG	O
did	T-obj
not	T-obj
predict	O
renal	B-Disease
failure	I-Disease
or	T-conj
significant	T-conj
proteinuria	O
after	O
follow	O
-	O
up	O
periods	T-obj
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	O
did	O
not	O
predict	T-conj
renal	T-conj
failure	O
or	O
significant	O
proteinuria	B-Disease
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	T-conj
between	T-conj
well	O
-	O
developed	T-conj
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	O
is	O
unclear	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	O
,	O
while	O
the	O
significance	T-nmod
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	T-nmod
the	T-nmod
absence	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

PTCR	T-obl
also	T-obl
occurs	O
in	O
certain	O
native	O
kidney	B-Disease
diseases	I-Disease
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	T-obl
as	O
that	O
for	O
TG	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	O
diseases	O
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	T-nmod
as	T-nmod
that	O
for	O
TG	B-Disease
.	O

We	O
suggest	T-nsubj
that	T-nsubj
repeated	O
endothelial	B-Disease
injury	I-Disease
,	O
including	T-nmod
immunologic	T-nmod
injury	O
,	O
may	T-nsubj
be	T-nsubj
the	T-nsubj
cause	O
of	O
this	O
lesion	T-nsubj
both	O
in	O
allografts	T-nsubj
and	O
native	O
kidneys	O
.	O

We	O
suggest	O
that	O
repeated	T-nmod
endothelial	T-nmod
injury	O
,	O
including	O
immunologic	B-Disease
injury	I-Disease
,	O
may	O
be	O
the	O
cause	T-nmod
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Caffeine	B-Chemical
-	O
induced	O
cardiac	O
arrhythmia	T-obl
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

Caffeine	T-amod
-	O
induced	O
cardiac	B-Disease
arrhythmia	I-Disease
:	O
an	T-dep
unrecognised	T-dep
danger	O
of	O
healthfood	O
products	T-dep
.	O

We	O
describe	T-nmod
a	T-nmod
25	O
-	O
year	O
-	O
old	T-nmod
woman	O
with	O
pre	T-amod
-	O
existing	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	T-acl:relcl
developed	O
intractable	O
ventricular	O
fibrillation	T-acl:relcl
after	O
consuming	T-acl:relcl
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	O
valve	O
prolapse	T-obj
who	T-obj
developed	O
intractable	O
ventricular	B-Disease
fibrillation	I-Disease
after	O
consuming	T-obj
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	O
valve	O
prolapse	O
who	O
developed	O
intractable	O
ventricular	O
fibrillation	O
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	T-nmod
a	T-nmod
high	T-nmod
concentration	O
of	O
caffeine	B-Chemical
.	O

Conformationally	O
restricted	T-nmod
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	T-nmod
produce	T-nmod
anti	O
-	O
cocaine	O
effects	O
in	O
mice	O
.	O

Conformationally	O
restricted	O
analogs	T-amod
of	O
BD1008	O
and	T-amod
an	T-amod
antisense	T-amod
oligodeoxynucleotide	B-Chemical
targeting	T-amod
sigma1	T-amod
receptors	O
produce	O
anti	O
-	O
cocaine	O
effects	O
in	O
mice	O
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	O
produce	T-compound
anti	O
-	O
cocaine	B-Chemical
effects	O
in	O
mice	O
.	O

Cocaine	B-Chemical
'	O
s	T-nmod:poss
ability	O
to	O
interact	T-nmod:poss
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	T-parataxis
,	O
three	O
novel	O
sigma	O
receptor	T-compound
ligands	T-parataxis
with	O
antagonist	O
activity	O
were	T-compound
evaluated	T-compound
in	T-nummod
Swiss	T-compound
Webster	T-nummod
mice	T-parataxis
:	O
BD1018	B-Chemical
(	T-compound
3S	T-parataxis
-	O
1	T-compound
-	T-compound
[	O
2	T-compound
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O

Therefore	T-conj
,	O
three	T-appos
novel	O
sigma	T-appos
receptor	T-conj
ligands	T-conj
with	T-nummod
antagonist	T-nummod
activity	O
were	T-dep
evaluated	T-compound
in	O
Swiss	O
Webster	T-nummod
mice	T-compound
:	O
BD1018	T-dep
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	T-nummod
,	O
BD1063	T-nummod
(	O
1	O
-	O
[	O
2	O
-	T-dep
(	T-dep
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	T-nmod
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	T-nmod
diazabicyclo	T-nmod
[	O
4	O
.	O
3	O
.	O
0	O
]	T-compound
nonane	O
)	O
,	O
BD1063	B-Chemical
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	T-appos
4	O
-	O
dichlorophenyl	O
)	T-compound
ethyl	O
]	O
-	O
1	O
,	T-compound
4	O
-	O
diazabicyclo	O
[	O
4	T-compound
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazine	I-Chemical
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	T-compound
negligible	O
affinities	O
for	O
dopamine	B-Chemical
,	O
opioid	O
,	O
GABA	O
(	O
A	T-conj
)	O
and	T-conj
NMDA	O
receptors	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	T-conj
dopamine	O
,	O
opioid	T-conj
,	O
GABA	B-Chemical
(	O
A	O
)	O
and	O
NMDA	T-conj
receptors	T-conj
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	T-conj
dopamine	O
,	O
opioid	T-conj
,	O
GABA	T-conj
(	O
A	O
)	O
and	O
NMDA	B-Chemical
receptors	T-conj
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	T-nmod
of	T-nmod
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	O
,	O
or	T-conj
LR132	O
significantly	O
attenuated	O
cocaine	O
-	O
induced	O
convulsions	T-conj
and	O
lethality	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	T-conj
with	T-conj
BD1018	O
,	O
BD1063	B-Chemical
,	O
or	O
LR132	T-conj
significantly	O
attenuated	O
cocaine	O
-	O
induced	O
convulsions	O
and	O
lethality	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	T-conj
with	T-conj
BD1018	O
,	O
BD1063	T-conj
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	T-obj
cocaine	O
-	O
induced	T-obj
convulsions	O
and	O
lethality	T-obj
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	O
attenuated	O
cocaine	B-Chemical
-	O
induced	O
convulsions	T-obl
and	O
lethality	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	T-obj
,	O
BD1063	O
,	O
or	T-obj
LR132	O
significantly	T-amod
attenuated	O
cocaine	T-amod
-	O
induced	O
convulsions	B-Disease
and	T-conj
lethality	O
.	O

Moreover	O
,	O
post	T-nmod
-	O
treatment	O
with	O
LR132	B-Chemical
prevented	T-nmod
cocaine	O
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	O
prevented	O
cocaine	B-Chemical
-	O
induced	O
lethality	T-obl
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	T-conj
by	T-conj
the	T-conj
putative	T-conj
antagonists	O
,	T-conj
the	O
well	T-amod
-	O
characterized	O
sigma	O
receptor	T-compound
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	T-conj
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	T-dep
,	O
the	T-dep
well	O
-	O
characterized	T-dep
sigma	O
receptor	O
agonist	T-dep
di	T-dep
-	O
o	T-dep
-	O
tolylguanidine	O
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	T-conj
by	T-conj
the	T-conj
putative	T-conj
antagonists	O
,	T-conj
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	T-conj
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	T-compound
agonist	O
BD1031	B-Chemical
(	O
3R	O
-	O
1	T-dep
-	O
[	O
2	T-dep
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	T-dep
,	O
4	O
-	O
diazabicyclo	T-dep
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	T-dep
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	T-dep
the	T-dep
novel	T-dep
sigma	O
receptor	O
agonist	T-dep
BD1031	O
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-Disease
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	O
of	O
cocaine	B-Chemical
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	T-conj
on	T-conj
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	T-conj
and	O
LR132	T-conj
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	T-conj
on	T-conj
locomotion	O
,	O
BD1018	T-conj
,	O
BD1063	B-Chemical
and	O
LR132	T-conj
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	T-conj
on	T-conj
locomotion	O
,	O
BD1018	T-conj
,	O
BD1063	T-conj
and	O
LR132	B-Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	O
,	O
BD1063	O
and	O
LR132	O
significantly	O
attenuated	T-nmod
the	T-nmod
locomotor	T-nmod
stimulatory	T-nmod
effects	O
of	O
cocaine	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	T-amod
anti	O
-	O
cocaine	B-Chemical
effects	O
of	O
the	O
novel	O
ligands	T-amod
involved	T-amod
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	O
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

To	O
further	O
validate	T-nsubj:pass
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
against	T-nmod
sigma1	T-nmod
receptors	O
was	T-nsubj:pass
also	T-nsubj:pass
shown	O
to	O
significantly	O
attenuate	T-nsubj:pass
the	O
convulsive	O
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	T-amod
the	T-amod
convulsive	B-Disease
and	T-conj
locomotor	O
stimulatory	T-amod
effects	O
of	O
cocaine	T-amod
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	T-nmod
the	T-nmod
convulsive	T-nmod
and	O
locomotor	O
stimulatory	T-nmod
effects	O
of	O
cocaine	B-Chemical
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	B-Chemical
-	O
induced	O
behaviors	T-obl
.	O

Ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	O
nephritis	T-obl
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	T-amod
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	T-nmod
a	T-nmod
cadaveric	T-nmod
renal	T-nmod
allograft	O
.	O

Ranitidine	B-Chemical
frequently	T-nsubj:pass
is	T-nsubj:pass
used	O
for	O
preventing	O
peptic	O
ulceration	T-nsubj:pass
after	O
renal	O
transplantation	T-nsubj:pass
.	O

This	O
drug	T-obl
occasionally	T-obl
has	T-obl
been	T-obl
associated	O
with	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	T-nmod
native	T-nmod
kidneys	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	O
nephritis	T-obl
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

We	O
report	T-nmod
a	T-nmod
case	O
of	O
ranitidine	T-amod
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
recipient	T-nmod
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

Liver	B-Disease
disease	I-Disease
caused	O
by	O
propylthiouracil	T-nsubj
.	O

Liver	O
disease	T-obl
caused	O
by	O
propylthiouracil	B-Chemical
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	T-nmod
on	T-nmod
a	T-nmod
patient	O
with	O
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	T-nmod
by	O
the	O
administration	O
of	O
propylthiouracil	O
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	O
active	O
(	O
aggressive	O
)	O
hepatitis	O
caused	T-nmod
by	T-nmod
the	T-nmod
administration	O
of	O
propylthiouracil	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	T-nmod
in	T-nmod
the	T-nmod
evaluation	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O

Withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
rabbit	I-Disease
syndrome	I-Disease
during	T-nmod
dose	T-nmod
reduction	O
of	O
risperidone	T-nmod
.	O

Withdrawal	O
-	O
emergent	O
rabbit	O
syndrome	T-nmod
during	T-nmod
dose	T-nmod
reduction	O
of	O
risperidone	B-Chemical
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	O
)	O
is	T-nsubj
a	T-nsubj
rare	T-nsubj
extrapyramidal	T-nsubj
side	T-nsubj
effect	O
caused	T-nsubj
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Rabbit	T-dep
syndrome	O
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	T-dep
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Here	O
we	O
present	T-nmod
a	T-nmod
case	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
,	O
which	T-acl:relcl
is	T-acl:relcl
the	T-acl:relcl
first	O
of	O
its	O
kind	T-acl:relcl
to	O
be	O
reported	T-acl:relcl
.	O

The	O
patient	O
developed	O
RS	B-Disease
during	T-nmod
dose	T-nmod
reduction	O
of	O
risperidone	T-nmod
.	O

The	O
patient	O
developed	O
RS	T-nmod
during	T-nmod
dose	T-nmod
reduction	O
of	O
risperidone	B-Chemical
.	O

The	O
symptom	O
was	O
treated	T-compound
successfully	O
with	T-compound
trihexyphenidyl	B-Chemical
anticholinergic	T-compound
therapy	O
.	O

The	T-nmod
underlying	T-nmod
mechanism	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
in	O
the	O
present	O
case	T-nmod
may	O
have	O
been	O
related	T-nmod
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	T-nmod
to	T-nmod
the	T-nmod
pharmacological	T-nmod
profile	O
of	O
risperidone	B-Chemical
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	T-nmod
,	O
suggesting	T-nmod
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	B-Chemical
-	O
dopamine	O
antagonist	T-compound
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	T-compound
of	O
risperidone	O
,	O
a	T-compound
serotonin	O
-	O
dopamine	B-Chemical
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	T-compound
of	T-compound
the	T-compound
serotonin	B-Chemical
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	T-nmod
of	O
the	O
serotonin	O
system	O
in	T-nmod
the	T-nmod
development	O
of	O
RS	B-Disease
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	T-nmod
of	T-nmod
the	T-nmod
effects	O
of	O
E4031	B-Chemical
,	O
cisapride	O
,	O
terfenadine	O
and	T-conj
terodiline	O
on	O
monophasic	O
action	O
potential	O
duration	T-nmod
in	O
dog	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-conj
of	T-conj
E4031	O
,	O
cisapride	B-Chemical
,	O
terfenadine	T-conj
and	O
terodiline	T-conj
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-conj
of	T-conj
E4031	O
,	O
cisapride	T-conj
,	O
terfenadine	B-Chemical
and	O
terodiline	T-conj
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-conj
of	T-conj
E4031	O
,	O
cisapride	T-conj
,	O
terfenadine	T-conj
and	O
terodiline	B-Chemical
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

Torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TDP	O
)	O
is	T-nsubj
a	T-nsubj
potentially	O
fatal	T-nsubj
ventricular	T-nsubj
tachycardia	O
associated	T-nsubj
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

Torsades	T-appos
de	T-appos
pointes	O
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	O
tachycardia	T-appos
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

Torsades	T-nsubj
de	T-nsubj
pointes	O
(	O
TDP	T-nsubj
)	O
is	O
a	O
potentially	T-amod
fatal	O
ventricular	B-Disease
tachycardia	I-Disease
associated	O
with	O
increases	T-acl
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

TDP	B-Disease
is	T-conj
a	T-nsubj
side	T-nsubj
-	O
effect	T-conj
that	O
has	O
led	T-nsubj
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	O
and	O
terodiline	O
)	O
.	O

TDP	O
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	B-Chemical
and	O
terodiline	O
)	O
.	O

TDP	O
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	O
and	O
terodiline	B-Chemical
)	O
.	O

The	O
potential	T-obj
of	O
compounds	O
to	T-obj
cause	O
TDP	B-Disease
was	O
evaluated	T-obj
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	T-obj
QT	O
interval	O
and	T-obj
cause	O
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E4031	O
.	O

Four	O
compounds	T-obj
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	T-obj
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	O
,	O
cisapride	O
and	T-conj
E4031	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	T-conj
:	O
terfenadine	O
,	O
terodiline	B-Chemical
,	O
cisapride	T-conj
and	O
E4031	T-conj
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	T-conj
:	O
terfenadine	O
,	O
terodiline	T-conj
,	O
cisapride	B-Chemical
and	O
E4031	T-conj
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	T-conj
:	O
terfenadine	O
,	O
terodiline	T-conj
,	O
cisapride	T-conj
and	O
E4031	B-Chemical
.	O

These	T-conj
data	O
indicate	T-conj
that	O
the	T-nsubj
free	T-nmod
ED50	T-nmod
in	T-nmod
plasma	O
for	T-nsubj
terfenadine	B-Chemical
(	T-appos
1	T-appos
.	T-nsubj
9	O
nM	O
)	T-conj
,	O
terodiline	O
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	O
data	T-dep
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	T-dep
)	O
,	O
terodiline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	O
(	O
76	O
nM	O
)	O
,	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	O
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

For	O
compounds	T-obj
that	T-obj
have	T-obj
shown	O
TDP	B-Disease
in	O
the	O
clinic	T-obj
(	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
)	O
there	O
is	T-obj
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	O
that	O
have	O
shown	T-dep
TDP	O
in	T-dep
the	T-dep
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	O
,	O
cisapride	O
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	O
in	O
the	O
clinic	T-appos
(	O
terfenadine	O
,	O
terodiline	B-Chemical
,	O
cisapride	T-appos
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	O
in	O
the	O
clinic	T-appos
(	O
terfenadine	O
,	O
terodiline	T-appos
,	O
cisapride	B-Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	T-nmod
the	O
therapeutic	O
ratio	O
with	T-nmod
respect	O
to	O
TDP	B-Disease
in	O
potential	O
development	O
candidates	T-nmod
and	O
the	O
importance	T-nmod
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O

Bladder	O
retention	B-Disease
of	I-Disease
urine	I-Disease
as	T-nmod
a	T-nmod
result	O
of	O
continuous	O
intravenous	O
infusion	T-nmod
of	O
fentanyl	O
:	O
2	O
case	T-dep
reports	O
.	O

Bladder	O
retention	O
of	O
urine	O
as	O
a	O
result	T-nmod
of	T-nmod
continuous	T-nmod
intravenous	T-nmod
infusion	O
of	O
fentanyl	B-Chemical
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	T-conj
the	T-conj
stress	O
and	O
pain	B-Disease
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	B-Chemical
,	O
an	T-appos
opioid	T-appos
analgesic	O
,	O
is	T-nsubj:pass
frequently	T-nsubj:pass
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	T-nsubj:pass
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	T-compound
of	T-compound
fentanyl	B-Chemical
administration	O
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	O
,	O
respiratory	O
depression	O
,	O
and	O
bradycardia	O
.	O

Various	O
reported	O
side	O
effects	T-obj
of	O
fentanyl	O
administration	O
include	O
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	O
,	O
respiratory	T-conj
depression	O
,	O
and	T-conj
bradycardia	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	T-conj
chest	T-conj
wall	T-conj
rigidity	O
,	O
hypotension	B-Disease
,	O
respiratory	O
depression	T-conj
,	O
and	O
bradycardia	T-conj
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	T-conj
chest	T-conj
wall	T-conj
rigidity	O
,	O
hypotension	T-conj
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	O
bradycardia	T-conj
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	T-conj
chest	T-conj
wall	T-conj
rigidity	O
,	O
hypotension	T-conj
,	O
respiratory	O
depression	T-conj
,	O
and	O
bradycardia	B-Disease
.	O

Here	O
,	T-nmod
2	T-nmod
cases	O
of	O
urinary	B-Disease
bladder	I-Disease
retention	I-Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	O
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	O
are	O
reported	T-acl
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	O
bladder	O
retention	O
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	T-obj
mimicking	O
hydronephrosis	B-Disease
as	O
a	O
result	T-obj
of	O
continuous	O
infusion	O
of	O
fentanyl	O
are	O
reported	O
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	O
bladder	O
retention	O
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	O
as	O
a	O
result	T-nmod
of	T-nmod
continuous	T-nmod
infusion	O
of	O
fentanyl	B-Chemical
are	O
reported	O
.	O

Fatal	O
myeloencephalopathy	B-Disease
due	T-nmod
to	O
accidental	T-nmod
intrathecal	T-nmod
vincristin	T-nmod
administration	O
:	O
a	T-dep
report	O
of	O
two	O
cases	T-dep
.	O

Fatal	O
myeloencephalopathy	T-compound
due	T-compound
to	O
accidental	T-compound
intrathecal	T-compound
vincristin	B-Chemical
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	T-compound
of	T-compound
accidental	T-compound
intrathecal	T-compound
vincristine	B-Chemical
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	O
lymphoblastic	O
leucemia	O
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	O
lymphoma	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	T-nmod
of	O
accidental	O
intrathecal	O
vincristine	O
instillation	O
in	T-nmod
a	T-nmod
5	O
-	O
year	T-nmod
old	T-nmod
girl	O
with	O
recurrent	O
acute	B-Disease
lymphoblastic	I-Disease
leucemia	I-Disease
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	O
lymphoma	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	T-nmod
of	O
accidental	O
intrathecal	O
vincristine	O
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	O
lymphoblastic	O
leucemia	O
and	T-nmod
a	T-nmod
57	O
-	O
year	T-nmod
old	T-nmod
man	O
with	O
lymphoblastic	B-Disease
lymphoma	I-Disease
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	T-nmod
after	O
intrathecal	T-nmod
injection	O
of	O
vincristine	B-Chemical
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	T-nmod
by	T-nmod
the	T-nmod
signs	O
of	O
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	O
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	T-obj
by	O
the	O
signs	O
of	O
opistothonus	O
,	O
sensory	O
and	O
motor	O
dysfunction	O
and	T-obj
ascending	O
paralysis	B-Disease
.	O

Histological	O
and	O
immunohistochemical	O
investigations	T-obj
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B-Disease
of	I-Disease
myelin	I-Disease
and	I-Disease
axons	I-Disease
as	O
well	O
as	O
pseudocystic	O
transformation	T-obj
in	O
areas	O
exposed	O
to	O
vincristine	O
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

Histological	O
and	O
immunohistochemical	O
investigations	T-conj
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	T-conj
of	O
myelin	O
and	O
axons	O
as	O
well	T-cc
as	T-cc
pseudocystic	B-Disease
transformation	I-Disease
in	T-nmod
areas	O
exposed	O
to	O
vincristine	T-acl
,	O
accompanied	O
by	O
secondary	O
changes	T-acl
with	O
numerous	O
prominent	O
macrophages	O
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	O
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	O
transformation	T-obl
in	O
areas	O
exposed	O
to	O
vincristine	B-Chemical
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

A	T-nmod
better	O
controlled	T-nmod
regimen	O
for	O
administering	O
vincristine	B-Chemical
and	T-conj
intrathecal	T-conj
chemotherapy	O
is	O
recommended	T-nmod
.	O

Palpebral	B-Disease
twitching	I-Disease
in	T-nmod
a	T-nmod
depressed	T-nmod
adolescent	O
on	O
citalopram	T-nmod
.	O

Palpebral	O
twitching	T-amod
in	T-amod
a	T-amod
depressed	B-Disease
adolescent	O
on	O
citalopram	T-amod
.	O

Palpebral	O
twitching	T-nmod
in	T-nmod
a	T-nmod
depressed	T-nmod
adolescent	O
on	O
citalopram	B-Chemical
.	O

We	O
report	O
a	O
favorable	O
response	T-nmod
to	T-nmod
treatment	O
with	O
citalopram	B-Chemical
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	O
depression	O
who	O
exhibited	O
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

We	O
report	O
a	O
favorable	O
response	T-nmod
to	O
treatment	O
with	O
citalopram	O
by	T-nmod
a	T-nmod
15	O
-	O
year	O
-	O
old	T-nmod
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	T-nmod
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	O
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	T-obj
with	O
major	O
depression	O
who	T-obj
exhibited	O
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	O
2	O
weeks	T-obj
of	O
treatment	O
.	O

This	T-nmod
may	T-nmod
have	T-nmod
been	T-nmod
a	T-nmod
side	T-nmod
effect	O
of	O
citalopram	B-Chemical
as	O
it	O
remitted	T-nmod
with	O
redistribution	O
of	O
doses	O
.	O

The	T-compound
3	O
-	O
week	T-compound
sulphasalazine	B-Chemical
syndrome	O
strikes	T-compound
again	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	T-nmod
a	T-nmod
constellation	O
of	O
dermatitis	B-Disease
,	O
fever	O
,	O
lymphadenopathy	O
and	T-conj
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	T-conj
of	T-conj
dermatitis	O
,	O
fever	B-Disease
,	O
lymphadenopathy	T-conj
and	O
hepatitis	T-conj
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	T-conj
of	T-conj
dermatitis	O
,	O
fever	T-conj
,	O
lymphadenopathy	B-Disease
and	O
hepatitis	T-conj
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	T-conj
of	T-conj
dermatitis	O
,	O
fever	T-conj
,	O
lymphadenopathy	T-conj
and	O
hepatitis	B-Disease
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	T-nmod
of	T-nmod
a	T-nmod
course	O
of	O
oral	O
sulphasalazine	B-Chemical
for	T-nmod
sero	O
-	O
negative	T-nmod
rheumatoid	T-nmod
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	T-nmod
of	T-nmod
oral	T-nmod
sulphasalazine	O
for	O
sero	T-amod
-	O
negative	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	T-nmod
biopsies	O
showed	T-nmod
the	T-nmod
features	T-amod
of	O
severe	T-det
necrotising	T-det
lymphadenitis	B-Disease
,	T-compound
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	T-det
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	T-amod
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	T-nmod
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	T-nmod
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	T-conj
biopsies	O
showed	T-conj
the	T-conj
features	O
of	O
severe	T-conj
necrotising	O
lymphadenitis	T-conj
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	T-obl
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
.	O
A	T-case
week	T-amod
later	O
,	T-case
fulminant	O
drug	T-conj
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	T-advmod
and	T-advmod
inguinal	O
lymph	O
node	T-nsubj
biopsies	O
showed	T-nsubj
the	T-nsubj
features	O
of	O
severe	T-nsubj
necrotising	O
lymphadenitis	T-nsubj
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	T-nsubj
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	B-Disease
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	B-Disease
-	I-Disease
organ	I-Disease
failure	I-Disease
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	B-Disease
,	O
supervened	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	T-amod
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	T-amod
acute	T-compound
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	T-case
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	B-Disease
,	T-case
focal	O
acute	O
tubulo	T-case
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	B-Disease
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	B-Disease
marrow	I-Disease
necrosis	I-Disease
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	B-Disease
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	T-compound
of	T-compound
the	T-compound
so	O
-	O
called	T-compound
"	O
3	O
-	O
week	T-compound
sulphasalazine	B-Chemical
syndrome	O
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphasalazine	O
syndrome	O
"	O
,	O
a	O
rare	T-nmod
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	T-nmod
reaction	O
to	O
sulphasalazine	B-Chemical
.	O

Intravenous	T-nmod
administration	O
of	O
prochlorperazine	B-Chemical
by	O
15	O
-	O
minute	O
infusion	T-nmod
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	T-nmod
the	O
incidence	O
of	O
akathisia	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	O
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	T-nmod
the	T-nmod
incidence	O
of	O
akathisia	B-Disease
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	T-nmod
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	T-nmod
the	T-nmod
rate	O
of	O
akathisia	B-Disease
after	O
administration	O
of	O
intravenous	O
prochlorperazine	O
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	T-nmod
the	O
rate	O
of	O
akathisia	O
after	T-nmod
administration	O
of	O
intravenous	O
prochlorperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

Patients	O
aged	O
18	O
years	T-obl
or	O
older	O
treated	O
with	O
prochlorperazine	B-Chemical
for	T-nmod
headache	O
,	O
nausea	T-nmod
,	O
or	O
vomiting	T-nmod
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	T-nmod
with	T-nmod
prochlorperazine	O
for	O
headache	B-Disease
,	O
nausea	O
,	O
or	T-conj
vomiting	O
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	T-conj
for	T-conj
headache	O
,	O
nausea	B-Disease
,	O
or	O
vomiting	T-conj
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	T-conj
for	T-conj
headache	O
,	O
nausea	T-conj
,	O
or	O
vomiting	B-Disease
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	T-nmod
mg	O
of	O
prochlorperazine	B-Chemical
administered	T-nmod
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	T-nmod
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	T-obj
experiencing	O
akathisia	B-Disease
within	O
60	O
minutes	T-obj
of	O
administration	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	T-conj
of	T-conj
restlessness	O
or	O
agitation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	O
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	O
rating	O
scale	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	B-Disease
rating	O
scale	T-compound
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	O
rating	O
scale	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	O
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	B-Disease
rating	O
scale	T-compound
.	O

The	T-nmod
intensity	O
of	O
headache	B-Disease
and	T-conj
nausea	O
was	O
measured	T-nmod
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

The	O
intensity	T-conj
of	T-conj
headache	O
and	O
nausea	B-Disease
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

The	T-nmod
efficacy	O
of	O
prochlorperazine	B-Chemical
in	O
the	O
treatment	T-nmod
of	O
headache	O
and	O
nausea	O
likewise	O
did	O
not	O
appear	T-nmod
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

The	O
efficacy	T-nmod
of	O
prochlorperazine	O
in	T-nmod
the	T-nmod
treatment	O
of	O
headache	B-Disease
and	T-conj
nausea	O
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	O
in	O
the	O
treatment	T-conj
of	T-conj
headache	O
and	O
nausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Combined	O
antiretroviral	O
therapy	T-obj
causes	O
cardiomyopathy	B-Disease
and	O
elevates	T-obj
plasma	O
lactate	O
in	O
transgenic	O
AIDS	O
mice	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	T-obj
cardiomyopathy	O
and	T-obj
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	O
mice	T-obj
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	O
and	O
elevates	T-compound
plasma	O
lactate	O
in	T-compound
transgenic	T-compound
AIDS	B-Disease
mice	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	T-obl
(	O
HAART	O
)	O
is	T-obl
implicated	O
in	O
cardiomyopathy	B-Disease
(	O
CM	O
)	O
and	T-conj
in	T-conj
elevated	T-conj
plasma	T-conj
lactate	O
(	O
LA	T-conj
)	O
in	O
AIDS	T-conj
through	O
mechanisms	T-obl
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-dep
in	T-dep
cardiomyopathy	O
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	T-dep
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-conj
in	T-conj
cardiomyopathy	O
(	O
CM	T-conj
)	O
and	O
in	O
elevated	O
plasma	O
lactate	B-Chemical
(	O
LA	O
)	O
in	T-nmod
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	T-appos
(	O
CM	O
)	O
and	T-appos
in	T-appos
elevated	T-appos
plasma	T-appos
lactate	O
(	O
LA	B-Chemical
)	O
in	O
AIDS	T-appos
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	T-nmod
(	O
CM	O
)	O
and	T-nmod
in	T-nmod
elevated	T-nmod
plasma	T-nmod
lactate	O
(	O
LA	T-nmod
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-nmod
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	O
through	T-nmod
mechanisms	O
of	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	T-compound
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	T-compound
hemizygous	T-compound
transgenic	T-compound
AIDS	B-Disease
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	T-compound
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	O
,	O
lamivudine	O
,	O
and	O
indinavir	O
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	O
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	T-nmod
with	T-nmod
the	T-nmod
HAART	T-nmod
combination	O
of	O
zidovudine	B-Chemical
,	O
lamivudine	O
,	O
and	T-conj
indinavir	O
or	O
vehicle	O
control	T-conj
for	O
10	O
days	T-conj
or	O
35	O
days	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	O
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	T-conj
of	T-conj
zidovudine	O
,	O
lamivudine	B-Chemical
,	O
and	O
indinavir	T-conj
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	O
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	T-conj
of	T-conj
zidovudine	O
,	O
lamivudine	T-conj
,	O
and	O
indinavir	B-Chemical
or	T-conj
vehicle	T-conj
control	O
for	T-nmod
10	T-nmod
days	O
or	O
35	O
days	T-nmod
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	T-nmod
of	T-nmod
molecular	T-nmod
markers	O
of	O
CM	B-Disease
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	O
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	O
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	T-compound
[	O
ANF	O
]	O
and	T-compound
sarcoplasmic	T-compound
calcium	B-Chemical
ATPase	O
[	O
SERCA2	T-compound
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	T-nmod
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	O
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	O
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	T-nmod
determination	O
of	O
plasma	O
LA	B-Chemical
.	O

Biochemically	T-nsubj:pass
,	O
LA	B-Chemical
was	T-nsubj:pass
elevated	O
(	O
8	T-nsubj:pass
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O

Results	O
show	T-obj
that	T-obj
cumulative	O
HAART	T-obj
caused	O
mitochondrial	O
CM	B-Disease
with	O
elevated	O
LA	T-obj
in	O
AIDS	O
transgenic	O
mice	O
.	O

Results	O
show	T-obl
that	T-obl
cumulative	O
HAART	T-obl
caused	O
mitochondrial	O
CM	T-obl
with	O
elevated	O
LA	B-Chemical
in	T-nmod
AIDS	T-nmod
transgenic	T-nmod
mice	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	O
with	O
elevated	O
LA	T-compound
in	T-compound
AIDS	B-Disease
transgenic	T-compound
mice	O
.	O

A	O
Phase	O
II	O
trial	T-dep
of	T-dep
cisplatin	B-Chemical
plus	T-conj
WR	O
-	O
2721	T-conj
(	O
amifostine	O
)	O
for	O
metastatic	O
breast	O
carcinoma	O
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	O
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
amifostine	T-conj
)	O
for	O
metastatic	O
breast	O
carcinoma	O
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

A	T-nmod
Phase	T-nmod
II	O
trial	O
of	O
cisplatin	O
plus	O
WR	T-dep
-	O
2721	O
(	O
amifostine	B-Chemical
)	O
for	O
metastatic	O
breast	O
carcinoma	T-nmod
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	T-nmod
)	O
.	O

A	T-nmod
Phase	T-nmod
II	O
trial	O
of	O
cisplatin	O
plus	O
WR	O
-	O
2721	O
(	O
amifostine	T-nmod
)	O
for	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	T-nmod
)	O
.	O

BACKGROUND	T-nsubj
:	O
Cisplatin	B-Chemical
has	O
minimal	O
antitumor	O
activity	T-nsubj
when	O
used	T-nsubj
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
has	O
minimal	O
antitumor	O
activity	O
when	O
used	T-nmod
as	T-nmod
second	T-nmod
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
.	O

Although	T-obl
a	O
dose	O
-	T-case
response	O
effect	T-obl
has	T-obl
been	T-obl
observed	T-case
with	T-nmod:poss
cisplatin	B-Chemical
,	T-case
the	O
dose	O
-	T-case
limiting	O
toxicities	O
associated	T-obl
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	T-compound
with	O
cisplatin	O
,	O
the	O
dose	T-amod
-	T-compound
limiting	T-compound
toxicities	B-Disease
associated	T-amod
with	O
cisplatin	T-compound
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	T-obl
with	O
cisplatin	O
,	O
the	O
dose	O
-	T-obl
limiting	T-obl
toxicities	T-obl
associated	O
with	O
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	B-Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O

WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	T-conj
amifostine	O
initially	T-nsubj:pass
was	T-nsubj:pass
developed	O
to	O
protect	T-nsubj:pass
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

WR	O
-	O
2721	T-conj
or	O
amifostine	B-Chemical
initially	O
was	O
developed	T-conj
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	B-Chemical
subsequently	T-nsubj:pass
was	T-nsubj:pass
shown	O
to	O
protect	T-nsubj:pass
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	O
agents	O
and	O
cisplatin	O
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	T-nmod
normal	O
tissues	O
from	T-nmod
the	T-nmod
toxic	T-nmod
effects	O
of	O
alkylating	B-Chemical
agents	I-Chemical
and	T-conj
cisplatin	O
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	T-conj
of	T-conj
alkylating	T-conj
agents	O
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Early	T-nmod
trials	O
of	O
cisplatin	B-Chemical
and	T-conj
amifostine	O
also	O
suggested	T-nmod
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	T-conj
of	T-conj
cisplatin	O
and	O
amifostine	B-Chemical
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	B-Chemical
-	O
induced	O
nephrotoxicity	T-obl
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	T-nmod
incidence	O
and	O
severity	T-nmod
of	O
cisplatin	T-amod
-	O
induced	O
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	T-conj
neuropathy	O
were	O
reduced	T-nmod
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-conj
and	O
severity	O
of	T-conj
cisplatin	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	T-conj
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-conj
and	O
severity	O
of	T-conj
cisplatin	O
-	O
induced	T-conj
nephrotoxicity	O
,	O
ototoxicity	T-conj
,	O
and	O
neuropathy	B-Disease
were	O
reduced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	T-nmod
of	T-nmod
the	T-nmod
combination	O
of	O
cisplatin	B-Chemical
plus	T-conj
amifostine	O
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	O
carcinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	T-conj
of	T-conj
cisplatin	O
plus	O
amifostine	B-Chemical
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	O
carcinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	O
plus	O
amifostine	O
was	O
conducted	T-nmod
in	T-nmod
patients	O
with	O
progressive	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
who	O
had	O
received	T-nmod
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	T-obj
received	O
amifostine	B-Chemical
,	O
910	T-appos
mg	O
/	O
m2	T-appos
intravenously	O
over	O
15	O
minutes	T-appos
.	O

After	O
completion	T-amod
of	T-amod
the	T-amod
amifostine	B-Chemical
infusion	O
,	O
cisplatin	O
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

After	O
completion	T-nsubj:pass
of	O
the	O
amifostine	O
infusion	O
,	O
cisplatin	B-Chemical
120	T-dep
mg	O
/	O
m2	T-dep
was	T-nsubj:pass
administered	O
over	O
30	O
minutes	T-nsubj:pass
.	O

Intravenous	T-conj
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	T-conj
before	O
and	O
after	O
cisplatin	O
.	O

Intravenous	O
hydration	T-conj
and	O
mannitol	O
was	T-conj
administered	O
before	T-conj
and	O
after	O
cisplatin	B-Chemical
.	O

Seven	O
different	O
life	T-amod
-	O
threatening	O
toxicities	B-Disease
were	T-nsubj:pass
observed	O
in	O
patients	T-nsubj:pass
while	O
receiving	O
treatment	T-nsubj:pass
.	O

Neither	O
a	O
tumor	B-Disease
-	O
protective	O
effect	T-obl:npmod
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Neither	T-conj
a	T-conj
tumor	O
-	O
protective	T-conj
effect	O
nor	O
reduced	O
toxicity	B-Disease
to	O
normal	O
tissues	T-conj
was	O
observed	T-conj
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Neither	O
a	O
tumor	O
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	T-nmod
with	T-nmod
the	T-nmod
addition	O
of	O
amifostine	B-Chemical
to	T-nmod
cisplatin	O
in	O
this	O
trial	T-nmod
.	O

Neither	O
a	O
tumor	O
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	T-nmod
of	T-nmod
amifostine	O
to	O
cisplatin	B-Chemical
in	O
this	O
trial	O
.	O

Oral	B-Chemical
contraceptives	I-Chemical
and	T-conj
the	T-conj
risk	O
of	O
myocardial	O
infarction	T-conj
.	O

Oral	O
contraceptives	T-nmod
and	T-nmod
the	T-nmod
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O

BACKGROUND	O
:	O
An	O
association	T-nmod
between	T-nmod
the	T-nmod
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	T-nmod
of	O
myocardial	O
infarction	O
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	T-nmod
of	O
oral	O
contraceptives	O
and	T-nmod
the	T-nmod
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	T-dep
this	O
association	O
,	O
according	T-dep
to	T-dep
the	T-dep
type	T-case
of	T-dep
progestagen	B-Chemical
included	T-dep
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	T-det
desogestrel	B-Chemical
or	T-det
gestodene	O
)	O
and	O
second	T-det
-	O
generation	O
(	O
i	T-det
.	O
e	O
.	O
,	T-det
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	B-Chemical
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	T-cc
levonorgestrel	B-Chemical
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	T-obj
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	T-obj
e	O
.	T-obj
,	O
levonorgestrel	O
)	T-obj
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
dose	O
of	T-dep
estrogen	O
,	O
and	T-dep
the	T-dep
presence	O
or	O
absence	O
of	O
prothrombotic	T-dep
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	T-dep
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	T-case
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-Disease
infarction	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	T-amod
on	T-amod
oral	B-Chemical
-	I-Chemical
contraceptive	I-Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	T-amod
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	T-nmod
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	T-nmod
odds	T-nmod
ratio	O
for	O
myocardial	B-Disease
infarction	I-Disease
among	T-nmod
women	O
who	T-acl:relcl
used	O
any	O
type	T-acl:relcl
of	O
combined	O
oral	O
contraceptive	O
,	O
as	O
compared	O
with	O
nonusers	T-acl:relcl
,	O
was	O
2	T-acl:relcl
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	O
infarction	O
among	O
women	O
who	O
used	T-nmod
any	T-nmod
type	O
of	O
combined	O
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	O
contraceptives	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

Among	T-obj
women	T-dep
who	T-dep
used	T-det
oral	B-Chemical
contraceptives	I-Chemical
,	T-det
the	T-obj
odds	O
ratio	T-det
was	O
2	T-obj
.	O
1	O
(	O
95	T-obj
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	O
infarction	O
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

Among	O
women	O
who	O
used	O
oral	O
contraceptives	O
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

Among	O
women	O
who	O
used	O
oral	O
contraceptives	O
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	O
infarction	O
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
results	O
with	O
respect	T-nmod
to	T-nmod
the	T-nmod
use	O
of	O
third	T-compound
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	O
contraceptives	O
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	T-obl
associated	O
with	O
second	T-compound
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	T-nmod
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	T-nmod
among	O
women	O
who	O
used	O
oral	O
contraceptives	O
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

The	O
risk	O
of	O
myocardial	O
infarction	O
was	O
similar	O
among	O
women	T-obj
who	T-obj
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	T-obj
a	O
prothrombotic	O
mutation	O
.	O

End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	O
)	O
after	T-nmod
orthotopic	T-nmod
liver	T-nmod
transplantation	O
(	O
OLTX	T-nmod
)	O
using	T-nmod
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

End	O
-	O
stage	T-dep
renal	T-dep
disease	O
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	T-dep
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	T-nsubj:pass
:	O
The	O
calcineurin	T-compound
inhibitors	O
cyclosporine	B-Chemical
and	T-conj
tacrolimus	O
are	T-nsubj:pass
both	T-nsubj:pass
known	O
to	O
be	O
nephrotoxic	T-nsubj:pass
.	O

BACKGROUND	O
:	O
The	T-conj
calcineurin	O
inhibitors	T-conj
cyclosporine	O
and	O
tacrolimus	B-Chemical
are	O
both	O
known	T-conj
to	O
be	O
nephrotoxic	O
.	O

BACKGROUND	T-xcomp
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	T-xcomp
and	O
tacrolimus	O
are	T-xcomp
both	T-xcomp
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	T-obl
who	T-obl
are	T-obl
presenting	O
after	O
OLTX	T-obl
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	O
)	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	T-appos
after	O
OLTX	O
with	T-appos
end	O
-	O
stage	T-appos
renal	T-appos
disease	O
(	O
ESRD	B-Disease
)	O
.	O

This	O
retrospective	O
study	O
examines	T-nmod
the	T-nmod
incidence	O
and	O
treatment	T-nmod
of	O
ESRD	B-Disease
and	T-conj
chronic	T-conj
renal	T-conj
failure	O
(	O
CRF	O
)	O
in	O
OLTX	O
patients	T-nmod
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	T-conj
and	O
treatment	O
of	T-conj
ESRD	O
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	T-conj
)	O
in	O
OLTX	O
patients	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	T-appos
and	O
treatment	O
of	T-appos
ESRD	O
and	O
chronic	O
renal	O
failure	T-appos
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	O
.	O

Patients	O
were	T-conj
divided	O
into	O
three	O
groups	T-conj
:	T-conj
Controls	O
,	O
no	O
CRF	B-Disease
or	T-conj
ESRD	T-dep
,	T-dep
n	T-conj
=	O
748	T-dep
;	O
CRF	T-conj
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-conj
,	O
no	T-conj
CRF	T-nsubj
or	O
ESRD	B-Disease
,	T-nsubj
n	T-conj
=	O
748	T-nsubj
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	T-dep
divided	O
into	O
three	O
groups	T-dep
:	T-dep
Controls	O
,	O
no	O
CRF	T-dep
or	O
ESRD	O
,	O
n	O
=	O
748	T-dep
;	O
CRF	B-Disease
,	O
sustained	T-appos
serum	T-appos
creatinine	O
>	O
2	T-appos
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-appos
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	B-Chemical
>	T-nummod
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-Disease
,	O
n	O
=	O
45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	T-compound
of	T-compound
ESRD	B-Disease
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	O
therapy	O
,	O
and	O
survival	T-nmod
from	T-nmod
onset	O
of	O
ESRD	B-Disease
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	T-conj
ESRD	O
patients	O
had	T-compound
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	B-Disease
patients	T-conj
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	T-compound
higher	T-compound
preoperative	T-compound
serum	O
creatinine	B-Chemical
levels	O
,	O
a	O
greater	O
percentage	T-compound
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	T-compound
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	T-compound
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	T-nmod
of	T-nmod
patients	O
with	O
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	T-conj
higher	T-conj
preoperative	T-conj
serum	O
creatinine	T-conj
levels	O
,	O
a	O
greater	O
percentage	T-conj
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	T-conj
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	T-compound
-	O
year	O
serum	O
creatinine	B-Chemical
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	T-nmod
an	T-nmod
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	T-nmod
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	O
or	O
ESRD	O
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	O
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	T-nmod
for	T-nmod
the	T-nmod
development	O
of	O
CRF	B-Disease
or	T-conj
ESRD	O
with	O
odds	O
ratios	T-nmod
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	O
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	T-conj
of	T-conj
CRF	O
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	T-obj
more	O
than	O
10	O
years	T-obj
post	O
-	O
OLTX	T-obj
have	O
CRF	B-Disease
and	T-conj
ESRD	O
at	O
a	O
high	O
rate	T-obj
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	T-conj
CRF	O
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O

The	T-nmod
development	O
of	O
ESRD	B-Disease
decreases	T-nmod
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	T-nsubj
who	T-nsubj
develop	T-nsubj
ESRD	B-Disease
have	O
a	T-nsubj
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	O
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	O
syndrome	O
.	O

Patients	O
who	O
develop	O
ESRD	O
have	O
a	T-conj
higher	T-conj
preoperative	O
and	O
1	T-compound
-	O
year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	T-conj
to	O
have	O
hepatorenal	O
syndrome	O
.	O

Patients	O
who	O
develop	O
ESRD	O
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	O
and	O
are	O
more	O
likely	T-obj
to	T-obj
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
an	T-nmod
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	T-nmod
postoperatively	O
is	O
more	O
predictive	T-nmod
of	O
the	O
development	O
of	O
CRF	O
or	O
ESRD	O
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	O
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	T-nmod
of	T-nmod
the	T-nmod
development	O
of	O
CRF	B-Disease
or	T-conj
ESRD	O
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	O
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	T-conj
of	T-conj
CRF	O
or	O
ESRD	B-Disease
.	O

Epileptic	B-Disease
seizures	I-Disease
following	T-nmod
cortical	T-nmod
application	O
of	O
fibrin	O
sealants	T-nmod
containing	O
tranexamic	O
acid	O
in	O
rats	O
.	O

Epileptic	O
seizures	O
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	T-obj
containing	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
rats	T-obj
.	O

Recently	O
,	O
synthetic	T-nmod
fibrinolysis	T-nmod
inhibitors	O
such	O
as	T-case
tranexamic	B-Chemical
acid	I-Chemical
(	O
tAMCA	O
)	O
have	O
been	O
considered	T-nmod
as	O
substitutes	O
for	O
aprotinin	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	T-dep
such	T-dep
as	O
tranexamic	T-dep
acid	O
(	O
tAMCA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O

However	T-nsubj:pass
,	O
tAMCA	B-Chemical
has	T-nsubj:pass
been	T-nsubj:pass
shown	O
to	O
cause	T-nsubj:pass
epileptic	O
seizures	O
.	O

However	O
,	O
tAMCA	O
has	O
been	O
shown	T-obj
to	T-obj
cause	O
epileptic	B-Disease
seizures	I-Disease
.	O

We	O
wanted	O
to	O
study	T-nsubj
whether	T-nsubj
tAMCA	B-Chemical
retains	O
its	O
convulsive	O
action	T-nsubj
if	O
incorporated	T-nsubj
into	O
a	O
FS	O
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	O
retains	T-amod
its	T-amod
convulsive	B-Disease
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	T-nmod
aprotinin	O
or	O
different	T-amod
concentrations	T-amod
of	T-amod
tAMCA	B-Chemical
(	T-case
0	O
.	O
5	T-amod
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

FINDINGS	O
:	O
FS	T-obj
containing	O
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	O
behaviours	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	O
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	T-amod
with	T-amod
distinct	T-amod
convulsive	B-Disease
behaviours	O
.	O

The	T-nmod
degree	O
of	O
these	O
seizures	B-Disease
increased	T-nmod
with	O
increasing	O
concentration	O
of	O
tAMCA	O
.	O

The	O
degree	O
of	O
these	O
seizures	O
increased	T-nmod
with	T-nmod
increasing	T-nmod
concentration	O
of	O
tAMCA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	T-amod
5	O
mg	O
/	T-amod
ml	T-amod
tAMCA	B-Chemical
evoked	O
generalized	O
seizures	O
in	T-obl
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	T-nsubj
5	O
mg	O
/	T-amod
ml	T-amod
tAMCA	O
evoked	T-obl
generalized	B-Disease
seizures	I-Disease
in	T-nsubj
all	T-amod
tested	T-nsubj
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	O
generalized	O
seizures	O
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	O
generalized	O
seizures	O
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	B-Disease
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

INTERPRETATION	T-nsubj
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	O
its	O
convulsive	O
action	T-nsubj
within	O
FS	T-nsubj
.	O

INTERPRETATION	O
:	O
Tranexamic	O
acid	O
retains	T-amod
its	T-amod
convulsive	B-Disease
action	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	T-obj
containing	O
tAMCA	B-Chemical
for	T-nmod
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

Sequential	T-nmod
observations	O
of	O
exencephaly	B-Disease
and	T-conj
subsequent	T-conj
morphological	T-conj
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	T-nmod
:	O
analysis	T-nmod
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

Sequential	O
observations	O
of	O
exencephaly	O
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	T-nmod
of	T-nmod
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	T-nmod
.	O

Sequential	O
observations	O
of	O
exencephaly	O
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	T-nmod
of	T-nmod
transformation	O
from	O
exencephaly	T-nmod
to	O
anencephaly	B-Disease
.	O

Anencephaly	B-Disease
has	T-nsubj:pass
been	T-nsubj:pass
suggested	O
to	O
develop	T-nsubj:pass
from	O
exencephaly	O
;	O
however	O
,	O
there	O
is	T-nsubj:pass
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

Anencephaly	O
has	O
been	O
suggested	T-obl
to	T-obl
develop	O
from	O
exencephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	T-dep
observed	T-nsubj
the	T-dep
exencephaly	B-Disease
induced	T-dep
by	T-ccomp
5	T-dep
-	O
azacytidine	T-dep
at	O
embryonic	T-dep
day	T-nsubj
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	T-obj
observed	T-obl
the	T-obj
exencephaly	T-obj
induced	T-obj
by	T-obl
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
at	T-obl
embryonic	T-obj
day	T-obl
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
cases	T-nmod
of	T-nmod
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	T-nmod
.	O

We	O
confirmed	O
several	O
cases	T-nmod
of	T-nmod
transformation	O
from	O
exencephaly	T-nmod
to	O
anencephaly	B-Disease
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	T-amod
exencephalic	B-Disease
brain	T-amod
tissue	O
was	O
preserved	T-amod
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O

To	O
analyze	T-obj
the	O
transformation	O
patterns	O
,	O
we	T-obj
classified	O
the	O
exencephaly	B-Disease
by	O
size	T-obj
and	O
shape	O
of	O
the	O
exencephalic	O
tissue	O
into	O
several	O
types	T-obj
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	O
by	O
size	T-amod
and	O
shape	O
of	T-amod
the	T-amod
exencephalic	B-Disease
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	T-nmod
found	T-nmod
that	O
the	T-det
transformation	T-case
of	T-amod
exencephalic	B-Disease
tissue	T-nmod
was	T-nmod
not	T-amod
simply	T-nmod
size	O
-	O
dependent	T-nmod
,	O
and	O
all	O
cases	O
of	O
anencephaly	O
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	O
tissue	O
at	O
E13	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	O
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	T-nmod
all	T-nmod
cases	O
of	O
anencephaly	B-Disease
at	O
E18	T-nmod
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	O
tissue	O
at	O
E13	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	O
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	O
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B-Disease
tissue	O
at	O
E13	O
.	O
5	O
.	O

Microscopic	T-nmod
observation	O
showed	T-nmod
the	T-nmod
configuration	T-case
of	T-nmod
exencephaly	B-Disease
at	T-nmod
E13	T-nmod
.	T-nmod
5	T-nmod
,	T-nmod
frequent	T-nmod
hemorrhaging	O
and	O
detachment	O
of	T-nmod
the	O
neural	T-nmod
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	T-case
hemorrhaging	B-Disease
and	T-case
detachment	T-case
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B-Disease
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-Disease
tissue	O
at	O
E18	O
.	O
5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	T-amod
in	T-amod
the	T-amod
exencephalic	B-Disease
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-amod
of	T-amod
the	T-amod
exencephalic	B-Disease
neural	T-amod
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	T-appos
the	T-appos
altered	T-appos
distribution	T-appos
patterns	O
of	O
vessels	T-appos
,	O
subsequent	O
peripheral	O
circulatory	B-Disease
failure	I-Disease
and	T-conj
/	O
or	O
hemorrhaging	O
in	T-nmod
various	T-nmod
parts	O
of	O
the	O
exencephalic	O
head	T-nmod
,	O
leading	T-appos
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	T-conj
of	O
vessels	O
,	O
subsequent	T-conj
peripheral	T-conj
circulatory	T-conj
failure	O
and	O
/	O
or	T-cc
hemorrhaging	B-Disease
in	O
various	O
parts	T-conj
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	T-amod
of	T-amod
the	T-amod
exencephalic	B-Disease
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	T-nmod
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	T-nmod
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	T-nmod
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	T-nmod
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	T-nmod
transformation	O
from	O
exencephaly	T-nmod
to	O
anencephaly	B-Disease
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
for	T-nmod
detection	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	O
infarction	T-nmod
in	O
rats	T-nmod
.	O

99mTc	O
-	O
glucarate	O
for	O
detection	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	O
infarction	T-obl
in	O
rats	O
.	O

99mTc	O
-	O
glucarate	T-nmod
for	T-nmod
detection	O
of	O
isoproterenol	T-amod
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	T-nmod
.	O

Infarct	B-Disease
-	O
avid	O
radiopharmaceuticals	T-obl:npmod
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
.	O

Infarct	O
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	T-nmod
for	T-nmod
rapid	T-nmod
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
animal	O
model	O
used	T-obj
to	T-obj
produce	O
infarction	B-Disease
implies	T-obj
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	O
.	O

The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	O
implies	O
artery	O
ligation	T-obl
but	T-obl
chemical	O
induction	T-obl
can	T-obl
be	T-obl
easily	T-obl
obtained	O
with	O
isoproterenol	B-Chemical
.	O

A	O
new	O
infarct	B-Disease
-	O
avid	O
radiopharmaceutical	T-obl:npmod
based	O
on	O
glucaric	O
acid	O
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

A	T-nmod
new	T-nmod
infarct	O
-	O
avid	T-nmod
radiopharmaceutical	O
based	O
on	O
glucaric	B-Chemical
acid	I-Chemical
was	O
prepared	T-nmod
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
was	T-nsubj
easy	O
to	O
prepare	T-nsubj
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	O
infarction	O
.	O

99mTc	O
-	O
glucarate	O
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	O
infarction	T-obl
.	O

99mTc	O
-	O
glucarate	O
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	T-nmod
its	O
biodistribution	O
in	T-nmod
rats	O
with	O
isoproterenol	T-amod
-	O
induced	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

Histological	O
studies	O
demonstrated	T-obj
that	T-obj
the	O
rats	T-obj
developed	O
an	O
infarct	B-Disease
18	O
h	T-obj
after	O
isoproterenol	O
administration	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	O
18	O
h	T-compound
after	T-compound
isoproterenol	B-Chemical
administration	O
.	O

Thirty	T-case
minutes	T-nmod
after	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
administration	T-obj
the	O
standardised	T-obj
heart	T-compound
uptake	O
value	T-obj
S	T-compound
(	T-obj
h	O
)	O
UV	O
was	O
4	T-compound
.	O
7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	T-obj
to	T-obj
detect	O
,	O
in	O
patients	T-obj
,	O
early	O
cardiac	B-Disease
infarction	I-Disease
.	O

Bupropion	B-Chemical
(	O
Zyban	O
)	O
toxicity	O
.	O

Bupropion	O
(	O
Zyban	B-Chemical
)	O
toxicity	T-appos
.	O

Bupropion	O
(	O
Zyban	T-compound
)	O
toxicity	B-Disease
.	O

Bupropion	B-Chemical
is	T-nsubj
a	T-nsubj
monocyclic	T-nsubj
antidepressant	O
structurally	O
related	T-nsubj
to	O
amphetamine	O
.	O

Bupropion	O
is	O
a	O
monocyclic	O
antidepressant	B-Chemical
structurally	T-amod
related	O
to	O
amphetamine	T-amod
.	O

Bupropion	O
is	O
a	O
monocyclic	O
antidepressant	T-obl
structurally	T-obl
related	O
to	O
amphetamine	B-Chemical
.	O

Zyban	B-Chemical
,	O
a	T-appos
sustained	O
-	O
release	T-appos
formulation	O
of	O
bupropion	O
hydrochloride	T-appos
,	O
was	T-nsubj:pass
recently	T-nsubj:pass
released	O
in	O
Ireland	T-nsubj:pass
,	O
as	O
a	O
smoking	O
cessation	O
aid	T-nsubj:pass
.	O

Zyban	T-nmod
,	O
a	T-nmod
sustained	O
-	O
release	T-nmod
formulation	O
of	O
bupropion	B-Chemical
hydrochloride	I-Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
'	O
s	O
introduction	O
,	O
12	T-compound
overdose	B-Disease
cases	O
have	O
been	O
reported	T-compound
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	T-nmod
symptoms	O
of	O
toxicity	B-Disease
.	O

Common	O
features	T-obj
included	O
tachycardia	B-Disease
,	O
drowsiness	O
,	O
hallucinations	O
and	T-conj
convulsions	O
.	O

Common	O
features	O
included	T-conj
tachycardia	O
,	O
drowsiness	T-conj
,	O
hallucinations	B-Disease
and	O
convulsions	T-conj
.	O

Common	O
features	O
included	T-conj
tachycardia	O
,	O
drowsiness	T-conj
,	O
hallucinations	T-conj
and	O
convulsions	B-Disease
.	O

Two	O
patients	T-obj
developed	O
severe	O
cardiac	B-Disease
arrhythmias	I-Disease
,	O
including	T-nmod
one	T-nmod
patient	O
who	O
was	O
resuscitated	T-nmod
following	O
a	O
cardiac	O
arrest	O
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	O
arrhythmias	O
,	O
including	O
one	O
patient	T-obl
who	T-obl
was	T-obl
resuscitated	O
following	O
a	O
cardiac	B-Disease
arrest	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13	O
.	O
5g	O
bupropion	B-Chemical
.	O

Recurrent	O
seizures	B-Disease
were	T-nsubj:pass
treated	O
with	O
diazepam	T-nsubj:pass
and	O
broad	O
complex	O
tachycardia	O
was	O
successfully	O
treated	T-nsubj:pass
with	O
adenosine	O
.	O

Recurrent	O
seizures	T-obl
were	T-obl
treated	O
with	O
diazepam	B-Chemical
and	T-conj
broad	T-conj
complex	T-conj
tachycardia	O
was	O
successfully	O
treated	T-obl
with	O
adenosine	O
.	O

Recurrent	O
seizures	O
were	O
treated	T-conj
with	T-conj
diazepam	O
and	O
broad	O
complex	O
tachycardia	B-Disease
was	O
successfully	O
treated	O
with	O
adenosine	O
.	O

Recurrent	O
seizures	O
were	O
treated	T-obl
with	O
diazepam	O
and	O
broad	O
complex	O
tachycardia	O
was	T-obl
successfully	T-obl
treated	O
with	O
adenosine	B-Chemical
.	O

Zyban	B-Chemical
caused	O
significant	O
neurological	O
and	O
cardiovascular	O
toxicity	T-nsubj
in	O
overdose	T-nsubj
.	O

Zyban	T-obj
caused	O
significant	O
neurological	B-Disease
and	I-Disease
cardiovascular	I-Disease
toxicity	I-Disease
in	O
overdose	T-obj
.	O

Zyban	T-obl
caused	O
significant	O
neurological	O
and	O
cardiovascular	O
toxicity	T-obl
in	O
overdose	B-Disease
.	O

GLEPP1	T-compound
receptor	T-compound
tyrosine	B-Chemical
phosphatase	O
(	O
Ptpro	T-compound
)	O
in	O
rat	O
PAN	O
nephrosis	T-compound
.	O

GLEPP1	T-nmod
receptor	T-nmod
tyrosine	T-nmod
phosphatase	O
(	O
Ptpro	T-nmod
)	O
in	O
rat	O
PAN	B-Chemical
nephrosis	B-Disease
.	O

Glomerular	O
epithelial	O
protein	T-compound
1	O
(	O
GLEPP1	O
)	O
is	T-compound
a	T-compound
podocyte	O
receptor	O
membrane	O
protein	T-compound
tyrosine	B-Chemical
phosphatase	O
located	T-compound
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

To	O
better	O
understand	T-nmod
the	O
utility	O
of	O
GLEPP1	O
as	T-nmod
a	T-nmod
marker	O
of	O
glomerular	B-Disease
injury	I-Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
was	T-nsubj:pass
induced	O
by	O
single	O
intraperitoneal	O
injection	T-nsubj:pass
of	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	O
was	O
induced	T-nmod
by	T-nmod
single	T-nmod
intraperitoneal	T-nmod
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	T-dep
)	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	T-dep
of	T-dep
puromycin	T-dep
aminonucleoside	O
(	O
PAN	B-Chemical
,	O
20	O
mg	T-appos
/	O
100g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	T-compound
after	O
PAN	B-Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	O
associated	O
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	T-nmod
both	T-nmod
the	T-nmod
acute	T-nmod
phase	O
of	O
proteinuria	B-Disease
associated	T-nmod
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	T-nmod
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	T-nmod
of	O
proteinuria	O
associated	O
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	T-nmod
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	T-nmod
the	T-nmod
chronic	T-nmod
phase	O
of	O
proteinuria	B-Disease
associated	T-nmod
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	T-obl
of	O
proteinuria	O
associated	O
with	O
glomerulosclerosis	B-Disease
(	O
days	O
45	O
-	O
126	O
)	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	T-obl
podocyte	O
injury	T-obl
induced	O
by	O
PAN	B-Chemical
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	T-nmod
the	T-nmod
treatment	O
of	O
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	O
anemia	T-nmod
.	O

Antithymocyte	O
globulin	O
in	O
the	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	O
anemia	T-obl
.	O

Antithymocyte	O
globulin	T-nmod
in	T-nmod
the	T-nmod
treatment	O
of	O
D	O
-	O
penicillamine	T-amod
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

A	O
patient	O
who	O
received	T-compound
antithymocyte	B-Chemical
globulin	I-Chemical
therapy	O
for	O
aplastic	O
anemia	O
due	O
to	O
D	O
-	O
penicillamine	O
therapy	O
is	O
described	O
.	O

A	O
patient	T-obl
who	T-obl
received	O
antithymocyte	O
globulin	O
therapy	T-obl
for	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
D	O
-	O
penicillamine	O
therapy	T-obl
is	O
described	O
.	O

A	O
patient	O
who	O
received	T-compound
antithymocyte	O
globulin	O
therapy	O
for	O
aplastic	O
anemia	O
due	T-compound
to	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
therapy	O
is	O
described	O
.	O

Use	O
of	O
antithymocyte	B-Chemical
globulin	I-Chemical
may	O
be	O
the	O
optimal	O
treatment	T-nmod
of	O
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	O
anemia	O
.	O

Use	O
of	O
antithymocyte	O
globulin	O
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	O
anemia	T-obl
.	O

Use	T-nmod
of	O
antithymocyte	O
globulin	O
may	T-nmod
be	T-nmod
the	T-nmod
optimal	T-nmod
treatment	O
of	O
D	O
-	O
penicillamine	T-amod
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

Metamizol	B-Chemical
potentiates	O
morphine	O
antinociception	T-compound
but	O
not	O
constipation	O
after	O
chronic	O
treatment	O
.	O

Metamizol	O
potentiates	T-compound
morphine	B-Chemical
antinociception	O
but	O
not	O
constipation	T-compound
after	O
chronic	O
treatment	T-compound
.	O

Metamizol	O
potentiates	T-conj
morphine	T-conj
antinociception	O
but	T-cc
not	O
constipation	B-Disease
after	O
chronic	O
treatment	T-conj
.	O

This	T-cc
work	T-conj
evaluates	T-conj
the	T-conj
antinociceptive	O
and	O
constipating	B-Disease
effects	T-conj
of	O
the	T-cc
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	O
effects	O
of	O
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	O
effects	O
of	O
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	B-Chemical
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B-Disease
-	O
induced	O
functional	O
impairment	O
model	T-obl
,	O
and	O
the	O
charcoal	O
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	O
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	B-Chemical
meal	O
test	T-compound
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	T-nummod
administration	T-compound
of	T-nummod
morphine	B-Chemical
with	T-compound
metamizol	T-nummod
resulted	T-dep
in	O
a	T-nummod
markedly	T-nummod
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O

Simultaneous	T-compound
administration	O
of	T-compound
morphine	T-compound
with	O
metamizol	B-Chemical
resulted	T-nmod
in	O
a	T-appos
markedly	T-appos
antinociceptive	T-parataxis
potentiation	T-parataxis
and	O
an	O
increasing	T-parataxis
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O

Antinociceptive	T-dep
effect	T-compound
of	O
morphine	B-Chemical
was	O
reduced	T-nummod
in	O
chronically	O
treated	O
rats	O
(	O
39	O
+	O
/	T-nummod
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	B-Chemical
s	O
.	O
c	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	T-obl
produced	O
by	O
morphine	B-Chemical
regardless	T-obl
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	O
-	O
induced	O
constipation	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	T-nsubj
that	T-nsubj
metamizol	B-Chemical
did	T-nsubj
not	T-nsubj
potentiate	O
morphine	O
-	O
induced	O
constipation	T-nsubj
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	B-Chemical
-	O
induced	O
constipation	T-obl
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	T-obj
that	T-obj
metamizol	T-obj
did	T-obj
not	T-obj
potentiate	O
morphine	T-amod
-	O
induced	O
constipation	B-Disease
.	O

These	O
findings	O
show	T-nmod
a	T-nmod
significant	T-nmod
interaction	O
between	O
morphine	B-Chemical
and	T-conj
metamizol	O
in	O
chronically	O
treated	O
rats	T-nmod
,	O
suggesting	T-nmod
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	T-conj
between	T-conj
morphine	O
and	O
metamizol	B-Chemical
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	O
and	O
metamizol	O
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	T-nmod
for	T-nmod
the	T-nmod
treatment	O
of	O
chronic	B-Disease
pain	I-Disease
.	O

Ifosfamide	B-Chemical
encephalopathy	B-Disease
presenting	O
with	O
asterixis	T-acl
.	O

Ifosfamide	O
encephalopathy	T-obl
presenting	O
with	O
asterixis	B-Disease
.	O

CNS	T-nmod
toxic	T-nmod
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	B-Chemical
(	O
IFX	O
)	O
are	O
frequent	T-nmod
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

CNS	O
toxic	O
effects	T-dep
of	T-dep
the	T-dep
antineoplastic	T-dep
agent	T-dep
ifosfamide	O
(	O
IFX	B-Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	T-obj
who	T-obj
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B-Disease
of	T-nmod
the	T-nmod
upper	T-nmod
and	O
lower	O
extremities	O
after	O
the	O
infusion	T-obj
of	O
ifosfamide	O
for	O
plasmacytoma	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	T-nmod
severe	O
,	O
disabling	O
negative	O
myoclonus	O
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	T-nmod
the	T-nmod
infusion	O
of	O
ifosfamide	B-Chemical
for	T-nmod
plasmacytoma	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	O
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	T-nmod
of	T-nmod
ifosfamide	O
for	O
plasmacytoma	B-Disease
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	T-obj
to	T-obj
reveal	O
structural	B-Disease
lesions	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
and	T-conj
metabolic	T-conj
abnormalities	O
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	O
lesions	T-conj
of	T-conj
the	T-conj
brain	O
and	O
metabolic	B-Disease
abnormalities	I-Disease
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	T-obj
with	T-obj
admixed	O
periodic	O
triphasic	O
waves	T-obj
indicating	O
symptomatic	O
encephalopathy	B-Disease
.	O

The	T-nmod
administration	O
of	O
ifosfamide	B-Chemical
was	O
discontinued	T-nmod
and	O
within	O
12	O
h	O
the	O
asterixis	O
resolved	O
completely	O
.	O

The	O
administration	O
of	O
ifosfamide	O
was	O
discontinued	T-nsubj
and	T-nsubj
within	O
12	O
h	T-nsubj
the	O
asterixis	B-Disease
resolved	O
completely	T-nsubj
.	O

In	O
the	O
patient	O
described	O
,	O
the	T-nmod
presence	O
of	O
asterixis	B-Disease
during	O
infusion	T-nmod
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	T-nmod
that	O
negative	O
myoclonus	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	T-nmod
of	O
asterixis	O
during	T-nmod
infusion	O
of	O
ifosfamide	B-Chemical
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	O
during	O
infusion	O
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	T-nsubj:pass
that	T-nsubj:pass
negative	O
myoclonus	B-Disease
is	T-nsubj:pass
associated	O
with	O
the	O
use	T-nsubj:pass
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	O
during	O
infusion	O
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	O
is	O
associated	T-nmod
with	T-nmod
the	T-nmod
use	O
of	O
IFX	B-Chemical
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	B-Chemical
-	O
induced	O
anemia	T-obl
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Antagonism	T-nmod
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	T-nmod
mice	O
with	O
azidothymidine	T-amod
-	O
induced	O
anemia	B-Disease
and	T-conj
in	T-conj
bone	O
marrow	T-conj
endothelial	T-conj
cells	O
.	O

Azidothymidine	B-Chemical
(	O
AZT	O
)	O
-	O
induced	O
anemia	T-obl
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Azidothymidine	O
(	O
AZT	B-Chemical
)	O
-	O
induced	T-appos
anemia	O
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Azidothymidine	T-amod
(	O
AZT	O
)	O
-	O
induced	O
anemia	B-Disease
in	T-nmod
mice	O
can	T-nsubj:pass
be	T-nsubj:pass
reversed	O
by	O
the	O
administration	T-nsubj:pass
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	B-Chemical
-	O
treated	O
mice	T-obl
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

There	O
was	O
a	O
significant	O
reduction	T-compound
of	T-compound
thymidine	B-Chemical
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	T-compound
treated	T-compound
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
reduced	T-compound
thymidine	B-Chemical
incorporation	O
into	O
erythroid	O
cells	T-compound
as	O
compared	O
to	O
identical	O
fractions	T-compound
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	T-compound
with	O
EPO	O
alone	O
.	O

The	O
relationship	T-compound
between	T-compound
hippocampal	T-compound
acetylcholine	B-Chemical
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	T-compound
in	O
withdrawal	O
seizure	O
-	O
prone	O
and	O
withdrawal	O
seizure	O
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	B-Disease
-	O
prone	O
and	O
withdrawal	T-obl:npmod
seizure	O
-	O
resistant	O
selected	O
mouse	O
lines	T-obl:npmod
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	O
-	O
prone	O
and	O
withdrawal	O
seizure	B-Disease
-	O
resistant	O
selected	O
mouse	O
lines	T-obl:npmod
.	O

BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	B-Chemical
withdrawal	O
severity	T-compound
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	T-compound
and	T-compound
alcohol	B-Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	O
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	O
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-Chemical
withdrawal	O
severity	T-compound
.	O

METHODS	T-obl
:	O
Cholinergic	O
convulsant	O
sensitivity	T-obl
was	T-obl
examined	O
in	O
alcohol	B-Chemical
-	O
na	O
ve	T-obl
Withdrawal	O
Seizure	O
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	O
-	O
na	O
ve	O
Withdrawal	T-compound
Seizure	B-Disease
-	O
Prone	O
(	O
WSP	T-compound
)	O
and	O
-	O
Resistant	T-compound
(	O
WSR	O
)	O
mice	T-compound
.	O

Animals	T-obj
were	T-obj
administered	O
nicotine	B-Chemical
,	O
carbachol	O
,	O
or	T-conj
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	T-obj
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	T-obj
and	O
converted	O
to	O
threshold	O
dose	O
.	O

Animals	O
were	O
administered	T-conj
nicotine	O
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	T-conj
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

Animals	O
were	O
administered	T-conj
nicotine	O
,	O
carbachol	T-conj
,	O
or	O
neostigmine	B-Chemical
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

Animals	O
were	O
administered	O
nicotine	O
,	O
carbachol	O
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	T-nmod
to	T-nmod
onset	O
of	O
tremor	B-Disease
and	T-conj
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	T-obl
and	T-obl
potassium	B-Chemical
-	O
stimulated	O
acetylcholine	O
(	O
ACh	O
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	T-compound
basal	O
and	O
potassium	O
-	O
stimulated	T-amod
acetylcholine	B-Chemical
(	O
ACh	O
)	O
release	O
in	O
the	O
CA1	O
region	T-compound
of	O
the	O
hippocampus	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	T-dep
and	O
potassium	O
-	O
stimulated	O
acetylcholine	O
(	O
ACh	B-Chemical
)	O
release	T-dep
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	B-Chemical
was	T-nsubj:pass
applied	O
by	O
reverse	O
dialysis	T-nsubj:pass
twice	T-nsubj:pass
,	O
separated	T-nsubj:pass
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	B-Chemical
also	T-nsubj:pass
was	T-nsubj:pass
measured	O
during	O
testing	T-nsubj:pass
for	O
handling	O
-	O
induced	O
convulsions	O
.	O

Hippocampal	O
ACh	O
also	O
was	O
measured	T-nmod
during	T-nmod
testing	O
for	O
handling	T-amod
-	O
induced	O
convulsions	B-Disease
.	O

RESULTS	O
:	O
Sensitivity	T-compound
to	T-compound
several	T-compound
convulsion	B-Disease
endpoints	O
induced	T-compound
by	O
nicotine	O
,	O
carbachol	O
,	O
and	O
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	T-obl
induced	O
by	O
nicotine	B-Chemical
,	O
carbachol	O
,	O
and	T-conj
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	T-conj
by	T-conj
nicotine	O
,	O
carbachol	B-Chemical
,	O
and	O
neostigmine	T-conj
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	T-conj
by	T-conj
nicotine	O
,	O
carbachol	T-conj
,	O
and	O
neostigmine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	T-nmod
in	T-nmod
basal	T-nmod
release	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	O
increased	O
ACh	O
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	T-nsubj
in	O
basal	O
release	O
of	O
ACh	O
,	O
and	T-nsubj
50	T-compound
mM	O
KCl	B-Chemical
increased	O
ACh	O
output	T-nsubj
in	O
both	O
lines	T-nsubj
of	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KCl	O
increased	T-compound
ACh	B-Chemical
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	T-nmod
in	T-nmod
release	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	O
produced	T-nmod
by	T-nmod
the	T-nmod
first	T-nmod
application	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	T-nmod
and	T-nmod
postsynaptic	T-nmod
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
may	O
be	O
associated	O
with	O
ethanol	O
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	O
may	O
be	O
associated	O
with	O
ethanol	B-Chemical
withdrawal	O
severity	T-compound
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	O
may	O
be	O
associated	O
with	O
ethanol	O
withdrawal	O
severity	O
and	O
implicate	T-compound
cholinergic	O
mechanisms	O
in	T-compound
alcohol	B-Chemical
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	T-nmod
lower	T-nmod
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Capsaicin	B-Chemical
-	O
induced	O
muscle	O
pain	T-obl
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

Capsaicin	T-amod
-	O
induced	O
muscle	B-Disease
pain	I-Disease
alters	O
the	O
excitability	T-nsubj
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

The	T-nmod
pathophysiology	O
of	O
painful	O
temporomandibular	B-Disease
disorders	I-Disease
is	O
not	O
fully	O
understood	T-nmod
,	O
but	O
evidence	O
suggests	O
that	O
muscle	O
pain	O
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	O
disorders	O
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	T-nsubj
that	T-nsubj
muscle	B-Disease
pain	I-Disease
modulates	O
motor	O
function	T-nsubj
in	O
characteristic	O
ways	T-nsubj
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	T-compound
of	T-compound
nociceptive	B-Disease
muscle	I-Disease
afferent	T-compound
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O

Capsaicin	B-Chemical
(	O
10	T-appos
micro	T-appos
g	O
)	O
was	T-nsubj:pass
injected	O
into	O
the	O
masseter	O
muscle	T-nsubj:pass
to	O
induce	T-nsubj:pass
pain	O
in	O
11	O
healthy	O
volunteers	O
.	O

Capsaicin	O
(	O
10	O
micro	O
g	O
)	O
was	O
injected	T-obj
into	O
the	O
masseter	O
muscle	O
to	T-obj
induce	O
pain	B-Disease
in	O
11	O
healthy	O
volunteers	T-obj
.	O

Short	O
-	O
latency	O
reflex	O
responses	T-conj
were	T-conj
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	T-conj
by	O
a	O
stretch	O
device	T-conj
with	O
different	O
velocities	O
and	O
displacements	O
before	T-conj
,	O
during	T-conj
,	O
and	O
after	O
the	O
pain	B-Disease
.	O

The	O
normalized	O
reflex	O
amplitude	T-obl
was	T-obl
significantly	T-obl
higher	O
during	O
pain	B-Disease
,	O
but	T-obl
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	O
muscle	O
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	O
,	O
but	T-nmod
only	T-nmod
at	T-nmod
faster	T-nmod
stretches	O
in	O
the	O
painful	B-Disease
muscle	I-Disease
.	O

Increased	T-nmod
sensitivity	O
of	O
the	O
fusimotor	O
system	T-nmod
during	O
acute	O
muscle	B-Disease
pain	I-Disease
could	O
be	O
one	O
likely	O
mechanism	T-nmod
to	O
explain	O
the	O
findings	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	B-Chemical
-	O
induced	O
locomotor	O
hyperactivity	T-obl
in	O
rats	O
.	O

Effects	T-obl
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	T-obl
or	O
core	O
on	O
the	O
cocaine	T-amod
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
in	T-nmod
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	T-nmod
into	T-nmod
the	T-nmod
subregions	O
of	O
the	O
nucleus	O
accumbens	T-nmod
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Disease
hyperactivity	I-Disease
induced	O
by	O
cocaine	T-acl
in	O
rats	T-acl
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	O
hyperactivity	T-obl
induced	O
by	O
cocaine	B-Chemical
in	O
rats	T-obl
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	T-obl
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	T-obl
then	T-obl
were	T-obl
locally	T-obl
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	T-dep
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	T-dep
)	O
or	T-conj
CP	O
93129	T-conj
(	O
an	O
agonist	T-conj
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	T-conj
with	T-conj
GR	O
55562	T-conj
(	O
an	O
antagonist	T-conj
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	T-appos
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	T-appos
)	O
.	O

Given	O
alone	O
to	T-conj
any	T-advmod
accumbal	O
subregion	T-conj
,	O
GR	B-Chemical
55562	I-Chemical
(	T-conj
0	O
.	O
1	T-advmod
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Systemic	O
cocaine	B-Chemical
(	O
10	T-dep
mg	O
/	O
kg	T-dep
)	O
significantly	T-nsubj
increased	O
the	O
locomotor	O
activity	T-nsubj
of	O
rats	O
.	O

GR	B-Chemical
55562	I-Chemical
(	T-nummod
0	T-dep
.	O
1	T-nummod
-	O
10	O
microg	O
/	O
side	O
)	O
,	T-nummod
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	T-nummod
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	O
hyperactivity	O
.	O

GR	T-nsubj
55562	O
(	T-nsubj
0	O
.	O
1	T-nsubj
-	O
10	O
microg	O
/	O
side	O
)	O
,	T-nsubj
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	B-Chemical
,	T-obj
dose	O
-	O
dependently	T-obj
attenuated	T-obj
the	O
psychostimulant	O
-	O
induced	O
locomotor	O
hyperactivity	O
.	O

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	O
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	T-obj
which	T-obj
had	T-obj
been	T-obj
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
into	T-nmod
the	T-nmod
accumbens	T-nmod
core	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	T-dep
not	T-nmod
the	T-nmod
core	T-case
)	T-case
before	T-nmod
cocaine	B-Chemical
,	O
CP	O
93129	T-dep
(	T-dep
0	O
.	O
1	O
-	T-dep
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	O
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	T-nsubj:pass
not	O
the	O
core	T-appos
)	O
before	T-appos
cocaine	T-nsubj:pass
,	O
CP	B-Chemical
93129	I-Chemical
(	T-nsubj:pass
0	T-appos
.	O
1	O
-	T-nsubj:pass
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	O
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	O
,	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	B-Chemical
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	T-nmod
after	T-nmod
intra	O
-	O
accumbens	T-nmod
shell	T-nmod
treatment	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	T-dep
microg	O
/	O
side	T-dep
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	O
hyperlocomotion	T-dep
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

Our	O
findings	O
indicate	T-nsubj:pass
that	T-nsubj:pass
cocaine	T-amod
induced	O
hyperlocomotion	B-Disease
is	T-nsubj:pass
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	T-nsubj:pass
microinjected	T-nsubj:pass
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	T-nsubj:pass
,	O
this	O
modification	T-nsubj:pass
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	T-nsubj:pass
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	O
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	T-appos
of	T-appos
the	T-appos
5	O
-	O
HT1B	T-appos
receptor	T-appos
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	T-appos
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	O
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	T-appos
(	O
GR	O
55562	O
)	O
and	T-appos
agonist	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

Cocaine	B-Chemical
related	T-compound
chest	T-compound
pain	O
:	O
are	O
we	O
seeing	T-compound
the	O
tip	O
of	O
an	O
iceberg	O
?	O

Cocaine	O
related	O
chest	B-Disease
pain	I-Disease
:	O
are	T-parataxis
we	T-parataxis
seeing	O
the	O
tip	T-parataxis
of	O
an	O
iceberg	O
?	O

The	T-nmod
recreational	T-nmod
use	O
of	O
cocaine	B-Chemical
is	O
on	O
the	O
increase	T-nmod
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	T-compound
of	T-compound
cocaine	B-Chemical
use	O
.	O

In	O
particular	O
,	O
the	T-nmod
tendency	O
of	O
cocaine	B-Chemical
to	O
produce	T-nmod
chest	O
pain	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	O
pain	O
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

In	O
particular	T-obj
,	O
the	O
tendency	T-obj
of	O
cocaine	O
to	T-obj
produce	O
chest	B-Disease
pain	I-Disease
ought	T-obj
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	O
pain	O
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	O
to	O
produce	O
chest	O
pain	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	T-nmod
with	T-nmod
a	T-nmod
young	T-nmod
victim	O
of	O
chest	B-Disease
pain	I-Disease
who	T-acl:relcl
is	T-acl:relcl
otherwise	T-acl:relcl
at	T-acl:relcl
low	T-acl:relcl
risk	O
.	O

The	T-nmod
mechanism	O
of	O
chest	B-Disease
pain	I-Disease
related	T-nmod
to	O
cocaine	O
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

The	O
mechanism	O
of	O
chest	O
pain	O
related	T-compound
to	T-compound
cocaine	B-Chemical
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	T-compound
of	T-compound
potential	T-compound
cocaine	B-Chemical
users	O
will	O
be	O
addressed	O
.	O

Crossover	O
comparison	T-nmod
of	T-nmod
efficacy	O
and	O
preference	T-nmod
for	O
rizatriptan	B-Chemical
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	T-dep
in	O
migraine	T-nmod
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	O
10	O
mg	T-compound
versus	T-compound
ergotamine	B-Chemical
/	O
caffeine	O
in	O
migraine	O
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	T-conj
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	B-Chemical
in	O
migraine	O
.	O

Crossover	O
comparison	T-nmod
of	T-nmod
efficacy	O
and	O
preference	T-nmod
for	O
rizatriptan	T-nmod
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	O
in	O
migraine	B-Disease
.	O

Rizatriptan	B-Chemical
is	T-nsubj
a	T-nsubj
selective	T-nsubj
5	O
-	O
HT	T-nsubj
(	O
1B	O
/	O
1D	O
)	O
receptor	T-nsubj
agonist	O
with	O
rapid	O
oral	O
absorption	T-nsubj
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	T-nsubj
of	O
migraine	O
.	O

Rizatriptan	T-compound
is	T-compound
a	T-compound
selective	T-compound
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	T-dep
/	O
1D	O
)	O
receptor	T-compound
agonist	O
with	O
rapid	O
oral	O
absorption	T-compound
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	T-compound
of	O
migraine	O
.	O

Rizatriptan	O
is	O
a	O
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	T-nmod
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	T-nmod
the	T-nmod
acute	T-nmod
treatment	O
of	O
migraine	B-Disease
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	T-nmod
the	T-nmod
preference	O
for	O
1	O
rizatriptan	B-Chemical
10	O
mg	T-dep
tablet	O
to	O
2	O
ergotamine	O
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	T-nmod
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	T-compound
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	T-compound
2	T-compound
ergotamine	B-Chemical
1	O
mg	O
/	O
caffeine	T-compound
100	O
mg	T-compound
tablets	O
in	O
439	O
patients	T-compound
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	T-compound
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	T-compound
2	T-compound
ergotamine	T-compound
1	O
mg	O
/	O
caffeine	B-Chemical
100	O
mg	T-compound
tablets	O
in	O
439	O
patients	T-compound
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	O
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	T-compound
a	T-compound
single	T-compound
migraine	B-Disease
attack	O
with	O
each	O
therapy	T-compound
.	O

The	O
co	O
-	O
primary	O
endpoint	T-obl:npmod
of	T-obl:npmod
being	T-obl:npmod
pain	B-Disease
free	O
at	O
2	O
h	T-obl:npmod
was	O
also	O
in	O
favor	O
of	O
rizatriptan	O
.	O

The	O
co	O
-	O
primary	O
endpoint	T-nmod
of	O
being	O
pain	O
free	O
at	O
2	O
h	O
was	T-nmod
also	T-nmod
in	T-nmod
favor	O
of	O
rizatriptan	B-Chemical
.	O

Rizatriptan	B-Chemical
was	T-nsubj
also	T-nsubj
superior	O
to	O
ergotamine	O
/	O
caffeine	T-nsubj
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	T-nsubj
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-compound
to	T-compound
ergotamine	B-Chemical
/	O
caffeine	O
in	O
the	O
proportions	T-compound
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	T-obl
was	T-obl
also	T-obl
superior	O
to	O
ergotamine	O
/	O
caffeine	B-Chemical
in	T-nmod
the	T-nmod
proportions	O
of	O
patients	T-nmod
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	T-obl
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	T-nmod
of	T-nmod
patients	O
with	O
no	O
nausea	B-Disease
,	O
vomiting	O
,	O
phonophobia	O
or	T-conj
photophobia	O
and	T-conj
for	T-conj
patients	O
with	O
normal	O
function	T-conj
2	O
h	T-conj
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	T-conj
with	T-conj
no	T-conj
nausea	O
,	O
vomiting	B-Disease
,	O
phonophobia	T-conj
or	O
photophobia	T-conj
and	O
for	O
patients	T-conj
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	T-conj
with	T-conj
no	T-conj
nausea	O
,	O
vomiting	T-conj
,	O
phonophobia	B-Disease
or	O
photophobia	T-conj
and	O
for	O
patients	T-conj
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	T-conj
with	T-conj
no	T-conj
nausea	O
,	O
vomiting	T-conj
,	O
phonophobia	T-conj
or	O
photophobia	B-Disease
and	O
for	O
patients	T-conj
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	T-nmod
for	O
recurrent	O
glioblastomas	T-nmod
.	O

Severe	O
ocular	O
and	O
orbital	O
toxicity	T-nmod
after	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	T-nmod
.	O

Severe	O
ocular	O
and	O
orbital	O
toxicity	T-nmod
after	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	T-nmod
for	O
recurrent	O
glioblastomas	B-Disease
.	O

BACKGROUND	T-nsubj
:	O
Glioblastoma	B-Disease
is	T-nsubj
a	T-nsubj
malignant	T-nsubj
tumor	O
that	O
occurs	T-nsubj
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

BACKGROUND	O
:	O
Glioblastoma	O
is	O
a	O
malignant	B-Disease
tumor	I-Disease
that	T-acl:relcl
occurs	O
in	O
the	O
cerebrum	T-acl:relcl
during	O
adulthood	T-acl:relcl
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	T-nmod
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	T-nsubj:pass
,	O
carboplatin	B-Chemical
is	T-nsubj:pass
said	O
to	O
have	T-nsubj:pass
milder	O
side	O
effects	O
than	O
cisplatin	O
,	O
whose	O
ocular	O
and	O
orbital	O
toxicity	O
are	O
well	O
known	O
.	O

Generally	O
,	O
carboplatin	O
is	O
said	O
to	O
have	T-nmod
milder	T-nmod
side	T-nmod
effects	O
than	O
cisplatin	B-Chemical
,	O
whose	O
ocular	O
and	O
orbital	O
toxicity	T-acl:relcl
are	T-acl:relcl
well	T-acl:relcl
known	O
.	O

Generally	O
,	O
carboplatin	O
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	T-nsubj:pass
,	O
whose	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
are	T-nsubj:pass
well	T-nsubj:pass
known	O
.	O

However	O
,	O
we	O
experienced	T-nmod
a	T-nmod
case	O
of	O
severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O

However	O
,	O
we	O
experienced	T-nmod
a	O
case	O
of	O
severe	O
ocular	O
and	O
orbital	O
toxicity	O
after	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	T-nmod
.	O

CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	T-nmod
an	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	O
in	O
his	O
left	O
temporal	O
lobe	O
.	O

CASE	T-obl
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	T-obl
received	O
an	O
intracarotid	O
injection	T-obl
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	B-Disease
in	O
his	O
left	O
temporal	O
lobe	T-obl
.	O

He	T-obl
complained	O
of	O
pain	B-Disease
and	I-Disease
visual	I-Disease
disturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilateral	I-Disease
eye	I-Disease
30	O
h	T-obl
after	O
the	O
injection	O
.	O

Various	O
ocular	O
symptoms	T-obl
and	O
findings	O
caused	O
by	O
carboplatin	B-Chemical
toxicity	B-Disease
were	O
seen	T-obl
.	O

RESULTS	O
:	O
He	O
was	O
treated	T-conj
with	T-conj
intravenous	T-conj
administration	O
of	O
corticosteroids	T-conj
and	O
glycerin	B-Chemical
for	T-nmod
6	T-nmod
days	O
after	O
the	O
injection	T-nmod
.	O

Although	T-obl
the	O
intraocular	O
pressure	O
elevation	T-obl
caused	O
by	O
secondary	O
acute	O
angle	T-compound
-	O
closure	O
glaucoma	B-Disease
decreased	T-obl
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	O
papilledema	O
and	O
exudative	O
retinal	O
detachment	O
continued	T-obl
for	O
3	O
weeks	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	O
decreased	T-nsubj
and	T-nsubj
ocular	B-Disease
pain	I-Disease
diminished	O
,	O
inexorable	O
papilledema	O
and	O
exudative	O
retinal	O
detachment	O
continued	O
for	O
3	O
weeks	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	T-nsubj
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	O
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	O
papilledema	B-Disease
and	T-conj
exudative	T-conj
retinal	T-conj
detachment	O
continued	O
for	O
3	O
weeks	T-nsubj
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	O
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	T-conj
papilledema	O
and	O
exudative	O
retinal	B-Disease
detachment	I-Disease
continued	T-conj
for	O
3	O
weeks	O
.	O

Finally	T-nsubj
,	O
6	O
weeks	O
later	T-nsubj
,	O
diffuse	O
chorioretinal	B-Disease
atrophy	I-Disease
with	T-nmod
optic	T-nmod
atrophy	O
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	T-nsubj
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	T-nmod
chorioretinal	T-nmod
atrophy	O
with	O
optic	B-Disease
atrophy	I-Disease
occurred	T-nmod
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	T-nmod
intracarotid	T-nmod
injection	O
of	O
carboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	O
toxicity	O
.	O

CONCLUSION	T-obl
:	O
When	O
performing	T-obl
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
we	T-obl
must	T-obl
be	T-obl
aware	O
of	O
its	O
potentially	T-amod
blinding	O
ocular	B-Disease
toxicity	I-Disease
.	O

Visual	B-Disease
hallucinations	I-Disease
associated	O
with	O
zonisamide	T-amod
.	O

Visual	O
hallucinations	T-obl
associated	O
with	O
zonisamide	B-Chemical
.	O

Zonisamide	B-Chemical
is	T-nsubj
a	T-nsubj
broad	O
-	O
spectrum	T-nsubj
antiepileptic	T-nsubj
drug	O
used	T-nsubj
to	O
treat	O
various	O
types	O
of	O
seizures	O
.	O

Zonisamide	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	T-nmod
various	T-nmod
types	O
of	O
seizures	B-Disease
.	O

Although	T-nsubj:pass
visual	B-Disease
hallucinations	I-Disease
have	T-nsubj:pass
not	T-nsubj:pass
been	T-nsubj:pass
reported	O
as	O
an	O
adverse	O
effect	T-nsubj:pass
of	O
this	O
agent	O
,	O
we	O
describe	T-nsubj:pass
three	O
patients	O
who	O
experienced	O
complex	O
visual	O
hallucinations	O
and	O
altered	O
mental	O
status	O
after	O
zonisamide	O
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

Although	O
visual	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	T-obj
who	T-obj
experienced	O
complex	O
visual	B-Disease
hallucinations	I-Disease
and	O
altered	T-obj
mental	O
status	O
after	O
zonisamide	O
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

Although	O
visual	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	O
hallucinations	O
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Chemical
treatment	O
was	O
begun	T-compound
or	O
its	O
dosage	O
increased	O
.	O

All	O
three	T-obl
had	T-obl
been	T-obl
diagnosed	O
earlier	T-obl
with	O
epilepsy	B-Disease
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	T-obl
.	O

During	O
monitoring	T-nsubj
,	O
visual	B-Disease
hallucinations	I-Disease
did	T-nsubj
not	T-nsubj
correlate	O
with	O
EEG	O
readings	T-nsubj
,	O
nor	O
did	T-nsubj
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	T-obj
of	O
the	O
patients	O
had	T-obj
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	T-obj
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	T-nmod
or	T-nmod
increased	T-nmod
dosage	O
of	O
zonisamide	B-Chemical
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	T-obl
associated	O
with	O
zonisamide	B-Chemical
.	O

Anti	O
-	O
epileptic	B-Disease
drugs	O
-	O
induced	T-amod
de	T-amod
novo	O
absence	T-amod
seizures	O
.	O

Anti	T-amod
-	O
epileptic	O
drugs	T-amod
-	O
induced	O
de	O
novo	T-amod
absence	B-Disease
seizures	I-Disease
.	O

The	O
authors	O
present	T-nmod
three	T-nmod
patients	O
with	O
de	O
novo	T-amod
absence	B-Disease
epilepsy	I-Disease
after	O
administration	T-nmod
of	O
carbamazepine	O
and	O
vigabatrin	O
.	O

The	O
authors	O
present	O
three	O
patients	T-nmod
with	O
de	O
novo	O
absence	O
epilepsy	O
after	T-nmod
administration	O
of	O
carbamazepine	B-Chemical
and	T-conj
vigabatrin	O
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	O
epilepsy	O
after	O
administration	T-conj
of	T-conj
carbamazepine	O
and	O
vigabatrin	B-Chemical
.	O

Despite	O
the	O
underlying	O
diseases	O
,	O
the	T-nmod
prognosis	O
for	O
drug	T-amod
-	O
induced	O
de	O
novo	T-amod
absence	B-Disease
seizure	I-Disease
is	O
good	T-nmod
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O

The	T-amod
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
transmitted	T-amod
thalamocortical	T-amod
circuitry	T-amod
accounts	T-obl
for	O
a	O
major	O
part	T-amod
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	O
epilepsy	O
.	O

The	O
gamma	O
-	O
aminobutyric	O
acid	O
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	T-nmod
of	T-nmod
the	T-nmod
underlying	T-nmod
neurophysiology	O
of	O
the	O
absence	B-Disease
epilepsy	I-Disease
.	O

Because	T-nsubj
drug	T-amod
-	O
induced	O
de	O
novo	T-amod
absence	B-Disease
seizure	I-Disease
is	T-nsubj
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	T-nsubj
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	T-obj
to	T-obj
trigger	O
the	O
de	O
novo	T-amod
absence	B-Disease
seizure	I-Disease
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	T-compound
in	T-compound
seizure	B-Disease
frequency	O
and	O
/	O
or	O
new	O
seizure	O
types	T-compound
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	O
frequency	T-compound
and	T-compound
/	O
or	O
new	T-compound
seizure	B-Disease
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

By	O
understanding	T-nmod
the	T-nmod
underlying	T-nmod
mechanism	O
of	O
absence	B-Disease
epilepsy	I-Disease
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	O
and	O
prevent	O
drug	O
-	O
induced	O
absence	O
seizures	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	O
epilepsy	O
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	T-nmod
of	O
anticonvulsants	O
in	T-nmod
children	O
with	O
epilepsy	B-Disease
and	O
prevent	O
drug	O
-	O
induced	O
absence	O
seizures	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	O
epilepsy	O
,	O
we	O
can	O
avoid	T-obj
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	O
and	T-obj
prevent	O
drug	T-amod
-	O
induced	O
absence	B-Disease
seizures	I-Disease
.	O

Prenatal	T-compound
dexamethasone	B-Chemical
programs	O
hypertension	T-compound
and	O
renal	O
injury	O
in	O
the	O
rat	O
.	O

Prenatal	T-dep
dexamethasone	T-dep
programs	O
hypertension	B-Disease
and	T-conj
renal	T-conj
injury	O
in	T-nmod
the	T-nmod
rat	O
.	O

Prenatal	O
dexamethasone	O
programs	T-conj
hypertension	O
and	O
renal	B-Disease
injury	I-Disease
in	O
the	O
rat	T-conj
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	T-nsubj
if	T-nsubj
prenatal	O
dexamethasone	B-Chemical
programmed	O
a	O
progressive	O
increase	T-nsubj
in	O
blood	O
pressure	O
and	O
renal	O
injury	O
in	O
rats	T-nsubj
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	T-obj
if	T-obj
prenatal	O
dexamethasone	T-obj
programmed	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	T-conj
renal	T-conj
injury	O
in	O
rats	T-obj
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	O
programmed	O
a	O
progressive	O
increase	T-conj
in	T-conj
blood	T-conj
pressure	O
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	T-conj
or	T-nmod
2	T-conj
daily	T-conj
intraperitoneal	T-nmod
injections	T-conj
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Male	O
rats	T-obj
that	T-obj
received	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	T-obj
15	O
and	O
16	O
,	O
17	T-obj
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	O
blood	O
pressures	O
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
.	O

Male	T-nsubj
rats	O
that	O
received	T-nsubj
prenatal	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B-Disease
blood	I-Disease
pressures	I-Disease
at	T-obl
6	T-obl
months	O
of	O
age	T-obl
;	O
the	O
latter	O
group	T-parataxis
did	T-parataxis
not	T-parataxis
have	O
a	O
reduction	T-parataxis
in	O
glomerular	O
number	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	T-obj
blood	O
pressures	O
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	T-obj
did	T-obj
not	T-obj
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
.	O

Adult	O
rats	T-obj
given	O
dexamethasone	B-Chemical
on	O
days	T-obj
15	O
and	O
16	O
of	O
gestation	O
had	T-obj
more	O
glomeruli	O
with	O
glomerulosclerosis	O
than	O
control	O
rats	O
.	O

Adult	O
rats	O
given	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	T-nmod
more	T-nmod
glomeruli	O
with	O
glomerulosclerosis	B-Disease
than	O
control	O
rats	T-nmod
.	O

This	O
study	O
shows	T-nsubj
that	T-nsubj
prenatal	O
dexamethasone	B-Chemical
in	T-nmod
rats	O
results	O
in	O
a	O
reduction	T-nsubj
in	O
glomerular	O
number	O
,	O
glomerulosclerosis	O
,	O
and	O
hypertension	O
when	O
administered	T-nsubj
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	T-obl
that	T-obl
prenatal	O
dexamethasone	T-obl
in	O
rats	O
results	O
in	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
glomerulosclerosis	O
,	O
and	T-conj
hypertension	O
when	O
administered	T-obl
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	O
in	O
a	O
reduction	T-conj
in	T-conj
glomerular	T-conj
number	O
,	O
glomerulosclerosis	B-Disease
,	O
and	O
hypertension	T-conj
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	O
in	O
a	O
reduction	T-conj
in	T-conj
glomerular	T-conj
number	O
,	O
glomerulosclerosis	T-conj
,	O
and	O
hypertension	B-Disease
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	B-Disease
was	T-nsubj:pass
observed	O
in	O
animals	T-nsubj:pass
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	O
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	T-obj
that	T-obj
did	T-obj
not	T-obj
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
suggesting	T-obj
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	T-nsubj
that	T-nsubj
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
is	T-nsubj
not	T-nsubj
the	T-nsubj
sole	T-nsubj
cause	O
for	O
the	O
development	T-nsubj
of	O
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	O
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	T-nmod
for	T-nmod
the	T-nmod
development	O
of	O
hypertension	B-Disease
.	O

Kidney	O
function	T-nmod
and	O
morphology	O
after	T-nmod
short	O
-	O
term	T-nmod
combination	T-nmod
therapy	O
with	O
cyclosporine	B-Chemical
A	I-Chemical
,	O
tacrolimus	O
and	T-conj
sirolimus	O
in	O
the	O
rat	T-nmod
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	T-conj
with	T-conj
cyclosporine	T-conj
A	O
,	O
tacrolimus	B-Chemical
and	O
sirolimus	T-conj
in	O
the	O
rat	O
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	T-conj
with	T-conj
cyclosporine	T-conj
A	O
,	O
tacrolimus	T-conj
and	O
sirolimus	B-Chemical
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
SRL	O
)	O
may	O
supplement	T-dep
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

BACKGROUND	T-appos
:	O
Sirolimus	O
(	O
SRL	B-Chemical
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	B-Disease
,	O
but	T-conj
SRL	T-conj
seems	O
to	O
act	T-conj
differently	O
displaying	O
only	O
minor	O
nephrotoxic	O
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

These	O
are	O
nephrotoxic	T-nsubj
,	O
but	T-nsubj
SRL	B-Chemical
seems	O
to	O
act	T-nsubj
differently	O
displaying	O
only	O
minor	O
nephrotoxic	O
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

These	O
are	O
nephrotoxic	O
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	T-amod
only	O
minor	T-amod
nephrotoxic	B-Disease
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	T-nsubj:pass
where	T-nsubj:pass
SRL	B-Chemical
was	T-nsubj:pass
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	T-nsubj:pass
of	O
a	O
synergistic	O
nephrotoxic	O
effect	O
were	O
described	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	O
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	T-amod
of	T-amod
a	T-amod
synergistic	T-amod
nephrotoxic	B-Disease
effect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	T-obl
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-Chemical
A	I-Chemical
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
FK506	T-conj
)	O
or	T-conj
SRL	O
as	O
monotherapies	T-obl
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-appos
with	T-appos
either	T-appos
cyclosporine	T-appos
A	O
(	O
CsA	B-Chemical
)	O
,	O
tacrolimus	T-appos
(	O
FK506	O
)	O
or	O
SRL	T-appos
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-conj
with	T-conj
either	T-conj
cyclosporine	T-conj
A	O
(	O
CsA	T-conj
)	O
,	O
tacrolimus	B-Chemical
(	O
FK506	O
)	O
or	O
SRL	T-conj
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	O
A	T-appos
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
FK506	B-Chemical
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-conj
with	T-conj
either	T-conj
cyclosporine	T-conj
A	O
(	O
CsA	T-conj
)	O
,	O
tacrolimus	T-conj
(	O
FK506	O
)	O
or	O
SRL	B-Chemical
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

METHODS	T-appos
:	T-dep
For	T-appos
a	T-appos
period	O
of	O
2	O
weeks	T-appos
,	O
CsA	B-Chemical
15	T-dep
mg	O
/	T-dep
kg	O
/	T-dep
day	T-dep
(	O
given	T-appos
orally	O
)	O
,	O
FK506	T-dep
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

METHODS	T-appos
:	T-advcl
For	T-appos
a	T-appos
period	T-nsubj:pass
of	O
2	O
weeks	T-appos
,	O
CsA	T-advcl
15	T-advcl
mg	T-mark
/	T-advcl
kg	T-mark
/	T-advcl
day	T-advcl
(	T-nsubj:pass
given	T-aux
orally	T-nsubj:pass
)	O
,	O
FK506	B-Chemical
3	T-xcomp
.	T-nummod
0	O
mg	O
/	O
kg	T-xcomp
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	O
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	T-nmod
the	T-nmod
degree	O
of	O
striped	O
fibrosis	B-Disease
,	O
subcapsular	O
fibrosis	O
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	T-conj
a	T-conj
semi	O
-	O
quantitative	T-conj
scoring	T-conj
system	O
analysing	T-conj
the	O
degree	O
of	O
striped	O
fibrosis	O
,	O
subcapsular	O
fibrosis	B-Disease
and	O
the	O
number	T-conj
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	T-conj
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	O
,	O
subcapsular	O
fibrosis	O
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	T-nmod
of	T-nmod
the	T-nmod
total	T-nmod
grade	O
of	O
fibrosis	B-Disease
in	O
the	O
cortex	T-nmod
stained	O
with	O
Sirius	O
Red	O
.	O

RESULTS	T-nsubj
:	O
CsA	B-Chemical
,	O
FK506	O
and	T-conj
SRL	O
all	T-nsubj
significantly	T-nsubj
decreased	O
the	O
GFR	T-nsubj
.	O

RESULTS	O
:	O
CsA	O
,	O
FK506	B-Chemical
and	O
SRL	T-conj
all	O
significantly	O
decreased	T-conj
the	O
GFR	O
.	O

RESULTS	O
:	O
CsA	O
,	O
FK506	T-conj
and	O
SRL	B-Chemical
all	O
significantly	O
decreased	T-conj
the	O
GFR	O
.	O

A	O
further	O
deterioration	O
was	O
seen	T-nsubj:pass
when	T-nsubj:pass
CsA	B-Chemical
was	T-nsubj:pass
combined	O
with	O
either	O
FK506	T-nsubj:pass
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	T-nsubj:pass
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	T-obl
when	T-obl
CsA	T-obl
was	T-obl
combined	O
with	O
either	O
FK506	B-Chemical
or	T-conj
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	T-obl
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	T-conj
with	T-conj
either	T-conj
FK506	O
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	T-obl
treated	O
with	O
FK506	B-Chemical
plus	T-conj
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	T-conj
with	T-conj
FK506	O
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

The	T-conj
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	T-nmod
in	T-nmod
the	T-nmod
group	T-nmod
treated	O
with	O
CsA	B-Chemical
plus	T-conj
SRL	O
(	O
P	O
<	T-conj
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	T-conj
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
semi	O
-	O
quantitative	T-nsubj
scoring	T-nsubj
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	T-conj
with	T-conj
CsA	O
plus	O
SRL	B-Chemical
(	T-obj
P	T-obj
<	O
0	T-obj
.	O
001	O
compared	T-obj
with	T-conj
controls	T-conj
)	T-conj
and	O
the	O
analysis	T-conj
of	O
the	O
total	O
grade	T-conj
of	O
fibrosis	O
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	O
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	T-compound
FK506	B-Chemical
plus	T-conj
SRL	O
combination	O
showed	T-compound
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	O
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
FK506	O
plus	O
SRL	B-Chemical
combination	T-conj
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	O
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
FK506	O
plus	O
SRL	O
combination	O
showed	T-nmod
only	T-nmod
a	T-nmod
marginally	O
higher	T-nmod
degree	O
of	O
fibrosis	B-Disease
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	T-amod
a	T-amod
synergistic	T-amod
nephrotoxic	B-Disease
effect	O
of	O
CsA	T-amod
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	T-nmod
a	T-nmod
synergistic	T-nmod
nephrotoxic	T-nmod
effect	O
of	O
CsA	B-Chemical
plus	T-conj
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	T-conj
of	T-conj
CsA	O
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	T-nsubj:pass
a	O
synergistic	O
nephrotoxic	O
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	T-nsubj:pass
FK506	B-Chemical
plus	T-conj
SRL	O
was	T-nsubj:pass
better	T-nsubj:pass
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	B-Chemical
was	O
better	O
tolerated	T-conj
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	T-nmod
and	O
T	O
levels	O
as	T-nmod
markers	O
of	O
myocardial	B-Disease
damage	I-Disease
in	T-nmod
doxorubicin	O
-	O
induced	T-nmod
cardiomyopathy	T-nmod
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	O
damage	O
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiomyopathy	O
rats	T-obl
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	O
damage	T-compound
in	T-compound
doxorubicin	O
-	O
induced	T-compound
cardiomyopathy	B-Disease
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	T-nmod
and	O
specific	O
markers	O
of	O
myocardial	B-Disease
cell	I-Disease
injury	I-Disease
.	O

We	O
investigated	T-nmod
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	T-nmod
the	T-nmod
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	T-nmod
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	T-nmod
a	T-nmod
rat	T-nmod
model	O
of	O
doxorubicin	B-Chemical
(	O
DOX	O
)	O
-	O
induced	T-dep
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	O
a	O
rat	O
model	T-dep
of	T-dep
doxorubicin	O
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiomyopathy	T-dep
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	O
a	O
rat	O
model	T-dep
of	T-dep
doxorubicin	O
(	O
DOX	T-dep
)	O
-	O
induced	O
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	T-nmod
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	T-nmod
the	T-nmod
development	O
of	O
cardiac	B-Disease
disorders	I-Disease
monitored	T-nmod
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	T-dep
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

By	T-obl
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	T-obl
measured	O
in	O
all	O
rats	T-obl
before	O
DOX	B-Chemical
or	T-conj
saline	O
,	O
and	T-obl
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	T-compound
in	T-compound
DOX	B-Chemical
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	O
dose	O
and	O
in	O
all	O
controls	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	O
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	T-compound
after	T-compound
the	T-compound
last	T-compound
DOX	B-Chemical
dose	O
and	O
in	O
all	O
controls	O
.	O

RESULTS	O
:	O
Eighteen	T-compound
of	T-compound
the	T-compound
DOX	B-Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	O
during	O
the	O
9	O
-	O
week	O
period	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rats	O
died	T-obl
prematurely	O
of	O
general	O
toxicity	B-Disease
during	O
the	O
9	O
-	O
week	O
period	O
.	O

End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	T-compound
in	T-compound
the	T-compound
DOX	B-Chemical
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Histological	T-nmod
evaluation	O
of	O
hearts	T-nmod
from	O
all	O
rats	O
given	O
DOX	B-Chemical
revealed	T-nmod
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	O
revealed	T-nmod
significant	T-nmod
slight	T-nmod
degrees	O
of	O
perivascular	O
and	O
interstitial	T-amod
fibrosis	B-Disease
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	T-nmod
evidence	O
of	O
very	T-amod
slight	O
perivascular	O
fibrosis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	T-case
in	T-case
DOX	B-Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	T-compound
in	T-compound
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	T-compound
unchanged	O
in	T-compound
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O

CONCLUSIONS	O
:	O
Among	T-nmod
markers	O
of	O
ischemic	B-Disease
injury	I-Disease
after	O
DOX	T-nmod
in	O
rats	O
,	O
cTnT	O
showed	T-nmod
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	O
damage	O
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

CONCLUSIONS	O
:	O
Among	T-nmod
markers	O
of	O
ischemic	O
injury	T-nmod
after	O
DOX	B-Chemical
in	T-nmod
rats	O
,	O
cTnT	O
showed	T-nmod
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	O
damage	O
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	O
injury	O
after	O
DOX	O
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	T-nsubj
myocardial	B-Disease
damage	I-Disease
assessed	O
by	O
echocardiographic	O
detection	T-nsubj
and	O
histological	O
changes	O
.	O

Although	T-obl
there	T-obl
was	O
a	O
discrepancy	T-obl
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heterogeneity	T-obl
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	O
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	T-nmod
after	O
DOX	B-Chemical
indicates	T-nmod
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	O
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	T-nmod
for	T-nmod
the	T-nmod
prediction	O
of	O
experimentally	T-amod
induced	O
cardiotoxicity	B-Disease
and	O
possibly	O
for	O
cardioprotective	O
experiments	T-nmod
.	O

Octreotide	B-Chemical
-	O
induced	O
hypoxemia	T-obl
and	O
pulmonary	O
hypertension	O
in	O
premature	O
neonates	O
.	O

Octreotide	T-amod
-	O
induced	O
hypoxemia	B-Disease
and	T-conj
pulmonary	T-conj
hypertension	O
in	T-nmod
premature	T-nmod
neonates	O
.	O

Octreotide	O
-	O
induced	T-conj
hypoxemia	O
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
premature	O
neonates	T-conj
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	T-obj
who	T-obj
had	O
enterocutaneous	O
fistula	B-Disease
complicating	O
necrotizing	O
enterocolitis	T-acl
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	T-obj
complicating	O
necrotizing	B-Disease
enterocolitis	I-Disease
.	O

Pulmonary	B-Disease
hypertension	I-Disease
developed	O
after	O
administration	T-nsubj
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	O
,	O
to	O
enhance	T-nsubj
resolution	O
of	O
the	O
fistula	O
.	O

Pulmonary	O
hypertension	O
developed	O
after	O
administration	T-appos
of	T-appos
a	T-appos
somatostatin	T-appos
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	O
.	O

Pulmonary	O
hypertension	O
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	O
,	O
to	O
enhance	T-nmod
resolution	O
of	O
the	O
fistula	B-Disease
.	O

The	T-nmod
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	T-nmod
women	O
prescribed	T-nmod
cyproterone	O
acetate	O
in	O
combination	O
with	O
ethinyl	O
estradiol	O
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

The	O
risk	T-obj
of	O
venous	O
thromboembolism	O
in	O
women	O
prescribed	O
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	T-obj
with	O
ethinyl	O
estradiol	O
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	T-obj
.	O

The	O
risk	O
of	O
venous	O
thromboembolism	O
in	O
women	O
prescribed	T-nmod
cyproterone	O
acetate	O
in	T-nmod
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

BACKGROUND	T-nsubj:pass
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	O
estradiol	T-acl
(	O
CPA	O
/	O
EE	O
)	O
is	T-nsubj:pass
licensed	O
in	O
the	O
UK	T-nsubj:pass
for	O
the	O
treatment	T-nsubj:pass
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	T-nsubj:pass
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	T-obl
combined	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA	T-appos
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	T-compound
(	O
CPA	B-Chemical
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	T-appos
with	T-appos
ethinyl	T-appos
estradiol	O
(	O
CPA	O
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	T-nmod
of	T-nmod
women	O
with	O
acne	B-Disease
and	T-conj
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	T-conj
with	T-conj
acne	O
and	O
hirsutism	B-Disease
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	T-nmod
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	T-nmod
is	T-nmod
also	T-nmod
a	T-nmod
treatment	T-nmod
option	O
for	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	T-dep
for	T-dep
polycystic	T-dep
ovary	T-dep
syndrome	O
(	O
PCOS	B-Disease
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	T-nmod
an	T-nmod
increased	T-nmod
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	O
with	O
CPA	O
/	O
EE	T-acl
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	T-acl
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	T-dep
of	T-dep
venous	T-dep
thromboembolism	O
(	O
VTE	B-Disease
)	O
associated	T-dep
with	O
CPA	O
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-compound
with	T-compound
CPA	B-Chemical
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	T-obl
(	O
VTE	O
)	O
associated	O
with	O
CPA	O
/	O
EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	T-obl
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	T-advcl
(	O
VTE	O
)	O
associated	O
with	O
CPA	O
/	O
EE	T-advcl
compared	O
with	O
conventional	O
combined	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
COCs	O
)	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	T-nmod
between	O
15	T-nmod
and	O
39	O
years	O
with	O
acne	B-Disease
,	O
hirsutism	O
or	T-conj
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	T-conj
with	T-conj
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	T-conj
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	T-conj
with	T-conj
acne	O
,	O
hirsutism	T-conj
or	O
PCOS	B-Disease
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	T-nmod
the	T-nmod
risk	O
of	O
VTE	B-Disease
associated	O
with	O
CPA	O
/	O
EE	T-amod
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	T-compound
with	T-compound
CPA	B-Chemical
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	T-obl
associated	O
with	O
CPA	O
/	O
EE	B-Chemical
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	T-nmod
an	T-nmod
increased	T-nmod
risk	O
of	O
VTE	B-Disease
associated	T-nmod
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-compound
of	T-compound
CPA	B-Chemical
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	T-nmod
with	T-nmod
the	T-nmod
use	O
of	O
CPA	O
/	O
EE	B-Chemical
in	O
women	T-nmod
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-nmod
of	O
CPA	O
/	O
EE	O
in	T-nmod
women	O
with	O
acne	B-Disease
,	O
hirsutism	O
or	T-conj
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	T-conj
with	T-conj
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	T-conj
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	T-conj
with	T-conj
acne	O
,	O
hirsutism	T-conj
or	O
PCOS	B-Disease
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

The	O
effect	T-nmod
of	T-nmod
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
gentamicin	O
nephrotoxicity	T-nmod
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

The	O
effect	T-nmod
of	T-nmod
treatment	O
with	O
gum	T-nmod
Arabic	O
on	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	T-obl
we	T-obl
assessed	O
the	O
effect	T-obl
of	O
treatment	O
of	O
rats	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	T-nmod
acute	T-nmod
renal	T-nmod
failure	O
induced	O
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	T-nmod
.	O

In	O
the	O
present	O
work	O
we	O
assessed	T-nmod
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	T-nmod
gum	O
Arabic	T-nmod
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	T-dep
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	O
by	O
gentamicin	B-Chemical
(	O
GM	O
)	O
nephrotoxicity	T-obl
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-appos
by	T-appos
gentamicin	O
(	O
GM	B-Chemical
)	O
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	T-dep
Arabic	O
on	T-dep
acute	T-dep
renal	T-dep
failure	O
induced	O
by	O
gentamicin	T-amod
(	O
GM	O
)	O
nephrotoxicity	B-Disease
.	O

Nephrotoxicity	B-Disease
was	T-nsubj:pass
assessed	O
by	O
measuring	T-nsubj:pass
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	T-nmod
the	T-nmod
concentrations	O
of	O
creatinine	B-Chemical
and	T-conj
urea	O
in	O
the	O
plasma	T-nmod
and	O
reduced	O
glutathione	T-nmod
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	T-conj
of	T-conj
creatinine	O
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	T-conj
the	T-conj
concentrations	O
of	O
creatinine	T-conj
and	O
urea	O
in	O
the	O
plasma	T-conj
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	T-appos
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	T-appos
reduced	T-appos
glutathione	O
(	O
GSH	B-Chemical
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	B-Chemical
Arabic	I-Chemical
treatment	O
has	O
induced	T-amod
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	O
nephrotoxicity	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Arabic	O
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	T-nmod
of	T-nmod
the	T-nmod
histological	T-nmod
and	O
biochemical	O
indices	O
of	O
GM	B-Chemical
nephrotoxicity	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	T-nmod
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	T-nmod
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

Increased	T-nmod
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
with	T-nmod
the	T-nmod
combination	O
of	O
docetaxel	T-nmod
and	O
thalidomide	O
in	O
patients	T-nmod
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	O
frequency	O
of	O
venous	O
thromboembolism	T-nmod
with	T-nmod
the	T-nmod
combination	O
of	O
docetaxel	B-Chemical
and	T-conj
thalidomide	O
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	O
frequency	O
of	O
venous	O
thromboembolism	O
with	O
the	O
combination	T-conj
of	T-conj
docetaxel	O
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	O
frequency	T-nmod
of	O
venous	O
thromboembolism	O
with	O
the	O
combination	O
of	O
docetaxel	O
and	O
thalidomide	O
in	T-nmod
patients	O
with	O
metastatic	O
androgen	T-amod
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	T-nmod
the	T-nmod
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	T-dep
of	T-dep
venous	T-dep
thromboembolism	O
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	T-nmod
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	T-nmod
patients	O
with	O
advanced	O
androgen	T-amod
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	T-obl
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	T-obl
were	T-obl
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	T-conj
in	T-conj
combination	O
with	O
thalidomide	T-conj
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	T-nmod
alone	O
or	T-nmod
in	T-nmod
combination	O
with	O
thalidomide	B-Chemical
.	O

PATIENTS	T-nmod
:	O
Seventy	T-nmod
men	O
,	O
aged	O
50	O
-	O
80	O
years	T-nmod
,	O
with	O
advanced	O
androgen	T-amod
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	T-dep
intravenous	O
docetaxel	B-Chemical
30	T-dep
mg	O
/	O
m2	T-dep
/	O
week	T-dep
for	O
3	O
consecutive	O
weeks	T-dep
,	O
followed	T-dep
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	O
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	O
regimen	O
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	T-nmod
off	O
,	O
or	T-nmod
the	T-nmod
combination	O
of	O
continuous	O
oral	O
thalidomide	B-Chemical
200	T-dep
mg	O
every	O
evening	T-nmod
plus	O
the	O
same	O
docetaxel	O
regimen	O
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	O
200	O
mg	O
every	O
evening	T-compound
plus	T-compound
the	T-compound
same	T-compound
docetaxel	B-Chemical
regimen	O
.	O

This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	T-nmod
evidence	O
of	O
excessive	O
toxicity	B-Disease
or	T-conj
disease	T-conj
progression	O
.	O

CONCLUSION	O
:	O
The	T-nmod
addition	O
of	O
thalidomide	B-Chemical
to	T-nmod
docetaxel	O
in	O
the	O
treatment	T-nmod
of	O
prostate	O
cancer	O
significantly	O
increases	T-nmod
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	T-nmod
of	T-nmod
thalidomide	O
to	O
docetaxel	B-Chemical
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	T-nmod
of	O
thalidomide	O
to	O
docetaxel	O
in	T-nmod
the	T-nmod
treatment	O
of	O
prostate	B-Disease
cancer	I-Disease
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	O
to	O
docetaxel	O
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
significantly	O
increases	T-nmod
the	T-nmod
frequency	O
of	O
VTE	B-Disease
.	O

Clinicians	O
should	O
be	O
aware	T-dep
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	B-Chemical
to	T-nmod
chemotherapeutic	T-nmod
regimens	O
.	O

Ticlopidine	B-Chemical
-	O
induced	O
cholestatic	O
hepatitis	T-obl
.	O

Ticlopidine	T-amod
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	B-Chemical
-	O
induced	O
cholestatic	O
hepatitis	T-obl
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

OBJECTIVE	O
:	O
To	O
report	T-nmod
2	T-nmod
cases	O
of	O
ticlopidine	T-amod
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	T-obj
:	O
Two	O
patients	T-obj
developed	O
prolonged	O
cholestatic	B-Disease
hepatitis	I-Disease
after	O
receiving	O
ticlopidine	T-obj
following	O
percutaneous	O
coronary	O
angioplasty	T-obj
,	O
with	O
complete	O
remission	T-obj
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

CASE	O
SUMMARIES	T-obl
:	O
Two	O
patients	T-obl
developed	O
prolonged	O
cholestatic	O
hepatitis	T-obl
after	O
receiving	O
ticlopidine	B-Chemical
following	O
percutaneous	O
coronary	O
angioplasty	T-obl
,	O
with	O
complete	O
remission	T-obl
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

T	O
-	O
cell	O
stimulation	T-nmod
by	T-nmod
therapeutic	T-nmod
concentration	O
of	O
ticlopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	T-nsubj
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	T-nsubj
a	T-nsubj
rare	T-nsubj
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	T-nsubj
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

DISCUSSION	T-nmod
:	O
Cholestatic	O
hepatitis	T-nmod
is	T-nmod
a	T-nmod
rare	T-nmod
complication	O
of	O
the	O
antiplatelet	T-compound
agent	O
ticlopidine	B-Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	T-obj
developed	O
jaundice	B-Disease
following	T-nmod
treatment	O
with	O
ticlopidine	T-nmod
and	O
showed	T-obj
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	O
hepatitis	O
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Our	O
patients	O
developed	O
jaundice	T-nmod
following	T-nmod
treatment	O
with	O
ticlopidine	B-Chemical
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	O
hepatitis	O
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Our	O
patients	O
developed	O
jaundice	O
following	O
treatment	O
with	O
ticlopidine	O
and	O
showed	T-nmod
the	T-nmod
clinical	T-nmod
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
which	O
resolved	T-nmod
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Hepatitis	B-Disease
may	T-nsubj
develop	O
weeks	T-nsubj
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	T-nsubj
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	T-nsubj
in	O
all	O
reported	O
cases	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	T-nmod
to	T-nmod
the	T-nmod
use	O
of	O
ticlopidine	B-Chemical
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	B-Chemical
-	O
induced	O
cholestasis	T-obl
are	O
unclear	O
.	O

The	T-nmod
mechanisms	O
of	O
this	O
ticlopidine	T-amod
-	O
induced	O
cholestasis	B-Disease
are	O
unclear	T-nmod
.	O

Immune	O
mechanisms	O
may	O
be	O
involved	T-dep
in	T-dep
the	T-dep
drug	O
'	O
s	T-dep
hepatotoxicity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O

CONCLUSIONS	T-nsubj
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	T-nsubj
a	T-nsubj
rare	T-nsubj
adverse	T-nsubj
effect	O
of	O
ticlopidine	T-nsubj
that	O
may	O
be	O
immune	O
mediated	T-nsubj
.	O

CONCLUSIONS	T-nmod
:	O
Cholestatic	O
hepatitis	T-nmod
is	T-nmod
a	T-nmod
rare	T-nmod
adverse	T-nmod
effect	O
of	O
ticlopidine	B-Chemical
that	O
may	O
be	O
immune	O
mediated	T-nmod
.	O

This	O
complication	O
will	O
be	O
observed	T-nsubj:pass
even	O
less	O
often	O
in	O
the	O
future	O
as	T-nsubj:pass
ticlopidine	B-Chemical
is	T-nsubj:pass
being	T-nsubj:pass
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	T-nsubj:pass
.	O

This	O
complication	O
will	O
be	O
observed	T-obl
even	O
less	O
often	O
in	O
the	O
future	O
as	T-obl
ticlopidine	T-obl
is	T-obl
being	T-obl
replaced	O
by	O
the	O
newer	O
antiplatelet	T-compound
agent	O
clopidogrel	B-Chemical
.	O

Epithelial	T-compound
sodium	B-Chemical
channel	O
(	O
ENaC	T-compound
)	O
subunit	O
mRNA	T-compound
and	O
protein	O
expression	T-compound
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	O
syndrome	O
.	O

Epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	T-compound
in	O
rats	O
with	T-compound
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	T-compound
nephrotic	T-compound
syndrome	T-obl
.	O

Epithelial	O
sodium	O
channel	T-nmod
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	T-nmod
protein	T-nmod
expression	O
in	O
rats	T-nmod
with	O
puromycin	O
aminonucleoside	T-amod
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

In	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
urinary	O
sodium	O
excretion	T-obl
is	T-obl
decreased	O
during	O
the	O
early	O
phase	T-obl
of	O
the	O
disease	O
.	O

In	O
experimental	O
nephrotic	O
syndrome	O
,	O
urinary	T-compound
sodium	B-Chemical
excretion	O
is	O
decreased	T-compound
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	T-compound
of	T-compound
collecting	O
duct	T-compound
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	T-compound
of	O
collecting	O
duct	O
sodium	O
transport	O
is	T-compound
the	T-compound
epithelial	T-compound
sodium	B-Chemical
channel	O
(	O
ENaC	T-compound
)	O
.	O

We	T-obl
examined	O
the	O
abundance	T-obl
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	O
)	O
-	O
induced	T-dep
nephrotic	T-dep
syndrome	O
.	O

We	O
examined	T-dep
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	T-dep
puromycin	T-dep
aminonucleoside	O
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephrotic	O
syndrome	T-dep
.	O

We	O
examined	T-dep
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	T-dep
puromycin	T-dep
aminonucleoside	O
(	O
PAN	T-dep
)	O
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
time	O
courses	T-compound
of	T-compound
urinary	T-compound
sodium	B-Chemical
excretion	O
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	O
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	O
courses	T-compound
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	O
aldosterone	B-Chemical
concentration	O
and	O
proteinuria	T-compound
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	O
courses	T-conj
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	O
aldosterone	T-conj
concentration	O
and	O
proteinuria	B-Disease
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	O
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-nmod
with	T-nmod
a	T-nmod
single	T-nmod
dose	O
of	O
either	O
PAN	B-Chemical
or	T-conj
vehicle	O
.	O

The	O
kinetics	T-compound
of	T-compound
urinary	T-compound
sodium	B-Chemical
excretion	O
and	O
the	O
appearance	T-compound
of	O
proteinuria	O
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	O
excretion	T-nmod
and	T-nmod
the	T-nmod
appearance	O
of	O
proteinuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Sodium	B-Chemical
retention	O
occurred	T-compound
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
injection	O
.	O

Sodium	O
retention	O
occurred	T-compound
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	T-compound
PAN	B-Chemical
injection	O
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	T-compound
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	T-compound
of	T-compound
high	T-compound
aldosterone	B-Chemical
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	O
excretion	O
to	O
control	O
values	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	O
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	T-compound
of	T-compound
sodium	B-Chemical
excretion	O
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	B-Chemical
-	O
induced	O
sodium	O
retention	T-obl
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	T-compound
during	T-compound
PAN	O
-	O
induced	T-compound
sodium	B-Chemical
retention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	B-Chemical
-	O
induced	O
nephrotic	O
syndrome	T-obl
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	O
after	O
day	O
3	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	T-nmod
of	T-nmod
the	T-nmod
experimental	T-nmod
model	O
of	O
PAN	T-amod
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	O
after	O
day	O
3	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	O
-	O
induced	O
nephrotic	O
syndrome	O
in	O
rats	O
,	O
but	O
appears	T-obl
to	T-obl
escape	O
from	O
the	O
regulation	T-obl
by	O
aldosterone	B-Chemical
after	O
day	T-obl
3	O
.	O

Sub	O
-	O
chronic	O
low	T-compound
dose	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
GABA	I-Chemical
(	O
vigabatrin	O
)	O
inhibits	T-dep
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	T-appos
-	O
chronic	T-appos
low	O
dose	T-appos
gamma	O
-	O
vinyl	T-appos
GABA	O
(	O
vigabatrin	B-Chemical
)	O
inhibits	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	O
)	O
inhibits	O
cocaine	B-Chemical
-	O
induced	O
increases	T-obl
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	O
)	O
inhibits	T-nmod
cocaine	O
-	O
induced	T-nmod
increases	O
in	O
nucleus	T-compound
accumbens	O
dopamine	B-Chemical
.	O

RATIONALE	T-nsubj
:	O
gamma	B-Chemical
-	I-Chemical
Vinyl	I-Chemical
GABA	I-Chemical
(	O
GVG	O
)	O
irreversibly	T-nsubj
inhibits	O
GABA	O
-	O
transaminase	T-nsubj
.	O

RATIONALE	O
:	O
gamma	O
-	O
Vinyl	T-appos
GABA	O
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhibits	T-appos
GABA	O
-	O
transaminase	O
.	O

RATIONALE	O
:	O
gamma	O
-	O
Vinyl	O
GABA	O
(	O
GVG	O
)	O
irreversibly	O
inhibits	T-compound
GABA	B-Chemical
-	O
transaminase	O
.	O

This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	T-compound
of	T-compound
functional	T-compound
GABA	B-Chemical
catabolism	O
.	O

OBJECTIVES	O
:	O
Given	T-nmod
its	T-nmod
preclinical	T-nmod
success	O
for	O
treating	O
substance	B-Disease
abuse	I-Disease
and	T-conj
the	T-conj
increased	T-conj
risk	O
of	O
visual	O
field	O
defects	T-conj
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	T-nmod
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	T-nmod
and	T-nmod
the	T-nmod
increased	T-nmod
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	T-acl
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	T-dep
of	T-dep
visual	T-dep
field	T-dep
defects	O
(	O
VFD	B-Disease
)	O
associated	T-dep
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	T-nmod
the	T-nmod
effects	O
of	O
sub	T-amod
-	O
chronic	O
low	T-compound
dose	O
GVG	B-Chemical
on	O
cocaine	O
-	O
induced	O
increases	T-nmod
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	B-Chemical
-	O
induced	O
increases	T-obl
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	T-dep
in	T-dep
nucleus	T-dep
accumbens	O
(	O
NAcc	T-dep
)	O
dopamine	B-Chemical
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	T-appos
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	B-Chemical
)	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	T-compound
GVG	B-Chemical
exposure	O
inhibited	T-compound
the	O
effect	O
of	O
cocaine	O
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	O
exposure	O
inhibited	T-nmod
the	T-nmod
effect	O
of	O
cocaine	B-Chemical
for	O
3	O
days	T-nmod
,	O
which	O
exceeded	T-nmod
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	T-compound
:	O
Sub	O
-	O
chronic	T-compound
low	O
dose	T-compound
GVG	B-Chemical
potentiates	O
and	O
extends	T-compound
the	O
inhibition	T-compound
of	O
cocaine	O
-	O
induced	O
increases	O
in	O
dopamine	O
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	B-Chemical
-	O
induced	O
increases	T-obl
in	O
dopamine	O
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	T-nmod
of	T-nmod
cocaine	O
-	O
induced	T-nmod
increases	O
in	O
dopamine	B-Chemical
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	T-obl
in	O
organ	O
transplant	O
patients	O
.	O

MR	O
imaging	T-nmod
with	T-nmod
quantitative	T-nmod
diffusion	T-nmod
mapping	O
of	O
tacrolimus	T-amod
-	O
induced	O
neurotoxicity	B-Disease
in	O
organ	O
transplant	O
patients	T-nmod
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	T-compound
neurologic	O
symptoms	O
during	T-compound
tacrolimus	B-Chemical
therapy	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	T-obj
receiving	O
tacrolimus	B-Chemical
who	T-acl:relcl
developed	O
neurologic	O
complications	T-acl:relcl
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	T-obj
who	T-obj
developed	O
neurologic	B-Disease
complications	I-Disease
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	T-obl
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	T-nmod
of	T-nmod
the	T-nmod
lesions	O
of	O
tacrolimus	T-amod
-	O
induced	O
neurotoxicity	B-Disease
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
in	O
humans	T-compound
with	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

L	O
-	O
arginine	O
transport	O
in	O
humans	O
with	O
cortisol	B-Chemical
-	O
induced	O
hypertension	T-obl
.	O

L	O
-	O
arginine	O
transport	T-nmod
in	T-nmod
humans	O
with	O
cortisol	T-amod
-	O
induced	O
hypertension	B-Disease
.	O

A	O
deficient	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	O
oxide	O
system	T-dep
is	O
implicated	O
in	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

A	T-compound
deficient	T-compound
L	T-dep
-	O
arginine	O
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	T-compound
in	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	O
is	O
implicated	O
in	O
cortisol	B-Chemical
-	O
induced	O
hypertension	T-obl
.	O

A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	T-obl
is	T-obl
implicated	O
in	O
cortisol	T-amod
-	O
induced	O
hypertension	B-Disease
.	O

We	O
investigate	O
whether	O
abnormalities	T-compound
in	T-compound
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

Hydrocortisone	B-Chemical
acetate	I-Chemical
(	O
50	T-appos
mg	O
)	O
was	T-nsubj:pass
given	O
orally	T-nsubj:pass
every	O
6	O
hours	T-nsubj:pass
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
was	O
assessed	T-compound
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

L	O
-	O
arginine	O
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	T-obl
incubated	O
with	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

L	O
-	O
arginine	O
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	T-dep
100	T-dep
nmol	O
/	O
L	T-dep
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
arginine	I-Chemical
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

Forearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	T-dep
was	T-dep
calculated	T-compound
after	O
infusion	T-dep
of	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
into	O
the	O
brachial	O
artery	T-dep
at	O
a	O
rate	T-dep
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	T-dep
.	O

Forearm	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
extraction	O
was	O
calculated	T-nmod
after	T-nmod
infusion	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	T-compound
of	T-compound
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
.	O

Plasma	T-compound
cortisol	B-Chemical
concentrations	O
were	O
significantly	O
raised	T-compound
during	O
the	O
active	O
phase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O

Neither	T-compound
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-dep
into	O
mononuclear	O
cells	T-compound
(	T-compound
placebo	T-compound
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	T-appos
5	T-appos
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
concentration	T-nmod
of	T-nmod
300	O
micromol	O
/	O
L	O
)	T-nmod
nor	T-nmod
L	O
-	O
arginine	T-nmod
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	T-nmod
,	O
respectively	O
,	O
at	O
an	O
l	O
-	T-nmod
arginine	O
concentration	O
of	O
300	T-nummod
micromol	T-nummod
/	T-nummod
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-Chemical
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O

We	O
conclude	O
that	O
cortisol	B-Chemical
-	O
induced	O
increases	T-obl
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

We	O
conclude	T-nsubj:pass
that	T-nsubj:pass
cortisol	T-amod
-	O
induced	O
increases	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
are	T-nsubj:pass
not	T-nsubj:pass
associated	O
with	O
abnormalities	T-nsubj:pass
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

We	O
conclude	O
that	O
cortisol	O
-	O
induced	O
increases	O
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	T-compound
in	T-compound
the	T-compound
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-compound
system	O
.	O

Amount	O
of	O
bleeding	B-Disease
and	T-conj
hematoma	T-conj
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	O
hemorrhage	O
rat	O
model	T-nmod
.	O

Amount	O
of	O
bleeding	T-compound
and	T-compound
hematoma	B-Disease
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	O
hemorrhage	O
rat	O
model	O
.	O

Amount	T-compound
of	O
bleeding	O
and	O
hematoma	O
size	O
in	T-compound
the	T-compound
collagenase	O
-	O
induced	T-compound
intracerebral	B-Disease
hemorrhage	I-Disease
rat	T-compound
model	O
.	O

The	T-nmod
aggravated	T-nmod
risk	O
on	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	O
)	O
with	T-nmod
drugs	O
used	T-nmod
for	O
stroke	O
patients	O
should	O
be	O
estimated	T-nmod
carefully	O
.	O

The	O
aggravated	O
risk	T-dep
on	T-dep
intracerebral	T-dep
hemorrhage	O
(	O
ICH	B-Disease
)	O
with	O
drugs	T-dep
used	O
for	O
stroke	O
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
with	O
drugs	O
used	T-compound
for	T-compound
stroke	B-Disease
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	T-compound
a	T-compound
rat	T-compound
ICH	B-Disease
model	O
for	O
detection	O
of	O
ICH	O
deterioration	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	O
model	O
for	O
detection	T-compound
of	T-compound
ICH	B-Disease
deterioration	O
.	O

In	O
ICH	B-Disease
intrastriatally	T-acl
induced	O
by	O
0	T-acl
.	T-acl
014	O
-	O
unit	O
,	T-acl
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	O
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	O
volume	O
.	O

In	O
ICH	O
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	T-obl
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	T-obl
-	T-obl
unit	O
collagenase	O
,	O
the	T-amod
amount	O
of	O
bleeding	B-Disease
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	O
volume	O
.	O

In	O
ICH	O
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	O
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B-Disease
volume	O
.	O

The	O
blood	O
amounts	T-cop
and	T-cop
hematoma	B-Disease
volumes	O
were	O
significantly	T-cop
correlated	O
,	O
and	O
the	O
hematoma	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	O
deterioration	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	O
volumes	O
were	O
significantly	O
correlated	T-nsubj
,	O
and	T-nsubj
the	O
hematoma	B-Disease
induced	O
by	O
0	T-nsubj
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	O
deterioration	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	O
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B-Disease
deterioration	O
.	O

In	T-compound
ICH	B-Disease
induction	O
using	T-compound
0	T-compound
.	T-compound
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	T-det
,	T-det
heparin	B-Chemical
enhanced	O
the	T-det
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	B-Disease
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B-Disease
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	T-compound
for	T-compound
ICH	B-Disease
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	O
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	O
detection	O
,	O
and	O
that	O
a	T-nmod
model	O
with	O
a	O
small	O
ICH	B-Disease
induced	T-nmod
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	O
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	O
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	T-obj
for	O
evaluation	O
of	O
drugs	O
that	T-obj
may	T-obj
affect	O
ICH	B-Disease
.	O

Estradiol	B-Chemical
reduces	O
seizure	O
-	O
induced	O
hippocampal	O
injury	T-nsubj
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estradiol	O
reduces	O
seizure	B-Disease
-	O
induced	O
hippocampal	O
injury	T-obl
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estradiol	T-obj
reduces	O
seizure	T-amod
-	O
induced	O
hippocampal	B-Disease
injury	I-Disease
in	T-nmod
ovariectomized	T-nmod
female	O
but	O
not	T-conj
in	T-conj
male	T-conj
rats	O
.	O

Estrogens	O
protect	O
ovariectomized	T-nmod
rats	O
from	O
hippocampal	B-Disease
injury	I-Disease
induced	T-nmod
by	O
kainic	O
acid	O
-	O
induced	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	T-amod
by	T-amod
kainic	B-Chemical
acid	I-Chemical
-	O
induced	T-amod
status	T-amod
epilepticus	T-obl
(	O
SE	T-amod
)	O
.	O

Estrogens	O
protect	T-obl
ovariectomized	O
rats	T-obl
from	O
hippocampal	O
injury	O
induced	O
by	O
kainic	O
acid	T-amod
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	O
)	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	T-appos
by	T-appos
kainic	T-appos
acid	O
-	O
induced	T-appos
status	T-appos
epilepticus	O
(	O
SE	B-Disease
)	O
.	O

We	O
compared	T-nmod
the	T-nmod
effects	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
in	O
adult	O
male	T-nmod
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	B-Chemical
-	O
pilocarpine	O
-	O
induced	T-compound
SE	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	O
-	O
pilocarpine	B-Chemical
-	O
induced	O
SE	T-obl
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	T-obl
female	O
rats	T-obl
subjected	O
to	O
lithium	O
-	O
pilocarpine	T-amod
-	O
induced	O
SE	B-Disease
.	O

Rats	O
received	T-nmod
subcutaneous	T-nmod
injections	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
2	T-dep
microg	O
/	O
rat	T-dep
)	O
or	T-conj
oil	O
once	O
daily	T-conj
for	O
four	O
consecutive	O
days	O
.	O

SE	B-Disease
was	T-nsubj:pass
induced	O
20	O
h	T-nsubj:pass
following	O
the	O
second	O
injection	T-nsubj:pass
and	O
terminated	T-nsubj:pass
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silver	B-Chemical
-	O
stained	O
CA3	T-obl
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	O
.	O

The	O
extent	O
of	O
silver	O
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	T-nmod
2	T-nmod
days	O
after	O
SE	B-Disease
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
did	T-nsubj
not	T-nsubj
alter	O
the	O
onset	T-nsubj
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	T-nsubj
but	O
accelerated	T-nsubj
it	O
in	O
males	O
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
reduced	O
the	O
argyrophilic	O
neurons	T-nsubj
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	T-nsubj
of	O
ovariectomized	O
rats	O
.	O

In	O
males	T-nsubj
,	O
estradiol	B-Chemical
increased	O
the	O
total	O
damage	O
score	T-nsubj
.	O

These	O
findings	O
suggest	O
that	O
the	T-nmod
effects	O
of	O
estradiol	B-Chemical
on	O
seizure	O
threshold	T-nmod
and	O
damage	O
may	O
be	O
altered	T-nmod
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	T-compound
of	O
estradiol	O
on	T-compound
seizure	B-Disease
threshold	O
and	O
damage	T-compound
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Pseudoacromegaly	B-Disease
induced	O
by	O
the	O
long	O
-	O
term	O
use	T-nsubj
of	O
minoxidil	O
.	O

Pseudoacromegaly	O
induced	T-nmod
by	T-nmod
the	T-nmod
long	O
-	O
term	T-nmod
use	O
of	O
minoxidil	B-Chemical
.	O

Acromegaly	B-Disease
is	T-nsubj
an	T-nsubj
endocrine	T-nsubj
disorder	O
caused	T-nsubj
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Acromegaly	O
is	O
an	O
endocrine	B-Disease
disorder	I-Disease
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	T-acl
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	T-dep
,	O
cartilage	O
,	O
and	T-dep
soft	T-dep
tissue	O
hypertrophy	B-Disease
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	O
verticis	O
gyrata	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	T-conj
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	O
,	O
including	T-conj
the	T-conj
thickening	O
of	O
the	O
skin	T-conj
,	O
coarsening	T-conj
of	O
facial	O
features	O
,	O
and	O
cutis	B-Disease
verticis	I-Disease
gyrata	I-Disease
.	O

Pseudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	T-advmod
,	O
is	T-advmod
the	T-advmod
presence	O
of	O
similar	O
acromegaloid	O
features	T-advmod
in	O
the	O
absence	T-advmod
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O

We	O
present	T-nmod
a	T-nmod
patient	O
with	O
pseudoacromegaly	B-Disease
that	O
resulted	T-nmod
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
at	O
an	O
unusually	O
high	O
dose	O
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	O
that	O
resulted	T-nmod
from	T-nmod
the	T-nmod
long	O
-	O
term	T-nmod
use	O
of	O
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	O
dose	T-nmod
.	O

This	T-nmod
is	T-nmod
the	T-nmod
first	T-nmod
case	T-nmod
report	O
of	O
pseudoacromegaly	B-Disease
as	T-nmod
a	T-nmod
side	T-nmod
effect	O
of	O
minoxidil	O
use	T-nmod
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	O
as	O
a	O
side	O
effect	T-compound
of	T-compound
minoxidil	B-Chemical
use	O
.	O

Combined	O
androgen	O
blockade	T-amod
-	O
induced	O
anemia	B-Disease
in	T-nmod
prostate	T-nmod
cancer	T-nmod
patients	O
without	T-nmod
bone	T-nmod
involvement	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	T-compound
in	T-compound
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	T-dep
and	O
extent	O
of	T-dep
combined	T-dep
androgen	T-dep
blockade	O
(	O
CAB	T-dep
)	O
-	O
induced	O
anemia	B-Disease
in	T-nmod
prostate	T-nmod
cancer	T-nmod
patients	O
without	T-nmod
bone	T-nmod
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	O
anemia	T-compound
in	T-compound
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	T-nmod
patients	O
with	O
biopsy	T-amod
-	O
proven	O
prostatic	B-Disease
adenocarcinoma	I-Disease
[	O
26	T-nmod
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	T-nmod
in	O
this	O
study	O
.	O

All	O
patients	T-nummod
received	T-dep
CAB	O
[	O
leuprolide	B-Chemical
acetate	I-Chemical
(	O
LHRH	T-appos
-	T-appos
A	O
)	T-nummod
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	O
received	O
CAB	O
[	T-appos
leuprolide	T-appos
acetate	O
(	T-compound
LHRH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	T-appos
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	T-obl
received	O
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	T-obl
every	T-obl
28	O
days	O
plus	T-obl
250	O
mg	O
flutamide	B-Chemical
,	T-conj
tid	T-conj
,	O
per	O
Os	T-obl
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	T-nummod
for	O
anemia	B-Disease
by	O
physical	T-nummod
examination	O
and	O
laboratory	O
tests	O
at	T-nummod
baseline	T-nummod
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	T-conj
and	O
Testosterone	B-Chemical
measurements	T-conj
were	O
recorded	O
.	O

This	O
CAB	T-amod
-	O
induced	O
anemia	B-Disease
was	T-nsubj
normochromic	O
and	O
normocytic	T-nsubj
.	O

At	O
six	T-case
months	O
post	O
-	O
CAB	T-nmod
,	O
patients	O
with	O
severe	O
anemia	B-Disease
had	T-nmod
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	O
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	O
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O

The	T-nmod
development	T-case
of	T-amod
severe	T-nmod
anemia	B-Disease
at	T-case
6	T-nmod
months	T-case
post	T-case
-	O
CAB	O
was	O
predictable	T-nmod
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	T-nmod
development	O
of	O
severe	O
CAB	T-amod
-	O
induced	O
anemia	B-Disease
in	O
prostate	O
cancer	O
patients	T-nmod
did	O
not	O
correlate	T-nmod
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

The	O
development	T-compound
of	O
severe	O
CAB	O
-	O
induced	O
anemia	O
in	T-compound
prostate	B-Disease
cancer	I-Disease
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

Severe	O
and	O
clinically	O
evident	T-amod
anemia	B-Disease
was	T-nsubj:pass
easily	T-nsubj:pass
corrected	O
by	O
subcutaneous	O
injections	T-nsubj:pass
(	O
3	O
times	T-nsubj:pass
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	T-nsubj:pass
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O

Delirium	B-Disease
during	T-nmod
clozapine	T-nmod
treatment	O
:	O
incidence	T-nmod
and	O
associated	O
risk	O
factors	O
.	O

Delirium	T-compound
during	T-compound
clozapine	B-Chemical
treatment	O
:	O
incidence	T-compound
and	O
associated	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	T-nmod
for	O
delirium	B-Disease
during	O
clozapine	O
treatment	T-nmod
require	T-nmod
further	O
clarification	O
.	O

BACKGROUND	O
:	O
Incidence	T-compound
and	O
risk	O
factors	O
for	O
delirium	O
during	T-compound
clozapine	B-Chemical
treatment	O
require	O
further	O
clarification	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	T-amod
all	T-amod
adult	T-amod
psychiatric	B-Disease
inpatients	O
treated	T-amod
with	O
clozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	O
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	O
inpatients	T-obl
treated	O
with	O
clozapine	B-Chemical
(	O
1995	O
-	O
96	T-dep
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	O
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	O
inpatients	O
treated	O
with	O
clozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	T-nmod
incidence	O
and	O
severity	T-nmod
of	O
delirium	B-Disease
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
,	O
hospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
days	O
,	O
and	O
given	O
clozapine	B-Chemical
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O

Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17	O
.	O
5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	B-Chemical
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

Delirium	B-Disease
was	T-nsubj:pass
inconsistently	T-nsubj:pass
recognized	O
clinically	T-nsubj:pass
in	O
milder	O
cases	T-nsubj:pass
and	O
was	O
associated	T-nsubj:pass
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Neuroprotective	T-nmod
action	O
of	O
MPEP	B-Chemical
,	O
a	T-appos
selective	T-appos
mGluR5	T-appos
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	T-nmod
is	O
associated	T-nmod
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	T-obl
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	T-nmod
action	O
of	O
MPEP	T-nmod
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	T-amod
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
is	O
associated	T-nmod
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	T-compound
in	T-compound
dopamine	B-Chemical
outflow	O
and	O
inhibition	T-compound
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	T-nmod
and	T-nmod
inhibition	O
of	O
hyperthermia	B-Disease
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	T-compound
of	T-compound
metabotropic	T-compound
glutamate	B-Chemical
receptor	O
5	T-compound
(	O
mGluR5	T-compound
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	O
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	T-nmod
of	O
metabotropic	O
glutamate	O
receptor	O
5	O
(	O
mGluR5	O
)	O
in	T-nmod
the	T-nmod
toxic	T-nmod
action	O
of	O
methamphetamine	B-Chemical
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

Methamphetamine	B-Chemical
(	O
10	T-appos
mg	O
/	O
kg	T-appos
sc	T-appos
)	O
,	O
administered	O
five	O
times	T-nsubj
,	O
reduced	T-nsubj
the	O
levels	O
of	O
dopamine	O
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

Methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	T-nmod
the	T-nmod
levels	O
of	O
dopamine	B-Chemical
and	T-conj
its	T-conj
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	T-appos
selective	T-appos
antagonist	O
of	O
mGluR5	T-appos
,	O
2	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
phenylethynyl	I-Chemical
)	I-Chemical
pyridine	I-Chemical
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	T-appos
)	O
,	O
when	T-appos
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	T-appos
of	O
mGluR5	O
,	O
2	O
-	O
methyl	T-appos
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	B-Chemical
;	O
5	O
mg	T-dep
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	T-compound
methamphetamine	B-Chemical
injection	O
reversed	T-compound
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	T-compound
the	T-compound
above	O
-	O
mentioned	T-compound
methamphetamine	B-Chemical
effects	O
.	O

A	O
single	O
MPEP	B-Chemical
(	O
5	T-dep
mg	O
/	O
kg	T-dep
ip	T-dep
)	O
injection	T-nsubj
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	T-nsubj
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	T-nsubj
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	T-compound
the	T-compound
basal	T-compound
extracellular	T-compound
dopamine	B-Chemical
level	O
in	O
the	O
striatum	T-compound
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	T-compound
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	T-compound
well	O
as	O
dopamine	B-Chemical
release	O
stimulated	T-compound
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	T-obl
stimulated	O
either	O
by	O
methamphetamine	B-Chemical
(	O
10	T-appos
mg	O
/	O
kg	T-appos
sc	T-appos
)	O
or	T-conj
by	T-conj
intrastriatally	O
administered	T-conj
veratridine	O
(	O
100	O
microM	T-conj
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	T-conj
either	T-conj
by	T-conj
methamphetamine	O
(	O
10	O
mg	T-conj
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	T-amod
administered	O
veratridine	B-Chemical
(	O
100	T-appos
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	T-compound
the	O
methamphetamine	B-Chemical
(	O
10	T-dep
mg	O
/	O
kg	T-dep
sc	T-dep
)	O
-	O
induced	O
hyperthermia	O
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

Moreover	T-obj
,	O
it	T-obj
transiently	T-obj
diminished	O
the	T-compound
methamphetamine	O
(	O
10	O
mg	T-compound
/	O
kg	O
sc	O
)	O
-	O
induced	T-compound
hyperthermia	B-Disease
and	O
reduced	T-obj
basal	O
body	O
temperature	O
.	O

MPEP	B-Chemical
administered	O
into	O
the	O
striatum	T-nsubj
at	O
high	O
concentrations	T-nsubj
(	O
500	O
microM	T-nsubj
)	O
increased	O
extracellular	O
dopamine	O
levels	T-nsubj
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	T-nsubj
of	O
any	O
effect	O
.	O

MPEP	O
administered	T-compound
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	T-compound
extracellular	T-compound
dopamine	B-Chemical
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	T-nmod
blockade	O
of	O
mGluR5	T-nmod
by	O
MPEP	B-Chemical
may	O
protect	T-nmod
dopaminergic	O
neurones	O
against	O
methamphetamine	O
-	O
induced	O
toxicity	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
toxicity	T-obl
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	T-nmod
dopaminergic	T-nmod
neurones	O
against	O
methamphetamine	T-amod
-	O
induced	O
toxicity	B-Disease
.	O

Neuroprotection	T-obl
rendered	O
by	O
MPEP	B-Chemical
may	O
be	O
associated	T-obl
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	O
dopamine	O
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
dopamine	O
efflux	T-obl
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	T-compound
of	T-compound
the	T-compound
methamphetamine	O
-	O
induced	T-compound
dopamine	B-Chemical
efflux	O
in	O
the	O
striatum	T-compound
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	O
dopamine	O
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	T-nmod
with	T-nmod
a	T-nmod
decrease	O
in	O
hyperthermia	B-Disease
.	O

Protective	T-nmod
efficacy	O
of	O
neuroactive	O
steroids	B-Chemical
against	O
cocaine	O
kindled	O
-	O
seizures	T-nmod
in	O
mice	T-nmod
.	O

Protective	O
efficacy	T-compound
of	O
neuroactive	O
steroids	O
against	T-compound
cocaine	B-Chemical
kindled	T-compound
-	O
seizures	O
in	O
mice	O
.	O

Protective	T-nmod
efficacy	O
of	O
neuroactive	O
steroids	T-nmod
against	O
cocaine	O
kindled	O
-	O
seizures	B-Disease
in	O
mice	T-nmod
.	O

Neuroactive	O
steroids	B-Chemical
demonstrate	O
pharmacological	O
actions	T-nsubj
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
.	O

Neuroactive	O
steroids	O
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	T-nmod
for	T-nmod
a	T-nmod
host	O
of	O
neurological	B-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O

They	O
offer	T-nmod
protection	O
against	O
seizures	B-Disease
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	O
dependence	O
in	O
preclinical	O
assessments	O
.	O

They	O
offer	O
protection	O
against	O
seizures	O
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	T-nmod
certain	T-nmod
stages	O
of	O
drug	B-Disease
dependence	I-Disease
in	O
preclinical	O
assessments	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	T-dep
and	O
one	O
synthetic	O
neuroactive	O
steroid	B-Chemical
that	T-acl:relcl
positively	T-acl:relcl
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	T-acl:relcl
against	O
the	O
increase	T-acl:relcl
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	T-compound
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	O
(	O
A	T-dep
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	T-dep
gamma	O
-	O
aminobutyric	T-dep
acid	O
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptor	T-dep
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	T-nmod
to	T-nmod
the	T-nmod
convulsant	T-nmod
effects	O
of	O
cocaine	B-Chemical
engendered	T-nmod
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	T-compound
by	T-compound
repeated	T-compound
cocaine	B-Chemical
administration	O
(	O
seizure	O
kindling	T-compound
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	T-compound
(	O
seizure	B-Disease
kindling	O
)	O
.	O

Allopregnanolone	B-Chemical
(	O
3alpha	T-appos
-	O
hydroxy	T-appos
-	O
5alpha	T-appos
-	O
pregnan	T-appos
-	O
20	T-appos
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	T-conj
)	O
and	T-conj
ganaxolone	O
(	O
a	O
synthetic	O
derivative	T-conj
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	T-nsubj:pass
tested	O
for	O
their	O
ability	O
to	O
suppress	T-nsubj:pass
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanolone	T-appos
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	T-appos
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	T-appos
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	T-conj
)	O
,	O
pregnanolone	B-Chemical
(	O
3alpha	T-appos
-	O
hydroxy	T-appos
-	O
5beta	T-appos
-	O
pregnan	T-appos
-	O
20	T-appos
-	O
one	O
)	O
and	O
ganaxolone	T-conj
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	T-conj
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	T-appos
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	T-conj
)	O
,	O
pregnanolone	T-conj
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	B-Chemical
(	O
a	T-dep
synthetic	T-dep
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	T-dep
)	O
were	O
tested	T-conj
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	T-nmod
(	O
a	T-nmod
synthetic	T-nmod
derivative	O
of	O
allopregnanolone	B-Chemical
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-Chemical
-	O
kindled	O
seizures	T-obl
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	T-nmod
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	T-nmod
development	O
(	O
antiepileptogenic	O
effect	T-nmod
)	O
of	O
cocaine	T-amod
-	O
kindled	O
seizures	B-Disease
in	T-nmod
male	O
,	O
Swiss	O
-	O
Webster	T-appos
mice	O
.	O

Kindled	O
seizures	B-Disease
were	T-nsubj:pass
induced	O
by	O
daily	O
administration	T-nsubj:pass
of	O
60	O
mg	O
/	O
kg	O
cocaine	O
for	O
5	O
days	T-nsubj:pass
.	O

Kindled	O
seizures	O
were	O
induced	T-nmod
by	T-nmod
daily	T-nmod
administration	O
of	O
60	T-compound
mg	O
/	O
kg	T-compound
cocaine	B-Chemical
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	O
GABA	B-Chemical
(	O
A	O
)	O
modulators	T-nmod
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	T-nmod
the	T-nmod
expression	O
of	O
kindled	O
seizures	B-Disease
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	T-nsubj
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	T-nsubj
only	O
allopregnanolone	B-Chemical
and	T-conj
ganaxolone	O
inhibited	O
the	O
development	T-nsubj
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	T-conj
allopregnanolone	O
and	O
ganaxolone	B-Chemical
inhibited	T-conj
the	O
development	O
of	O
kindling	O
.	O

Allopregnanolone	B-Chemical
and	T-conj
pregnanolone	O
,	O
but	O
not	T-conj
ganaxolone	O
,	O
also	O
reduced	T-appos
cumulative	T-appos
lethality	O
associated	T-appos
with	O
kindling	O
.	O

Allopregnanolone	O
and	O
pregnanolone	B-Chemical
,	O
but	O
not	O
ganaxolone	T-conj
,	O
also	O
reduced	O
cumulative	O
lethality	T-conj
associated	O
with	O
kindling	O
.	O

Allopregnanolone	O
and	O
pregnanolone	T-conj
,	O
but	T-cc
not	O
ganaxolone	B-Chemical
,	O
also	O
reduced	O
cumulative	O
lethality	T-conj
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	T-nsubj
that	T-nsubj
some	O
neuroactive	O
steroids	B-Chemical
attenuate	O
convulsant	T-nsubj
and	O
sensitizing	T-nsubj
properties	O
of	O
cocaine	O
and	O
add	T-nsubj
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	O
attenuate	O
convulsant	O
and	O
sensitizing	T-nmod
properties	O
of	O
cocaine	B-Chemical
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	B-Chemical
-	O
induced	O
increase	T-obl
in	O
locomotor	O
activity	O
of	O
mice	O
.	O

Effect	T-nmod
of	T-nmod
humoral	T-nmod
modulators	O
of	O
morphine	T-amod
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	T-nmod
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-Chemical
-	O
induced	O
increase	T-obl
in	O
locomotor	O
activity	O
of	O
mice	O
was	O
studied	O
.	O

The	T-nmod
effect	O
of	O
humoral	O
modulators	T-nmod
on	O
the	O
morphine	T-amod
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	T-nmod
mice	O
was	O
studied	T-nmod
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg	T-compound
/	O
kg	O
of	T-compound
morphine	B-Chemical
-	O
HC1	O
produced	O
a	O
marked	O
increase	O
in	O
locomotor	O
activity	O
in	O
mice	O
.	O

The	O
subcutaneous	O
administration	T-obj
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	O
-	O
HC1	O
produced	O
a	O
marked	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	T-nmod
mice	O
.	O

The	O
morphine	B-Chemical
-	O
induced	O
hyperactivity	T-obl
was	O
potentiated	O
by	O
scopolamine	O
and	O
attenuated	O
by	O
physostigmine	O
.	O

The	O
morphine	T-amod
-	O
induced	O
hyperactivity	B-Disease
was	T-nsubj:pass
potentiated	O
by	O
scopolamine	T-nsubj:pass
and	O
attenuated	T-nsubj:pass
by	O
physostigmine	O
.	O

The	O
morphine	O
-	O
induced	O
hyperactivity	T-obl
was	T-obl
potentiated	O
by	O
scopolamine	B-Chemical
and	O
attenuated	T-obl
by	O
physostigmine	O
.	O

The	O
morphine	O
-	O
induced	O
hyperactivity	O
was	O
potentiated	T-obl
by	O
scopolamine	O
and	T-obl
attenuated	O
by	O
physostigmine	B-Chemical
.	O

In	O
contrast	T-nsubj
,	O
both	O
methscopolamine	B-Chemical
and	T-conj
neostigmine	O
,	O
which	T-acl:relcl
do	T-acl:relcl
not	T-acl:relcl
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	T-acl:relcl
,	O
had	O
no	O
effect	T-nsubj
on	O
the	O
hyperactivity	O
produced	O
by	O
morphine	O
.	O

In	O
contrast	O
,	O
both	T-conj
methscopolamine	O
and	O
neostigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrate	T-conj
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	T-conj
no	O
effect	O
on	O
the	O
hyperactivity	O
produced	O
by	O
morphine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	T-nmod
no	T-nmod
effect	O
on	O
the	O
hyperactivity	B-Disease
produced	O
by	O
morphine	T-acl
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	T-obl
produced	O
by	O
morphine	B-Chemical
.	O

Pretreatment	T-appos
of	T-appos
mice	T-nmod
with	O
alpha	B-Chemical
-	I-Chemical
methyltyrosine	I-Chemical
(	T-nmod
20	T-nmod
mg	O
/	O
kg	T-nmod
i	T-nmod
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	O
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	B-Chemical
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	O
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
.	O

On	O
the	T-nsubj
other	O
hand	T-nsubj
,	T-nmod
pretreatment	O
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalamine	I-Chemical
(	T-obj
3	T-obj
X	O
320	T-obj
mg	O
/	T-obj
kg	T-dep
i	T-dep
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	O
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	O
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	B-Disease
.	O

The	O
study	O
suggests	O
that	O
the	T-nmod
activity	O
-	O
increasing	T-nmod
effects	O
of	O
morphine	B-Chemical
are	O
mediated	T-nmod
by	O
the	O
release	O
of	O
catecholamines	O
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O

The	O
study	O
suggests	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
are	O
mediated	T-nmod
by	T-nmod
the	T-nmod
release	O
of	O
catecholamines	B-Chemical
from	T-nmod
adrenergic	T-nmod
neurons	O
in	O
the	O
brain	T-nmod
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	T-nsubj
that	T-nsubj
morphine	B-Chemical
acts	O
by	O
retarding	T-nsubj
the	O
release	T-nsubj
of	O
acetylcholine	O
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	O
acts	T-nmod
by	O
retarding	O
the	T-nmod
release	O
of	O
acetylcholine	B-Chemical
at	O
some	O
central	O
cholinergic	O
synapses	T-nmod
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	T-nmod
activity	O
-	O
increasing	T-nmod
effects	O
of	O
morphine	B-Chemical
in	O
mice	T-nmod
are	O
mediated	T-nmod
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
in	O
rats	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	T-nmod
the	T-nmod
activity	O
-	O
increasing	T-nmod
effects	O
of	O
morphine	B-Chemical
in	O
rats	T-nmod
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	B-Chemical
-	O
induced	O
chronic	O
renal	O
failure	T-obl
in	O
rats	O
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	T-nmod
on	O
lithium	T-amod
-	O
induced	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	T-nmod
rats	O
.	O

Rats	O
with	O
lithium	B-Chemical
-	O
induced	O
nephropathy	T-obl
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	O
failure	O
.	O

Rats	O
with	O
lithium	T-amod
-	O
induced	O
nephropathy	B-Disease
were	O
subjected	T-nmod
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	O
failure	O
.	O

Rats	O
with	O
lithium	O
-	O
induced	O
nephropathy	O
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	T-nmod
and	T-nmod
further	T-nmod
progression	O
of	O
renal	B-Disease
failure	I-Disease
.	O

Corresponding	T-amod
non	O
-	O
lithium	B-Chemical
pretreated	T-amod
groups	O
were	O
generated	T-amod
.	O

When	T-obj
comparing	O
all	O
lithium	B-Chemical
treated	O
versus	O
non	O
-	O
lithium	O
-	O
treated	O
groups	T-acl
,	O
lithium	T-conj
caused	O
a	O
reduction	T-conj
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	T-conj
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	T-conj
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	T-conj
lithium	T-conj
clearance	O
.	O

When	O
comparing	O
all	O
lithium	O
treated	O
versus	O
non	O
-	O
lithium	B-Chemical
-	O
treated	O
groups	T-obl
,	O
lithium	O
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	O
clearance	O
.	O

When	O
comparing	O
all	O
lithium	T-nsubj
treated	O
versus	O
non	O
-	O
lithium	O
-	O
treated	O
groups	O
,	O
lithium	B-Chemical
caused	O
a	O
reduction	T-nsubj
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	T-nsubj
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	T-nsubj
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	O
clearance	O
.	O

When	O
comparing	O
all	O
lithium	T-compound
treated	O
versus	O
non	O
-	O
lithium	O
-	O
treated	O
groups	O
,	O
lithium	O
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	T-compound
lithium	B-Chemical
clearance	O
.	O

Consequently	O
,	O
lithium	B-Chemical
pretreatment	O
caused	T-compound
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	O
excretion	O
.	O

Consequently	O
,	O
lithium	O
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	T-compound
in	T-compound
fractional	T-compound
Li	B-Chemical
excretion	O
.	O

Lithium	B-Chemical
also	T-nsubj
caused	O
proteinuria	T-nsubj
and	O
systolic	O
hypertension	O
in	O
absence	T-nsubj
of	O
glomerulosclerosis	O
.	O

Lithium	T-obj
also	T-obj
caused	O
proteinuria	B-Disease
and	T-conj
systolic	T-conj
hypertension	O
in	O
absence	T-obj
of	O
glomerulosclerosis	O
.	O

Lithium	O
also	O
caused	T-conj
proteinuria	O
and	O
systolic	O
hypertension	B-Disease
in	O
absence	O
of	O
glomerulosclerosis	O
.	O

Lithium	O
also	O
caused	T-nmod
proteinuria	O
and	O
systolic	O
hypertension	O
in	T-nmod
absence	O
of	O
glomerulosclerosis	B-Disease
.	O

HP	O
failed	O
to	O
accentuante	T-nmod
progression	O
of	O
renal	B-Disease
failure	I-Disease
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	O
levels	O
in	O
lithium	O
pretreated	O
rats	O
.	O

HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	O
failure	O
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	T-compound
plasma	O
creatinine	B-Chemical
levels	T-conj
in	O
lithium	O
pretreated	O
rats	O
.	O

HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	O
failure	O
and	O
in	O
fact	O
tended	O
to	O
increase	T-compound
GFR	O
and	O
decrease	O
plasma	O
creatinine	O
levels	O
in	T-compound
lithium	B-Chemical
pretreated	T-compound
rats	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	B-Chemical
-	O
pretreated	O
rats	O

The	O
results	O
indicate	O
that	O
Li	B-Chemical
-	O
induced	O
nephropathy	T-obl
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	O
and	O
arterial	O
systolic	O
hypertension	O
.	O

The	O
results	O
indicate	T-dep
that	O
Li	T-amod
-	O
induced	O
nephropathy	B-Disease
,	O
even	T-dep
when	T-dep
the	O
GFR	T-dep
is	T-dep
only	O
modestly	T-dep
reduced	O
,	O
is	O
associated	T-dep
with	O
proteinuria	O
and	O
arterial	O
systolic	O
hypertension	O
.	O

The	O
results	O
indicate	O
that	O
Li	O
-	O
induced	O
nephropathy	O
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	T-obl
,	O
is	T-obl
associated	O
with	O
proteinuria	B-Disease
and	T-conj
arterial	T-conj
systolic	T-conj
hypertension	O
.	O

The	O
results	O
indicate	O
that	O
Li	O
-	O
induced	O
nephropathy	O
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	T-conj
with	T-conj
proteinuria	O
and	O
arterial	O
systolic	O
hypertension	B-Disease
.	O

In	T-nmod
this	T-nmod
model	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	T-nmod
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O

Treatment	O
of	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
with	O
fusidic	O
acid	T-nmod
:	O
an	O
antibiotic	T-nmod
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	O
.	O

Treatment	O
of	O
Crohn	O
'	O
s	O
disease	T-nmod
with	O
fusidic	B-Chemical
acid	I-Chemical
:	O
an	O
antibiotic	T-nmod
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	O
.	O

Treatment	O
of	O
Crohn	O
'	O
s	O
disease	O
with	O
fusidic	O
acid	O
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	T-obl
similar	O
to	O
cyclosporin	B-Chemical
.	O

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	T-nmod
to	T-nmod
those	O
of	O
cyclosporin	B-Chemical
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	T-nmod
of	T-nmod
new	T-nmod
treatments	O
for	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	O
acid	O
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	O
'	O
s	O
disease	O
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	T-compound
and	O
tolerability	O
of	T-compound
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

Eight	T-compound
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
were	O
included	T-compound
.	O

Fusidic	B-Chemical
acid	I-Chemical
was	T-nsubj:pass
administered	T-det
orally	T-det
in	O
a	T-cc
dose	T-nsubj:pass
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks	O
.	O

There	O
were	T-obl
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	T-obl
dose	O
reduction	T-obl
was	T-obl
required	O
in	O
two	O
patients	T-obl
because	O
of	T-case
nausea	B-Disease
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	T-nsubj
that	T-nsubj
fusidic	B-Chemical
acid	I-Chemical
may	T-nsubj
be	T-nsubj
of	T-nsubj
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	O
'	O
s	O
disease	O
patients	T-nsubj
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	O
acid	O
may	O
be	O
of	O
benefit	T-compound
in	T-compound
selected	T-compound
chronic	T-compound
active	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	T-compound
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	T-nmod
for	T-nmod
the	T-nmod
use	O
of	O
fusidic	B-Chemical
acid	I-Chemical
at	O
the	O
cytokine	O
level	T-nmod
in	O
inflammatory	O
bowel	O
disease	O
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	T-nmod
of	O
fusidic	O
acid	O
at	T-nmod
the	T-nmod
cytokine	T-nmod
level	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O

Changes	T-amod
in	T-amod
depressive	B-Disease
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O

Depression	B-Disease
and	T-conj
sexual	T-conj
dysfunction	O
have	T-nsubj:pass
been	T-nsubj:pass
related	O
to	O
side	O
effects	T-nsubj:pass
of	O
topical	O
beta	O
-	O
blockers	O
.	O

Depression	O
and	O
sexual	B-Disease
dysfunction	I-Disease
have	O
been	O
related	T-conj
to	O
side	O
effects	O
of	O
topical	O
beta	O
-	O
blockers	O
.	O

We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	T-nmod
any	T-nmod
difference	O
between	O
a	O
non	T-amod
selective	O
beta	T-dep
-	O
blocker	O
(	O
timolol	B-Chemical
)	O
and	O
a	O
selective	O
beta	O
-	O
blocker	O
(	O
betaxolol	O
)	O
regarding	O
CNS	O
side	O
effects	O
.	O

We	O
performed	T-conj
a	O
preliminary	O
study	O
in	T-conj
order	O
to	T-conj
determine	O
any	O
difference	T-conj
between	O
a	O
non	O
selective	O
beta	O
-	O
blocker	O
(	O
timolol	O
)	O
and	O
a	O
selective	O
beta	T-dep
-	O
blocker	O
(	O
betaxolol	B-Chemical
)	O
regarding	T-nmod
CNS	T-nmod
side	T-nmod
effects	O
.	O

During	T-nsubj:pass
the	T-nsubj:pass
six	O
-	O
month	O
follow	T-nsubj:pass
up	O
,	O
depression	B-Disease
was	T-nsubj:pass
quantified	O
through	T-nsubj:pass
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	O
.	O

In	O
a	O
double	O
blind	O
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	T-compound
under	T-compound
timolol	B-Chemical
treatment	O
presented	O
higher	O
depression	O
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
)	O
.	O

In	O
a	O
double	O
blind	O
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	O
treatment	O
presented	T-compound
higher	T-compound
depression	B-Disease
values	O
measured	T-compound
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
control	O
)	O
.	O

These	O
results	O
suggest	T-nsubj
that	T-nsubj
betaxolol	B-Chemical
could	T-nsubj
be	T-nsubj
less	O
of	O
a	O
depression	O
-	O
inducer	T-nsubj
than	O
timolol	T-nsubj
in	O
predisposed	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
betaxolol	O
could	O
be	O
less	T-compound
of	T-compound
a	T-compound
depression	B-Disease
-	O
inducer	O
than	O
timolol	O
in	O
predisposed	O
patients	O
.	O

These	O
results	O
suggest	T-obl
that	T-obl
betaxolol	T-obl
could	T-obl
be	T-obl
less	O
of	O
a	O
depression	O
-	O
inducer	T-obl
than	O
timolol	B-Chemical
in	T-nmod
predisposed	T-nmod
patients	O
.	O

Protection	O
against	O
amphetamine	B-Chemical
-	O
induced	O
neurotoxicity	T-obl
toward	O
striatal	O
dopamine	O
neurons	O
in	O
rodents	O
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	O
.	O

Protection	O
against	O
amphetamine	T-amod
-	O
induced	O
neurotoxicity	B-Disease
toward	O
striatal	O
dopamine	O
neurons	T-nmod
in	O
rodents	T-nmod
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	T-nmod
.	O

Protection	T-compound
against	O
amphetamine	O
-	O
induced	O
neurotoxicity	O
toward	T-compound
striatal	T-compound
dopamine	B-Chemical
neurons	O
in	O
rodents	O
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	O
.	O

Protection	T-nmod
against	O
amphetamine	O
-	O
induced	O
neurotoxicity	O
toward	O
striatal	O
dopamine	O
neurons	O
in	T-nmod
rodents	O
by	O
LY274614	B-Chemical
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	O
.	O

Protection	T-compound
against	O
amphetamine	O
-	O
induced	O
neurotoxicity	O
toward	O
striatal	O
dopamine	O
neurons	O
in	O
rodents	O
by	O
LY274614	O
,	O
an	T-compound
excitatory	T-compound
amino	B-Chemical
acid	I-Chemical
antagonist	O
.	O

LY274614	B-Chemical
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	T-appos
-	O
6	O
-	O
[	O
phosphonomethyl	O
]	O
decahydr	T-appos
oisoquinoline	O
-	O
3	T-appos
-	O
carboxylic	O
acid	T-appos
,	O
has	T-nsubj:pass
been	T-nsubj:pass
described	O
as	O
a	O
potent	O
antagonist	T-nsubj:pass
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
subtype	O
of	O
glutamate	O
receptor	O
.	O

LY274614	O
,	O
3SR	B-Chemical
,	I-Chemical
4aRS	I-Chemical
,	I-Chemical
6SR	I-Chemical
,	I-Chemical
8aRS	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
[	I-Chemical
phosphonomethyl	I-Chemical
]	I-Chemical
decahydr	I-Chemical
oisoquinoline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylic	I-Chemical
acid	I-Chemical
,	O
has	O
been	O
described	T-appos
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
subtype	O
of	O
glutamate	O
receptor	O
.	O

LY274614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphonomethyl	O
]	O
decahydr	O
oisoquinoline	O
-	O
3	O
-	O
carboxylic	O
acid	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	O
)	O
subtype	T-dep
of	O
glutamate	O
receptor	O
.	O

LY274614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphonomethyl	O
]	O
decahydr	O
oisoquinoline	O
-	O
3	O
-	O
carboxylic	O
acid	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	T-compound
of	T-compound
the	T-compound
N	T-dep
-	O
methyl	T-dep
-	O
D	T-dep
-	O
aspartate	O
(	O
NMDA	B-Chemical
)	O
subtype	O
of	O
glutamate	O
receptor	T-compound
.	O

LY274614	O
,	O
3SR	O
,	O
4aRS	O
,	O
6SR	O
,	O
8aRS	O
-	O
6	O
-	O
[	O
phosphonomethyl	O
]	O
decahydr	O
oisoquinoline	O
-	O
3	O
-	O
carboxylic	O
acid	O
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
subtype	T-compound
of	T-compound
glutamate	B-Chemical
receptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	T-nmod
the	T-nmod
prolonged	T-nmod
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	T-nmod
by	O
amphetamine	T-nmod
in	O
iprindole	O
-	O
treated	O
rats	O
is	O
reported	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	T-nmod
the	T-nmod
prolonged	T-nmod
depletion	O
of	O
dopamine	T-nmod
in	O
the	O
striatum	T-nmod
by	O
amphetamine	B-Chemical
in	T-nmod
iprindole	O
-	O
treated	T-nmod
rats	O
is	O
reported	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
by	O
amphetamine	O
in	O
iprindole	B-Chemical
-	O
treated	O
rats	T-obl
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	T-nmod
/	T-nmod
-	T-nmod
)	O
-	O
amphetamine	B-Chemical
hemisulfate	O
,	O
given	T-nmod
to	O
rats	O
pretreated	T-nmod
with	O
iprindole	O
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
1	O
week	O
later	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamine	O
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	B-Chemical
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
1	O
week	O
later	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamine	O
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	O
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
1	O
week	O
later	O

This	T-nmod
prolonged	T-nmod
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	T-nmod
was	O
antagonized	T-nmod
by	O
dizocilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
.	O

This	O
prolonged	O
depletion	T-obl
of	O
dopamine	O
in	O
the	O
striatum	O
was	T-obl
antagonized	O
by	O
dizocilpine	B-Chemical
(	O
MK	T-dep
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	T-dep
of	O
NMDA	O
receptors	O
)	O
or	T-conj
by	T-conj
LY274614	O
(	O
a	O
competitive	O
antagonist	T-conj
of	O
NMDA	O
receptors	O
)	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
antagonized	T-dep
by	T-dep
dizocilpine	O
(	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	T-appos
non	O
-	O
competitive	T-appos
antagonist	O
of	O
NMDA	O
receptors	T-appos
)	O
or	O
by	O
LY274614	T-dep
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	T-compound
of	T-compound
NMDA	B-Chemical
receptors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
antagonized	T-conj
by	T-conj
dizocilpine	O
(	O
MK	O
-	O
801	T-conj
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
or	O
by	O
LY274614	B-Chemical
(	O
a	T-dep
competitive	T-dep
antagonist	O
of	O
NMDA	O
receptors	T-dep
)	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	O
(	O
MK	O
-	O
801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	T-compound
of	T-compound
NMDA	B-Chemical
receptors	O
)	O
.	O

The	T-nmod
protective	T-nmod
effect	O
of	O
LY274614	B-Chemical
was	O
dose	O
-	O
dependent	T-nmod
,	O
being	O
maximum	O
at	O
10	O
-	O
40	O
mgkg	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	T-nmod
10	O
mg	T-nmod
/	O
kg	O
dose	O
of	O
LY274614	B-Chemical
was	O
effective	T-nmod
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	O
was	O
effective	O
in	O
antagonizing	T-nmod
the	T-nmod
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	T-nmod
,	O
when	T-nmod
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	O
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
,	O
when	O
given	T-advcl
as	T-advcl
long	O
as	O
8	O
hr	T-advcl
prior	O
to	O
amphetamine	B-Chemical
but	O
not	T-advcl
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	O
.	O

A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	O
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	O
but	O
not	O
when	T-nmod
given	T-nmod
24	T-nmod
hr	O
prior	O
to	O
amphetamine	B-Chemical
.	O

Depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	T-nmod
was	O
also	O
antagonized	T-nmod
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
also	O
antagonized	T-nsubj:pass
when	T-nsubj:pass
LY274614	B-Chemical
was	T-nsubj:pass
given	O
after	O
the	O
injection	T-nsubj:pass
of	O
amphetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	O
was	O
given	T-nmod
after	T-nmod
the	T-nmod
injection	O
of	O
amphetamine	B-Chemical
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
also	O
antagonized	T-nsubj
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	O
;	O
LY274614	B-Chemical
protected	O
when	T-nsubj
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	T-nmod
given	T-nmod
8	T-nmod
or	O
24	O
hr	O
after	O
amphetamine	B-Chemical
.	O

The	T-nmod
prolonged	T-nmod
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	T-nmod
in	O
mice	T-nmod
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	O
,	O
was	O
also	O
antagonized	T-nmod
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	O
.	O

The	O
prolonged	O
depletion	O
of	O
dopamine	O
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	T-nmod
multiple	T-nmod
injections	O
of	O
methamphetamine	B-Chemical
,	O
was	O
also	O
antagonized	T-nmod
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	O
.	O

The	O
prolonged	O
depletion	T-conj
of	O
dopamine	O
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	T-conj
of	O
methamphetamine	O
,	O
was	T-conj
also	T-conj
antagonized	O
dose	O
-	O
dependently	T-conj
and	O
completely	O
by	O
LY274614	B-Chemical
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	T-amod
neurotoxic	B-Disease
effect	O
of	O
amphetamine	T-amod
and	O
related	O
compounds	T-amod
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	T-nmod
neurotoxic	T-nmod
effect	O
of	O
amphetamine	B-Chemical
and	T-conj
related	O
compounds	T-nmod
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	O
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	T-compound
toward	T-compound
nigrostriatal	T-compound
dopamine	B-Chemical
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	O
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	T-compound
NMDA	B-Chemical
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

The	O
data	O
strengthen	T-nsubj
the	O
evidence	O
that	O
the	O
neurotoxic	O
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	O
NMDA	O
receptors	O
and	T-nsubj
that	T-nsubj
LY274614	B-Chemical
is	T-nsubj
an	T-nsubj
NMDA	O
receptor	T-nsubj
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	T-nsubj
in	O
rats	O
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	O
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	O
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	B-Chemical
receptor	O
antagonist	T-compound
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Ketoconazole	B-Chemical
-	O
induced	O
neurologic	O
sequelae	T-obl
.	O

Ketoconazole	T-amod
-	O
induced	O
neurologic	B-Disease
sequelae	I-Disease
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	T-obj
developed	O
weakness	B-Disease
of	I-Disease
extremities	I-Disease
,	O
legs	T-conj
paralysis	O
,	O
dysarthria	O
and	T-conj
tremor	O
1	O
h	T-obj
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	O
for	O
the	O
first	O
time	T-obj
in	O
his	O
life	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	T-conj
of	T-conj
extremities	O
,	O
legs	B-Disease
paralysis	I-Disease
,	O
dysarthria	T-conj
and	O
tremor	T-conj
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	O
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	T-conj
of	T-conj
extremities	O
,	O
legs	O
paralysis	T-conj
,	O
dysarthria	B-Disease
and	O
tremor	T-conj
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	O
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	T-conj
of	T-conj
extremities	O
,	O
legs	O
paralysis	T-conj
,	O
dysarthria	T-conj
and	O
tremor	B-Disease
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	O
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	O
of	O
extremities	O
,	O
legs	O
paralysis	O
,	O
dysarthria	O
and	O
tremor	O
1	O
h	T-nmod
after	O
ingestion	O
of	O
200	T-compound
mg	O
ketoconazole	B-Chemical
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

Few	O
days	O
later	O
,	O
the	O
patient	O
used	T-compound
another	T-compound
200	O
mg	T-compound
ketoconazole	B-Chemical
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O

This	O
case	O
illustrates	O
the	O
need	T-nmod
for	T-nmod
close	T-nmod
vigilance	O
in	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
particularly	O
in	O
the	O
elderly	T-nmod
.	O

Development	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	T-obl
in	O
parkinsonian	O
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and	O
/	O
or	O
duration	O
of	O
symptoms	O
.	O

Development	O
of	O
levodopa	T-amod
-	O
induced	O
dyskinesias	B-Disease
in	T-nmod
parkinsonian	T-nmod
monkeys	O
may	O
depend	T-nmod
upon	O
rate	O
of	O
symptom	O
onset	O
and	O
/	O
or	O
duration	O
of	O
symptoms	O
.	O

Development	O
of	O
levodopa	O
-	O
induced	O
dyskinesias	T-amod
in	T-amod
parkinsonian	B-Disease
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and	O
/	O
or	O
duration	O
of	O
symptoms	O
.	O

Levodopa	B-Chemical
-	O
induced	O
dyskinesias	T-obl
(	O
LIDs	O
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
patients	O
.	O

Levodopa	T-amod
-	O
induced	O
dyskinesias	B-Disease
(	O
LIDs	O
)	O
present	O
a	O
major	O
problem	T-nsubj
for	O
the	O
long	O
-	O
term	O
management	T-nsubj
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
patients	O
.	O

Levodopa	O
-	O
induced	T-dep
dyskinesias	O
(	O
LIDs	B-Disease
)	O
present	T-dep
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
patients	O
.	O

Levodopa	O
-	O
induced	O
dyskinesias	O
(	O
LIDs	O
)	O
present	T-nmod
a	O
major	O
problem	O
for	T-nmod
the	T-nmod
long	O
-	O
term	T-nmod
management	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	O
)	O
patients	O
.	O

Levodopa	O
-	O
induced	O
dyskinesias	O
(	O
LIDs	O
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	T-dep
of	T-dep
Parkinson	T-dep
'	O
s	T-dep
disease	O
(	O
PD	B-Disease
)	O
patients	T-dep
.	O

Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	T-nmod
the	T-nmod
development	O
of	O
LIDs	B-Disease
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	B-Chemical
-	O
induced	O
parkinsonism	T-obl
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	O
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	O
.	O

Using	O
macaque	O
monkeys	T-nmod
with	T-nmod
different	T-nmod
types	O
of	O
MPTP	T-amod
-	O
induced	O
parkinsonism	B-Disease
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	O
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	O
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	O
-	O
induced	O
parkinsonism	O
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	T-compound
of	T-compound
levodopa	B-Chemical
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	O
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	O
-	O
induced	O
parkinsonism	O
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	O
therapy	O
may	O
be	O
involved	T-nmod
in	T-nmod
the	T-nmod
development	O
of	O
LIDs	B-Disease
.	O

Monkeys	T-compound
with	T-compound
acute	T-compound
(	O
short	O
-	O
term	O
)	O
MPTP	B-Chemical
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
developed	O
dyskinesia	O
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	O
administration	O
.	O

Monkeys	O
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	T-compound
of	T-compound
levodopa	B-Chemical
therapy	O
developed	O
dyskinesia	O
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	O
administration	O
.	O

Monkeys	T-obl:tmod
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	T-obl:tmod
to	T-obl:tmod
initiation	O
of	O
levodopa	O
therapy	T-obl:tmod
developed	O
dyskinesia	B-Disease
between	T-nmod
11	T-nmod
and	O
24	O
days	O
of	O
daily	O
levodopa	O
administration	T-nmod
.	O

Monkeys	O
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
developed	O
dyskinesia	O
between	O
11	O
and	O
24	O
days	T-compound
of	T-compound
daily	T-compound
levodopa	B-Chemical
administration	O
.	O

In	O
contrast	O
,	O
monkeys	T-compound
with	T-compound
long	O
-	O
term	T-case
MPTP	B-Chemical
exposure	T-case
,	T-case
slow	T-compound
symptom	O
progression	T-case
and	O
/	O
or	O
long	O
symptom	O
duration	T-compound
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	O
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	O
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	O
administration	O
)	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	T-compound
of	T-compound
levodopa	B-Chemical
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	O
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	O
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	O
administration	O
)	O
.	O

In	O
contrast	T-obl
,	O
monkeys	T-obl
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
were	T-obl
more	T-obl
resistant	O
to	O
developing	O
LIDs	B-Disease
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	O
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	O
administration	O
)	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	O
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	B-Disease
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	O
administration	O
)	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and	O
/	O
or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	O
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	O
(	O
e	O
.	O
g	O
.	O
,	O
dyskinesia	O
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	B-Chemical
administration	O
)	O
.	O

All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	T-compound
of	T-compound
levodopa	B-Chemical
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	O
.	O

These	O
data	O
suggest	T-obj
distinct	O
differences	O
in	O
the	O
propensity	O
to	T-obj
develop	O
LIDs	B-Disease
in	T-nmod
monkeys	O
with	O
different	O
rates	T-obj
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	T-obj
and	O
demonstrate	T-obj
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	O
.	O

These	O
data	O
suggest	T-advcl
distinct	O
differences	O
in	O
the	O
propensity	O
to	T-advcl
develop	O
LIDs	T-advcl
in	O
monkeys	O
with	O
different	O
rates	T-advcl
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	B-Chemical
and	O
demonstrate	T-advcl
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	O
.	O

These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	O
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	O
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	T-nmod
the	T-nmod
pathophysiology	O
of	O
LIDs	B-Disease
.	O

A	O
diet	T-amod
promoting	O
sugar	B-Disease
dependency	I-Disease
causes	O
behavioral	O
cross	O
-	O
sensitization	T-nsubj
to	O
a	O
low	O
dose	T-nsubj
of	O
amphetamine	O
.	O

A	O
diet	O
promoting	O
sugar	O
dependency	T-obj
causes	O
behavioral	B-Disease
cross	I-Disease
-	I-Disease
sensitization	I-Disease
to	O
a	O
low	O
dose	T-obj
of	O
amphetamine	O
.	O

A	O
diet	O
promoting	O
sugar	O
dependency	O
causes	T-nmod
behavioral	O
cross	O
-	O
sensitization	O
to	T-nmod
a	T-nmod
low	T-nmod
dose	O
of	O
amphetamine	B-Chemical
.	O

Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	T-nmod
a	O
state	O
with	T-nmod
neurochemical	T-nmod
and	O
behavioral	O
similarities	O
to	O
drug	B-Disease
dependency	I-Disease
.	O

The	O
present	O
study	O
examined	T-obj
whether	T-obj
female	O
rats	T-obj
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	T-obj
show	O
behavioral	B-Disease
cross	I-Disease
-	I-Disease
sensitization	I-Disease
to	O
a	O
low	O
dose	T-obj
of	O
amphetamine	O
.	O

The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	T-nmod
behavioral	O
cross	O
-	O
sensitization	O
to	T-nmod
a	T-nmod
low	T-nmod
dose	O
of	O
amphetamine	B-Chemical
.	O

Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	T-nmod
to	T-nmod
a	T-nmod
single	T-nmod
low	T-nmod
dose	O
of	O
amphetamine	B-Chemical
(	O
0	T-nmod
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	T-nmod
of	T-nmod
increased	T-nmod
sensitivity	O
to	O
amphetamine	B-Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	O
system	O
.	O

These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	O
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	T-compound
in	T-compound
the	T-compound
dopamine	B-Chemical
system	O
.	O

Reversible	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
amphotericin	O
B	O
therapy	T-amod
.	O

Reversible	O
dilated	O
cardiomyopathy	O
related	T-compound
to	T-compound
amphotericin	B-Chemical
B	I-Chemical
therapy	O
.	O

We	O
describe	O
a	O
patient	T-obj
who	T-obj
developed	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	T-conj
clinical	T-conj
congestive	T-conj
heart	T-conj
failure	O
after	O
2	O
months	T-obj
of	O
therapy	O
with	O
amphotericin	O
B	O
(	O
AmB	O
)	O
for	O
disseminated	O
coccidioidomycosis	T-obj
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	T-conj
dilated	T-conj
cardiomyopathy	O
and	O
clinical	O
congestive	O
heart	B-Disease
failure	I-Disease
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	O
B	O
(	O
AmB	O
)	O
for	O
disseminated	O
coccidioidomycosis	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	O
cardiomyopathy	O
and	O
clinical	O
congestive	O
heart	O
failure	O
after	O
2	O
months	T-nmod
of	T-nmod
therapy	O
with	O
amphotericin	B-Chemical
B	I-Chemical
(	O
AmB	O
)	O
for	O
disseminated	O
coccidioidomycosis	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	O
cardiomyopathy	O
and	O
clinical	O
congestive	O
heart	O
failure	O
after	O
2	O
months	O
of	O
therapy	T-appos
with	T-appos
amphotericin	T-appos
B	O
(	O
AmB	B-Chemical
)	O
for	O
disseminated	O
coccidioidomycosis	O
.	O

We	O
describe	O
a	O
patient	T-obl
who	T-obl
developed	O
dilated	O
cardiomyopathy	T-obl
and	O
clinical	O
congestive	O
heart	O
failure	O
after	O
2	O
months	T-obl
of	O
therapy	O
with	O
amphotericin	O
B	O
(	O
AmB	O
)	O
for	O
disseminated	O
coccidioidomycosis	B-Disease
.	O

His	T-conj
echocardiographic	T-conj
abnormalities	O
and	O
heart	B-Disease
failure	I-Disease
resolved	T-conj
after	O
posaconazole	O
was	O
substituted	O
for	O
AmB	O
.	O

His	O
echocardiographic	O
abnormalities	O
and	O
heart	O
failure	O
resolved	T-nsubj:pass
after	T-nsubj:pass
posaconazole	B-Chemical
was	T-nsubj:pass
substituted	O
for	O
AmB	T-nsubj:pass
.	O

His	O
echocardiographic	O
abnormalities	O
and	O
heart	O
failure	O
resolved	T-obl
after	T-obl
posaconazole	T-obl
was	T-obl
substituted	O
for	O
AmB	B-Chemical
.	O

It	O
is	O
important	T-obj
to	T-obj
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	T-amod
toxicity	B-Disease
of	T-nmod
AmB	O
.	O

It	O
is	O
important	O
to	O
recognize	T-nmod
the	T-nmod
rare	T-nmod
and	O
potentially	O
reversible	O
toxicity	O
of	O
AmB	B-Chemical
.	O

NO	B-Chemical
-	O
induced	O
migraine	O
attack	T-advmod
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	O
release	O
.	O

NO	O
-	O
induced	T-compound
migraine	B-Disease
attack	O
:	O
strong	O
increase	T-compound
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	O
release	O
.	O

NO	O
-	O
induced	O
migraine	O
attack	T-nmod
:	O
strong	T-nmod
increase	O
in	O
plasma	O
calcitonin	B-Chemical
gene	I-Chemical
-	I-Chemical
related	I-Chemical
peptide	I-Chemical
(	O
CGRP	T-nmod
)	O
concentration	T-nmod
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	O
release	O
.	O

NO	O
-	O
induced	O
migraine	O
attack	T-dep
:	O
strong	T-dep
increase	O
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	T-dep
(	O
CGRP	B-Chemical
)	O
concentration	T-dep
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	O
release	O
.	O

NO	O
-	O
induced	O
migraine	O
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
negative	O
correlation	T-compound
with	T-compound
platelet	O
serotonin	B-Chemical
release	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	T-obl
in	O
the	O
plasma	O
calcitonin	B-Chemical
gene	I-Chemical
-	I-Chemical
related	I-Chemical
peptide	I-Chemical
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	T-obl
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	O
by	O
nitroglycerin	T-obl
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	T-dep
the	T-dep
plasma	O
calcitonin	T-dep
gene	O
-	O
related	T-dep
peptide	O
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	O
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	T-dep
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	B-Chemical
(	O
5	O
-	O
hydroxytriptamine	T-conj
,	O
5	O
-	O
HT	O
)	O
content	T-conj
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	O
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	T-dep
(	O
5	B-Chemical
-	I-Chemical
hydroxytriptamine	I-Chemical
,	O
5	T-dep
-	O
HT	O
)	O
content	T-dep
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	O
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	T-dep
and	O
platelet	O
serotonin	O
(	O
5	T-dep
-	T-dep
hydroxytriptamine	O
,	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
content	O
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	O
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	T-nmod
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	O
during	O
the	O
immediate	O
headache	B-Disease
and	T-conj
the	T-conj
delayed	T-conj
genuine	T-conj
migraine	T-conj
attack	O
provoked	T-nmod
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	O
during	O
the	O
immediate	O
headache	T-compound
and	T-compound
the	T-compound
delayed	T-compound
genuine	T-compound
migraine	B-Disease
attack	O
provoked	O
by	O
nitroglycerin	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	T-obl
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	T-obl
(	O
CGRP	O
)	O
concentration	O
and	O
platelet	O
serotonin	O
(	O
5	O
-	O
hydroxytriptamine	O
,	O
5	O
-	O
HT	O
)	O
content	T-obl
during	O
the	O
immediate	O
headache	O
and	O
the	O
delayed	O
genuine	O
migraine	O
attack	O
provoked	O
by	O
nitroglycerin	B-Chemical
.	O

Fifteen	O
female	O
migraineurs	B-Disease
(	I-Disease
without	I-Disease
aura	I-Disease
)	I-Disease
and	T-conj
eight	T-conj
controls	O
participated	O
in	O
the	O
study	T-nsubj
.	O

Sublingual	O
nitroglycerin	B-Chemical
(	O
0	T-nsubj:pass
.	T-dep
5	O
mg	O
)	O
was	O
administered	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	T-compound
before	O
and	T-compound
after	T-compound
the	T-compound
nitroglycerin	B-Chemical
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	O
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	O
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	T-compound
of	T-compound
the	T-compound
migraine	B-Disease
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O

In	O
those	O
subjects	O
who	O
had	T-compound
no	T-compound
migraine	B-Disease
attack	O
(	O
11	O
subjects	T-compound
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O

Plasma	O
CGRP	B-Chemical
concentration	O
increased	T-compound
significantly	O
(	T-compound
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migraine	O
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	O
.	O

Plasma	O
CGRP	O
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	T-det
the	T-det
migraine	B-Disease
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	O
.	O

Plasma	O
CGRP	O
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migraine	O
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	B-Disease
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	T-compound
significant	O
positive	O
correlations	O
with	T-compound
migraine	B-Disease
headache	B-Disease
intensity	O
(	O
P	O
<	O
0	T-compound
.	O
001	O
)	O
.	O

However	O
,	O
plasma	O
CGRP	B-Chemical
concentrations	O
failed	T-compound
to	O
change	O
during	O
immediate	O
headache	O
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	O
attack	O
.	O

However	O
,	O
plasma	O
CGRP	O
concentrations	O
failed	T-obl
to	T-obl
change	O
during	O
immediate	O
headache	B-Disease
and	T-conj
in	T-conj
the	T-conj
subjects	O
with	O
no	O
migraine	O
attack	T-conj
.	O

However	O
,	O
plasma	O
CGRP	O
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	O
and	O
in	O
the	O
subjects	T-compound
with	T-compound
no	T-compound
migraine	B-Disease
attack	O
.	O

Basal	T-compound
CGRP	B-Chemical
concentration	O
was	O
significantly	O
higher	T-compound
and	O
platelet	O
5	O
-	O
HT	O
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	O
attack	O
.	O

Basal	O
CGRP	O
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	T-compound
5	B-Chemical
-	I-Chemical
HT	I-Chemical
content	O
tended	T-compound
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	O
attack	O
.	O

Basal	O
CGRP	O
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5	O
-	O
HT	O
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	T-compound
a	T-compound
migraine	B-Disease
attack	O
.	O

Platelet	T-compound
serotonin	B-Chemical
content	O
decreased	T-compound
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	O
in	O
subjects	O
with	O
no	O
migraine	O
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	O
attack	O
.	O

Platelet	O
serotonin	O
content	O
decreased	T-nsubj:pass
significantly	O
(	O
P	O
<	O
0	O
.	O
01	T-nsubj:pass
)	O
after	O
nitroglycerin	B-Chemical
in	T-nsubj:pass
subjects	O
with	O
no	T-nsubj:pass
migraine	O
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	O
attack	O
.	O

Platelet	O
serotonin	O
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	O
in	O
subjects	O
with	O
no	T-case
migraine	B-Disease
attack	T-case
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	O
attack	O
.	O

Platelet	O
serotonin	O
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	O
in	O
subjects	O
with	O
no	O
migraine	O
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	B-Disease
attack	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	T-compound
CGRP	B-Chemical
concentration	O
correlates	T-compound
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	O
headache	O
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	O
and	O
migraine	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	O
concentration	O
correlates	T-nmod
with	T-nmod
the	T-nmod
timing	O
and	O
severity	T-nmod
of	O
a	O
migraine	B-Disease
headache	B-Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	O
and	O
migraine	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	O
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	O
headache	O
suggests	T-nmod
a	T-nmod
direct	T-nmod
relationship	O
between	O
CGRP	B-Chemical
and	T-conj
migraine	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	O
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	O
headache	O
suggests	O
a	O
direct	O
relationship	T-conj
between	T-conj
CGRP	O
and	O
migraine	B-Disease
.	O

In	O
contrast	O
,	O
serotonin	B-Chemical
release	O
from	O
platelets	T-compound
does	O
not	O
provoke	T-compound
migraine	O
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	O
and	O
the	O
concomitant	O
CGRP	O
release	O
in	O
this	O
model	O
.	O

In	O
contrast	T-obj
,	O
serotonin	O
release	T-obj
from	O
platelets	O
does	T-obj
not	T-obj
provoke	O
migraine	B-Disease
,	O
it	O
may	O
even	O
counteract	T-obj
the	O
headache	O
and	O
the	O
concomitant	O
CGRP	O
release	O
in	O
this	O
model	O
.	O

In	O
contrast	O
,	O
serotonin	O
release	O
from	O
platelets	O
does	O
not	O
provoke	T-obj
migraine	O
,	O
it	T-obj
may	T-obj
even	T-obj
counteract	O
the	O
headache	B-Disease
and	T-conj
the	T-conj
concomitant	T-conj
CGRP	T-conj
release	O
in	O
this	O
model	T-obj
.	O

In	O
contrast	O
,	O
serotonin	O
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	O
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	T-compound
and	T-compound
the	T-compound
concomitant	T-compound
CGRP	B-Chemical
release	O
in	O
this	O
model	O
.	O

Hyperbaric	T-compound
oxygen	B-Chemical
therapy	O
for	O
control	T-compound
of	O
intractable	O
cyclophosphamide	O
-	O
induced	O
hemorrhagic	O
cystitis	O
.	O

Hyperbaric	O
oxygen	O
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	B-Chemical
-	O
induced	O
hemorrhagic	O
cystitis	T-obl
.	O

Hyperbaric	O
oxygen	O
therapy	T-nmod
for	T-nmod
control	O
of	O
intractable	O
cyclophosphamide	T-amod
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

We	O
report	T-nmod
a	T-nmod
case	O
of	O
intractable	O
hemorrhagic	B-Disease
cystitis	I-Disease
due	O
to	O
cyclophosphamide	O
therapy	T-nmod
for	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

We	O
report	O
a	O
case	T-compound
of	O
intractable	O
hemorrhagic	O
cystitis	O
due	T-compound
to	O
cyclophosphamide	B-Chemical
therapy	O
for	O
Wegener	O
'	O
s	O
granulomatosis	T-compound
.	O

We	O
report	O
a	O
case	T-nmod
of	O
intractable	O
hemorrhagic	O
cystitis	O
due	T-nmod
to	O
cyclophosphamide	T-nmod
therapy	O
for	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	T-nmod
with	T-nmod
physiological	T-nmod
saline	O
and	O
instillation	T-nmod
of	O
prostaglandin	B-Chemical
F2	I-Chemical
alpha	I-Chemical
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	O
.	O

Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	O
F2	O
alpha	O
,	O
failed	T-obj
to	T-obj
totally	T-obj
control	O
hemorrhage	B-Disease
.	O

We	T-obj
then	T-obj
used	O
hyperbaric	O
oxygen	B-Chemical
at	O
an	O
absolute	O
pressure	T-obj
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O

The	O
bleeding	B-Disease
ceased	O
completely	T-nsubj
by	O
the	O
end	T-nsubj
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	O
thereafter	O
.	O

The	O
bleeding	O
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	T-obl
free	O
of	O
hematuria	B-Disease
thereafter	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	B-Chemical
-	O
induced	O
hemorrhagic	O
cystitis	T-obl
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	T-nmod
a	O
safe	O
alternative	O
in	T-nmod
the	T-nmod
treatment	O
of	O
cyclophosphamide	T-amod
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

Acute	B-Disease
psychosis	I-Disease
due	T-nmod
to	O
treatment	O
with	O
phenytoin	T-nmod
in	O
a	O
nonepileptic	O
patient	T-nmod
.	O

Acute	O
psychosis	T-nmod
due	T-nmod
to	O
treatment	O
with	O
phenytoin	B-Chemical
in	O
a	O
nonepileptic	O
patient	T-nmod
.	O

The	T-nmod
development	O
of	O
psychosis	B-Disease
related	T-nmod
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	O
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	O
.	O

The	O
development	O
of	O
psychosis	O
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	T-amod
between	T-amod
the	T-amod
epileptic	B-Disease
brain	T-amod
substratum	O
and	O
the	O
antiepileptic	O
drugs	T-amod
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	T-obj
who	T-obj
developed	O
psychosis	B-Disease
following	O
phenytoin	O
treatment	T-obj
for	O
trigeminal	O
neuralgia	O
is	O
described	O
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	T-compound
psychosis	O
following	T-compound
phenytoin	B-Chemical
treatment	O
for	O
trigeminal	O
neuralgia	T-compound
is	O
described	O
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	T-nmod
psychosis	O
following	T-nmod
phenytoin	T-nmod
treatment	O
for	O
trigeminal	B-Disease
neuralgia	I-Disease
is	O
described	O
.	O

This	O
case	O
suggests	T-dep
that	O
the	O
psychotic	B-Disease
symptoms	I-Disease
that	T-acl:relcl
occur	T-acl:relcl
following	O
phenytoin	O
treatment	O
in	O
some	O
epileptic	O
patients	O
may	T-acl:relcl
be	T-acl:relcl
the	T-acl:relcl
direct	T-acl:relcl
result	O
of	O
medication	T-acl:relcl
,	O
unrelated	O
to	O
seizures	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	O
symptoms	O
that	O
occur	T-compound
following	T-compound
phenytoin	B-Chemical
treatment	O
in	O
some	O
epileptic	O
patients	T-compound
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	O
symptoms	O
that	O
occur	O
following	O
phenytoin	O
treatment	T-amod
in	T-amod
some	T-amod
epileptic	B-Disease
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	O
symptoms	O
that	O
occur	O
following	O
phenytoin	O
treatment	O
in	O
some	O
epileptic	O
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	T-obl
,	O
unrelated	O
to	O
seizures	B-Disease
.	O

Risks	O
of	O
the	O
consumption	O
of	O
beverages	T-obj
containing	O
quinine	B-Chemical
.	O

Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	T-nmod
its	T-nmod
use	O
for	O
nocturnal	B-Disease
leg	I-Disease
cramps	I-Disease
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	O
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O

Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	T-nsubj
its	O
use	O
for	O
nocturnal	O
leg	O
cramps	O
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	B-Chemical
is	T-nsubj
widely	T-nsubj
available	O
in	O
beverages	T-nsubj
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	T-obj
containing	O
quinine	B-Chemical
may	O
produce	O
neurological	O
complications	O
,	O
including	O
confusion	O
,	O
altered	O
mental	O
status	O
,	O
seizures	O
,	O
and	O
coma	O
,	O
particularly	O
in	O
older	O
women	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	T-obj
that	T-obj
products	T-obj
containing	O
quinine	O
may	T-obj
produce	O
neurological	B-Disease
complications	I-Disease
,	O
including	T-nmod
confusion	O
,	O
altered	O
mental	O
status	T-nmod
,	O
seizures	T-nmod
,	O
and	O
coma	T-nmod
,	O
particularly	O
in	O
older	O
women	T-nmod
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	O
may	O
produce	T-nmod
neurological	T-nmod
complications	O
,	O
including	O
confusion	B-Disease
,	O
altered	T-conj
mental	T-conj
status	O
,	O
seizures	O
,	O
and	T-conj
coma	O
,	O
particularly	T-nmod
in	T-nmod
older	T-nmod
women	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	O
may	O
produce	O
neurological	O
complications	T-conj
,	O
including	T-conj
confusion	O
,	O
altered	O
mental	O
status	T-conj
,	O
seizures	B-Disease
,	O
and	O
coma	T-conj
,	O
particularly	O
in	O
older	O
women	T-conj
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	O
may	O
produce	O
neurological	O
complications	T-conj
,	O
including	T-conj
confusion	O
,	O
altered	O
mental	O
status	T-conj
,	O
seizures	T-conj
,	O
and	O
coma	B-Disease
,	O
particularly	O
in	O
older	O
women	T-conj
.	O

Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	B-Chemical
-	O
containing	O
beverages	T-obl
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O

Transient	O
platypnea	B-Disease
-	I-Disease
orthodeoxia	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
induced	O
by	O
propafenone	O
overdose	T-nsubj
in	O
a	O
young	O
woman	T-nsubj
with	O
Ebstein	O
'	O
s	O
anomaly	O
.	O

Transient	O
platypnea	O
-	O
orthodeoxia	O
-	O
like	O
syndrome	T-obl
induced	O
by	O
propafenone	B-Chemical
overdose	B-Disease
in	O
a	O
young	O
woman	T-obl
with	O
Ebstein	O
'	O
s	O
anomaly	O
.	O

Transient	O
platypnea	O
-	O
orthodeoxia	O
-	O
like	O
syndrome	O
induced	T-nmod
by	O
propafenone	O
overdose	O
in	T-nmod
a	T-nmod
young	T-nmod
woman	O
with	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	T-nmod
of	T-nmod
a	T-nmod
37	O
-	O
year	O
-	O
old	T-nmod
white	T-nmod
woman	O
with	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
,	O
who	O
developed	T-nmod
a	O
rare	O
syndrome	O
called	O
platypnea	O
-	O
orthodeoxia	O
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	O
and	O
cyanosis	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	O
'	O
s	O
anomaly	O
,	O
who	O
developed	T-dep
a	T-dep
rare	T-dep
syndrome	O
called	O
platypnea	B-Disease
-	I-Disease
orthodeoxia	I-Disease
,	O
characterized	O
by	T-acl
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	O
and	O
cyanosis	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	O
'	O
s	O
anomaly	O
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea	O
-	O
orthodeoxia	O
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	T-obl
shunting	O
with	O
transient	O
profound	O
hypoxia	B-Disease
and	T-conj
cyanosis	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	O
'	O
s	O
anomaly	O
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea	O
-	O
orthodeoxia	O
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	T-conj
with	T-conj
transient	T-conj
profound	T-conj
hypoxia	O
and	O
cyanosis	B-Disease
.	O

This	T-nmod
shunt	O
of	O
blood	T-nmod
via	O
a	O
patent	B-Disease
foramen	I-Disease
ovale	I-Disease
occurred	T-nmod
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	O
overdose	O
.	O

This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	O
foramen	O
ovale	O
occurred	T-obl
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	T-obl
was	T-obl
probably	T-obl
precipitated	O
by	O
a	O
propafenone	B-Chemical
overdose	B-Disease
.	O

This	O
drug	T-obj
caused	O
biventricular	B-Disease
dysfunction	I-Disease
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	T-obj
,	O
and	O
hypotension	T-obj
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O

This	O
drug	T-conj
caused	O
biventricular	O
dysfunction	T-conj
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	T-conj
,	O
and	O
hypotension	B-Disease
,	O
due	T-obl
to	O
its	T-obl
peripheral	T-obl
vasodilatory	T-obl
effect	O
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	T-nmod
intracranial	O
blood	O
flow	O
through	T-nmod
a	T-nmod
trigemino	O
-	O
parasympathetic	T-nmod
reflex	T-nmod
-	O
-	O
an	T-nmod
experimental	T-nmod
model	O
for	O
vascular	B-Disease
dysfunctions	I-Disease
in	T-nmod
cluster	T-nmod
headache	O
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
-	O
-	O
an	O
experimental	O
model	T-nmod
for	T-nmod
vascular	T-nmod
dysfunctions	O
in	O
cluster	B-Disease
headache	I-Disease
.	O

Cluster	B-Disease
headache	I-Disease
is	T-nsubj:pass
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	T-nsubj:pass
including	O
facial	O
and	O
intracranial	O
vascular	O
disturbances	O
.	O

Cluster	O
headache	O
is	O
characterized	T-nmod
by	T-nmod
typical	T-nmod
autonomic	T-nmod
dysfunctions	O
including	O
facial	O
and	O
intracranial	B-Disease
vascular	I-Disease
disturbances	I-Disease
.	O

Capsaicin	B-Chemical
(	O
0	O
.	T-compound
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	O
in	O
dural	O
and	O
cortical	O
blood	O
flow	O
and	O
provoked	O
lacrimation	O
.	O

Capsaicin	O
(	O
0	O
.	T-conj
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	T-conj
nasal	T-conj
mucosa	O
induced	O
increases	B-Disease
in	I-Disease
dural	I-Disease
and	I-Disease
cortical	I-Disease
blood	I-Disease
flow	I-Disease
and	O
provoked	O
lacrimation	O
.	O

These	O
responses	O
were	O
blocked	T-nmod
by	T-nmod
systemic	T-nmod
pre	T-nmod
-	O
administration	O
of	O
hexamethonium	B-Chemical
chloride	I-Chemical
(	O
20	T-dep
mg	O
/	O
kg	T-dep
)	O
.	O

The	T-amod
evoked	T-amod
increases	B-Disease
in	I-Disease
dural	I-Disease
blood	I-Disease
flow	I-Disease
were	T-nsubj:pass
also	T-nsubj:pass
abolished	T-amod
by	O
topical	T-amod
pre	O
-	O
administration	T-nsubj:pass
of	O
atropine	O
(	O
1	O
mm	O
)	O
and	T-nsubj:pass
[	O
Lys1	O
,	O
Pro2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Tyr6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O

The	O
evoked	O
increases	O
in	O
dural	O
blood	O
flow	O
were	O
also	O
abolished	T-nmod
by	T-nmod
topical	T-compound
pre	T-nmod
-	T-compound
administration	T-compound
of	T-compound
atropine	B-Chemical
(	T-nmod
1	T-appos
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Tyr6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O

The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	T-nmod
by	T-nmod
the	T-nmod
release	O
of	O
acetylcholine	B-Chemical
and	T-conj
VIP	O
within	O
the	O
meninges	T-nmod
.	O

Similar	O
mechanisms	O
may	O
be	O
involved	T-nmod
in	T-nmod
the	T-nmod
pathogenesis	O
of	O
cluster	B-Disease
headache	I-Disease
.	O

Organophosphate	B-Chemical
-	O
induced	O
convulsions	T-obl
and	O
prevention	O
of	O
neuropathological	O
damages	O
.	O

Organophosphate	T-amod
-	O
induced	O
convulsions	B-Disease
and	T-conj
prevention	O
of	T-nmod
neuropathological	T-nmod
damages	O
.	O

Organophosphate	O
-	O
induced	T-nmod
convulsions	O
and	O
prevention	T-nmod
of	O
neuropathological	B-Disease
damages	I-Disease
.	O

Such	O
organophosphorus	B-Chemical
(	O
OP	O
)	O
compounds	T-dep
as	O
diisopropylfluorophosphate	O
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

Such	T-dep
organophosphorus	O
(	O
OP	B-Chemical
)	O
compounds	O
as	O
diisopropylfluorophosphate	T-compound
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	O
are	O
potent	O
inhibitors	T-compound
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

Such	O
organophosphorus	O
(	O
OP	T-nmod
)	O
compounds	O
as	O
diisopropylfluorophosphate	B-Chemical
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	T-appos
are	O
potent	O
inhibitors	T-nmod
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	T-appos
as	T-appos
diisopropylfluorophosphate	O
(	O
DFP	B-Chemical
)	O
,	O
sarin	T-appos
and	O
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	T-appos
as	T-appos
diisopropylfluorophosphate	O
(	O
DFP	T-appos
)	O
,	O
sarin	B-Chemical
and	T-conj
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	O
as	O
diisopropylfluorophosphate	T-conj
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	B-Chemical
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

The	O
acute	O
toxicity	B-Disease
of	T-nmod
OPs	O
is	T-nsubj
the	T-nsubj
result	O
of	O
their	O
irreversible	O
binding	T-nsubj
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	O
)	O
levels	O
.	O

The	T-nmod
acute	T-nmod
toxicity	O
of	O
OPs	B-Chemical
is	O
the	O
result	T-nmod
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	O
)	O
levels	O
.	O

The	O
acute	O
toxicity	O
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	T-compound
(	O
CNS	O
)	O
,	O
which	T-compound
elevates	T-compound
acetylcholine	B-Chemical
(	O
ACh	O
)	O
levels	O
.	O

The	O
acute	O
toxicity	O
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	B-Chemical
)	O
levels	T-dep
.	O

The	T-nmod
protective	T-nmod
action	O
of	T-nmod
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	T-nummod
or	T-nummod
their	T-nummod
combinations	O
in	O
DFP	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	T-dep
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O

The	T-compound
rats	T-iobj
received	T-compound
AChE	T-iobj
reactivator	T-dep
pralidoxime	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
chloride	I-Chemical
(	T-case
2PAM	T-compound
)	T-case
(	T-compound
30	T-case
.	T-compound
0	T-dep
mg	T-compound
/	O
kg	O
BW	T-compound
)	T-compound
,	O
anticonvulsant	O
diazepam	O
(	O
2	T-compound
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	T-dep
AChE	T-dep
reactivator	T-det
pralidoxime	T-dep
-	T-det
2	T-compound
-	T-dep
chloride	T-det
(	T-det
2PAM	B-Chemical
)	T-det
(	T-det
30	T-compound
.	T-det
0	T-det
mg	T-compound
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	B-Chemical
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	B-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
-	I-Chemical
cyclopentyl	I-Chemical
adenosine	I-Chemical
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	B-Chemical
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	B-Chemical
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	B-Chemical
maleate	I-Chemical
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	B-Chemical
sulfate	I-Chemical
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime	O
-	O
2	O
-	O
chloride	O
(	O
2PAM	O
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosine	O
receptor	O
agonist	O
N	O
(	O
6	O
)	O
-	O
cyclopentyl	O
adenosine	O
(	O
CPA	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-	O
MK801	O
hydrogen	O
maleate	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	B-Chemical

The	O
control	O
rats	T-obj
received	O
atropine	B-Chemical
sulfate	I-Chemical
,	O
but	T-obj
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	O
,	O
respectively	O
.	O

The	O
control	O
rats	O
received	O
atropine	O
sulfate	O
,	O
but	O
also	O
saline	T-conj
and	O
olive	O
oil	O
instead	T-conj
of	O
other	T-conj
antidotes	O
and	O
DFP	B-Chemical
,	O
respectively	O
.	O

All	O
rats	O
were	O
terminated	T-compound
either	O
24	O
h	O
or	O
3	O
weeks	O
after	T-compound
the	T-compound
DFP	B-Chemical
injection	O
.	O

The	O
rats	O
treated	T-compound
with	T-compound
DFP	B-Chemical
-	O
atropine	O
showed	O
severe	O
typical	O
OP	O
-	O
induced	O
toxicity	O
signs	O
.	O

The	O
rats	T-obl
treated	O
with	O
DFP	O
-	O
atropine	B-Chemical
showed	T-obl
severe	O
typical	O
OP	O
-	O
induced	O
toxicity	O
signs	O
.	O

The	O
rats	O
treated	O
with	O
DFP	O
-	O
atropine	O
showed	O
severe	O
typical	O
OP	B-Chemical
-	O
induced	O
toxicity	O
signs	T-obl
.	O

The	O
rats	O
treated	O
with	O
DFP	O
-	O
atropine	O
showed	T-compound
severe	T-compound
typical	T-compound
OP	O
-	O
induced	T-compound
toxicity	B-Disease
signs	O
.	O

When	T-nsubj:pass
CPA	B-Chemical
,	O
diazepam	O
or	T-conj
2PAM	O
was	T-nsubj:pass
given	O
immediately	T-nsubj:pass
after	O
DFP	O
-	O
atropine	T-nsubj:pass
,	O
these	O
treatments	O
prevented	T-nsubj:pass
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

When	O
CPA	O
,	O
diazepam	B-Chemical
or	O
2PAM	T-conj
was	O
given	T-conj
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

When	O
CPA	O
,	O
diazepam	T-conj
or	O
2PAM	B-Chemical
was	O
given	T-conj
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

When	O
CPA	O
,	O
diazepam	O
or	O
2PAM	O
was	O
given	T-compound
immediately	O
after	T-compound
DFP	B-Chemical
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

When	T-obl
CPA	T-obl
,	O
diazepam	O
or	O
2PAM	O
was	T-obl
given	O
immediately	T-obl
after	O
DFP	O
-	O
atropine	B-Chemical
,	O
these	O
treatments	O
prevented	T-obl
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

When	O
CPA	O
,	O
diazepam	O
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	T-nmod
of	T-nmod
serious	T-nmod
signs	O
of	O
poisoning	B-Disease
.	O

Atropine	B-Chemical
-	O
MK801	O
did	O
not	O
offer	T-compound
any	O
additional	O
protection	O
against	O
DFP	O
toxicity	O
.	O

Atropine	O
-	O
MK801	B-Chemical
did	T-nsubj
not	T-nsubj
offer	O
any	O
additional	O
protection	T-nsubj
against	O
DFP	O
toxicity	O
.	O

Atropine	O
-	O
MK801	O
did	O
not	O
offer	T-nmod
any	T-nmod
additional	T-nmod
protection	O
against	O
DFP	B-Chemical
toxicity	B-Disease
.	O

In	O
conclusion	T-nsubj
,	O
CPA	B-Chemical
,	O
diazepam	O
and	T-conj
2PAM	O
in	T-nmod
combination	O
with	O
atropine	T-nmod
prevented	O
the	O
occurrence	T-nsubj
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	T-nsubj
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	B-Chemical
and	O
2PAM	T-conj
in	O
combination	T-conj
with	O
atropine	O
prevented	T-conj
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	O
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	T-conj
and	O
2PAM	B-Chemical
in	O
combination	T-conj
with	O
atropine	O
prevented	T-conj
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	O
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

In	O
conclusion	O
,	O
CPA	T-nmod
,	O
diazepam	O
and	O
2PAM	O
in	T-nmod
combination	O
with	O
atropine	B-Chemical
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	O
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	O
and	O
2PAM	O
in	O
combination	O
with	O
atropine	O
prevented	O
the	O
occurrence	T-nmod
of	T-nmod
serious	T-nmod
signs	O
of	O
poisoning	B-Disease
and	O
thus	O
reduced	O
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	O
and	O
2PAM	O
in	O
combination	O
with	O
atropine	O
prevented	T-obj
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	T-obj
thus	T-obj
reduced	O
the	O
toxicity	B-Disease
of	T-nmod
DFP	O
in	O
rat	T-obj
.	O

In	O
conclusion	O
,	O
CPA	O
,	O
diazepam	O
and	O
2PAM	O
in	O
combination	O
with	O
atropine	O
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	T-nmod
the	T-nmod
toxicity	O
of	O
DFP	B-Chemical
in	O
rat	O
.	O

A	O
pyridoxine	B-Chemical
-	O
dependent	O
behavioral	O
disorder	T-obl:npmod
unmasked	O
by	O
isoniazid	O
.	O

A	O
pyridoxine	T-amod
-	O
dependent	O
behavioral	B-Disease
disorder	I-Disease
unmasked	O
by	O
isoniazid	T-nsubj
.	O

A	O
pyridoxine	O
-	O
dependent	O
behavioral	O
disorder	T-obl
unmasked	O
by	O
isoniazid	B-Chemical
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	T-obj
had	O
behavioral	B-Disease
deterioration	I-Disease
,	O
with	O
hyperkinesis	T-obj
,	O
irritability	O
,	O
and	O
sleeping	O
difficulties	O
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	O
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	T-obl
had	O
behavioral	O
deterioration	T-obl
,	O
with	O
hyperkinesis	B-Disease
,	O
irritability	O
,	O
and	T-conj
sleeping	T-conj
difficulties	O
after	O
the	O
therapeutic	O
administration	T-conj
of	O
isoniazid	O
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	T-conj
behavioral	O
deterioration	O
,	O
with	T-conj
hyperkinesis	O
,	O
irritability	B-Disease
,	O
and	O
sleeping	O
difficulties	T-conj
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	O
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	T-conj
behavioral	O
deterioration	O
,	O
with	T-conj
hyperkinesis	O
,	O
irritability	T-conj
,	O
and	O
sleeping	B-Disease
difficulties	I-Disease
after	T-nmod
the	T-nmod
therapeutic	T-nmod
administration	O
of	O
isoniazid	T-nmod
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	O
behavioral	O
deterioration	O
,	O
with	O
hyperkinesis	O
,	O
irritability	O
,	O
and	O
sleeping	O
difficulties	T-nmod
after	T-nmod
the	T-nmod
therapeutic	T-nmod
administration	O
of	O
isoniazid	B-Chemical
.	O

The	O
administration	T-nmod
of	T-nmod
pharmacologic	T-nmod
doses	O
of	O
pyridoxine	B-Chemical
hydrochloride	I-Chemical
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O

After	T-compound
discontinuing	T-compound
isoniazid	B-Chemical
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	T-compound
that	O
was	O
controlled	O
by	O
pyridoxine	O
.	O

After	O
discontinuing	O
isoniazid	O
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	T-obl
that	T-obl
was	T-obl
controlled	O
by	O
pyridoxine	B-Chemical
.	O

A	O
placebo	O
had	T-nsubj
no	O
effect	O
,	O
but	T-nsubj
niacinamide	B-Chemical
was	T-nsubj
as	T-nsubj
effective	O
as	O
pyridoxine	T-nsubj
.	O

A	O
placebo	O
had	T-obl
no	O
effect	O
,	O
but	T-obl
niacinamide	T-obl
was	T-obl
as	T-obl
effective	O
as	O
pyridoxine	B-Chemical
.	O

Periodic	T-nmod
withdrawal	O
of	O
pyridoxine	B-Chemical
was	O
associated	T-nmod
with	O
return	O
of	O
the	O
hyperkinesis	O
.	O

Periodic	O
withdrawal	O
of	O
pyridoxine	O
was	O
associated	T-nmod
with	T-nmod
return	O
of	O
the	O
hyperkinesis	B-Disease
.	O

The	T-nmod
level	O
of	O
pyridoxal	B-Chemical
in	O
the	O
blood	T-nmod
was	O
normal	T-nmod
during	O
the	O
periods	O
of	O
relapse	O
.	O

Metabolic	O
studies	O
suggested	O
a	O
block	T-compound
in	T-compound
the	T-compound
kynurenine	B-Chemical
pathway	O
of	O
tryptophan	O
metabolism	T-compound
.	O

Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	O
pathway	T-compound
of	T-compound
tryptophan	B-Chemical
metabolism	O
.	O

The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	T-nmod
pharmacologic	T-nmod
doses	O
of	O
pyridoxine	B-Chemical
to	O
control	O
her	O
behavior	O
.	O

Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	T-nmod
of	T-nmod
a	T-nmod
murine	T-nmod
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Similar	O
to	O
rats	O
,	O
systemic	T-compound
pilocarpine	B-Chemical
injection	O
causes	T-compound
status	O
epilepticus	O
(	O
SE	O
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	O
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Similar	T-obj
to	O
rats	O
,	O
systemic	O
pilocarpine	O
injection	T-obj
causes	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	O
)	O
and	T-conj
the	T-conj
eventual	T-conj
development	O
of	O
spontaneous	O
seizures	T-conj
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	T-obj
in	O
mice	O
.	O

Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	O
injection	O
causes	T-appos
status	T-appos
epilepticus	O
(	O
SE	B-Disease
)	O
and	O
the	O
eventual	O
development	T-appos
of	O
spontaneous	O
seizures	O
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	O
injection	O
causes	O
status	O
epilepticus	T-nmod
(	O
SE	O
)	O
and	T-nmod
the	T-nmod
eventual	T-nmod
development	O
of	O
spontaneous	O
seizures	B-Disease
and	T-conj
mossy	T-conj
fiber	O
sprouting	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
mice	T-acl
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	B-Chemical
-	O
treated	O
and	O
untreated	T-dep
mice	T-dep
.	O

In	O
Mg	B-Chemical
(	O
2	O
+	O
)	O
-	O
free	O
bathing	T-obl
medium	O
containing	O
bicuculline	O
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	O
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	O

In	O
Mg	O
(	O
2	O
+	O
)	O
-	O
free	O
bathing	O
medium	O
containing	O
bicuculline	B-Chemical
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	O
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	O

In	O
Mg	O
(	O
2	O
+	O
)	O
-	O
free	O
bathing	O
medium	O
containing	O
bicuculline	O
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	B-Chemical
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	O

In	O
Mg	O
(	O
2	O
+	O
)	O
-	O
free	O
bathing	O
medium	O
containing	O
bicuculline	O
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	O
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	B-Disease

In	T-compound
SE	B-Disease
survivors	O
,	O
similar	O
stimulation	O
resulted	T-compound
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	O
receptor	O
antagonists	O
.	O

In	O
SE	O
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	B-Chemical
receptor	O
antagonists	T-compound
.	O

Focal	T-compound
glutamate	B-Chemical
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	T-compound
at	O
sites	T-compound
distant	O
from	O
the	O
recording	O
pipette	O
resulted	T-compound
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	O
survivors	O
but	O
not	O
other	O
groups	O
.	O

Focal	O
glutamate	O
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	T-compound
in	O
slices	O
from	T-compound
SE	B-Disease
survivors	O
but	O
not	O
other	O
groups	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	B-Disease
-	O
induced	O
mossy	O
fiber	T-obl
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	O
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	O
lobe	O
epilepsy	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	O
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	T-compound
of	T-compound
seizure	B-Disease
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	O
lobe	O
epilepsy	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	O
-	O
induced	O
mossy	O
fiber	T-nmod
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	O
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	T-nmod
rat	T-nmod
models	O
of	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Urinary	B-Disease
bladder	I-Disease
cancer	I-Disease
in	T-nmod
Wegener	T-nmod
'	O
s	T-nmod
granulomatosis	O
:	O
risks	O
and	O
relation	T-dep
to	O
cyclophosphamide	T-dep
.	O

Urinary	T-nmod
bladder	T-nmod
cancer	O
in	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
:	O
risks	T-nmod
and	O
relation	O
to	O
cyclophosphamide	O
.	O

Urinary	O
bladder	O
cancer	T-nmod
in	O
Wegener	O
'	O
s	O
granulomatosis	O
:	O
risks	O
and	O
relation	T-nmod
to	O
cyclophosphamide	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
assess	T-nmod
and	O
characterise	O
the	T-nmod
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	O
,	O
in	O
patients	O
with	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

OBJECTIVE	O
:	O
To	O
assess	T-nmod
and	O
characterise	O
the	O
risk	O
of	O
bladder	O
cancer	O
,	O
and	T-nmod
its	T-nmod
relation	O
to	O
cyclophosphamide	B-Chemical
,	O
in	O
patients	T-nmod
with	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	O
cancer	O
,	O
and	O
its	O
relation	T-nmod
to	O
cyclophosphamide	O
,	O
in	T-nmod
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	T-nmod
of	T-nmod
1065	T-nmod
patients	O
with	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
1969	T-nmod
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	T-compound
with	T-compound
the	T-compound
Swedish	T-compound
Cancer	B-Disease
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	O
cancer	O
were	O
identified	O
.	O

Through	O
linkage	T-obl
with	O
the	O
Swedish	O
Cancer	O
Register	O
,	O
all	O
subjects	T-obl
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-Disease
cancer	I-Disease
were	O
identified	T-obl
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	T-compound
between	T-compound
cyclophosphamide	B-Chemical
and	T-conj
bladder	O
cancer	O
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	T-nmod
the	T-nmod
association	O
between	O
cyclophosphamide	O
and	O
bladder	B-Disease
cancer	I-Disease
using	T-nmod
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	T-nmod
cumulative	T-nmod
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
after	O
Wegener	O
'	O
s	O
granulomatosis	T-nmod
,	O
and	O
the	O
relative	O
prevalence	T-nmod
of	O
a	O
history	O
of	O
bladder	O
cancer	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
were	O
also	O
estimated	T-nmod
.	O

In	O
the	O
cohort	O
the	T-nmod
cumulative	T-nmod
risk	O
of	O
bladder	O
cancer	T-nmod
after	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
the	O
relative	O
prevalence	T-nmod
of	O
a	O
history	O
of	O
bladder	O
cancer	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
were	O
also	O
estimated	T-nmod
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	O
cancer	O
after	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
and	O
the	O
relative	O
prevalence	T-nmod
of	T-nmod
a	T-nmod
history	O
of	O
bladder	B-Disease
cancer	I-Disease
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
were	O
also	O
estimated	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	O
cancer	O
after	O
Wegener	O
'	O
s	O
granulomatosis	O
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	O
cancer	O
at	O
the	O
time	T-nmod
of	T-nmod
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	T-nmod
median	T-nmod
cumulative	T-nmod
doses	O
of	O
cyclophosphamide	B-Chemical
among	O
cases	T-nmod
(	O
n	O
=	O
11	T-nmod
)	O
and	O
controls	T-nmod
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	T-nmod
and	O
25	O
g	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	T-nmod
a	T-nmod
dose	O
-	O
response	T-nmod
relationship	O
between	O
cyclophosphamide	B-Chemical
and	T-conj
the	T-conj
risk	O
of	O
bladder	O
cancer	T-conj
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	T-nmod
and	T-nmod
the	T-nmod
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
high	T-conj
cumulative	T-conj
risks	O
in	O
the	O
entire	O
cohort	T-conj
,	O
and	T-conj
also	T-conj
the	T-conj
possibility	O
of	O
risk	O
factors	T-conj
operating	T-conj
even	O
before	O
Wegener	O
'	O
s	O
granulomatosis	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	O
and	O
the	O
risk	O
of	O
bladder	O
cancer	O
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	T-obl
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

Differential	T-nmod
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2	O
-	O
adrenergic	T-acl
and	O
I1	O
-	O
imidazoline	O
receptor	O
-	O
mediated	O
hypotension	O
in	O
female	O
rats	O
.	O

Differential	O
modulation	O
by	O
estrogen	O
of	O
alpha2	O
-	O
adrenergic	T-compound
and	T-compound
I1	O
-	O
imidazoline	B-Chemical
receptor	O
-	O
mediated	T-compound
hypotension	O
in	O
female	O
rats	O
.	O

Differential	O
modulation	O
by	O
estrogen	O
of	T-conj
alpha2	T-conj
-	O
adrenergic	O
and	O
I1	T-compound
-	O
imidazoline	O
receptor	T-amod
-	O
mediated	O
hypotension	B-Disease
in	O
female	O
rats	T-conj
.	O

We	O
have	O
recently	O
shown	T-nsubj
that	T-nsubj
estrogen	B-Chemical
negatively	T-nsubj
modulates	O
the	O
hypotensive	O
effect	T-nsubj
of	O
clonidine	O
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	T-nsubj
and	O
implicates	T-nsubj
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	O
negatively	O
modulates	T-amod
the	T-amod
hypotensive	B-Disease
effect	O
of	O
clonidine	T-amod
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	O
negatively	O
modulates	T-nmod
the	T-nmod
hypotensive	T-nmod
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	T-appos
alpha2	O
-	O
/	O
I1	O
-	O
receptor	T-appos
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
this	T-nmod
effect	O
of	O
estrogen	B-Chemical
involves	T-nmod
interaction	O
with	O
alpha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
receptors	O
.	O

Changes	O
evoked	T-nmod
by	T-nmod
a	T-nmod
single	T-nmod
intraperitoneal	T-nmod
injection	O
of	O
rilmenidine	B-Chemical
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	O
-	O
methyldopa	O
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	O
replacement	O
.	O

Changes	T-conj
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	T-conj
of	O
rilmenidine	O
(	O
600	O
microg	T-conj
/	O
kg	O
)	O
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
(	O
100	T-dep
mg	O
/	O
kg	T-dep
)	O
,	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	T-conj
,	O
respectively	T-conj
,	O
in	O
blood	O
pressure	T-conj
,	O
hemodynamic	O
variability	T-conj
,	O
and	O
locomotor	O
activity	O
were	O
assessed	T-conj
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	O
replacement	O
.	O

Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	O
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	O
-	O
methyldopa	O
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	T-compound
with	T-compound
or	O
without	O
12	O
-	O
wk	T-compound
estrogen	B-Chemical
replacement	O
.	O

In	O
sham	O
-	O
operated	O
rats	T-nsubj
,	O
rilmenidine	B-Chemical
or	T-conj
alpha	T-conj
-	O
methyldopa	O
elicited	O
similar	O
hypotension	T-nsubj
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

In	O
sham	O
-	O
operated	O
rats	O
,	O
rilmenidine	O
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
elicited	T-conj
similar	O
hypotension	O
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

In	O
sham	O
-	O
operated	O
rats	T-obj
,	O
rilmenidine	T-obj
or	O
alpha	O
-	O
methyldopa	O
elicited	O
similar	O
hypotension	B-Disease
that	T-acl:relcl
lasted	O
at	O
least	O
5	O
h	T-acl:relcl
and	O
was	O
associated	T-acl:relcl
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

SDRR	T-obl
was	T-obl
reduced	O
only	O
by	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
.	O

Ovx	O
significantly	O
enhanced	T-amod
the	T-amod
hypotensive	B-Disease
response	O
to	O
alpha	O
-	O
methyldopa	T-amod
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	O
hypotension	O
.	O

Ovx	O
significantly	O
enhanced	T-nmod
the	T-nmod
hypotensive	T-nmod
response	O
to	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	O
hypotension	O
.	O

Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	O
response	O
to	O
alpha	O
-	O
methyldopa	O
,	O
in	O
contrast	T-nmod
to	T-nmod
no	T-nmod
effect	O
on	O
rilmenidine	B-Chemical
hypotension	B-Disease
.	O

The	O
enhanced	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
hypotension	B-Disease
in	T-nmod
Ovx	T-nmod
rats	O
was	T-nsubj:pass
paralleled	O
with	O
further	O
reduction	T-nsubj:pass
in	O
SDRR	O
and	O
a	O
reduced	O
locomotor	O
activity	O
.	O

The	O
enhanced	O
alpha	O
-	O
methyldopa	O
hypotension	O
in	O
Ovx	O
rats	O
was	O
paralleled	T-conj
with	T-conj
further	T-conj
reduction	O
in	O
SDRR	T-conj
and	O
a	B-Disease
reduced	I-Disease
locomotor	I-Disease
activity	I-Disease
.	O

Estrogen	T-compound
replacement	T-compound
(	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
subcutaneous	T-compound
pellet	T-nummod
,	O
14	T-compound
.	T-nummod
2	T-nummod
microg	O
/	O
day	O
,	O
12	T-obl:tmod
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	T-obl:tmod
locomotor	O
effects	O
of	O
alpha	O
-	O
methyldopa	O
to	O
sham	O
-	O
operated	O
levels	O
.	O

Estrogen	O
replacement	O
(	O
17beta	O
-	O
estradiol	O
subcutaneous	O
pellet	O
,	O
14	O
.	O
2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
to	O
sham	O
-	O
operated	O
levels	O
.	O

These	O
findings	O
suggest	O
that	T-compound
estrogen	B-Chemical
downregulates	O
alpha2	T-compound
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	O
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	O
-	O
methyldopa	O
-	O
estrogen	O
interaction	O
.	O

These	O
findings	O
suggest	O
that	O
estrogen	O
downregulates	T-conj
alpha2	O
-	O
but	T-cc
not	O
I1	O
-	O
receptor	T-amod
-	O
mediated	O
hypotension	B-Disease
and	O
highlight	T-conj
a	O
role	T-conj
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	O
-	O
methyldopa	O
-	O
estrogen	O
interaction	O
.	O

These	O
findings	O
suggest	O
that	O
estrogen	O
downregulates	O
alpha2	O
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	O
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
-	O
estrogen	O
interaction	T-compound
.	O

These	O
findings	O
suggest	O
that	O
estrogen	O
downregulates	O
alpha2	O
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	O
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	T-compound
in	T-compound
alpha	O
-	O
methyldopa	O
-	O
estrogen	B-Chemical
interaction	O
.	O

Severe	O
reversible	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
due	T-nmod
to	O
accidental	T-nmod
iatrogenic	T-nmod
epinephrine	T-nmod
overdose	O
.	O

Severe	T-nmod
reversible	T-nmod
left	T-nmod
ventricular	T-nmod
systolic	T-nmod
and	O
diastolic	O
dysfunction	O
due	O
to	T-case
accidental	O
iatrogenic	O
epinephrine	B-Chemical
overdose	B-Disease
.	O

Catecholamine	B-Chemical
-	O
induced	O
cardiomyopathy	T-obl
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	O
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O

Catecholamine	T-amod
-	O
induced	O
cardiomyopathy	B-Disease
due	T-nmod
to	O
chronic	T-nmod
excess	O
of	O
endogenous	O
catecholamines	T-nmod
has	T-nsubj:pass
been	T-nsubj:pass
recognized	O
for	O
decades	T-nsubj:pass
as	O
a	O
clinical	O
phenomenon	T-nsubj:pass
.	O

Catecholamine	O
-	O
induced	O
cardiomyopathy	T-nmod
due	T-nmod
to	O
chronic	T-nmod
excess	O
of	O
endogenous	O
catecholamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O

In	O
contrast	O
,	O
reports	O
of	O
myocardial	B-Disease
dysfunction	I-Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	T-nmod
are	O
rare	T-nmod
.	O

In	O
contrast	O
,	O
reports	O
of	O
myocardial	O
dysfunction	T-nmod
due	O
to	T-case
acute	O
iatrogenic	O
overdose	B-Disease
are	O
rare	T-nmod
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	T-nmod
with	T-nmod
8	T-nmod
mg	O
of	O
epinephrine	B-Chemical
developed	O
myocardial	O
stunning	O
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
dysfunction	O
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	O
necrosis	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	T-obj
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	O
developed	O
myocardial	B-Disease
stunning	I-Disease
that	T-advmod
was	T-advmod
characterized	O
by	O
severe	O
hemodynamic	O
compromise	T-advmod
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
dysfunction	O
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	O
necrosis	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	O
developed	O
myocardial	O
stunning	O
that	O
was	O
characterized	T-conj
by	T-conj
severe	T-conj
hemodynamic	T-conj
compromise	O
,	O
profound	T-conj
,	O
albeit	O
transient	O
,	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	T-conj
of	O
myocardial	O
necrosis	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	O
developed	O
myocardial	O
stunning	O
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	T-nmod
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
dysfunction	O
,	O
and	T-nmod
only	T-nmod
modestly	O
elevated	T-nmod
biochemical	T-nmod
markers	O
of	O
myocardial	B-Disease
necrosis	I-Disease
.	O

Cardioprotective	T-nmod
effect	O
of	O
tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
on	O
isoproterenol	O
-	O
induced	O
myocardial	O
infarction	T-nmod
in	O
rats	O
.	O

Cardioprotective	O
effect	O
of	O
tincture	O
of	O
Crataegus	O
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	O
infarction	T-obl
in	O
rats	O
.	O

Cardioprotective	T-nmod
effect	O
of	O
tincture	T-nmod
of	O
Crataegus	O
on	O
isoproterenol	T-amod
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	T-nmod
rats	O
.	O

Tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
(	O
TCR	O
)	O
,	O
an	T-appos
alcoholic	T-appos
extract	O
of	O
the	O
berries	T-appos
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
)	O
,	O
is	T-nsubj:pass
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	T-nsubj:pass
.	O

Tincture	T-dep
of	T-dep
Crataegus	O
(	O
TCR	B-Chemical
)	O
,	O
an	O
alcoholic	O
extract	T-dep
of	O
the	O
berries	O
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

Tincture	T-appos
of	T-appos
Crataegus	O
(	O
TCR	T-appos
)	O
,	O
an	O
alcoholic	B-Chemical
extract	I-Chemical
of	I-Chemical
the	I-Chemical
berries	I-Chemical
of	I-Chemical
hawthorn	I-Chemical
(	O
Crataegus	T-appos
oxycantha	O
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

Tincture	O
of	O
Crataegus	O
(	O
TCR	O
)	O
,	O
an	O
alcoholic	O
extract	O
of	O
the	O
berries	T-appos
of	T-appos
hawthorn	O
(	O
Crataegus	B-Chemical
oxycantha	I-Chemical
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	T-nmod
the	T-nmod
protective	T-nmod
effect	O
of	O
TCR	B-Chemical
on	O
experimentally	O
induced	O
myocardial	O
infarction	T-nmod
in	O
rats	T-nmod
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	T-nmod
the	T-nmod
protective	T-nmod
effect	O
of	O
TCR	T-nmod
on	O
experimentally	T-amod
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	T-nmod
.	O

Pretreatment	T-nummod
of	T-nmod
TCR	B-Chemical
,	T-nmod
at	T-nmod
a	T-nummod
dose	T-nmod
of	T-nmod
0	T-nmod
.	O
5	O
mL	O
/	T-nummod
100	O
g	T-nummod
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	O
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

Pretreatment	O
of	O
TCR	O
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	T-nummod
activity	O
of	O
marker	T-nummod
enzymes	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	B-Chemical
prevented	O
the	O
isoproterenol	O
-	O
induced	O
decrease	T-nsubj
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	T-nsubj
the	O
rate	O
of	O
ADP	O
-	O
stimulated	O
oxygen	O
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	O
prevented	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
decrease	T-obl
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	O
-	O
stimulated	O
oxygen	O
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	O
prevented	O
the	O
isoproterenol	O
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	B-Chemical
-	O
stimulated	O
oxygen	O
uptake	T-obl
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	O
prevented	O
the	O
isoproterenol	O
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	T-compound
of	T-compound
ADP	O
-	O
stimulated	T-compound
oxygen	B-Chemical
uptake	O
and	O
respiratory	O
coupling	O
ratio	T-compound
.	O

TCR	B-Chemical
protected	O
against	O
pathological	O
changes	T-nsubj
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O

TCR	O
protected	O
against	O
pathological	O
changes	T-obl
induced	O
by	O
isoproterenol	B-Chemical
in	T-nmod
rat	T-nmod
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	B-Chemical
may	O
be	O
useful	T-nmod
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	O
in	O
rat	O
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	T-obl
induced	O
by	O
isoproterenol	B-Chemical
in	T-nmod
rat	T-nmod
heart	O
.	O

Treatment	O
of	O
tinnitus	B-Disease
by	O
intratympanic	O
instillation	T-nmod
of	O
lignocaine	O
(	O
lidocaine	O
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	T-nmod
.	O

Treatment	T-nmod
of	O
tinnitus	O
by	T-nmod
intratympanic	T-nmod
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	O
)	O
2	T-dep
per	T-dep
cent	O
through	O
ventilation	O
tubes	O
.	O

Treatment	O
of	O
tinnitus	O
by	O
intratympanic	O
instillation	T-appos
of	T-appos
lignocaine	O
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	T-appos
through	O
ventilation	O
tubes	O
.	O

Idiopathic	B-Disease
subjective	I-Disease
tinnitus	I-Disease
(	O
IST	O
)	O
is	T-nsubj
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	T-nsubj
.	O

Idiopathic	T-dep
subjective	T-dep
tinnitus	O
(	O
IST	B-Disease
)	O
is	O
one	T-dep
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O

This	O
paper	O
presents	T-nmod
the	T-nmod
results	O
of	O
treating	O
IST	B-Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	O
(	O
lidocaine	O
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O

This	O
paper	O
presents	T-nmod
the	O
results	O
of	O
treating	O
IST	O
by	T-nmod
intratympanic	T-nmod
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	O
)	O
2	T-dep
per	T-dep
cent	O
through	O
a	O
grommet	T-nmod
,	O
for	O
five	O
weekly	O
courses	O
.	O

This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	O
by	O
intratympanic	O
instillation	T-appos
of	T-appos
lignocaine	O
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	T-appos
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O

Fifty	O
-	O
two	O
patients	T-obl
suffering	O
from	O
intractable	O
tinnitus	B-Disease
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O

In	O
one	O
patient	T-nsubj:pass
,	O
the	O
tinnitus	B-Disease
was	T-nsubj:pass
almost	O
completely	T-nsubj:pass
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	O
changed	T-nsubj:pass
to	O
a	O
compensated	O
one	O
.	O

In	O
one	O
patient	O
,	O
the	O
tinnitus	O
was	O
almost	O
completely	O
abolished	T-nsubj
,	O
but	T-nsubj
in	O
all	O
the	O
nine	O
patients	T-nsubj
the	O
decompensated	O
tinnitus	B-Disease
changed	O
to	O
a	O
compensated	O
one	T-nsubj
.	O

Patients	O
should	O
be	O
warned	T-nmod
about	T-nmod
the	T-nmod
side	T-nmod
effects	O
of	O
vertigo	B-Disease
and	T-conj
vomiting	O
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	T-nmod
,	O
and	O
that	O
the	O
tinnitus	O
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O

Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	T-conj
of	T-conj
vertigo	O
and	O
vomiting	B-Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	O
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O

Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	O
and	O
vomiting	O
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	T-nsubj
,	O
and	T-nsubj
that	T-nsubj
the	O
tinnitus	B-Disease
may	T-nsubj
not	T-nsubj
disappear	O
but	O
will	O
be	O
alleviated	T-nsubj
,	O
enabling	T-nsubj
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	B-Chemical
receptor	O
subunits	T-compound
are	O
necessary	O
for	O
nicotine	O
-	O
induced	O
seizures	O
and	O
hypolocomotion	O
in	O
mice	O
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	O
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	B-Chemical
-	O
induced	O
seizures	T-obl
and	O
hypolocomotion	O
in	O
mice	O
.	O

The	O
alpha3	T-obl
and	O
beta4	O
nicotinic	O
acetylcholine	O
receptor	O
subunits	O
are	T-obl
necessary	O
for	O
nicotine	T-amod
-	O
induced	O
seizures	B-Disease
and	T-conj
hypolocomotion	O
in	O
mice	T-obl
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	O
receptor	O
subunits	O
are	O
necessary	T-conj
for	T-conj
nicotine	O
-	O
induced	T-conj
seizures	O
and	O
hypolocomotion	B-Disease
in	O
mice	O
.	O

Binding	O
of	O
nicotine	B-Chemical
to	O
nicotinic	O
acetylcholine	O
receptors	T-nmod
(	O
nAChRs	O
)	O
elicits	T-nmod
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	O
,	O
to	O
seizures	O
and	O
death	O
.	O

Binding	T-compound
of	O
nicotine	O
to	T-compound
nicotinic	T-compound
acetylcholine	B-Chemical
receptors	O
(	O
nAChRs	T-compound
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	O
,	O
to	O
seizures	O
and	O
death	O
.	O

Binding	O
of	O
nicotine	O
to	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	T-conj
from	T-conj
altered	T-conj
exploration	O
,	O
sedation	T-conj
,	O
and	O
tremors	B-Disease
,	O
to	O
seizures	T-conj
and	O
death	O
.	O

Binding	O
of	O
nicotine	O
to	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	T-obl
from	T-obl
altered	T-obl
exploration	O
,	O
sedation	T-obl
,	O
and	O
tremors	T-obl
,	O
to	O
seizures	B-Disease
and	T-conj
death	O
.	O

Binding	O
of	O
nicotine	O
to	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	T-conj
,	O
sedation	O
,	O
and	O
tremors	O
,	O
to	T-conj
seizures	O
and	O
death	B-Disease
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	B-Chemical
-	O
induced	O
seizures	T-obl
and	O
hypolocomotion	O
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
mice	O

We	O
examined	T-nmod
the	T-nmod
role	O
of	O
the	O
beta4	O
subunits	T-nmod
in	O
nicotine	T-amod
-	O
induced	O
seizures	B-Disease
and	T-conj
hypolocomotion	O
in	T-nmod
beta4	O
homozygous	O
null	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
mice	O

We	O
examined	O
the	O
role	T-conj
of	O
the	O
beta4	O
subunits	O
in	T-conj
nicotine	O
-	O
induced	T-conj
seizures	O
and	O
hypolocomotion	B-Disease
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/	O
-	O
)	O
mice	O

beta4	O
-	O
/	O
-	O
mice	O
were	O
less	O
sensitive	T-nmod
to	T-nmod
the	T-nmod
effects	O
of	O
nicotine	B-Chemical
both	O
at	O
low	O
doses	T-nmod
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	O
-	O
induced	O
seizures	O
.	O

beta4	O
-	O
/	O
-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	O
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	B-Chemical
-	O
induced	O
seizures	T-obl
.	O

beta4	O
-	O
/	O
-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	O
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	T-nmod
as	T-nmod
sensitivity	O
to	O
nicotine	T-amod
-	O
induced	O
seizures	B-Disease
.	O

alpha3	O
+	O
/	O
-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine	B-Chemical
-	O
induced	O
seizures	O
when	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O

alpha3	O
+	O
/	O
-	O
mice	O
were	O
partially	T-advmod
resistant	O
to	O
nicotine	O
-	O
induced	O
seizures	B-Disease
when	T-advmod
compared	T-advmod
to	O
wild	O
-	T-advmod
type	O
littermates	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	B-Chemical
-	O
induced	O
seizures	T-obl
and	O
hypolocomotion	O
.	O

Together	O
,	O
these	O
results	O
suggest	T-nmod
that	T-nmod
the	O
beta4	T-nmod
and	O
the	O
alpha3	O
subunits	O
are	T-nmod
mediators	O
of	O
nicotine	T-amod
-	O
induced	O
seizures	B-Disease
and	T-conj
hypolocomotion	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	T-conj
of	T-conj
nicotine	O
-	O
induced	T-conj
seizures	O
and	O
hypolocomotion	B-Disease
.	O

The	T-nmod
effects	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	O
-	O
induced	O
convulsions	T-nmod
.	O

The	O
effects	O
of	O
sevoflurane	O
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	T-obl
.	O

The	T-nmod
effects	O
of	O
sevoflurane	T-nmod
on	O
lidocaine	T-amod
-	O
induced	O
convulsions	B-Disease
.	O

The	T-nmod
influence	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	O
-	O
induced	O
convulsions	T-nmod
was	O
studied	T-nmod
in	O
cats	O
.	O

The	O
influence	O
of	O
sevoflurane	O
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	T-obl
was	O
studied	O
in	O
cats	O
.	O

The	T-nmod
influence	O
of	O
sevoflurane	T-nmod
on	O
lidocaine	T-amod
-	O
induced	O
convulsions	B-Disease
was	O
studied	T-nmod
in	O
cats	O
.	O

The	T-dep
convulsive	B-Disease
threshold	T-nummod
(	T-nummod
mean	O
+	O
/	O
-	T-amod
SD	O
)	O
was	T-amod
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O

l	T-compound
(	O
-	O
1	O
)	O
with	T-compound
lidocaine	B-Chemical
infusion	O
(	T-compound
6	O
mg	T-compound
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O

There	O
was	O
no	O
significant	O
difference	T-amod
in	T-amod
the	T-amod
convulsive	B-Disease
threshold	O
between	O
sevoflurane	T-amod
and	O
enflurane	O
.	O

There	O
was	O
no	O
significant	O
difference	T-nmod
in	T-nmod
the	T-nmod
convulsive	T-nmod
threshold	O
between	O
sevoflurane	B-Chemical
and	T-conj
enflurane	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	O
threshold	T-conj
between	T-conj
sevoflurane	O
and	O
enflurane	B-Chemical
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	T-compound
in	T-compound
the	T-compound
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

Apamin	B-Chemical
(	T-dep
10	T-dep
ng	T-nummod
)	O
had	O
a	T-conj
tendency	T-conj
to	T-conj
decrease	T-conj
the	T-conj
convulsive	O
threshold	T-conj
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O

Apamin	O
(	T-conj
10	T-conj
ng	T-conj
)	O
had	T-conj
a	T-nsubj
tendency	T-cc
to	T-advmod
decrease	T-cop
the	T-amod
convulsive	B-Disease
threshold	T-advmod
(	O
21	T-amod
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O

It	O
is	O
suggested	T-nsubj
that	T-nsubj
sevoflurane	B-Chemical
reduces	O
the	O
convulsive	O
effect	T-nsubj
of	O
lidocaine	O
toxicity	O
but	O
carries	T-nsubj
some	O
risk	O
due	O
to	O
circulatory	O
depression	O
.	O

It	O
is	O
suggested	O
that	O
sevoflurane	O
reduces	T-amod
the	T-amod
convulsive	B-Disease
effect	O
of	O
lidocaine	O
toxicity	T-amod
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	O
.	O

It	O
is	O
suggested	O
that	O
sevoflurane	O
reduces	T-nmod
the	T-nmod
convulsive	T-nmod
effect	O
of	O
lidocaine	B-Chemical
toxicity	B-Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	O
.	O

It	O
is	O
suggested	O
that	O
sevoflurane	O
reduces	O
the	O
convulsive	O
effect	O
of	O
lidocaine	O
toxicity	O
but	O
carries	T-nmod
some	T-nmod
risk	O
due	O
to	T-case
circulatory	O
depression	B-Disease
.	O

Cardiac	B-Disease
toxicity	I-Disease
observed	O
in	O
association	T-nsubj
with	O
high	O
-	O
dose	O
cyclophosphamide	O
-	O
based	O
chemotherapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

Cardiac	O
toxicity	O
observed	O
in	O
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	B-Chemical
-	O
based	O
chemotherapy	T-obl
for	O
metastatic	O
breast	O
cancer	O
.	O

Cardiac	O
toxicity	O
observed	T-nmod
in	T-nmod
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	O
-	O
based	O
chemotherapy	T-nmod
for	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

INTRODUCTION	T-nsubj
:	O
Cyclophosphamide	B-Chemical
is	T-nsubj
an	T-nsubj
alkylating	T-nsubj
agent	O
given	O
frequently	T-nsubj
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O

In	O
high	O
doses	T-nsubj
,	O
its	O
nonhematological	O
dose	T-amod
-	O
limiting	O
toxicity	B-Disease
is	T-nsubj
cardiomyopathy	O
.	O

In	T-obl
high	T-obl
doses	O
,	O
its	T-nsubj
nonhematological	T-nsubj
dose	O
-	O
limiting	T-nsubj
toxicity	O
is	O
cardiomyopathy	B-Disease
.	O

STUDY	O
DESIGN	T-obj
:	O
We	T-obj
combined	O
paclitaxel	B-Chemical
,	O
melphalan	O
and	T-conj
high	O
-	O
dose	T-conj
cyclophosphamide	O
,	O
thiotepa	O
,	O
and	T-conj
carboplatin	O
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	T-obj
for	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	T-conj
paclitaxel	O
,	O
melphalan	B-Chemical
and	O
high	O
-	O
dose	O
cyclophosphamide	T-conj
,	O
thiotepa	T-conj
,	O
and	O
carboplatin	T-conj
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	T-conj
paclitaxel	O
,	O
melphalan	T-conj
and	O
high	T-compound
-	O
dose	O
cyclophosphamide	B-Chemical
,	O
thiotepa	T-conj
,	O
and	O
carboplatin	T-conj
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	T-conj
paclitaxel	O
,	O
melphalan	T-conj
and	O
high	O
-	O
dose	O
cyclophosphamide	T-conj
,	O
thiotepa	B-Chemical
,	O
and	O
carboplatin	T-conj
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	T-conj
paclitaxel	O
,	O
melphalan	T-conj
and	O
high	O
-	O
dose	O
cyclophosphamide	T-conj
,	O
thiotepa	T-conj
,	O
and	O
carboplatin	B-Chemical
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	O
paclitaxel	O
,	O
melphalan	O
and	O
high	O
-	O
dose	O
cyclophosphamide	O
,	O
thiotepa	O
,	O
and	O
carboplatin	O
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	T-nmod
for	T-nmod
patients	O
with	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

Analysis	O
was	O
performed	T-nsubj
on	O
61	O
women	O
with	T-nsubj
chemotherapy	T-amod
-	O
responsive	O
metastatic	O
breast	B-Disease
cancer	I-Disease
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	T-nsubj
as	O
part	T-nsubj
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	O
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Analysis	O
was	O
performed	T-obj
on	O
61	O
women	O
with	T-obj
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	T-obj
receiving	O
96	T-compound
-	O
h	O
infusional	O
cyclophosphamide	B-Chemical
as	O
part	T-obj
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	O
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	O
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	T-nmod
between	T-nmod
presence	O
of	O
peritransplant	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	T-nmod
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	O
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	O
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	T-dep
of	T-dep
peritransplant	T-dep
congestive	T-dep
heart	T-dep
failure	O
(	O
CHF	B-Disease
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	O
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	O
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	T-conj
:	O
presence	T-conj
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	T-conj
,	O
hypertension	B-Disease
,	O
prior	O
cardiac	O
history	T-conj
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	O
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	T-conj
,	O
age	O
,	O
hypertension	O
,	O
prior	T-conj
cardiac	T-conj
history	O
,	O
smoking	T-conj
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
prior	O
use	T-conj
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	T-conj
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	O
cancer	O
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	O
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	O
,	O
prior	O
cardiac	O
history	T-nmod
,	O
smoking	O
,	O
diabetes	O
mellitus	O
,	O
prior	T-nmod
use	O
of	O
anthracyclines	B-Chemical
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O

Older	O
age	O
was	O
significantly	O
correlated	T-compound
with	T-compound
the	T-compound
CHF	B-Disease
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	O
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	O
development	O
;	O
with	O
median	O
ages	T-dep
for	O
the	O
entire	O
group	O
and	T-dep
for	T-dep
patients	O
developing	O
CHF	B-Disease
of	T-nmod
45	O
and	O
59	T-nmod
,	O
respectively	O
.	O

Routine	T-nmod
EKG	T-nmod
monitoring	O
during	O
infusional	O
cyclophosphamide	B-Chemical
did	O
not	O
predict	T-nmod
CHF	O
development	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	O
did	O
not	O
predict	T-compound
CHF	B-Disease
development	O
.	O

Tremor	B-Disease
side	T-compound
effects	O
of	O
salbutamol	T-compound
,	O
quantified	T-compound
by	O
a	O
laser	O
pointer	O
technique	O
.	O

Tremor	T-nmod
side	T-nmod
effects	O
of	O
salbutamol	B-Chemical
,	O
quantified	T-nmod
by	O
a	O
laser	O
pointer	O
technique	O
.	O

OBJECTIVE	O
:	O
To	O
study	T-compound
tremor	B-Disease
side	T-compound
effects	O
of	O
salbutamol	T-compound
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O

OBJECTIVE	O
:	O
To	O
study	T-nmod
tremor	T-nmod
side	T-nmod
effects	O
of	O
salbutamol	B-Chemical
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O

METHODS	T-nsubj:pass
:	O
Tremor	B-Disease
was	T-nsubj:pass
measured	O
using	T-nsubj:pass
a	O
laser	O
pointer	O
technique	O
.	O

To	O
determine	T-obj
sensitivity	O
we	T-obj
assessed	O
tremor	B-Disease
in	O
44	O
patients	T-obj
with	O
obstructive	O
lung	O
disease	O
after	O
administration	T-obj
of	O
cumulative	O
doses	O
of	O
salbutamol	O
.	O

To	O
determine	O
sensitivity	O
we	O
assessed	T-nmod
tremor	O
in	T-nmod
44	T-nmod
patients	O
with	O
obstructive	B-Disease
lung	I-Disease
disease	I-Disease
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	O
.	O

To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	O
in	O
44	O
patients	O
with	O
obstructive	O
lung	O
disease	O
after	O
administration	T-nmod
of	T-nmod
cumulative	T-nmod
doses	O
of	O
salbutamol	B-Chemical
.	O

In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	T-nmod
and	O
reference	O
values	O
of	O
the	O
tremor	B-Disease
was	O
assessed	T-nmod
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Postural	O
tremor	B-Disease
was	T-nsubj:pass
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	O
with	O
the	O
arm	O
supported	T-nsubj:pass
by	O
an	O
armrest	O
and	O
finally	O
tremor	O
was	O
measured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O

Postural	O
tremor	O
was	O
measured	T-nsubj
with	O
the	O
arm	T-nsubj
horizontally	T-amod
outstretched	O
rest	O
tremor	B-Disease
with	T-nmod
the	T-nmod
arm	O
supported	O
by	O
an	O
armrest	T-nsubj
and	O
finally	O
tremor	O
was	O
measured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O

Postural	O
tremor	O
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	O
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	T-nsubj:pass
and	T-nsubj:pass
finally	T-nsubj:pass
tremor	B-Disease
was	T-nsubj:pass
measured	O
after	O
holding	T-nsubj:pass
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O

Tremor	B-Disease
was	T-nsubj:pass
measured	O
simultaneously	T-nsubj:pass
by	O
two	O
independent	O
observers	T-nsubj:pass
.	O

RESULTS	T-nsubj
:	O
Salbutamol	B-Chemical
significantly	T-nsubj
increased	O
tremor	O
severity	T-nsubj
in	O
patients	T-nsubj
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

RESULTS	O
:	O
Salbutamol	O
significantly	O
increased	T-compound
tremor	B-Disease
severity	O
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	T-compound
and	T-compound
tremor	B-Disease
severity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Postural	O
tremor	B-Disease
showed	O
no	O
significant	O
difference	T-nsubj
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0	T-nsubj
.	O
07	O
)	O
.	O

Support	O
of	O
the	O
arm	O
decreased	T-compound
tremor	B-Disease
severity	O
,	O
exhaustion	O
increased	O
tremor	O
severity	O
significantly	O
.	O

Support	O
of	O
the	O
arm	O
decreased	O
tremor	O
severity	O
,	O
exhaustion	O
increased	T-compound
tremor	B-Disease
severity	O
significantly	O
.	O

DISCUSSION	T-obj
:	O
Quantifying	O
tremor	B-Disease
by	O
using	T-obj
an	O
inexpensive	O
laser	O
pointer	O
is	T-obj
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O

Safety	T-obl
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	B-Chemical
:	O
multiple	O
outcomes	T-obl
of	O
raloxifene	O
evaluation	O
.	O

Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	O
:	O
multiple	O
outcomes	T-compound
of	T-compound
raloxifene	B-Chemical
evaluation	O
.	O

OBJECTIVE	O
:	O
To	O
examine	T-nmod
the	T-nmod
effect	O
of	O
raloxifene	B-Chemical
on	O
major	O
adverse	O
events	T-nmod
that	O
occur	O
with	O
postmenopausal	O
estrogen	O
therapy	O
or	O
tamoxifen	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	O
on	O
major	O
adverse	O
events	O
that	O
occur	T-compound
with	T-compound
postmenopausal	T-compound
estrogen	B-Chemical
therapy	O
or	O
tamoxifen	T-compound
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	O
on	O
major	O
adverse	O
events	O
that	O
occur	T-conj
with	T-conj
postmenopausal	T-conj
estrogen	T-conj
therapy	O
or	O
tamoxifen	B-Chemical
.	O

METHODS	O
:	O
The	O
Multiple	O
Outcomes	T-compound
of	T-compound
Raloxifene	B-Chemical
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
enrolled	O
7	O
,	O
705	O
postmenopausal	O
women	O
with	O
osteoporosis	O
.	O

METHODS	O
:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	O
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
enrolled	O
7	T-nmod
,	O
705	T-nmod
postmenopausal	T-nmod
women	O
with	O
osteoporosis	B-Disease
.	O

Women	O
were	O
randomly	O
assigned	T-compound
to	T-compound
raloxifene	B-Chemical
60	T-compound
mg	O
/	O
d	T-compound
or	O
120	O
mg	T-compound
/	O
d	O
or	O
placebo	O
.	O

Outcomes	T-obj
included	O
venous	B-Disease
thromboembolism	I-Disease
,	O
cataracts	O
,	O
gallbladder	T-conj
disease	O
,	O
and	T-conj
endometrial	T-conj
hyperplasia	O
or	O
cancer	T-conj
.	O

Outcomes	O
included	T-conj
venous	T-conj
thromboembolism	O
,	O
cataracts	B-Disease
,	O
gallbladder	O
disease	T-conj
,	O
and	O
endometrial	O
hyperplasia	T-conj
or	O
cancer	O
.	O

Outcomes	O
included	T-conj
venous	T-conj
thromboembolism	O
,	O
cataracts	T-conj
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
and	O
endometrial	O
hyperplasia	T-conj
or	O
cancer	O
.	O

Outcomes	O
included	T-conj
venous	T-conj
thromboembolism	O
,	O
cataracts	T-conj
,	O
gallbladder	O
disease	T-conj
,	O
and	O
endometrial	B-Disease
hyperplasia	I-Disease
or	I-Disease
cancer	I-Disease
.	O

Risk	T-compound
in	T-compound
the	T-compound
raloxifene	B-Chemical
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O

CONCLUSION	T-nsubj:pass
:	O
Raloxifene	B-Chemical
was	T-nsubj:pass
associated	O
with	O
an	O
increased	O
risk	T-nsubj:pass
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	T-nsubj:pass
no	O
increased	O
risk	O
for	O
cataracts	O
,	O
gallbladder	O
disease	O
,	O
endometrial	O
hyperplasia	O
,	O
or	O
endometrial	O
cancer	O
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	T-nmod
with	T-nmod
an	T-nmod
increased	T-nmod
risk	O
for	O
venous	B-Disease
thromboembolism	I-Disease
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	O
,	O
gallbladder	O
disease	O
,	O
endometrial	O
hyperplasia	O
,	O
or	O
endometrial	O
cancer	O
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	T-nmod
no	T-nmod
increased	T-nmod
risk	O
for	O
cataracts	B-Disease
,	O
gallbladder	T-conj
disease	O
,	O
endometrial	T-conj
hyperplasia	O
,	O
or	T-conj
endometrial	T-conj
cancer	O
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	T-conj
for	T-conj
cataracts	O
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
endometrial	O
hyperplasia	T-conj
,	O
or	O
endometrial	O
cancer	T-conj
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	T-conj
for	T-conj
cataracts	O
,	O
gallbladder	O
disease	T-conj
,	O
endometrial	B-Disease
hyperplasia	I-Disease
,	O
or	O
endometrial	O
cancer	T-conj
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	T-conj
for	T-conj
cataracts	O
,	O
gallbladder	O
disease	T-conj
,	O
endometrial	O
hyperplasia	T-conj
,	O
or	O
endometrial	B-Disease
cancer	I-Disease
.	O

Optimization	T-compound
of	T-compound
levodopa	B-Chemical
therapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	T-compound
for	T-compound
levodopa	B-Chemical
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	O
-	O
levodopa	O
to	O
the	O
point	O
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxicity	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	O
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	T-compound
carbidopa	B-Chemical
-	O
levodopa	O
to	O
the	O
point	O
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxicity	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	O
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	T-obj
to	T-obj
titrate	O
carbidopa	O
-	O
levodopa	B-Chemical
to	O
the	O
point	T-obj
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxicity	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	O
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	O
-	O
levodopa	O
to	O
the	O
point	O
of	O
"	O
normality	T-obl
,	O
"	O
which	T-obl
can	T-obl
lead	O
to	O
toxicity	B-Disease
.	O

Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	T-compound
of	T-compound
a	T-compound
dopamine	B-Chemical
agonist	O
.	O

Other	T-nmod
possible	T-nmod
adverse	T-nmod
effects	O
-	O
-	O
such	O
as	T-case
gastrointestinal	B-Disease
disorders	I-Disease
,	O
orthostatic	T-conj
hypotension	O
,	O
levodopa	O
-	O
induced	T-conj
psychosis	O
,	O
sleep	T-conj
disturbances	O
or	T-conj
parasomnias	O
,	O
or	T-conj
drug	T-conj
interactions	O
-	O
-	O
also	O
require	T-nmod
carefully	O
monitored	O
individual	O
treatment	O
.	O

Other	O
possible	O
adverse	O
effects	T-conj
-	O
-	O
such	T-conj
as	O
gastrointestinal	T-conj
disorders	O
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
levodopa	O
-	O
induced	O
psychosis	T-conj
,	O
sleep	O
disturbances	T-conj
or	O
parasomnias	T-conj
,	O
or	O
drug	O
interactions	T-conj
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Other	O
possible	O
adverse	O
effects	O
-	O
-	O
such	O
as	O
gastrointestinal	O
disorders	O
,	O
orthostatic	O
hypotension	O
,	O
levodopa	B-Chemical
-	O
induced	O
psychosis	T-obl
,	O
sleep	O
disturbances	O
or	O
parasomnias	O
,	O
or	O
drug	O
interactions	O
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Other	O
possible	O
adverse	O
effects	T-conj
-	O
-	O
such	T-conj
as	O
gastrointestinal	T-conj
disorders	O
,	O
orthostatic	O
hypotension	T-conj
,	O
levodopa	T-amod
-	O
induced	O
psychosis	B-Disease
,	O
sleep	O
disturbances	T-conj
or	O
parasomnias	T-conj
,	O
or	O
drug	O
interactions	T-conj
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Other	O
possible	O
adverse	O
effects	T-conj
-	O
-	O
such	T-conj
as	O
gastrointestinal	T-conj
disorders	O
,	O
orthostatic	O
hypotension	T-conj
,	O
levodopa	O
-	O
induced	O
psychosis	T-conj
,	O
sleep	B-Disease
disturbances	I-Disease
or	O
parasomnias	T-conj
,	O
or	O
drug	O
interactions	T-conj
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Other	O
possible	O
adverse	O
effects	T-conj
-	O
-	O
such	T-conj
as	O
gastrointestinal	T-conj
disorders	O
,	O
orthostatic	O
hypotension	T-conj
,	O
levodopa	O
-	O
induced	O
psychosis	T-conj
,	O
sleep	O
disturbances	T-conj
or	O
parasomnias	B-Disease
,	O
or	O
drug	O
interactions	T-conj
-	O
-	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Nonpharmacologic	O
concerns	O
can	O
help	O
the	T-compound
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patient	O
achieve	T-compound
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O

Long	O
term	O
audiological	O
evaluation	T-amod
of	T-amod
beta	B-Disease
-	I-Disease
thalassemic	I-Disease
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	T-nmod
the	T-nmod
progression	O
of	O
hearing	B-Disease
loss	I-Disease
in	T-nmod
children	O
and	O
young	O
adults	T-nmod
with	O
beta	O
-	O
thalassemia	O
major	T-nmod
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	T-dep
of	O
hearing	O
loss	O
in	O
children	O
and	O
young	O
adults	O
with	T-dep
beta	B-Disease
-	I-Disease
thalassemia	I-Disease
major	O
.	O

Subjects	O
were	O
receiving	T-compound
desferrioxamine	B-Chemical
(	O
DFO	O
)	O
chelation	T-compound
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O

Subjects	O
were	O
receiving	O
desferrioxamine	O
(	O
DFO	B-Chemical
)	O
chelation	O
treatment	T-dep
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O

No	T-amod
ototoxic	B-Disease
factor	O
,	O
other	T-amod
than	O
DFO	O
,	O
was	O
present	T-amod
in	O
any	O
of	O
the	O
patients	O
.	O

No	O
ototoxic	O
factor	T-obl
,	O
other	O
than	O
DFO	B-Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
SNHL	B-Disease
presented	T-nmod
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O

Subjects	O
with	O
SNHL	B-Disease
were	O
submitted	T-nmod
to	O
DFO	O
reduction	O
or	O
temporary	O
withdrawal	O
.	O

Subjects	O
with	O
SNHL	O
were	O
submitted	T-compound
to	T-compound
DFO	B-Chemical
reduction	O
or	O
temporary	O
withdrawal	T-compound
.	O

CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	T-nmod:poss
of	T-nmod:poss
DFO	B-Chemical
'	O
s	O
contributing	O
role	T-nmod:poss
in	O
the	O
development	O
of	O
hearing	O
impairment	O
.	O

CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	O
'	O
s	O
contributing	O
role	T-nmod
in	T-nmod
the	T-nmod
development	O
of	O
hearing	B-Disease
impairment	I-Disease
.	O

Regular	O
audiologic	O
evaluation	O
is	O
imperative	T-amod
in	T-amod
all	T-amod
thalassemic	B-Disease
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	O
impairment	O
.	O

Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	O
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	T-obj
in	T-obj
order	O
to	T-obj
prevent	O
or	O
reverse	T-obj
hearing	B-Disease
impairment	I-Disease
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	B-Chemical
-	O
induced	O
renal	O
damage	T-obl
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	T-nmod
susceptibility	O
to	O
adriamycin	T-amod
-	O
induced	O
renal	B-Disease
damage	I-Disease
.	O

BACKGROUND	O
:	O
In	O
man	O
,	O
differences	O
in	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	T-obl
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	O
prognosis	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	T-nmod
of	O
renal	O
ACE	O
activity	O
for	T-nmod
the	T-nmod
severity	O
of	O
renal	B-Disease
damage	I-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	O
in	O
rats	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	O
damage	O
induced	T-nmod
by	T-nmod
a	T-nmod
single	T-nmod
injection	O
of	O
adriamycin	B-Chemical
in	O
rats	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activity	T-compound
(	O
Hip	B-Chemical
-	I-Chemical
His	I-Chemical
-	I-Chemical
Leu	I-Chemical
cleavage	O
by	O
cortical	O
homogenates	T-compound
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O

After	T-dep
1	O
week	T-dep
of	T-compound
recovery	O
,	O
proteinuria	B-Disease
was	T-nsubj:pass
induced	T-dep
by	O
adriamycin	T-nsubj:pass
[	O
1	T-nsubj:pass
.	O
5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

After	O
1	O
week	T-obl
of	O
recovery	O
,	O
proteinuria	T-obl
was	T-obl
induced	O
by	O
adriamycin	B-Chemical
[	O
1	T-obl
.	O
5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Proteinuria	B-Disease
was	T-nsubj:pass
measured	O
every	O
2	O
weeks	T-nsubj:pass
.	O

RESULTS	T-nsubj
:	O
As	O
anticipated	T-nsubj
,	O
adriamycin	B-Chemical
elicited	O
nephrotic	O
range	O
proteinuria	T-nsubj
,	O
renal	O
interstitial	O
damage	O
and	O
mild	O
focal	O
glomerulosclerosis	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	O
elicited	O
nephrotic	B-Disease
range	O
proteinuria	T-amod
,	O
renal	O
interstitial	O
damage	O
and	O
mild	O
focal	O
glomerulosclerosis	O
.	O

RESULTS	T-obj
:	O
As	O
anticipated	T-obj
,	O
adriamycin	T-obj
elicited	O
nephrotic	T-compound
range	O
proteinuria	B-Disease
,	O
renal	T-conj
interstitial	T-conj
damage	O
and	T-conj
mild	T-conj
focal	T-conj
glomerulosclerosis	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	O
elicited	T-conj
nephrotic	O
range	T-conj
proteinuria	O
,	O
renal	B-Disease
interstitial	I-Disease
damage	I-Disease
and	O
mild	O
focal	O
glomerulosclerosis	T-conj
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	O
elicited	T-conj
nephrotic	O
range	T-conj
proteinuria	O
,	O
renal	O
interstitial	O
damage	T-conj
and	O
mild	O
focal	B-Disease
glomerulosclerosis	I-Disease
.	O

Baseline	T-nmod
renal	O
ACE	O
positively	T-nmod
correlated	T-nmod
with	T-nmod
the	T-nmod
relative	T-nmod
rise	T-nsubj
in	T-nmod
proteinuria	B-Disease
after	T-nsubj
adriamycin	T-nmod
(	T-nsubj
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Baseline	T-dep
renal	O
ACE	O
positively	T-dep
correlated	T-dep
with	T-dep
the	T-dep
relative	T-dep
rise	T-nsubj
in	T-dep
proteinuria	T-dep
after	T-dep
adriamycin	B-Chemical
(	T-dep
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Baseline	O
renal	O
ACE	T-obl
did	T-obl
not	T-obl
correlate	O
with	O
focal	B-Disease
glomerulosclerosis	I-Disease
(	O
r	O
=	O
0	T-obl
.	O
22	O
,	O
NS	O
)	O
.	O

CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	B-Chemical
-	O
induced	O
renal	O
damage	T-obl
in	O
this	O
outbred	O
rat	O
strain	O
.	O

CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	T-nmod
the	T-nmod
severity	O
of	O
adriamycin	T-amod
-	O
induced	O
renal	B-Disease
damage	I-Disease
in	O
this	O
outbred	O
rat	O
strain	T-nmod
.	O

This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	T-nmod
to	T-nmod
a	T-nmod
less	O
favourable	T-nmod
course	O
of	O
renal	B-Disease
damage	I-Disease
.	O

Recurrent	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
azithromycin	T-nsubj
.	O

Recurrent	O
acute	O
interstitial	O
nephritis	T-obl
induced	O
by	O
azithromycin	B-Chemical
.	O

A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	B-Chemical
-	O
induced	O
,	O
acute	O
interstitial	O
nephritis	T-obl
.	O

A	O
14	O
-	O
year	O
-	O
old	O
girl	T-obl
is	T-obl
reported	O
with	O
recurrent	O
,	O
azithromycin	T-amod
-	O
induced	O
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
.	O

Although	O
most	T-nmod
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
are	O
benign	T-nmod
and	O
self	O
-	O
limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	O
injury	O
.	O

Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	O
nephritis	O
are	O
benign	T-nmod
and	O
self	O
-	O
limited	O
,	O
some	O
patients	T-nmod
are	T-nmod
at	T-nmod
risk	O
for	O
permanent	O
renal	B-Disease
injury	I-Disease
.	O

Spironolactone	B-Chemical
-	O
induced	O
renal	O
insufficiency	T-obl
and	O
hyperkalemia	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

Spironolactone	T-amod
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
and	T-conj
hyperkalemia	O
in	T-nmod
patients	O
with	O
heart	O
failure	T-nmod
.	O

Spironolactone	O
-	O
induced	T-conj
renal	T-conj
insufficiency	O
and	O
hyperkalemia	B-Disease
in	O
patients	T-conj
with	O
heart	O
failure	O
.	O

Spironolactone	O
-	O
induced	O
renal	O
insufficiency	T-nmod
and	O
hyperkalemia	O
in	T-nmod
patients	O
with	O
heart	B-Disease
failure	I-Disease
.	O

Because	O
treatments	O
for	O
heart	B-Disease
failure	I-Disease
have	O
changed	T-nmod
since	O
the	O
benefits	O
of	O
spironolactone	O
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O

Because	O
treatments	O
for	O
heart	O
failure	O
have	O
changed	O
since	O
the	T-nmod
benefits	O
of	O
spironolactone	B-Chemical
were	O
reported	T-nmod
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	T-nmod
the	T-nmod
prevalence	O
and	O
clinical	O
associations	T-nmod
of	O
hyperkalemia	B-Disease
and	T-conj
renal	T-conj
insufficiency	O
in	O
heart	O
failure	O
patients	O
treated	O
with	O
spironolactone	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	T-conj
and	O
clinical	O
associations	O
of	T-conj
hyperkalemia	O
and	O
renal	B-Disease
insufficiency	I-Disease
in	O
heart	O
failure	O
patients	O
treated	O
with	O
spironolactone	O
.	O

We	O
therefore	O
sought	O
to	O
determine	T-compound
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	O
and	O
renal	O
insufficiency	O
in	T-compound
heart	B-Disease
failure	I-Disease
patients	O
treated	T-compound
with	O
spironolactone	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	O
and	O
renal	O
insufficiency	O
in	O
heart	O
failure	O
patients	T-obl
treated	O
with	O
spironolactone	B-Chemical
.	O

METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	T-compound
of	T-compound
heart	B-Disease
failure	I-Disease
patients	O
treated	O
with	O
spironolactone	O
in	O
our	O
clinical	O
practice	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	T-obl
of	O
heart	O
failure	O
patients	O
treated	O
with	O
spironolactone	B-Chemical
in	O
our	O
clinical	O
practice	T-obl
.	O

Cases	O
were	T-cc
patients	T-obj
who	T-obj
developed	O
hyperkalemia	B-Disease
(	T-cc
K	O
(	O
+	T-cc
)	O
>	T-cc
5	O
.	T-cc
0	O
mEq	O
/	O
L	O
)	O
or	O
renal	O
insufficiency	O
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O

Cases	T-conj
were	T-nsubj:pass
patients	T-conj
who	T-conj
developed	T-cc
hyperkalemia	O
(	T-nsubj:pass
K	B-Chemical
(	T-nsubj:pass
+	T-dep
)	T-dep
>	T-dep
5	T-dep
.	T-nsubj:pass
0	T-nsubj:pass
mEq	O
/	O
L	O
)	O
or	O
renal	O
insufficiency	O
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O

Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	O
(	O
K	O
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
renal	B-Disease
insufficiency	I-Disease
(	O
Cr	O
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O

Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	O
(	O
K	O
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
renal	O
insufficiency	O
(	O
Cr	B-Chemical
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O

Patients	T-obj
who	T-obj
developed	O
hyperkalemia	B-Disease
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	O
,	O
had	O
higher	O
baseline	O
serum	O
potassium	O
levels	O
and	O
lower	O
baseline	O
potassium	O
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	O
were	O
older	O
and	O
more	O
likely	T-obj
to	T-obj
have	O
diabetes	B-Disease
,	O
had	T-obj
higher	O
baseline	O
serum	O
potassium	O
levels	O
and	O
lower	O
baseline	O
potassium	O
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	T-obj
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	O
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	O
,	O
had	T-compound
higher	T-compound
baseline	T-compound
serum	T-compound
potassium	B-Chemical
levels	O
and	O
lower	O
baseline	O
potassium	O
supplement	O
doses	T-compound
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	O
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	O
,	O
had	O
higher	O
baseline	O
serum	O
potassium	O
levels	O
and	O
lower	T-compound
baseline	T-compound
potassium	B-Chemical
supplement	O
doses	T-compound
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	T-obj
who	T-obj
developed	O
renal	B-Disease
insufficiency	I-Disease
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	O
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	O
diuretics	O
than	O
controls	O
.	O

Patients	O
who	O
developed	O
renal	O
insufficiency	O
had	T-conj
lower	T-conj
baseline	T-conj
body	T-conj
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	B-Chemical
,	O
required	O
higher	O
doses	T-conj
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	O
diuretics	O
than	O
controls	O
.	O

Patients	O
who	O
developed	O
renal	O
insufficiency	O
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	O
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	T-amod
with	T-amod
thiazide	B-Chemical
diuretics	O
than	O
controls	T-amod
.	O

CONCLUSIONS	O
:	O
Spironolactone	B-Chemical
-	O
induced	O
hyperkalemia	T-obl
and	O
renal	O
insufficiency	O
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O

CONCLUSIONS	T-nsubj
:	O
Spironolactone	T-amod
-	O
induced	O
hyperkalemia	B-Disease
and	T-conj
renal	T-conj
insufficiency	O
are	T-nsubj
more	T-nsubj
common	O
in	O
our	O
clinical	O
experience	T-nsubj
than	O
reported	T-nsubj
previously	O
.	O

CONCLUSIONS	O
:	O
Spironolactone	O
-	O
induced	T-conj
hyperkalemia	O
and	O
renal	B-Disease
insufficiency	I-Disease
are	O
more	O
common	T-conj
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O

Acute	O
reserpine	B-Chemical
and	T-conj
subchronic	T-conj
haloperidol	T-conj
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	O
uptake	T-nsubj
and	O
elicit	T-nsubj
orofacial	O
dyskinesia	O
in	O
rats	O
.	O

Acute	O
reserpine	T-compound
and	T-compound
subchronic	T-compound
haloperidol	B-Chemical
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	O
uptake	O
and	O
elicit	O
orofacial	O
dyskinesia	O
in	O
rats	O
.	O

Acute	O
reserpine	O
and	O
subchronic	O
haloperidol	O
treatments	O
change	T-compound
synaptosomal	T-compound
brain	O
glutamate	B-Chemical
uptake	O
and	O
elicit	O
orofacial	O
dyskinesia	O
in	O
rats	O
.	O

Acute	O
reserpine	O
and	O
subchronic	O
haloperidol	O
treatments	O
change	T-obj
synaptosomal	O
brain	O
glutamate	O
uptake	O
and	T-obj
elicit	O
orofacial	B-Disease
dyskinesia	I-Disease
in	O
rats	T-obj
.	O

Reserpine	B-Chemical
-	O
and	T-conj
haloperidol	O
-	O
induced	T-conj
orofacial	T-conj
dyskinesia	O
are	T-nsubj
putative	T-nsubj
animal	T-nsubj
models	O
of	O
tardive	O
dyskinesia	O
(	O
TD	O
)	O
whose	O
pathophysiology	O
has	O
been	O
related	T-nsubj
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

Reserpine	O
-	O
and	O
haloperidol	B-Chemical
-	O
induced	O
orofacial	O
dyskinesia	T-obl
are	O
putative	O
animal	O
models	O
of	O
tardive	O
dyskinesia	O
(	O
TD	O
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

Reserpine	O
-	O
and	O
haloperidol	T-amod
-	O
induced	O
orofacial	B-Disease
dyskinesia	I-Disease
are	O
putative	O
animal	O
models	T-conj
of	O
tardive	O
dyskinesia	O
(	O
TD	O
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

Reserpine	O
-	O
and	O
haloperidol	O
-	O
induced	O
orofacial	O
dyskinesia	O
are	O
putative	O
animal	O
models	T-obl
of	O
tardive	B-Disease
dyskinesia	I-Disease
(	O
TD	O
)	O
whose	O
pathophysiology	T-obl
has	T-obl
been	T-obl
related	O
to	O
free	O
radical	O
generation	T-obl
and	O
oxidative	O
stress	O
.	O

Reserpine	O
-	O
and	O
haloperidol	O
-	O
induced	O
orofacial	O
dyskinesia	O
are	O
putative	O
animal	O
models	O
of	T-dep
tardive	T-dep
dyskinesia	O
(	O
TD	B-Disease
)	O
whose	O
pathophysiology	O
has	O
been	O
related	T-dep
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	T-obj
,	O
the	O
authors	T-obj
induced	O
orofacial	B-Disease
dyskinesia	I-Disease
by	O
acute	O
reserpine	T-obj
and	O
subchronic	O
haloperidol	O
administration	O
to	O
rats	T-obj
.	O

In	O
the	O
present	O
study	T-obl
,	O
the	O
authors	T-obl
induced	O
orofacial	O
dyskinesia	T-obl
by	O
acute	O
reserpine	B-Chemical
and	T-conj
subchronic	T-conj
haloperidol	T-conj
administration	O
to	O
rats	T-obl
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	O
dyskinesia	O
by	O
acute	O
reserpine	T-compound
and	T-compound
subchronic	T-compound
haloperidol	B-Chemical
administration	O
to	O
rats	O
.	O

Reserpine	B-Chemical
injection	T-det
(	T-compound
one	O
dose	T-compound
of	T-det
1	T-det
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O

Haloperidol	B-Chemical
administration	T-case
(	T-compound
one	T-case
dose	T-compound
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations	O
.	O

After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	B-Chemical
uptake	O
by	O
segments	T-compound
of	O
the	O
brain	O
was	O
analyzed	T-compound
.	O

A	T-compound
decreased	O
glutamate	B-Chemical
uptake	O
was	O
observed	T-compound
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	O
and	O
haloperidol	O
,	O
compared	O
to	O
the	O
control	O
.	O

A	O
decreased	O
glutamate	O
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	T-obl
of	O
animals	O
treated	O
with	O
reserpine	B-Chemical
and	T-conj
haloperidol	O
,	O
compared	O
to	O
the	O
control	O
.	O

A	O
decreased	O
glutamate	O
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	T-conj
with	T-conj
reserpine	O
and	O
haloperidol	B-Chemical
,	O
compared	O
to	O
the	O
control	O
.	O

Importantly	O
,	O
a	O
decrease	T-compound
in	T-compound
glutamate	B-Chemical
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	O
diskinesia	O
.	O

Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	O
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	T-nmod
in	T-nmod
the	T-nmod
incidence	O
of	O
orofacial	B-Disease
diskinesia	I-Disease
.	O

These	O
results	O
indicate	O
that	O
early	O
changes	T-compound
in	T-compound
glutamate	B-Chemical
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O

Ceftriaxone	B-Chemical
-	O
associated	O
biliary	O
pseudolithiasis	T-obl
in	O
paediatric	O
surgical	O
patients	O
.	O

Ceftriaxone	T-amod
-	O
associated	O
biliary	B-Disease
pseudolithiasis	I-Disease
in	T-nmod
paediatric	T-nmod
surgical	T-nmod
patients	O
.	O

It	O
is	O
well	O
known	T-nsubj
that	T-nsubj
ceftriaxone	B-Chemical
leads	O
to	O
pseudolithiasis	T-nsubj
in	O
some	O
patients	T-nsubj
.	O

It	O
is	O
well	O
known	T-obl
that	T-obl
ceftriaxone	T-obl
leads	O
to	O
pseudolithiasis	B-Disease
in	O
some	O
patients	T-obl
.	O

Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	T-obj
causing	O
gallbladder	B-Disease
dysfunction	I-Disease
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	O
.	O

Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	O
dysfunction	O
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	T-nmod
for	T-nmod
the	T-nmod
development	O
of	O
pseudolithiasis	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	T-nmod
the	T-nmod
incidence	O
and	O
clinical	O
importance	T-nmod
of	O
pseudolithiasis	B-Disease
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	O
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O

In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	O
in	O
paediatric	O
surgical	O
patients	O
receiving	T-compound
ceftriaxone	B-Chemical
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O

Fifty	O
children	T-nsubj:pass
who	T-nsubj:pass
were	T-nsubj:pass
given	O
ceftriaxone	B-Chemical
were	T-nsubj:pass
evaluated	O
by	O
serial	O
abdominal	O
sonograms	T-nsubj:pass
.	O

Comparison	T-nmod
of	T-nmod
the	T-nmod
patients	O
with	O
or	O
without	T-case
pseudolithiasis	B-Disease
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables	O
.	O

After	O
cessation	T-nsubj
of	O
the	O
treatment	O
,	O
pseudolithiasis	B-Disease
resolved	O
spontaneously	T-nsubj
within	O
a	O
short	O
period	T-nsubj
.	O

The	T-nmod
incidence	O
of	O
pseudolithiasis	B-Disease
is	O
not	O
affected	T-nmod
by	O
fasting	O
.	O

Coronary	B-Disease
aneurysm	I-Disease
after	T-nmod
implantation	O
of	O
a	O
paclitaxel	O
-	O
eluting	O
stent	T-nmod
.	O

Coronary	O
aneurysm	O
after	O
implantation	O
of	O
a	O
paclitaxel	B-Chemical
-	O
eluting	O
stent	T-obl
.	O

Formation	O
of	O
coronary	B-Disease
aneurysm	I-Disease
is	O
a	O
rare	O
complication	T-nmod
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	O
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	O
or	O
vessel	O
rupture	O
.	O

Formation	O
of	O
coronary	O
aneurysm	O
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	T-compound
,	O
aneurysm	B-Disease
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	O
or	O
vessel	O
rupture	O
.	O

Formation	O
of	O
coronary	O
aneurysm	O
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	T-nmod
,	O
aneurysm	O
formation	O
and	T-nmod
with	T-nmod
the	T-nmod
potential	O
of	O
stent	O
thrombosis	B-Disease
or	T-conj
vessel	T-conj
rupture	O
.	O

Formation	O
of	O
coronary	O
aneurysm	O
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	O
formation	O
and	O
with	O
the	O
potential	T-conj
of	T-conj
stent	T-conj
thrombosis	O
or	O
vessel	B-Disease
rupture	I-Disease
.	O

We	O
present	O
a	O
43	O
-	O
year	O
-	O
old	O
man	T-obj
who	T-obj
developed	O
a	O
coronary	B-Disease
aneurysm	I-Disease
in	O
the	O
right	O
coronary	O
artery	T-obj
6	O
months	T-obj
after	O
receiving	O
a	O
paclitaxel	O
-	O
eluting	O
stent	O
.	O

We	O
present	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
a	O
coronary	O
aneurysm	O
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	B-Chemical
-	O
eluting	O
stent	T-obl
.	O

The	O
patient	O
was	O
asymptomatic	T-nsubj:pass
and	T-nsubj:pass
the	O
aneurysm	B-Disease
was	T-nsubj:pass
detected	O
in	O
a	O
routine	O
control	T-nsubj:pass
.	O

METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	T-nmod
a	T-nmod
single	T-nmod
oral	T-nmod
dose	O
of	O
desipramine	B-Chemical
(	O
50	O
mg	T-nmod
)	O
on	O
two	O
separate	O
occasions	T-nmod
,	O
once	O
alone	T-nmod
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	O
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O

METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	O
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	T-nmod
once	T-nmod
after	T-nmod
multiple	T-nmod
doses	O
of	O
cinacalcet	B-Chemical
(	O
90	O
mg	T-nmod
for	O
7	O
days	O
)	O
.	O

Relative	T-cc
to	O
desipramine	B-Chemical
alone	T-dep
,	T-cc
mean	T-nummod
AUC	T-dep
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	O
increased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	O
.	O

Relative	O
to	O
desipramine	O
alone	O
,	T-nmod
mean	T-nmod
AUC	O
and	O
C	T-nmod
(	O
max	T-nmod
)	O
of	O
desipramine	B-Chemical
increased	T-nmod
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

The	O
prevalence	O
rate	O
for	O
CIMD	B-Disease
was	O
12	O
%	O
at	O
baseline	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B-Disease
.	O

Three	O
patients	O
with	O
severe	O
neutropenia	B-Disease
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-Disease
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
MAP	B-Chemical
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
induced	O
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-Chemical
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

After	O
4	O
-	O
week	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O

During	O
activation	O
with	O
Na	B-Chemical
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	B-Chemical
+	O
-	O
binding	O
site	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B-Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	B-Chemical
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

Patients	O
with	O
a	O
DBP	B-Disease
reduction	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-Disease
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
and	O
thrombocytopenia	B-Disease
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	B-Disease
or	O
mania	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-Disease
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B-Disease
episodes	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-Chemical
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-Disease
depression	I-Disease
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B-Disease
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nausea	B-Disease
.	O

In	O
the	O
bolus	O
group	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathisia	B-Disease
compared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-Disease
intensity	O
within	O
30	O
minutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-Disease
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B-Disease
when	O
prochlorperazine	B-Chemical
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	B-Chemical
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O

Neurologic	B-Disease
toxicity	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O

Patients	O
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

In	O
independent	O
groups	O
,	O
morphine	B-Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B-Disease
effects	O
.	O

When	O
hippocampal	O
ACh	B-Chemical
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-Disease
,	O
extracellular	O
ACh	B-Chemical
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-Chemical
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Faster	O
relief	O
of	O
headache	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	B-Chemical
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	B-Disease
free	O
2	O
h	O
after	O
rizatriptan	B-Chemical
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	B-Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	B-Disease
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
within	O
30	O
min	O
of	O
dosing	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	B-Chemical
were	O
pain	B-Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recurrence	O
rates	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatriptan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	B-Chemical
and	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
,	O
respectively	O
,	O
were	O
dizziness	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	B-Disease
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
versus	O
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Chemical
Arabic	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-Chemical
Arabic	I-Chemical
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Chemical
Arabic	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increased	O
creatinine	B-Chemical
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
group	O
)	O
The	O
GM	B-Chemical
-	O
induced	O
proximal	O
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Arabic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
cellulose	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	B-Chemical
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-Chemical
plus	O
thalidomide	B-Chemical
developed	O
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	O
the	O
5	O
patients	O
with	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
4	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O

The	O
remaining	O
1	O
patient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-Disease
laminar	I-Disease
necrosis	I-Disease
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	B-Disease
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prostate	B-Disease
cancer	I-Disease
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O

Delirium	B-Disease
was	O
diagnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidence	O
,	O
or	O
1	O
.	O
48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

CONCLUSIONS	O
:	O
Delirium	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-Chemical
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	B-Chemical
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
weeks	O
.	O

Five	O
of	O
8	O
patients	O
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

Eight	O
glaucomatous	B-Disease
patients	O
chronically	O
treated	O
with	O
timolol	B-Chemical
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
suffering	O
from	O
depression	B-Disease
diagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

After	O
a	O
30	O
-	O
min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12	O
-	O
h	O
deprivation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucrose	B-Chemical
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O

The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	B-Chemical
and	O
chow	O
were	O
hyperactive	B-Disease
in	O
response	O
to	O
amphetamine	B-Chemical
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	B-Chemical
,	O
or	O
cyclic	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O

The	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-Chemical
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	B-Disease
cancer	I-Disease
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
,	O
and	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
'	I-Disease
s	I-Disease
granulomatosis	I-Disease
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	B-Chemical
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
threshold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
,	O
indicating	O
a	O
celling	O
effect	O
.	O

The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-Chemical
or	O
enflurane	B-Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-Disease
decreased	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enflurane	B-Chemical
.	O

Apamin	B-Chemical
,	O
a	O
selective	O
blocker	O
of	O
calcium	B-Chemical
-	O
dependent	O
potassium	B-Chemical
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O

RESULTS	O
:	O
Six	O
of	O
61	O
women	O
(	O
10	O
%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	B-Disease
following	O
infusional	O
cyclophosphamide	B-Chemical
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31	O
%	O
.	O

Incidence	O
of	O
transient	O
cyclophosphamide	B-Chemical
-	O
related	O
cardiac	B-Disease
toxicity	I-Disease
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O

RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
years	O
,	O
raloxifene	B-Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-Disease
thromboembolism	I-Disease
(	O
relative	O
risk	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

Raloxifene	B-Chemical
did	O
not	O
increase	O
risk	O
for	O
cataracts	B-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallbladder	B-Disease
disease	I-Disease
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
endometrial	B-Disease
hyperplasia	I-Disease
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endometrial	B-Disease
cancer	I-Disease
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
(	O
SNHL	B-Disease
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O

BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	B-Chemical
in	O
heart	B-Disease
failure	I-Disease
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B-Disease
(	O
2	O
%	O
)	O
and	O
renal	B-Disease
insufficiency	I-Disease
(	O
0	O
%	O
)	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patients	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	B-Chemical
due	O
to	O
hyperkalemia	B-Disease
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-Disease
failure	I-Disease
(	O
n	O
=	O
34	O
)	O
.	O

Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15	O
-	O
mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	B-Disease
diameter	O
of	O
6	O
.	O
0	O
mm	O
.	O

Causes	O
of	O
acute	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O

OBJECTIVES	O
:	O
Thrombotic	B-Disease
microangiopathy	I-Disease
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O

In	O
postrenal	O
transplantation	O
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
during	O
a	O
1	O
-	O
year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
interval	O
.	O

RESULTS	O
:	O
Five	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
were	O
found	O
.	O

Three	O
cases	O
were	O
related	O
to	O
cyclosporine	B-Chemical
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
.	O

The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
related	O
to	O
an	O
antiphospholipid	B-Disease
syndrome	I-Disease
in	O
a	O
patient	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

CONCLUSIONS	O
:	O
In	O
the	O
literature	O
,	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

Other	O
causes	O
include	O
drug	O
-	O
related	O
(	O
cyclosporine	B-Chemical
,	O
tacrolimus	B-Chemical
)	O
toxicity	B-Disease
,	O
procoagulant	O
status	O
,	O
and	O
antibody	O
-	O
mediated	O
rejection	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
drug	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	B-Chemical
.	O

In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20	O
%	O
)	O
.	O

Comparison	O
of	O
developmental	O
toxicity	B-Disease
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibitors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wistar	O
rats	O
-	O
-	O
DFU	B-Chemical
and	O
piroxicam	B-Chemical
study	O
.	O

Unlike	O
general	O
toxicity	B-Disease
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	B-Disease
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-	I-Chemical
furanon	I-Chemical
)	O
COX	O
-	O
2	O
inhibitors	O
.	O

Doses	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piroxicam	B-Chemical
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	B-Chemical
.	O

The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	B-Disease
septal	I-Disease
(	I-Disease
VSD	I-Disease
)	I-Disease
and	I-Disease
midline	I-Disease
(	I-Disease
MD	I-Disease
)	I-Disease
defects	I-Disease
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	B-Chemical
,	O
selective	O
and	O
non	O
-	O
selective	O
COX	O
-	O
2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O

RESULTS	O
:	O
Maternal	O
toxicity	B-Disease
,	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
,	O
and	O
increase	B-Disease
of	I-Disease
external	I-Disease
and	I-Disease
skeletal	I-Disease
variations	I-Disease
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	B-Chemical
.	O

Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	B-Chemical
developmental	O
toxicity	B-Disease
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O

Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	B-Chemical
and	O
DFU	B-Chemical
-	O
exposed	O
groups	O
.	O

Unlike	O
DFU	B-Chemical
,	O
piroxicam	B-Chemical
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O

Prenatal	O
exposure	O
to	O
selective	O
COX	O
-	O
2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	B-Disease
septal	I-Disease
and	I-Disease
midline	I-Disease
defects	I-Disease
in	O
rat	O
when	O
compared	O
to	O
non	O
-	O
selective	O
drugs	O
and	O
historic	O
control	O
.	O

Lone	O
atrial	B-Disease
fibrillation	I-Disease
associated	O
with	O
creatine	B-Chemical
monohydrate	O
supplementation	O
.	O

Atrial	B-Disease
fibrillation	I-Disease
in	O
young	O
patients	O
without	O
structural	O
heart	B-Disease
disease	I-Disease
is	O
rare	O
.	O

Therefore	O
,	O
when	O
the	O
arrhythmia	B-Disease
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O

Thyroid	B-Disease
disorders	I-Disease
,	O
illicit	O
drug	O
or	O
stimulant	O
use	O
,	O
and	O
acute	B-Disease
alcohol	I-Disease
intoxication	I-Disease
are	O
among	O
these	O
causes	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	B-Disease
fibrillation	I-Disease
with	O
rapid	O
ventricular	O
response	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B-Disease
of	O
the	O
fingers	O
and	O
foot	O
.	O

Thyroid	O
-	O
stimulating	O
hormone	O
,	O
magnesium	B-Chemical
,	O
and	O
potassium	B-Chemical
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	O
screen	O
was	O
negative	O
,	O
and	O
alcohol	B-Chemical
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-Chemical
monohydrate	O
was	O
revealed	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-Chemical
,	O
and	O
given	O
intravenous	O
diltiazem	B-Chemical
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	B-Chemical
for	O
rate	O
and	O
rhythm	O
control	O
.	O

When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	B-Chemical
and	O
aspirin	B-Chemical
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O

Exogenous	O
creatine	B-Chemical
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O

Vegetarians	O
may	O
also	O
take	O
creatine	B-Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O

Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	B-Chemical
to	O
the	O
development	O
of	O
arrhythmia	B-Disease
.	O

Seizures	B-Disease
induced	O
by	O
the	O
cocaine	B-Chemical
metabolite	O
benzoylecgonine	B-Chemical
in	O
rats	O
.	O

The	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
cocaine	B-Chemical
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B-Disease
and	O
strokes	B-Disease
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	B-Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O

We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	B-Chemical
,	O
benzoylecgonine	B-Chemical
(	O
BE	B-Chemical
)	O
,	O
to	O
cause	O
seizures	B-Disease
.	O

Two	O
separate	O
equimolar	O
doses	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
mumol	O
)	O
of	O
either	O
cocaine	B-Chemical
or	O
BE	B-Chemical
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O

Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	B-Disease
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	B-Disease
.	O

BE	B-Chemical
-	O
Induced	O
seizures	B-Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	B-Chemical
.	O

Whereas	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	B-Disease
,	O
those	O
induced	O
by	O
BE	B-Chemical
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	B-Disease
.	O

Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	B-Disease
expression	O
.	O

BE	B-Chemical
-	O
Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	B-Disease
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	B-Chemical
-	O
injected	O
animals	O
without	O
seizures	B-Disease
.	O

The	O
finding	O
that	O
cocaine	B-Chemical
-	O
and	O
BE	B-Chemical
-	O
induced	O
seizures	B-Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	B-Chemical
metabolite	O
,	O
BE	B-Chemical
.	O

The	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
Ro4368554	B-Chemical
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	B-Disease
deficiency	I-Disease
in	O
the	O
rat	O
.	O

Antagonists	O
at	O
serotonin	B-Chemical
type	O
6	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O

Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O

The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
antagonist	O
Ro4368554	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesulfonyl	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
piperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
indole	I-Chemical
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	B-Chemical
pretreatment	O
)	O
and	O
a	O
serotonergic	O
-	O
(	O
tryptophan	B-Chemical
(	O
TRP	B-Chemical
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	B-Chemical
.	O

Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	B-Chemical
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro4368554	B-Chemical
was	O
inactive	O
.	O

Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4368554	B-Chemical
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	B-Disease
deficit	I-Disease
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
receptor	O
antagonists	O
.	O

Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	B-Chemical
as	O
an	O
immunotherapy	O
for	O
cocaine	B-Disease
overdose	I-Disease
.	O

The	O
illicit	O
use	O
of	O
cocaine	B-Chemical
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B-Disease
overdose	I-Disease
remains	O
elusive	O
.	O

The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	B-Chemical
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-Disease
overdose	I-Disease
.	O

Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocaine	B-Chemical
and	O
GNC92H2	B-Chemical
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC92H2	B-Chemical
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	B-Chemical
treatment	O
.	O

Significant	O
blockade	O
of	O
cocaine	B-Chemical
toxicity	B-Disease
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	B-Chemical
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40	O
%	O
,	O
seizures	B-Disease
up	O
to	O
77	O
%	O
and	O
death	B-Disease
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC92H2	B-Chemical
prevented	O
death	B-Disease
even	O
post	O
-	O
cocaine	B-Chemical
injection	O
.	O

The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	B-Chemical
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-Disease
overdose	I-Disease
.	O

Electrocardiographic	O
evidence	O
of	O
myocardial	B-Disease
injury	I-Disease
in	O
psychiatrically	O
hospitalized	O
cocaine	B-Chemical
abusers	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-Chemical
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O

Eleven	O
of	O
the	O
cocaine	B-Chemical
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B-Disease
injury	I-Disease
defined	O
as	O
myocardial	B-Disease
infarction	I-Disease
,	O
ischemia	B-Disease
,	O
and	O
bundle	B-Disease
branch	I-Disease
block	I-Disease
.	O

Behavioral	O
effects	O
of	O
urotensin	B-Chemical
-	I-Chemical
II	I-Chemical
centrally	O
administered	O
in	O
mice	O
.	O

Urotensin	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O

However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
have	O
received	O
little	O
attention	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
injections	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O

Administration	O
of	O
graded	O
doses	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O

Intracerebroventricular	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
.	O

Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	B-Chemical
-	O
induced	O
penile	B-Disease
erection	I-Disease
and	O
climbing	O
behavior	O
,	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	B-Chemical
level	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
at	O
doses	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic	O
-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O

These	O
data	O
suggest	O
that	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O

Learning	O
of	O
rats	O
under	O
amnesia	B-Disease
caused	O
by	O
pentobarbital	B-Chemical
.	O

Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	B-Disease
produced	O
by	O
pentobarbital	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O

It	O
was	O
shown	O
that	O
memory	B-Disease
dissociation	I-Disease
occurred	O
in	O
both	O
groups	O
.	O

Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O

These	O
findings	O
show	O
that	O
the	O
brain	O
-	O
dissociated	O
state	O
induced	O
by	O
pentobarbital	B-Chemical
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O

The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	B-Chemical
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	O
-	O
activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
,	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	B-Chemical
administration	O
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	B-Disease
or	O
osteoporosis	B-Disease
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	B-Chemical
hydrochloride	I-Chemical
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-Chemical
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-Chemical
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	B-Disease
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
due	O
to	O
raloxifene	B-Chemical
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O

Valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O

Valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-Disease
individuals	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B-Disease
.	O

A	O
case	O
of	O
valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
is	O
presented	O
.	O

Recurrent	O
dysphonia	B-Disease
and	O
acitretin	B-Chemical
.	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B-Disease
while	O
she	O
was	O
treated	O
by	O
acitretin	B-Chemical
.	O

Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	B-Chemical
was	O
reintroduced	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	B-Chemical
-	O
induced	O
dysphonia	B-Disease
.	O

Nitro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
:	O
a	O
potential	O
protector	O
against	O
gentamicin	B-Chemical
ototoxicity	B-Disease
.	O

The	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
inhibitor	O
nitro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high	B-Disease
-	I-Disease
frequency	I-Disease
hearing	I-Disease
loss	I-Disease
caused	O
by	O
gentamicin	B-Chemical
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglycoside	B-Chemical
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O

Their	O
ototoxicity	B-Disease
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	B-Disease
mechanism	O
involves	O
the	O
production	O
of	O
NO	B-Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	B-Chemical
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	B-Chemical
-	O
induced	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	B-Chemical
instilled	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoprotectant	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
was	O
administered	O
topically	O
to	O
12	O
/	O
27	O
animals	O
.	O

Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B-Disease
loss	I-Disease
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O

L	B-Chemical
-	I-Chemical
NAME	I-Chemical
reduced	O
gentamicin	B-Chemical
-	O
induced	O
hearing	B-Disease
loss	I-Disease
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O

Safety	O
profile	O
of	O
a	O
nicotine	B-Chemical
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	B-Chemical
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12	O
-	O
week	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
.	O

BACKGROUND	O
:	O
Nicotine	B-Chemical
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	B-Chemical
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	B-Chemical
polacrilex	O
gum	O
.	O

The	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
in	O
smokers	O
with	O
selected	O
label	O
-	O
restricted	O
diseases	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B-Disease
disease	I-Disease
,	O
hypertension	B-Disease
not	O
controlled	O
by	O
medication	O
,	O
and	O
/	O
or	O
diabetes	B-Disease
mellitus	I-Disease
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
or	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
.	O

The	O
nicotine	B-Chemical
lozenge	O
and	O
nicotine	B-Chemical
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	B-Disease
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hiccups	B-Disease
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
headache	B-Disease
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
nicotine	B-Chemical
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-Chemical
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label	O
-	O
restricted	O
medical	O
conditions	O
.	O

Pharmacological	O
modulation	O
of	O
pain	B-Disease
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O

Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B-Disease
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B-Disease
injury	I-Disease
(	O
secondary	B-Disease
hyperalgesia	I-Disease
)	O
.	O

Secondary	B-Disease
hyperalgesia	I-Disease
shares	O
clinical	O
characteristics	O
with	O
neurogenic	B-Disease
hyperalgesia	I-Disease
in	O
patients	O
with	O
neuropathic	B-Disease
pain	I-Disease
.	O

Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B-Disease
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	B-Chemical
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B-Disease
pain	I-Disease
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O

Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	B-Chemical
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	B-Chemical
-	O
induced	O
secondary	B-Disease
hyperalgesia	I-Disease
.	O

The	O
dose	O
of	O
gabapentin	B-Chemical
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	B-Chemical
suppressed	O
stimulus	O
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	B-Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-Chemical
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O

Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
.	O

Mitochondrial	B-Disease
abnormalities	I-Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	B-Disease
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B-Disease
epilepticus	I-Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	B-Chemical
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Although	O
evidences	O
of	O
mitochondrial	B-Disease
abnormalities	I-Disease
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O

Adverse	O
effect	O
of	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
on	O
nephrosclerosis	B-Disease
in	O
rats	O
with	O
renovascular	B-Disease
hypertension	I-Disease
.	O

The	O
effect	O
of	O
a	O
6	O
-	O
week	O
treatment	O
with	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
or	O
the	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
enalapril	B-Chemical
on	O
blood	O
pressure	O
,	O
albuminuria	B-Disease
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two	O
-	O
kidney	O
,	O
one	O
clip	O
renovascular	B-Disease
hypertension	I-Disease
.	O

Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	B-Disease
rats	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	B-Disease
controls	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapril	B-Chemical
-	O
treated	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipine	B-Chemical
-	O
treated	O
(	O
n	O
=	O
10	O
)	O
.	O

Enalapril	B-Chemical
but	O
not	O
nitrendipine	B-Chemical
reduced	O
blood	O
pressure	O
significantly	O
.	O

Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	B-Disease
did	O
not	O
change	O
after	O
enalapril	B-Chemical
treatment	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
albuminuria	B-Disease
increased	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compared	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertensive	B-Disease
controls	O
.	O

Furthermore	O
,	O
glomerulosclerosis	B-Disease
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	B-Chemical
-	O
treated	O
group	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	B-Chemical
-	O
treated	O
group	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ketoconazole	B-Chemical
induced	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drug	O
.	O

Ketoconazole	B-Chemical
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drugs	O
.	O

We	O
report	O
a	O
woman	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
who	O
developed	O
a	O
markedly	O
prolonged	B-Disease
QT	I-Disease
interval	I-Disease
and	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
after	O
taking	O
ketoconazole	B-Chemical
for	O
treatment	O
of	O
fungal	B-Disease
infection	I-Disease
.	O

Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	B-Chemical
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	B-Chemical
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	B-Disease
.	O

This	O
calls	O
for	O
attention	O
when	O
ketoconazole	B-Chemical
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O

Cerebral	B-Disease
vasculitis	I-Disease
following	O
oral	O
methylphenidate	B-Chemical
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O

Methylphenidate	B-Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	B-Chemical
.	O

Cerebral	B-Disease
vasculitis	I-Disease
associated	O
with	O
amphetamine	B-Disease
abuse	I-Disease
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	B-Disease
stroke	I-Disease
has	O
been	O
reported	O
after	O
methylphenidate	B-Chemical
intake	O
in	O
children	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
63	O
-	O
year	O
-	O
old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	B-Chemical
due	O
to	O
hyperactivity	B-Disease
and	O
suffered	O
from	O
multiple	O
ischaemic	B-Disease
strokes	I-Disease
.	O

We	O
consider	O
drug	O
-	O
induced	O
cerebral	B-Disease
vasculitis	I-Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	B-Disease
strokes	I-Disease
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylphenidate	B-Chemical
mediated	O
vasculitis	B-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-Chemical
therapy	O
.	O

This	O
potential	O
side	O
-	O
effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	B-Chemical
.	O

MDMA	B-Chemical
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O

In	O
recent	O
years	O
working	O
memory	B-Disease
deficits	I-Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
,	O
ecstasy	B-Chemical
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrontal	O
"	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	B-Chemical
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA	B-Chemical
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	B-Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical
use	O
.	O

Phase	O
II	O
study	O
of	O
the	O
amsacrine	B-Chemical
analogue	O
CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
)	O
in	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
.	O

CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
;	O
9	B-Chemical
-	I-Chemical
[	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
phenyl	I-Chemical
]	I-Chemical
amino	I-Chemical
]	I-Chemical
-	I-Chemical
N	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
acridinecarboxamide	I-Chemical
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O

It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery	O
/	O
radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O

The	O
histology	O
comprised	O
squamous	B-Disease
carcinoma	I-Disease
(	O
11	O
)	O
,	O
adenocarcinoma	B-Disease
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio	B-Disease
-	I-Disease
alveolar	I-Disease
carcinoma	I-Disease
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	B-Disease
carcinoma	I-Disease
(	O
1	O
)	O
.	O

Neutropenia	B-Disease
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	B-Disease
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B-Disease
in	O
1	O
patient	O
.	O

Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	B-Disease
and	O
vomiting	B-Disease
occurred	O
in	O
66	O
%	O
courses	O
and	O
phlebitis	B-Disease
in	O
the	O
infusion	O
arm	O
in	O
37	O
%	O
.	O

1	O
patient	O
with	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O

Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	B-Disease
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O

Pharmacokinetics	O
of	O
desipramine	B-Chemical
HCl	I-Chemical
when	O
administered	O
with	O
cinacalcet	B-Chemical
HCl	I-Chemical
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	B-Chemical
on	O
CYP2D6	O
activity	O
,	O
using	O
desipramine	B-Chemical
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O

Relative	O
to	O
desipramine	O
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	O
increased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	B-Chemical
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
desipramine	B-Chemical
was	O
longer	O
when	O
desipramine	B-Chemical
was	O
coadministered	O
with	O
cinacalcet	B-Chemical
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	B-Chemical
alone	O
than	O
when	O
receiving	O
desipramine	B-Chemical
with	O
cinacalcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-Disease
and	O
headache	B-Disease
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	B-Chemical
or	O
cinacalcet	B-Chemical
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O

These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	B-Chemical
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O

Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	B-Chemical
intoxication	O
.	O

INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	B-Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O

We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	B-Disease
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
year	O
-	O
old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	B-Chemical
'	O
;	O
that	O
is	O
,	O
carbachol	B-Chemical
.	O

He	O
bought	O
25	O
g	O
of	O
carbachol	B-Chemical
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O

Carbachol	B-Chemical
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC	O
-	O
mass	O
spectrometry	O
.	O

RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B-Disease
,	O
sweating	O
and	O
hypotension	B-Disease
,	O
and	O
finally	O
collapsed	O
.	O

Bradycardia	B-Disease
,	O
cholinergic	O
symptoms	O
and	O
asystole	B-Disease
occurred	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
,	O
atropine	B-Chemical
and	O
furosemide	B-Chemical
was	O
successful	O
.	O

Further	O
signs	O
were	O
hyperhidrosis	B-Disease
,	O
hypersalivation	B-Disease
,	O
bronchorrhoea	B-Disease
,	O
and	O
severe	O
miosis	B-Disease
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio	B-Disease
-	I-Disease
ventricular	I-Disease
dissociation	I-Disease
.	O

High	O
doses	O
of	O
atropine	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	B-Chemical
and	O
dopamine	B-Chemical
were	O
necessary	O
.	O

However	O
,	O
increased	O
dyspnoea	B-Disease
and	O
bronchospasm	B-Disease
necessitated	O
reintubation	O
.	O

Respiratory	B-Disease
insufficiency	I-Disease
was	O
further	O
worsened	O
by	O
Proteus	B-Disease
mirabilis	I-Disease
infection	I-Disease
and	O
severe	O
bronchoconstriction	O
.	O

On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B-Disease
failure	I-Disease
.	O

Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbachol	B-Chemical
,	O
respectively	O
.	O

For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	B-Chemical
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O

The	O
analysed	O
carbachol	B-Chemical
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	O
)	O
as	O
a	O
cause	O
of	O
acute	B-Disease
cardiovascular	I-Disease
failure	I-Disease
.	O

Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O

The	O
ethanolic	O
extract	B-Chemical
of	I-Chemical
Daucus	I-Chemical
carota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O

Diazepam	B-Chemical
-	O
,	O
scopolamine	B-Chemical
-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O

DCE	B-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O

Furthermore	O
,	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Daucus	B-Chemical
carota	I-Chemical
extract	I-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	B-Chemical
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	B-Chemical
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O

There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-Chemical
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	B-Chemical
.	O

Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	B-Chemical
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O

Valproic	B-Chemical
acid	I-Chemical
induced	O
encephalopathy	B-Disease
-	O
-	O
19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
effect	O
associated	O
to	O
VPA	B-Chemical
-	O
therapy	O
not	O
only	O
in	O
young	O
children	O
.	O

Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-Disease
,	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
,	O
VPA	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
and	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O

The	O
typical	O
signs	O
of	O
VPA	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
are	O
impaired	B-Disease
consciousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B-Disease
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B-Disease
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	B-Chemical
in	O
patients	O
with	O
encephalopathy	B-Disease
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
report	O
19	O
patients	O
with	O
VPA	B-Chemical
-	O
associated	O
encephalopathy	B-Disease
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O

Cerebral	B-Disease
haemorrhage	I-Disease
induced	O
by	O
warfarin	B-Chemical
-	O
the	O
influence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin	B-Chemical
-	O
induced	O
cerebral	B-Disease
haemorrhages	I-Disease
due	O
to	O
warfarin	B-Chemical
and	O
warfarin	B-Chemical
-	O
drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
tland	O
,	O
Sweden	O
.	O

METHODS	O
:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B-Disease
haemorrhage	I-Disease
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000	O
-	O
2002	O
were	O
identified	O
.	O

Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	B-Chemical
and	O
warfarin	B-Chemical
-	O
drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O

RESULTS	O
:	O
Among	O
593	O
patients	O
with	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	B-Chemical
treatment	O
.	O

Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfarin	B-Chemical
patients	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	B-Disease
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	B-Chemical
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B-Disease
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUSIONS	O
:	O
Warfarin	B-Chemical
-	O
induced	O
cerebral	B-Disease
haemorrhages	I-Disease
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
.	O

A	O
significant	O
proportion	O
of	O
warfarin	B-Chemical
-	O
related	O
cerebral	B-Disease
haemorrhages	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	B-Chemical
.	O

Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	B-Chemical
,	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-	O
receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
,	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O

Catalepsy	B-Disease
was	O
induced	O
by	O
haloperidol	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apomorphine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
amphetamine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O

(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
(	O
RAMH	B-Chemical
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thioperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-Disease
.	O

Administration	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloperidol	B-Chemical
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-Disease
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
pretreatment	O
with	O
RAMH	B-Chemical
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RAMH	B-Chemical
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O

On	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
THP	B-Chemical
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretreatment	O
with	O
RAMH	B-Chemical
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-Chemical
.	O

Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	B-Chemical
.	O

THP	B-Chemical
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
reducing	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
in	O
mice	O
.	O

Such	O
effects	O
of	O
THP	B-Chemical
were	O
reversed	O
by	O
RAMH	B-Chemical
indicating	O
the	O
involvement	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-	O
receptors	O
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)	O
-	O
receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
epidural	O
steroid	B-Chemical
injection	O
:	O
a	O
case	O
report	O
.	O

OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-Disease
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	B-Chemical
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O

The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	B-Chemical
and	O
bupivacaine	B-Chemical
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
low	B-Disease
back	I-Disease
and	I-Disease
right	I-Disease
leg	I-Disease
pain	I-Disease
was	O
scheduled	O
for	O
epidural	O
steroid	B-Chemical
injection	O
.	O

After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	B-Chemical
and	O
triamcinolone	B-Chemical
diacetate	I-Chemical
were	O
injected	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	B-Disease
and	O
lower	B-Disease
extremity	I-Disease
weakness	I-Disease
.	O

The	O
neurologic	O
evaluation	O
revealed	O
loss	B-Disease
of	I-Disease
sensation	I-Disease
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O

CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	B-Chemical
injections	O
are	O
rare	O
.	O

Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B-Disease
deterioration	I-Disease
after	O
epidural	O
steroid	B-Chemical
injections	O
is	O
important	O
.	O

High	O
-	O
dose	O
testosterone	B-Chemical
is	O
associated	O
with	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
long	O
-	O
term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
In	O
a	O
population	O
-	O
based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54	O
-	O
67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self	O
-	O
reported	O
intramuscularly	O
administered	O
high	O
-	O
dose	O
estrogen	B-Chemical
-	O
testosterone	B-Chemical
therapy	O
(	O
estradiol	B-Chemical
-	I-Chemical
and	I-Chemical
testosterone	I-Chemical
esters	I-Chemical
)	O
and	O
aortic	O
atherosclerosis	B-Disease
.	O

Aortic	O
atherosclerosis	B-Disease
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	B-Disease
.	O

In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	B-Disease
of	O
the	O
aorta	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	B-Disease
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	O
,	O
smoking	O
,	O
and	O
body	O
mass	O
index	O
)	O
.	O

The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	B-Disease
,	O
cholesterol	B-Chemical
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	B-Chemical
use	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	B-Chemical
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O

Optimising	O
stroke	B-Disease
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Atrial	B-Disease
fibrillation	I-Disease
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	B-Chemical
reduces	O
the	O
risk	O
of	O
stroke	B-Disease
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	B-Chemical
alone	O
reduces	O
the	O
risk	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	B-Chemical
is	O
superior	O
to	O
aspirin	B-Chemical
in	O
preventing	O
strokes	B-Disease
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O

Ximelagatran	B-Chemical
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	B-Disease
events	I-Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B-Disease
liver	I-Disease
function	I-Disease
tests	O
.	O

The	O
ACTIVE	O
-	O
W	O
(	O
Atrial	B-Disease
Fibrillation	I-Disease
Clopidogrel	B-Chemical
Trial	O
with	O
Irbesartan	B-Chemical
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	B-Chemical
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	B-Chemical
plus	O
aspirin	B-Chemical
)	O
in	O
the	O
prevention	O
af	O
embolic	B-Disease
events	I-Disease
.	O

Idraparinux	B-Chemical
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
-	O
blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	B-Disease
fibrillation	I-Disease
through	O
cardiac	B-Disease
remodelling	I-Disease
.	O

Preliminary	O
studies	O
suggest	O
that	O
statins	B-Chemical
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O

Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	B-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O

Dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)	O
-	O
induced	O
hypertension	B-Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	B-Chemical
(	O
O2	B-Chemical
-	I-Chemical
)	O
production	O
.	O

Atorvastatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	B-Chemical
and	O
reduced	O
O2	B-Chemical
-	I-Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	B-Disease
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	B-Chemical
could	O
prevent	O
endothelial	O
NO	B-Chemical
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O

Male	O
SD	O
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dexamethasone	B-Chemical
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	B-Chemical
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O

Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	B-Chemical
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O

In	O
rats	O
treated	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aortic	O
superoxide	B-Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Treatment	O
with	O
Ato	B-Chemical
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	B-Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex	B-Chemical
-	O
treated	O
SD	O
rats	O
.	O

Severe	O
citrate	B-Chemical
toxicity	B-Disease
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
citrate	B-Chemical
toxicity	B-Disease
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O

Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	B-Disease
,	O
hyperlipidemia	B-Disease
,	O
and	O
depression	B-Disease
.	O

Reported	O
medications	O
included	O
bumetanide	B-Chemical
,	O
pravastatin	B-Chemical
,	O
and	O
paroxetine	B-Chemical
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B-Disease
.	O

Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-Chemical
gluconate	I-Chemical
was	O
initiated	O
,	O
and	O
muscle	B-Disease
contractions	I-Disease
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O

The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	B-Chemical
chelation	O
by	O
sodium	B-Chemical
citrate	I-Chemical
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	B-Disease
.	O

Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	B-Chemical
is	O
a	O
loop	B-Chemical
diuretic	I-Chemical
that	O
may	O
cause	O
significant	O
hypocalcemia	B-Disease
.	O

We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	B-Disease
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	B-Chemical
toxicity	B-Disease
.	O

Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	B-Chemical
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O

Sirolimus	B-Chemical
-	O
associated	O
proteinuria	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
.	O

Sirolimus	B-Chemical
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
protein	O
kinase	O
.	O

Sirolimus	B-Chemical
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	B-Disease
.	O

Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B-Disease
,	O
autoimmunity	B-Disease
,	O
cystic	B-Disease
renal	I-Disease
diseases	I-Disease
and	O
renal	B-Disease
cancer	I-Disease
is	O
under	O
investigation	O
.	O

Because	O
sirolimus	B-Chemical
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	B-Disease
drug	O
'	O
.	O

However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	B-Chemical
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
.	O

A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre	O
-	O
existing	O
chronic	B-Disease
renal	I-Disease
damage	I-Disease
.	O

The	O
mechanisms	O
of	O
sirolimus	B-Chemical
-	O
associated	O
proteinuria	B-Disease
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
associated	O
with	O
sirolimus	B-Chemical
(	O
such	O
as	O
in	O
delayed	O
graft	O
function	O
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival	O
/	O
repair	O
processes	O
.	O

Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	B-Chemical
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	B-Chemical
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	B-Disease
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockers	O
if	O
proteinuria	B-Disease
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	B-Chemical
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

Proteinuria	B-Disease
after	O
conversion	O
to	O
sirolimus	B-Chemical
in	O
renal	O
transplant	O
recipients	O
.	O

Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O

More	O
recently	O
,	O
proteinuria	B-Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	B-Chemical
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O

We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B-Disease
after	O
SRL	B-Chemical
conversion	O
.	O

The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	B-Chemical
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
(	O
CAN	B-Disease
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	B-Disease
(	O
n	O
=	O
8	O
)	O
;	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
,	O
Four	O
skin	B-Disease
cancers	I-Disease
,	O
One	O
intestinal	B-Disease
tumors	I-Disease
,	O
One	O
renal	B-Disease
cell	I-Disease
carsinom	I-Disease
)	O
or	O
BK	O
virus	O
nephropathy	B-Disease
(	O
n	O
=	O
2	O
)	O
.	O

SRL	B-Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	O
after	O
transplantation	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	B-Chemical
therapy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O

Proteinuria	B-Disease
increased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
conversion	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
conversion	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B-Disease
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-Disease
.	O

In	O
28	O
%	O
of	O
patients	O
proteinuria	B-Disease
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68	O
%	O
of	O
patients	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B-Disease
to	O
the	O
nephrotic	B-Disease
range	O
.	O

Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B-Disease
glomerulopathy	I-Disease
and	O
interstitial	B-Disease
nephritis	I-Disease
.	O

Serum	O
creatinine	B-Chemical
values	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
therapy	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
patients	O
displayed	O
CAN	B-Disease
and	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
.	O

Mean	O
serum	O
creatinine	B-Chemical
level	O
before	O
conversion	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Heavy	O
proteinuria	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O

Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	B-Disease
and	O
proteinuria	B-Disease
.	O

The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	B-Chemical
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	B-Chemical
renal	B-Disease
toxicity	I-Disease
in	O
children	O
treated	O
for	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O

The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	B-Chemical
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B-Disease
Mesenchymal	I-Disease
Tumor	I-Disease
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O

Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-Chemical
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	B-Chemical
,	I-Chemical
vincristine	I-Chemical
,	I-Chemical
and	I-Chemical
dactinomycin	I-Chemical
[	O
IVA	B-Chemical
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cisplatin	B-Chemical
chemotherapy	O
.	O

The	O
most	O
common	O
primary	O
tumor	B-Disease
site	O
was	O
the	O
head	O
and	O
neck	O
.	O

Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	B-Disease
,	O
proteinuria	B-Disease
,	O
aminoaciduria	B-Disease
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	B-Chemical
clearance	O
,	O
phosphate	B-Chemical
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O

Fifty	O
-	O
eight	O
patients	O
(	O
78	O
%	O
)	O
had	O
normal	O
renal	O
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22	O
%	O
)	O
had	O
renal	B-Disease
abnormalities	I-Disease
.	O

Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group	O
:	O
the	O
first	O
included	O
four	O
patients	O
(	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	B-Disease
resulting	O
in	O
Fanconi	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
(	O
TDFS	B-Disease
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	B-Chemical
reabsorption	O
.	O

Severe	O
toxicity	B-Disease
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-Chemical
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B-Disease
involvement	O
.	O

This	O
low	O
percentage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	B-Chemical
in	O
the	O
treatment	O
of	O
mesenchymal	B-Disease
tumors	I-Disease
in	O
children	O
.	O

Progressive	O
myopathy	B-Disease
with	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	B-Chemical
therapy	O
.	O

Statins	B-Chemical
can	O
cause	O
a	O
necrotizing	O
myopathy	B-Disease
and	O
hyperCKaemia	B-Disease
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-Chemical
may	O
induce	O
a	O
myopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O

All	O
had	O
myofibre	O
necrosis	B-Disease
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O

In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
necrotic	B-Disease
fibres	O
.	O

Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	B-Chemical
and	O
methotrexate	B-Chemical
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O

These	O
observations	O
suggest	O
that	O
statins	B-Chemical
may	O
initiate	O
an	O
immune	O
-	O
mediated	O
myopathy	B-Disease
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B-Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	B-Chemical
of	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
with	O
associated	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O

Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	B-Disease
susceptibility	O
loci	O
in	O
mice	O
.	O

Seizure	B-Disease
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O

Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	B-Disease
susceptibility	O
.	O

QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
,	O
a	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	B-Disease
susceptibility	O
genes	O
.	O

We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A	O
/	O
J	O
(	O
donor	O
)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
adult	O
male	O
CSS	O
mice	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O

B6	O
mice	O
were	O
resistant	O
to	O
seizures	B-Disease
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O

CSS	O
mapping	O
suggests	O
seizure	B-Disease
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
.	O

In	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O

Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O

Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	B-Chemical
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O

Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
methylene	I-Chemical
adenosine	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
triphosphate	I-Chemical
(	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
meATP	I-Chemical
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscarinic	O
receptor	O
antagonists	O
atropine	B-Chemical
,	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methoctramine	B-Chemical
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirenzepine	B-Chemical
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O

4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O

In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
-	O
-	O
instead	O
of	O
decreased	O
-	O
-	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

While	O
contractions	O
to	O
carbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-Chemical
response	O
,	O
isoprenaline	B-Chemical
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O

Thus	O
,	O
in	O
cystitis	B-Disease
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O

Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Chemical
nucleotide	I-Chemical
-	O
gated	O
pacemaker	O
channels	O
by	O
clonidine	B-Chemical
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B-Disease
disease	I-Disease
,	O
including	O
arrhythmia	B-Disease
,	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
chronic	O
heart	B-Disease
failure	I-Disease
.	O

Activation	O
of	O
presynaptic	O
alpha2	O
-	O
adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	B-Chemical
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	B-Chemical
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	B-Chemical
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2	O
-	O
adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2	O
-	O
adrenoceptor	O
subtypes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Alpha2ABC	O
-	O
/	O
-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	B-Chemical
;	O
however	O
,	O
clonidine	B-Chemical
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clonidine	B-Chemical
-	O
induced	O
bradycardia	B-Disease
in	O
conscious	O
alpha2ABC	O
-	O
/	O
-	O
mice	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
microg	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
microg	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wild	O
-	O
type	O
mice	O
.	O

A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	B-Chemical
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Clonidine	B-Chemical
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperpolarization	O
-	O
activated	O
cyclic	B-Chemical
nucleotide	I-Chemical
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O

As	O
a	O
consequence	O
of	O
blocking	O
I	O
(	O
f	O
)	O
,	O
clonidine	B-Chemical
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild	O
-	O
type	O
and	O
alpha2ABC	O
-	O
knockout	O
mice	O
.	O

CONCLUSIONS	O
:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	B-Chemical
gene	O
-	O
targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine	B-Chemical
-	O
like	O
drugs	O
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O

Granulomatous	B-Disease
hepatitis	I-Disease
due	O
to	O
combination	B-Chemical
of	I-Chemical
amoxicillin	I-Chemical
and	I-Chemical
clavulanic	I-Chemical
acid	I-Chemical
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin	B-Chemical
-	I-Chemical
clavulanic	I-Chemical
acid	I-Chemical
-	O
induced	O
hepatitis	B-Disease
with	O
histologic	O
multiple	O
granulomas	B-Disease
.	O

This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B-Disease
injury	I-Disease
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B-Disease
syndrome	I-Disease
.	O

The	O
association	O
of	O
granulomas	B-Disease
and	O
eosinophilia	B-Disease
favor	O
an	O
immunoallergic	O
mechanism	O
.	O

As	O
penicillin	B-Chemical
derivatives	O
and	O
amoxicillin	B-Chemical
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	B-Chemical
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	B-Chemical
acid	I-Chemical
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobutamine	B-Chemical
stress	O
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	B-Chemical
-	O
treated	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
.	O

Doxorubicin	B-Chemical
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	B-Disease
.	O

To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B-Disease
damage	I-Disease
due	O
to	O
doxorubicin	B-Chemical
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	B-Chemical
infusion	O
to	O
differentiate	O
asymptomatic	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
treated	O
with	O
doxorubicin	B-Chemical
from	O
healthy	O
control	O
subjects	O
.	O

Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(	O
mean	O
age	O
16	O
+	O
/	O
-	O
5	O
years	O
)	O
treated	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
years	O
(	O
median	O
5	O
.	O
3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicin	B-Chemical
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

Graded	O
dobutamine	B-Chemical
infusions	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
were	O
administered	O
.	O

Dobutamine	B-Chemical
infusion	O
at	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50	O
%	O
incidence	O
rate	O
of	O
adverse	O
symptoms	O
.	O

The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	B-Chemical
-	O
treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	B-Chemical
stimulation	O
.	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	B-Chemical
-	O
treated	O
group	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5	O
-	O
micrograms	O
/	O
kg	O
per	O
min	O
dobutamine	B-Chemical
infusion	O
for	O
the	O
doxorubicin	B-Chemical
-	O
treated	O
group	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Influence	O
of	O
smoking	B-Chemical
on	O
developing	O
cochlea	O
.	O

Does	O
smoking	B-Chemical
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O

OBJECTIVE	O
:	O
Maternal	O
tobacco	O
smoking	B-Chemical
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O

The	O
influence	O
of	O
smoking	B-Chemical
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	B-Chemical
has	O
been	O
positively	O
associated	O
with	O
hearing	B-Disease
loss	I-Disease
in	O
adults	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	B-Chemical
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	B-Disease
impairment	I-Disease
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O

Newborns	O
whose	O
mothers	O
reported	O
smoking	B-Chemical
during	O
pregnancy	O
(	O
n	O
=	O
200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(	O
n	O
=	O
200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non	O
-	O
smokers	O
.	O

However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B-Disease
of	I-Disease
TEOAEs	I-Disease
amplitudes	I-Disease
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O

CONCLUSION	O
:	O
In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	B-Chemical
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O

Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	B-Chemical
on	O
the	O
neonate	O
'	O
s	O
hearing	O
acuity	O
.	O

Simvastatin	B-Chemical
-	O
induced	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
associated	O
with	O
hypothyroidism	B-Disease
.	O

A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B-Disease
male	O
taking	O
thyroxine	B-Chemical
and	O
simvastatin	B-Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
.	O

Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	B-Chemical
.	O

It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B-Disease
patients	O
.	O

Neuroinflammation	B-Disease
and	O
behavioral	B-Disease
abnormalities	I-Disease
after	O
neonatal	O
terbutaline	B-Chemical
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	B-Disease
.	O

Autism	B-Disease
is	O
a	O
neurodevelopmental	B-Disease
disorder	I-Disease
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B-Disease
in	I-Disease
communication	I-Disease
and	I-Disease
social	I-Disease
skills	I-Disease
and	O
repetitive	B-Disease
behaviors	I-Disease
.	O

In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	B-Disease
.	O

Terbutaline	B-Chemical
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Disease
labor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-Disease
in	O
dizygotic	O
twins	O
.	O

We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-Chemical
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O

Newborn	O
rats	O
were	O
given	O
terbutaline	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O

None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	B-Chemical
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O

Our	O
findings	O
indicate	O
that	O
beta2	O
-	O
adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B-Disease
abnormalities	I-Disease
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B-Disease
.	O

This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
.	O

Upregulation	O
of	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2	O
-	O
deficient	O
TR	O
(	O
-	O
)	O
rats	O
resembles	O
seizure	B-Disease
-	O
induced	O
up	O
-	O
regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O

By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	B-Chemical
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O

Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	B-Chemical
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	B-Chemical
in	O
TR	O
(	O
-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	B-Disease
to	I-Disease
the	I-Disease
brain	I-Disease
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B-Disease
or	O
other	O
Pgp	O
-	O
enhancing	O
events	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xanthine	B-Chemical
oxidase	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
.	O

Glucocorticoid	O
-	O
induced	O
hypertension	B-Disease
(	O
GC	O
-	O
HT	B-Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
-	O
redox	O
imbalance	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthine	B-Chemical
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
dex	B-Chemical
-	O
HT	B-Disease
)	O
.	O

Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
,	O
allopurinol	B-Chemical
plus	O
saline	O
,	O
and	O
allopurinol	B-Chemical
plus	O
dex	B-Chemical
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	B-Chemical
to	O
assess	O
XO	O
inhibition	O
.	O

Dex	B-Chemical
increased	B-Disease
SBP	I-Disease
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decreased	B-Disease
thymus	I-Disease
(	I-Disease
P	I-Disease
<	I-Disease
0	I-Disease
.	I-Disease
001	I-Disease
)	I-Disease
and	I-Disease
bodyweights	I-Disease
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Allopurinol	B-Chemical
decreased	O
serum	O
urate	B-Chemical
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-Chemical
-	O
treated	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
groups	O
.	O

Allopurinol	B-Chemical
did	O
not	O
prevent	O
dex	B-Chemical
-	O
HT	B-Disease
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	B-Chemical
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	B-Disease
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	O
-	O
HT	B-Disease
in	O
the	O
rat	O
.	O

Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	B-Disease
surgery	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
double	O
-	O
armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub	O
-	O
Tenon	O
'	O
s	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	B-Chemical
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylprednisolone	B-Chemical
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentamicin	B-Chemical
injected	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
.	O

Postoperatively	O
,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B-Disease
,	I-Disease
vomiting	I-Disease
,	O
and	O
headache	B-Disease
.	O

RESULTS	O
:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	B-Disease
emetic	I-Disease
symptoms	I-Disease
,	O
headache	B-Disease
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
in	O
the	O
posterior	O
sub	O
-	O
Tenon	O
'	O
s	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B-Disease
,	I-Disease
vomiting	I-Disease
,	O
and	O
headache	B-Disease
.	O

Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
,	O
using	O
Tc99m	B-Chemical
-	I-Chemical
Sestamibi	I-Chemical
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-Disease
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	B-Chemical
-	O
SPECT	O
/	O
dobutamine	B-Chemical
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	B-Chemical
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	B-Disease
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	B-Chemical
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-Disease
ischemia	I-Disease
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O

Cocaine	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O

Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	B-Chemical
may	O
result	O
in	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

In	O
individuals	O
with	O
preexisting	O
,	O
high	O
-	O
grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	B-Chemical
demand	O
associated	O
with	O
cocaine	B-Chemical
-	O
induced	O
increase	O
in	O
rate	O
-	O
pressure	O
product	O
.	O

In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-Disease
obstruction	I-Disease
,	O
coronary	B-Disease
occlusion	I-Disease
may	O
be	O
due	O
to	O
spasm	B-Disease
,	O
thrombus	B-Disease
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spasm	B-Disease
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	B-Disease
involves	O
the	O
epicardial	O
,	O
medium	O
-	O
size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O

Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B-Disease
.	O

The	O
finding	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	B-Disease
effect	O
of	O
cocaine	B-Chemical
has	O
not	O
been	O
excluded	O
.	O

Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesia	B-Disease
.	O

L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesia	B-Disease
(	O
LID	B-Disease
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
.	O

To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	B-Disease
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
-	O
lesion	O
rat	O
model	O
of	O
PD	B-Disease
treated	O
with	O
saline	O
,	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
or	O
bromocriptine	B-Chemical
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

Rats	O
treated	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	B-Disease
.	O

Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	B-Disease
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	O
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha	O
-	O
2	O
subunit	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	B-Disease
.	O

Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	B-Chemical
medium	I-Chemical
iopamidol	B-Chemical
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	B-Chemical
medium	I-Chemical
iodixanol	B-Chemical
in	O
high	O
-	O
risk	O
patients	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
comparison	O
of	O
iopamidol	B-Chemical
and	O
iodixanol	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O

Serum	O
creatinine	B-Chemical
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Disease
mellitus	I-Disease
,	O
use	O
of	O
N	B-Chemical
-	I-Chemical
acetylcysteine	I-Chemical
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	B-Chemical
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	B-Chemical
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
patients	O
with	O
diabetes	B-Disease
,	O
SCr	O
increases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	B-Chemical
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	B-Chemical
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	B-Chemical
(	O
all	O
patients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patients	O
with	O
diabetes	B-Disease
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-Disease
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	B-Chemical
or	O
iodixanol	B-Chemical
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-Disease
mellitus	I-Disease
.	O

A	O
novel	O
compound	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
attenuates	O
cognitive	B-Disease
deficits	I-Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-Disease
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
by	O
the	O
esterification	O
of	O
maltol	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
coumaric	I-Chemical
acid	I-Chemical
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
could	O
improve	O
cognitive	B-Disease
decline	I-Disease
in	O
scopolamine	B-Chemical
-	O
injected	O
rats	O
and	O
in	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	O
.	O

Maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
was	O
found	O
to	O
attenuate	O
cognitive	B-Disease
deficits	I-Disease
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	O
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
before	O
exposed	O
to	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
,	O
glutamate	B-Chemical
or	O
H2O2	B-Chemical
.	O

We	O
found	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	O
3	O
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Disease
death	I-Disease
and	O
progressive	O
decline	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
.	O

Attenuation	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B-Disease
in	O
mice	O
by	O
lipopolysaccharide	B-Chemical
pretreatment	O
.	O

Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	B-Disease
terminal	I-Disease
damage	I-Disease
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	B-Chemical
,	O
a	O
pro	O
-	O
inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O

Lipopolysaccharide	B-Chemical
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	B-Chemical
-	O
elicited	O
hyperthermia	B-Disease
three	O
days	O
later	O
.	O

Such	O
systemic	O
lipopolysaccharide	B-Chemical
treatment	O
mitigated	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	B-Chemical
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-Chemical
dosing	O
regimen	O
,	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
remained	O
unaltered	O
.	O

Moreover	O
,	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	B-Chemical
infusion	O
-	O
produced	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	B-Chemical
.	O

We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O

Acute	O
myocarditis	B-Disease
associated	O
with	O
clozapine	B-Chemical
.	O

OBJECTIVE	O
:	O
A	O
case	O
of	O
acute	O
myocarditis	B-Disease
associated	O
with	O
the	O
commencement	O
of	O
clozapine	B-Chemical
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	B-Chemical
use	O
.	O

RESULTS	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
male	O
with	O
schizophrenia	B-Disease
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	B-Disease
after	O
commencement	O
of	O
clozapine	B-Chemical
.	O

The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	B-Chemical
in	O
an	O
inpatient	O
setting	O
.	O

Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	B-Chemical
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O

CONCLUSIONS	O
:	O
Myocarditis	B-Disease
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O

Considering	O
that	O
clozapine	B-Chemical
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	B-Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O

Severe	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
resulting	O
in	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
,	O
atrial	B-Disease
fibrillation	I-Disease
,	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
hyperlipidemia	B-Disease
presented	O
with	O
generalized	O
pain	B-Disease
,	O
fatigue	B-Disease
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O

The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	B-Chemical
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	B-Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	B-Chemical
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O

Laboratory	O
evaluation	O
revealed	O
66	O
,	O
680	O
U	O
/	O
L	O
creatine	B-Chemical
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatinine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
aspartate	B-Chemical
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	B-Chemical
aminotransferase	O
.	O

Simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
the	O
patient	O
'	O
s	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O

Nine	O
days	O
later	O
the	O
patient	O
'	O
s	O
creatine	B-Chemical
kinase	O
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-Chemical
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	B-Chemical
metabolism	O
.	O

Simvastatin	B-Chemical
is	O
metabolized	O
by	O
CYP3A4	O
.	O

Amiodarone	B-Chemical
and	O
atazanavir	B-Chemical
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O

CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O

In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-Chemical
and	O
CYP3A4	O
inhibitors	O
,	O
pravastatin	B-Chemical
,	O
fluvastatin	B-Chemical
,	O
and	O
rosuvastatin	B-Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	B-Chemical
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	B-Chemical
and	O
lovastatin	B-Chemical
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	O
inhibitors	O
.	O

Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O

Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

Levofloxacin	B-Chemical
,	O
a	O
fluoroquinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	O
.	O

While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-Chemical
.	O

We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
.	O

Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-Chemical
to	O
patients	O
taking	O
warfarin	B-Chemical
.	O

Mutations	O
associated	O
with	O
lamivudine	B-Chemical
-	O
resistance	O
in	O
therapy	O
-	O
na	B-Chemical
ve	O
hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infected	I-Disease
patients	O
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
South	O
African	O
patients	O
.	O

This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
in	O
South	O
African	O
patients	O
.	O

Thirty	O
-	O
five	O
lamivudine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	B-Disease
infected	I-Disease
patients	O
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-Disease
mono	I-Disease
-	I-Disease
infected	I-Disease
patients	O
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O

The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
positive	O
)	O
patients	O
.	O

HBsAg	B-Chemical
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	B-Chemical
-	O
methionine	B-Chemical
-	O
aspartate	B-Chemical
-	O
aspartate	B-Chemical
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O

HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-Disease
B	I-Disease
patients	O
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	B-Chemical
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	B-Chemical
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O

Rabbit	B-Disease
syndrome	I-Disease
,	O
antidepressant	B-Chemical
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O

The	O
rabbit	B-Disease
syndrome	I-Disease
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O

Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	B-Chemical
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	B-Chemical
.	O

Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B-Disease
basal	I-Disease
ganglia	I-Disease
perfusion	I-Disease
while	O
the	O
movement	B-Disease
disorder	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-Disease
syndrome	I-Disease
resolved	O
.	O

Estrogen	O
prevents	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O

Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	B-Chemical
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	B-Chemical
treatment	O
increases	O
atherosclerotic	B-Disease
lesion	I-Disease
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	B-Chemical
-	O
treated	O
females	O
had	O
less	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	B-Chemical
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
progesterone	B-Chemical
or	O
vehicle	O
(	O
0	O
.	O
01	O
%	O
ethanol	B-Chemical
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	B-Chemical
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

E2	B-Chemical
decreased	O
the	O
accumulation	O
of	O
cholesteryl	B-Chemical
esters	I-Chemical
in	O
macrophages	O
following	O
ritonavir	B-Chemical
treatment	O
.	O

Ritonavir	B-Chemical
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	B-Chemical
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	B-Chemical
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	B-Chemical
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
following	O
ritonavir	B-Chemical
treatment	O
.	O

Acute	O
hepatitis	B-Disease
attack	O
after	O
exposure	O
to	O
telithromycin	B-Chemical
.	O

INTRODUCTION	O
:	O
Antibiotic	O
-	O
associated	O
hepatotoxicity	B-Disease
is	O
rare	O
.	O

With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	B-Disease
injury	I-Disease
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
male	O
patient	O
,	O
with	O
a	O
height	O
of	O
175	O
cm	O
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	O
Department	O
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	B-Disease
,	O
malaise	O
,	O
nausea	B-Disease
,	O
and	O
vomiting	B-Disease
.	O

He	O
had	O
been	O
prescribed	O
telithromycin	B-Chemical
400	O
mg	O
/	O
d	O
PO	O
to	O
treat	O
an	O
upper	B-Disease
respiratory	I-Disease
tract	I-Disease
infection	I-Disease
7	O
days	O
prior	O
.	O

Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	B-Chemical
aminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reference	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	B-Chemical
aminotransferase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	O
phosphatase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bilirubin	B-Chemical
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirubin	B-Chemical
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albumin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toxin	O
,	O
alcohol	B-Chemical
,	O
or	O
other	O
drugs	O
were	O
reported	O
.	O

The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
"	O
acute	O
hepatitis	B-Disease
of	O
unknown	O
origin	O
,	O
"	O
that	O
occurred	O
after	O
telithromycin	B-Chemical
usage	O
.	O

DISCUSSION	O
:	O
Telithromycin	B-Chemical
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	B-Disease
dysfunction	I-Disease
.	O

Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
probability	O
scale	O
,	O
telithromycin	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	B-Disease
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug	O
-	O
induced	O
toxic	B-Disease
hepatitis	I-Disease
.	O

Recurrence	O
of	O
hepatitis	B-Disease
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	B-Chemical
the	O
second	O
time	O
.	O

CONCLUSION	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	B-Disease
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	B-Chemical
.	O

A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	B-Chemical
injection	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
.	O

AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	B-Disease
and	O
pain	B-Disease
is	O
little	O
documented	O
.	O

METHOD	O
:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	B-Chemical
was	O
administered	O
.	O

Heparin	B-Chemical
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O

Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	B-Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O

Dimensions	O
of	O
the	O
bruising	B-Disease
on	O
the	O
heparin	B-Chemical
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	B-Disease
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	B-Disease
period	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
bruising	B-Disease
occurrence	O
was	O
64	O
%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O

It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	B-Disease
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O

Pain	B-Disease
intensity	O
and	O
pain	B-Disease
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30	O
-	O
second	O
injection	O
than	O
for	O
the	O
10	O
-	O
second	O
injection	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	B-Chemical
.	O

RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	B-Chemical
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O

Acute	B-Disease
liver	I-Disease
failure	I-Disease
in	O
two	O
patients	O
with	O
regular	O
alcohol	B-Chemical
consumption	O
ingesting	O
paracetamol	B-Chemical
at	O
therapeutic	O
dosage	O
.	O

BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcohol	B-Chemical
in	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
is	O
currently	O
debated	O
.	O

CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	B-Chemical
and	O
who	O
developed	O
liver	B-Disease
failure	I-Disease
within	O
3	O
-	O
5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	B-Chemical
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	B-Chemical
/	O
day	O
.	O

A	O
paracetamol	B-Chemical
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O

Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
are	O
discussed	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
risk	O
factors	O
,	O
e	O
.	O
g	O
.	O
regular	O
consumption	O
of	O
alcohol	B-Chemical
,	O
liver	B-Disease
failure	I-Disease
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O

We	O
propose	O
that	O
the	O
paracetamol	B-Chemical
dose	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	B-Chemical
.	O

Associations	O
between	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	O
(	O
BZDs	B-Chemical
/	O
RDs	O
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O

Data	O
on	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	B-Chemical
,	O
temazepam	B-Chemical
and	O
zopiclone	B-Chemical
were	O
analysed	O
.	O

Two	O
or	O
three	O
BZDs	B-Chemical
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O

Long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	B-Disease
.	O

After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B-Disease
,	O
inability	B-Disease
to	I-Disease
sleep	I-Disease
after	O
awaking	O
at	O
night	O
and	O
tiredness	B-Disease
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-Disease
symptoms	I-Disease
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O

Use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	B-Chemical
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O

Acute	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
after	O
acute	O
disulfiram	B-Chemical
intoxication	O
.	O

Acute	O
peripheral	B-Disease
neuropathy	I-Disease
caused	O
by	O
a	O
disulfiram	B-Chemical
overdose	B-Disease
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
.	O

A	O
49	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	B-Disease
,	O
lancinating	O
pain	B-Disease
,	O
sensory	B-Disease
loss	I-Disease
,	O
and	O
paresthesia	B-Disease
of	O
the	O
distal	O
limbs	O
.	O

One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	B-Chemical
(	O
130	O
tablets	O
of	O
ALCOHOL	B-Chemical
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O
Co	O
.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	O
attempt	O
.	O

For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	B-Disease
and	O
giddiness	B-Disease
.	O

She	O
noticed	O
hoarseness	B-Disease
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O

A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
.	O

This	O
was	O
a	O
case	O
of	O
acute	O
palsy	B-Disease
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
caused	O
by	O
high	O
-	O
dose	O
disulfiram	B-Chemical
intoxication	O
.	O

Encephalopathy	B-Disease
induced	O
by	O
levetiracetam	B-Chemical
added	O
to	O
valproate	B-Chemical
.	O

BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	B-Chemical
(	O
LEV	B-Chemical
)	O
-	O
induced	O
encephalopathy	B-Disease
.	O

FINDINGS	O
:	O
A	O
28	O
-	O
year	O
-	O
old	O
man	O
suffering	O
from	O
idiopathic	B-Disease
epilepsy	I-Disease
with	O
generalized	O
seizures	B-Disease
was	O
treated	O
with	O
LEV	B-Chemical
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	B-Chemical
(	O
VPA	B-Chemical
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequency	O
of	O
generalized	O
tonic	B-Disease
-	I-Disease
clonic	I-Disease
seizures	I-Disease
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O

Neuropsychological	O
testing	O
showed	O
impaired	B-Disease
word	I-Disease
fluency	I-Disease
,	I-Disease
psychomotor	I-Disease
speed	I-Disease
and	I-Disease
working	I-Disease
memory	I-Disease
.	O

OUTCOME	O
:	O
Following	O
discontinuation	O
of	O
LEV	B-Chemical
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	B-Disease
frequency	O
decreased	O
.	O

Norepinephrine	B-Chemical
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O

BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
,	O
such	O
as	O
anxiety	B-Disease
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	B-Chemical
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-	O
/	O
-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O

RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-Chemical
dose	O
-	O
dependently	O
increased	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+	O
/	O
-	O
)	O
mice	O
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O

The	O
Dbh	O
-	O
/	O
-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-Chemical
.	O

Cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/	O
-	O
mice	O
following	O
administration	O
of	O
disulfiram	B-Chemical
,	O
a	O
dopamine	B-Chemical
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O

In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists	O
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	B-Chemical
blocked	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	O
,	O
while	O
the	O
alpha	O
(	O
1	O
)	O
antagonist	O
prazosin	B-Chemical
and	O
the	O
alpha	O
(	O
2	O
)	O
antagonist	O
yohimbine	B-Chemical
had	O
no	O
effect	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
in	O
mice	O
.	O

Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	B-Chemical
acid	I-Chemical
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	B-Disease
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	B-Chemical
.	O

Hyperprolactinemia	B-Disease
can	O
reduce	O
fertility	O
and	O
libido	O
.	O

We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	B-Chemical
-	O
induced	O
LH	O
surge	O
.	O

Chronic	O
hyperprolactinemia	B-Disease
induced	O
by	O
the	O
dopamine	B-Chemical
antagonist	O
sulpiride	B-Chemical
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	B-Chemical
.	O

Sulpiride	B-Chemical
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	B-Chemical
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O

Estradiol	B-Chemical
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
'	O
s	O
signaling	O
pathway	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
estrogen	B-Chemical
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-Chemical
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O

Lastly	O
,	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	B-Chemical
and	O
estradiol	B-Chemical
.	O

Sulpiride	B-Chemical
induced	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O

Estradiol	B-Chemical
enhanced	O
these	O
effects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradiol	B-Chemical
also	O
induced	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O

These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-Disease
in	O
a	O
steroid	B-Chemical
-	O
dependent	O
manner	O
.	O

They	O
also	O
provide	O
evidence	O
for	O
estradiol	B-Chemical
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O

Clonidine	B-Chemical
for	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
:	O
II	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clonidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O

Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clonidine	B-Chemical
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-Disease
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O

There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
regarding	O
cardiovascular	O
outcomes	O
.	O

Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-Chemical
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O

Drowsiness	B-Disease
was	O
common	O
on	O
clonidine	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O

CONCLUSIONS	O
:	O
Clonidine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-Disease
.	O

Physicians	O
prescribing	O
clonidine	B-Chemical
should	O
monitor	O
for	O
bradycardia	B-Disease
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-Disease
.	O

Renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
and	O
myopathy	B-Disease
after	O
liver	O
transplantation	O
:	O
drug	O
-	O
related	O
mitochondrial	B-Disease
cytopathy	I-Disease
?	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

Tacrolimus	B-Chemical
,	O
MMF	B-Chemical
,	O
and	O
steroids	B-Chemical
were	O
given	O
as	O
immunosuppressant	O
.	O

Lamivudine	B-Chemical
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B-Disease
B	I-Disease
infection	I-Disease
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
with	O
severe	O
metabolic	B-Disease
acidosis	I-Disease
,	O
hypophosphatemia	B-Disease
,	O
glycosuria	B-Disease
,	O
and	O
aminoaciduria	B-Disease
.	O

Although	O
tacrolimus	B-Chemical
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post	O
-	O
transplant	O
renal	O
acidosis	B-Disease
and	O
was	O
replaced	O
by	O
sirolimus	B-Chemical
,	O
acidosis	B-Disease
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O

Proximal	O
muscle	B-Disease
weakness	I-Disease
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fanconi	B-Disease
syndrome	I-Disease
,	O
as	O
well	O
as	O
myopathy	B-Disease
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	B-Disease
disorders	I-Disease
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O

We	O
suggest	O
that	O
our	O
patient	O
'	O
s	O
tubular	B-Disease
dysfunction	I-Disease
and	O
myopathy	B-Disease
may	O
have	O
resulted	O
from	O
mitochondrial	B-Disease
dysfunction	I-Disease
which	O
is	O
triggered	O
by	O
tacrolimus	B-Chemical
and	O
augmented	O
by	O
lamivudine	B-Chemical
.	O

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
.	O

OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two	O
-	O
step	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
antigen	O
assay	O
with	O
thrombosis	B-Disease
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	B-Chemical
concentration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B-Disease
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
exposure	O
to	O
heparin	B-Chemical
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	B-Chemical
]	O
were	O
included	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
patients	O
had	O
thrombosis	B-Disease
at	O
diagnosis	O
;	O
54	O
/	O
94	O
had	O
isolated	O
-	O
HIT	B-Disease
without	O
thrombosis	B-Disease
.	O

Eight	O
of	O
the	O
isolated	O
-	O
HIT	B-Disease
patients	O
developed	O
thrombosis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-Disease
at	O
day	O
30	O
.	O

At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patients	O
with	O
thrombosis	B-Disease
and	O
those	O
with	O
isolated	O
-	O
HIT	B-Disease
.	O

However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	B-Disease
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolated	O
-	O
HIT	B-Disease
patients	O
who	O
later	O
developed	O
thrombosis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
compared	O
to	O
isolated	O
-	O
HIT	B-Disease
patients	O
who	O
did	O
not	O
develop	O
thrombosis	B-Disease
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
isolated	O
-	O
HIT	B-Disease
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B-Disease
by	O
day	O
30	O
.	O

Multivariate	O
analysis	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
increased	O
risk	O
of	O
thrombosis	B-Disease
in	O
females	O
.	O

Similarly	O
,	O
thrombotic	B-Disease
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O

CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	B-Disease
in	O
patients	O
with	O
isolated	O
-	O
HIT	B-Disease
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O

Thalidomide	B-Chemical
has	O
limited	O
single	O
-	O
agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
lymphomas	I-Disease
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	B-Disease
and	O
Leukemia	B-Disease
Group	O
B	O
.	O

Thalidomide	B-Chemical
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B-Disease
myeloma	I-Disease
,	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
and	O
lymphoplasmacytic	B-Disease
lymphoma	I-Disease
.	O

Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	B-Disease
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed	O
/	O
refractory	O
indolent	O
lymphomas	B-Disease
received	O
thalidomide	B-Chemical
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1	O
-	O
2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O

Grade	O
3	O
-	O
4	O
adverse	O
effects	O
included	O
myelosuppression	B-Disease
,	O
fatigue	B-Disease
,	O
somnolence	B-Disease
/	O
depressed	B-Disease
mood	I-Disease
,	O
neuropathy	B-Disease
and	O
dyspnea	B-Disease
.	O

Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	B-Disease
events	O
.	O

Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	B-Chemical
in	O
indolent	O
lymphomas	B-Disease
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	B-Chemical
.	O

Sex	O
differences	O
in	O
NMDA	B-Chemical
antagonist	O
enhancement	O
of	O
morphine	B-Chemical
antihyperalgesia	O
in	O
a	O
capsaicin	B-Chemical
model	O
of	O
persistent	O
pain	B-Disease
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-Disease
pain	I-Disease
.	O

In	O
acute	B-Disease
pain	I-Disease
models	O
,	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	B-Chemical
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	B-Disease
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B-Disease
pain	I-Disease
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O

To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	B-Disease
was	O
induced	O
by	O
administration	O
of	O
capsaicin	B-Chemical
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail	O
-	O
withdrawal	O
latencies	O
measured	O
.	O

For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B-Disease
pain	I-Disease
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail	O
-	O
withdrawal	O
procedures	O
.	O

In	O
males	O
,	O
the	O
non	O
-	O
competitive	O
NMDA	B-Chemical
antagonist	O
dextromethorphan	B-Chemical
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	B-Chemical
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Enhancement	O
of	O
morphine	B-Chemical
antinociception	O
by	O
dextromethorphan	B-Chemical
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B-Disease
pain	I-Disease
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O

These	O
findings	O
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	O
between	O
NMDA	B-Chemical
antagonists	O
and	O
morphine	B-Chemical
in	O
a	O
persistent	O
pain	B-Disease
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-Disease
pain	I-Disease
models	O
.	O

Development	O
of	O
proteinuria	B-Disease
after	O
switch	O
to	O
sirolimus	B-Chemical
-	O
based	O
immunosuppression	O
in	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
.	O

Calcineurin	O
-	O
inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	B-Disease
dysfunction	I-Disease
in	O
heart	O
transplantation	O
patients	O
.	O

The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	O
sirolmus	B-Chemical
(	O
Srl	B-Chemical
)	O
lacks	O
nephrotoxic	B-Disease
effects	O
;	O
however	O
,	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O

In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
Srl	B-Chemical
-	O
based	O
IS	O
.	O

Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	B-Chemical
mofetil	I-Chemical
+	O
/	O
-	O
steroids	B-Chemical
.	O

Before	O
the	O
switch	O
,	O
11	O
.	O
5	O
%	O
of	O
patients	O
had	O
high	O
-	O
grade	O
proteinuria	B-Disease
(	O
>	O
1	O
.	O
0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	O
to	O
22	O
.	O
9	O
%	O
postswitch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	B-Chemical
inhibitor	I-Chemical
and	O
angiotensin	B-Chemical
-	I-Chemical
releasing	I-Chemical
blocker	I-Chemical
(	O
ARB	B-Chemical
)	O
therapy	O
reduced	O
proteinuria	B-Disease
development	O
.	O

Patients	O
without	O
proteinuria	B-Disease
had	O
increased	O
renal	O
function	O
(	O
median	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high	O
-	O
grade	O
proteinuria	B-Disease
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
median	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proteinuria	B-Disease
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	B-Chemical
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O

Srl	B-Chemical
should	O
be	O
used	O
with	O
ACEi	B-Chemical
/	O
ARB	B-Chemical
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	B-Disease
and	O
increased	O
renal	B-Disease
dysfunction	I-Disease
.	O

Ginsenoside	B-Chemical
Rg1	I-Chemical
restores	O
the	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
induced	O
by	O
chronic	O
morphine	B-Chemical
administration	O
in	O
rats	O
.	O

Rg1	B-Chemical
,	O
as	O
a	O
ginsenoside	B-Chemical
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	B-Disease
impairment	I-Disease
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-Chemical
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	B-Chemical
on	O
learning	B-Disease
impairment	I-Disease
by	O
chronic	O
morphine	B-Chemical
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O

Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-Chemical
once	O
a	O
day	O
for	O
10	O
days	O
.	O

The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	B-Chemical
/	O
Rg1	B-Chemical
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O

By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	B-Chemical
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O

The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline	O
-	O
or	O
morphine	B-Chemical
/	O
Rg1	B-Chemical
-	O
treated	O
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
antagonist	O
MK801	B-Chemical
.	O

We	O
conclude	O
that	O
Rg1	B-Chemical
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	B-Chemical
administration	O
and	O
restore	O
the	O
morphine	B-Chemical
-	O
inhibited	O
LTP	O
.	O

This	O
effect	O
is	O
NMDA	B-Chemical
receptor	O
dependent	O
.	O

Synthesis	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyacetamides	I-Chemical
as	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonists	O
.	O

A	O
series	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenoxyacetamide	I-Chemical
adenosine	B-Chemical
A	O
(	O
2A	O
)	O
antagonists	O
is	O
described	O
.	O

SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
model	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
in	O
rats	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	B-Chemical
-	O
induced	O
locomotor	O
stimulation	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	B-Chemical
in	O
rats	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine	B-Chemical
-	O
induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	B-Chemical
.	O

Nicotine	B-Chemical
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O

The	O
stimulant	O
action	O
of	O
nicotine	B-Chemical
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	B-Chemical
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	B-Chemical
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O

Nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	B-Chemical
23390	I-Chemical
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	B-Chemical
and	O
the	O
D1	O
/	O
D2	O
antagonist	O
fluphenazine	B-Chemical
.	O

Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	B-Chemical
enhanced	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effect	O
.	O

The	O
results	O
indicate	O
that	O
acute	O
nicotine	B-Chemical
injection	O
induces	O
a	O
pronounced	O
hyperactivity	B-Disease
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O

The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	B-Chemical
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptors	O
.	O

Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
-	O
induced	O
ovulation	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
)	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	B-Disease
clinic	O
for	O
blurred	B-Disease
vision	I-Disease
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Ophthalmic	O
examination	O
after	O
CC	B-Chemical
therapy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
ovulation	O
induction	O
with	O
CC	B-Chemical
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
eight	O
courses	O
of	O
CC	B-Chemical
.	O

A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	B-Disease
complications	O
of	O
CC	B-Chemical
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	B-Disease
disturbance	I-Disease
after	O
CC	B-Chemical
intake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	B-Disease
patients	O
with	O
CC	B-Chemical
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O

Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
and	O
theophylline	B-Chemical
in	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O

The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	B-Chemical
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O

Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	B-Chemical
.	O

The	O
average	O
FEV1	O
increases	O
during	O
the	O
6	O
-	O
hour	O
observation	O
period	O
were	O
18	O
%	O
for	O
ipratropium	B-Chemical
and	O
8	O
%	O
for	O
theophylline	B-Chemical
.	O

The	O
mean	O
duration	O
of	O
action	O
was	O
3	O
.	O
8	O
hours	O
with	O
ipratropium	B-Chemical
and	O
2	O
.	O
4	O
hours	O
with	O
theophylline	B-Chemical
.	O

While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	B-Chemical
use	O
did	O
involve	O
the	O
cardiovascular	B-Disease
and	I-Disease
gastrointestinal	I-Disease
systems	I-Disease
.	O

These	O
results	O
show	O
that	O
ipratropium	B-Chemical
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
airflow	I-Disease
obstruction	I-Disease
.	O

Methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O

Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damages	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

[	O
Nat	O
.	O
Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	B-Chemical
-	O
induced	O
neurodegeneration	B-Disease
of	O
DA	B-Chemical
neurons	O
.	O

Because	O
the	O
CNS	B-Disease
damage	I-Disease
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
.	O

Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-Disease
.	O

METH	B-Chemical
depleted	O
DA	B-Chemical
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O

The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O

Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O

This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	B-Chemical
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O

Nicotine	B-Chemical
-	O
induced	O
nystagmus	B-Disease
correlates	O
with	O
midpontine	O
activation	O
.	O

The	O
pathomechanism	O
of	O
nicotine	B-Chemical
-	O
induced	O
nystagmus	B-Disease
(	O
NIN	B-Disease
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	B-Disease
generation	O
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O

NIN	B-Disease
correlated	O
with	O
blood	O
oxygen	B-Chemical
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O

NIN	B-Disease
-	O
induced	O
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O

Acute	O
effects	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylpentanoyl	I-Chemical
)	I-Chemical
urea	I-Chemical
on	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
(	O
glutamate	B-Chemical
,	O
aspartate	B-Chemical
,	O
glycine	B-Chemical
and	O
GABA	B-Chemical
)	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylpentanoyl	I-Chemical
)	I-Chemical
urea	I-Chemical
(	O
VPU	B-Chemical
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
.	O

VPU	B-Chemical
was	O
more	O
potent	O
than	O
VPA	B-Chemical
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-Chemical
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	B-Chemical
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	B-Chemical
and	O
GABA	B-Chemical
.	O

Pretreatment	O
with	O
either	O
VPU	B-Chemical
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	B-Chemical
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	B-Chemical
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	B-Chemical
and	O
glycine	B-Chemical
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	B-Chemical
and	O
VPA	B-Chemical
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O

Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
finding	O
that	O
VPU	B-Chemical
could	O
drastically	O
reduce	O
pilocarpine	B-Chemical
-	O
induced	O
increases	O
in	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
in	O
experimental	O
animals	O
.	O

Protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcers	B-Disease
in	O
severe	O
atherosclerotic	B-Disease
rats	O
.	O

Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-Disease
rats	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	B-Chemical
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
ulcer	B-Disease
in	O
rats	O
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O

Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
this	O
ulcer	B-Disease
model	O
was	O
evaluated	O
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
corn	O
oil	O
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O

Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	B-Chemical
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	B-Chemical
hemoglobin	O
content	O
and	O
ulcer	B-Disease
areas	O
were	O
determined	O
.	O

Elevated	O
atherosclerotic	B-Disease
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-Chemical
,	O
total	O
cholesterol	B-Chemical
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	O
.	O

Severe	O
gastric	O
ulcers	B-Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	B-Chemical
release	O
,	O
LPO	O
generation	O
and	O
luminal	B-Chemical
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O

Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	O
.	O

This	O
hemorrhagic	B-Disease
ulcer	B-Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-Chemical
.	O

Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	B-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	O
.	O

Lamivudine	B-Chemical
for	O
the	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
reactivation	O
in	O
hepatitis	B-Chemical
-	I-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
seropositive	O
cancer	B-Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
worldwide	O
.	O

Cancer	B-Disease
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	B-Disease
complication	I-Disease
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O

In	O
this	O
study	O
,	O
cancer	B-Disease
patients	O
who	O
have	O
solid	O
and	O
hematological	B-Disease
malignancies	I-Disease
with	O
chronic	O
HBV	B-Disease
infection	I-Disease
received	O
the	O
antiviral	O
agent	O
lamivudine	B-Chemical
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	B-Chemical
.	O

The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	B-Chemical
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT	O
.	O

The	O
prophylactic	O
lamivudin	B-Chemical
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	B-Chemical
treatment	O
.	O

The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	B-Chemical
.	O

Of	O
our	O
control	O
group	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitis	B-Disease
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	B-Disease
.	O

In	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
severe	O
hepatitis	B-Disease
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	B-Chemical
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	B-Chemical
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	B-Disease
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	B-Chemical
or	O
nucleotide	B-Chemical
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O

Recovery	O
of	O
tacrolimus	B-Chemical
-	O
associated	O
brachial	B-Disease
neuritis	I-Disease
after	O
conversion	O
to	O
everolimus	B-Chemical
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
-	O
-	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	B-Disease
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	B-Disease
,	O
headaches	B-Disease
,	O
seizures	B-Disease
,	O
or	O
neurological	B-Disease
deficits	I-Disease
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-Disease
and	O
right	O
brachial	B-Disease
plexitis	I-Disease
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	B-Chemical
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	B-Chemical
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	B-Chemical
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-Chemical
.	O

Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
without	O
increasing	O
pain	B-Disease
,	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-Chemical
,	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
occurs	O
frequently	O
.	O

Fentanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
pain	B-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O

RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-Disease
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-Chemical
and	O
fentanyl	B-Chemical
-	O
dexamethasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Dexamethasone	B-Chemical
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
.	O

Combining	O
the	O
two	O
fentanyl	B-Chemical
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pain	B-Disease
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-Chemical
.	O

Fentanyl	B-Chemical
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-Chemical
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-Disease
depression	I-Disease
,	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O

CONCLUSION	O
:	O
As	O
fentanyl	B-Chemical
exacerbated	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
without	O
an	O
improvement	O
in	O
postoperative	B-Disease
pain	I-Disease
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-Chemical
in	O
day	O
surgery	O
.	O

Valvular	B-Disease
heart	I-Disease
disease	I-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
treated	O
with	O
pergolide	B-Chemical
.	O

Valvular	B-Disease
heart	I-Disease
abnormalities	I-Disease
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
treated	O
with	O
pergolide	B-Chemical
.	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B-Disease
heart	I-Disease
abnormality	I-Disease
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
All	O
PD	B-Disease
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O

Thirty	O
PD	B-Disease
patients	O
participated	O
in	O
the	O
study	O
.	O

A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	B-Chemical
withdrawal	O
(	O
n	O
=	O
10	O
patients	O
)	O
.	O

Controls	O
were	O
age	O
-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	B-Disease
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O

RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitral	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	B-Disease
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affected	O
valves	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
higher	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	B-Chemical
group	O
.	O

Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	B-Chemical
cumulative	O
dose	O
.	O

A	O
restrictive	O
pattern	O
of	O
valvular	B-Disease
regurgitation	I-Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	B-Chemical
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
patients	O
including	O
two	O
with	O
heart	B-Disease
failure	I-Disease
.	O

Pergolide	B-Chemical
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O

This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	B-Disease
regurgitation	I-Disease
in	O
PD	B-Disease
patients	O
treated	O
with	O
pergolide	B-Chemical
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non	O
-	O
ergot	O
dopamine	B-Chemical
agonists	O
.	O

Adriamycin	B-Chemical
-	O
induced	O
autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B-Disease
failure	I-Disease
.	O

METHODS	O
:	O
3	B-Chemical
-	I-Chemical
methyladenine	I-Chemical
(	O
3MA	B-Chemical
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-Disease
failure	I-Disease
model	O
of	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	B-Chemical
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriamycin	B-Chemical
-	O
treated	O
group	O
.	O

We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	B-Chemical
+	O
ATPase	O
activity	O
in	O
vivo	O
.	O

RESULTS	O
:	O
3MA	B-Chemical
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O

Furthermore	O
,	O
adriamycin	B-Chemical
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	B-Chemical
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	B-Chemical
-	O
induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O

CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-Disease
failure	I-Disease
in	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
caused	O
by	O
adriamycin	B-Chemical
via	O
the	O
autophagy	O
pathway	O
.	O

mToR	O
inhibitors	O
-	O
induced	O
proteinuria	B-Disease
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O

Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	B-Chemical
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
.	O

Because	O
proteinuria	B-Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O

Whether	O
proteinuria	B-Disease
was	O
due	O
to	O
sirolimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-Disease
has	O
been	O
observed	O
during	O
sirolimus	B-Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	B-Chemical
de	O
novo	O
.	O

Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	B-Disease
.	O

Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-Chemical
.	O

This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	B-Chemical
.	O

Reactions	O
consisted	O
mainly	O
of	O
seizures	B-Disease
,	O
acute	O
psychoses	B-Disease
,	O
anxiety	B-Disease
neurosis	I-Disease
,	O
and	O
major	O
disturbances	B-Disease
of	I-Disease
sleep	I-Disease
-	I-Disease
wake	I-Disease
rhythm	I-Disease
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8	O
,	O
000	O
mefloquine	B-Chemical
users	O
suffers	O
from	O
such	O
reactions	O
.	O

The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	B-Chemical
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O

Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B-Disease
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	B-Chemical
are	O
recommended	O
.	O

Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	B-Chemical
-	O
mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding	O
.	O

Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	B-Disease
.	O

The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	B-Disease
.	O

We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	B-Chemical
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	B-Chemical
in	O
adulthood	O
.	O

No	O
changes	O
in	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
induced	O
locomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
haloperidol	B-Chemical
binding	O
and	O
decreased	O
dopamine	B-Chemical
transporter	O
binding	O
in	O
striatum	O
.	O

No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binding	O
in	O
cortex	O
.	O

This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	B-Disease
deficiency	I-Disease
enhances	O
risk	O
for	O
schizophrenia	B-Disease
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	O
of	O
abuse	O
.	O

Adverse	O
effects	O
of	O
topical	O
papaverine	B-Chemical
on	O
auditory	O
nerve	O
function	O
.	O

BACKGROUND	O
:	O
Papaverine	B-Chemical
hydrochloride	I-Chemical
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B-Disease
during	O
various	O
neurosurgical	O
operations	O
.	O

Transient	O
cranial	B-Disease
nerve	I-Disease
dysfunction	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	B-Chemical
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	B-Chemical
for	O
vasospasm	B-Disease
.	O

Topical	O
papaverine	B-Chemical
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B-Disease
in	O
a	O
total	O
of	O
11	O
patients	O
.	O

The	O
timing	O
of	O
papaverine	B-Chemical
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O

FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	B-Chemical
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O

The	O
average	O
temporal	O
delay	O
between	O
papaverine	B-Chemical
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	B-Chemical
.	O

One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	B-Chemical
baseline	O
values	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topical	O
papaverine	B-Chemical
for	O
the	O
treatment	O
of	O
vasospasm	B-Disease
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B-Disease
effect	I-Disease
on	I-Disease
the	I-Disease
proximal	I-Disease
eighth	I-Disease
nerve	I-Disease
.	O

Recommendations	O
to	O
avoid	O
potential	O
cranial	B-Disease
nerve	I-Disease
deficits	I-Disease
from	O
papaverine	B-Chemical
are	O
provided	O
.	O

Simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
hepatic	B-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
.	O

Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	B-Chemical
)	O
therapy	O
.	O

However	O
,	O
hepatotoxic	B-Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-Chemical
or	O
the	O
combination	O
agent	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
.	O

We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-Chemical
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-Chemical
10	I-Chemical
mg	I-Chemical
-	I-Chemical
ezetimibe	I-Chemical
40	I-Chemical
mg	I-Chemical
/	O
day	O
.	O

The	O
patient	O
'	O
s	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B-Disease
.	O

Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O

A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-Disease
toxicity	I-Disease
.	O

Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Chemical
diphosphate	I-Chemical
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
liver	B-Disease
failure	I-Disease
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O

We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
is	O
the	O
increased	O
simvastatin	B-Chemical
exposure	O
by	O
ezetimibe	B-Chemical
inhibition	O
of	O
UGT	O
enzymes	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B-Disease
with	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O

Massive	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
.	O

A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
due	O
to	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	B-Chemical
therapy	O
.	O

Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

After	O
discontinuing	O
the	O
oral	O
alendronate	B-Chemical
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O

Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O

This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	B-Chemical
can	O
aggravate	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Doxorubicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
leads	O
to	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
-	O
dependent	O
volume	B-Disease
retention	I-Disease
and	O
renal	O
fibrosis	B-Disease
.	O

The	O
aldosterone	B-Chemical
-	O
sensitive	O
serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	B-Disease
following	O
mineralocorticoid	O
and	O
salt	O
excess	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B-Disease
retention	I-Disease
and	O
fibrosis	B-Disease
during	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxorubicin	B-Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-Disease
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-Disease
syndrome	I-Disease
with	O
ascites	B-Disease
,	O
lipidemia	B-Disease
,	O
and	O
hypoalbuminemia	B-Disease
in	O
both	O
genotypes	O
.	O

Plasma	O
aldosterone	B-Chemical
levels	O
increased	O
in	O
nephrotic	B-Disease
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
.	O

Urinary	O
sodium	B-Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
15	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
35	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Disease
gain	I-Disease
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
compared	O
with	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
course	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
serum	O
urea	B-Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
leading	O
to	O
uremia	B-Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
29	O
vs	O
.	O
40	O
days	O
in	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
mice	O
)	O
.	O

In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B-Disease
retention	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	B-Disease
during	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Severe	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
associated	O
with	O
ciprofloxacin	B-Chemical
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O

Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	B-Chemical
.	O

A	O
30	O
-	O
year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B-Disease
pain	I-Disease
and	O
jaundice	B-Disease
after	O
3	O
-	O
day	O
administration	O
of	O
oral	O
ciprofloxacin	B-Chemical
for	O
a	O
suspect	O
of	O
urinary	B-Disease
tract	I-Disease
infection	I-Disease
.	O

Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	B-Disease
and	O
haemolysis	B-Disease
.	O

The	O
patient	O
progressively	O
developed	O
petechiae	B-Disease
and	O
purpura	B-Disease
on	O
thorax	O
and	O
lower	O
limbs	O
.	O

An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	B-Disease
.	O

No	O
signs	O
of	O
bone	B-Disease
marrow	I-Disease
depression	I-Disease
were	O
found	O
.	O

No	O
thrombi	B-Disease
or	O
signs	O
of	O
microangiopathies	B-Disease
were	O
observed	O
in	O
arterial	O
vessels	O
.	O

This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	B-Chemical
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O

Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
prevents	O
mitochondrial	B-Disease
damage	I-Disease
and	O
neurotoxicity	B-Disease
in	O
experimental	O
chemotherapy	O
neuropathy	B-Disease
.	O

The	O
study	O
investigates	O
if	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
,	O
if	O
mitochondrial	B-Disease
damage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Disease
neurodegenerative	I-Disease
cascade	I-Disease
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
depend	O
on	O
mitochondria	O
protection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O

This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	B-Disease
damage	I-Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
.	O

Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-Chemical
and	O
paclitaxel	B-Chemical
cause	O
early	O
mitochondrial	B-Disease
impairment	I-Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O

Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Disease
toxicity	I-Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O

In	O
conclusion	O
mitochondrial	B-Disease
toxicity	I-Disease
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O

Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O

These	O
findings	O
suggest	O
that	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Disease
nerve	I-Disease
toxicity	I-Disease
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O

Toxicity	B-Disease
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8	B-Chemical
-	I-Chemical
aminoquinoline	I-Chemical
8	B-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
methylbutyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
(	I-Chemical
l	I-Chemical
-	I-Chemical
hexyloxy	I-Chemical
)	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylquinoline	I-Chemical
(	O
WR242511	B-Chemical
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	B-Disease
.	O

Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	B-Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	B-Chemical
-	I-Chemical
aminoquinoline	I-Chemical
WR242511	B-Chemical
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	B-Chemical
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	B-Chemical
orally	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

RESULTS	O
:	O
The	O
selected	O
doses	O
of	O
WR242511	B-Chemical
,	O
which	O
produced	O
significant	O
methemoglobinemia	B-Disease
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O

Furthermore	O
,	O
transient	O
hemoglobinuria	B-Disease
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	B-Chemical
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O

Myoglobinuria	B-Disease
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O

Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B-Disease
and	I-Disease
kidney	I-Disease
toxicity	I-Disease
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
direct	O
and	O
/	O
or	O
indirect	O
drug	O
-	O
induced	O
toxicity	B-Disease
.	O

It	O
is	O
concluded	O
that	O
WR242511	B-Chemical
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	B-Disease
unless	O
the	O
anti	O
-	O
CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	B-Disease
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	O
sham	O
"	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O

Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B-Disease
severity	O
.	O

However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystonia	B-Disease
subscore	O
.	O

Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-Disease
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B-Disease
symptoms	O
were	O
noted	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B-Disease
in	O
PD	B-Disease
.	O

Intracavernous	O
epinephrine	B-Chemical
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	B-Disease
in	O
the	O
emergency	O
department	O
.	O

Priapism	B-Disease
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O

A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	B-Chemical
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B-Disease
after	O
cocaine	B-Chemical
use	O
.	O

The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	B-Chemical
instillation	O
,	O
are	O
discussed	O
.	O

Prophylactic	O
use	O
of	O
lamivudine	B-Chemical
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	B-Disease
disorders	I-Disease
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBs	B-Chemical
Ag	I-Chemical
)	O
positive	O
patients	O
with	O
rheumatologic	B-Disease
disease	I-Disease
.	O

From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	B-Chemical
Ag	I-Chemical
positive	O
patients	O
with	O
rheumatologic	B-Disease
diseases	I-Disease
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	B-Chemical
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O

Liver	O
function	O
tests	O
,	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O

Lamivudine	B-Chemical
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O

Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	B-Disease
liver	I-Disease
function	I-Disease
tests	O
.	O

Lamivudine	B-Chemical
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O

Prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O

Effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
combination	O
in	O
isoproterenol	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca	B-Chemical
+	O
2	O
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPase	O
and	O
Mg	B-Chemical
+	O
2	O
ATPase	O
levels	O
.	O

Administration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
vitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca	B-Chemical
+	O
2	O
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPase	O
and	O
Mg	B-Chemical
+	O
2	O
ATPase	O
when	O
compared	O
with	O
ISO	B-Chemical
treated	O
group	O
and	O
green	B-Chemical
tea	I-Chemical
or	O
vitamin	B-Chemical
E	I-Chemical
alone	O
treated	O
groups	O
.	O

These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	B-Disease
in	O
F344	O
rats	O
.	O

Renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
(	O
RPN	B-Disease
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long	O
-	O
term	O
treatment	O
with	O
aspirin	B-Chemical
and	O
paracetamol	B-Chemical
in	O
female	O
Fischer	O
344	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B-Disease
.	O

Testosterone	B-Chemical
-	O
dependent	O
hypertension	B-Disease
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	B-Chemical
-	O
sensitive	O
rats	O
.	O

Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	B-Chemical
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O

In	O
Dahl	O
salt	B-Chemical
-	O
sensitive	O
rats	O
(	O
DS	O
)	O
,	O
high	O
-	O
salt	B-Chemical
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O

In	O
contrast	O
to	O
the	O
systemic	O
renin	O
-	O
angiotensin	B-Chemical
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	B-Chemical
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-Disease
injury	I-Disease
.	O

On	O
a	O
low	O
-	O
salt	B-Chemical
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O

Testosterone	B-Chemical
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B-Disease
injury	I-Disease
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O

Testosterone	B-Chemical
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	B-Chemical
system	O
.	O

Explicit	O
episodic	O
memory	O
for	O
sensory	O
-	O
discriminative	O
components	O
of	O
capsaicin	B-Chemical
-	O
induced	O
pain	B-Disease
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O

Pain	B-Disease
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	B-Disease
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	B-Disease
conditions	O
.	O

Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	B-Disease
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
pain	B-Disease
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	B-Chemical
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O

Pain	B-Disease
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O

Subjects	O
also	O
recalled	O
their	O
pains	B-Disease
one	O
week	O
later	O
.	O

Capsaicin	B-Chemical
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

The	O
strong	O
burning	O
pain	B-Disease
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O

Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B-Disease
magnitude	O
and	O
duration	O
across	O
capsaicin	B-Chemical
doses	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pain	B-Disease
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
duration	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-Disease
.	O

Severe	O
and	O
long	O
lasting	O
cholestasis	B-Disease
after	O
high	O
-	O
dose	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
Pneumocystis	B-Disease
pneumonia	I-Disease
in	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
-	O
-	O
a	O
report	O
of	O
two	O
cases	O
.	O

Pneumocystis	B-Disease
pneumonia	I-Disease
(	O
PCP	B-Disease
)	O
,	O
a	O
common	O
opportunistic	B-Disease
infection	I-Disease
in	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
who	O
developed	O
severe	O
intrahepatic	B-Disease
cholestasis	I-Disease
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-Disease
abscess	I-Disease
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
PCP	B-Disease
.	O

Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O

Bradykinin	B-Chemical
receptors	O
antagonists	O
and	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
inhibitors	O
in	O
vincristine	B-Chemical
and	O
streptozotocin	B-Chemical
induced	O
hyperalgesia	B-Disease
in	O
chemotherapy	O
and	O
diabetic	B-Disease
neuropathy	I-Disease
rat	O
model	O
.	O

PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	B-Chemical
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	B-Chemical
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	B-Chemical
synthase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hyp3	O
,	O
Thi5	O
,	O
D	O
-	O
Tic7	O
,	O
Oic8	O
]	O
bradykinin	B-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-Disease
(	I-Disease
streptozotocin	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
and	I-Disease
toxic	I-Disease
(	I-Disease
vincristine	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
neuropathy	I-Disease
was	O
investigated	O
.	O

METHODS	O
:	O
The	O
changes	O
in	O
pain	B-Disease
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
-	O
-	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O

RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	B-Chemical
receptors	O
and	O
inducible	O
NO	B-Chemical
synthase	O
but	O
not	O
neuronal	O
NO	B-Chemical
synthase	O
activity	O
reduces	O
diabetic	B-Disease
hyperalgesia	I-Disease
.	O

Pretreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	B-Chemical
140	I-Chemical
and	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	B-Chemical
synthase	O
and	O
neuronal	O
NO	B-Chemical
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	B-Chemical
are	O
involved	O
in	O
hyperalgesia	B-Disease
produced	O
by	O
vincristine	B-Chemical
.	O

Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	B-Chemical
140	I-Chemical
or	O
des	B-Chemical
-	I-Chemical
Arg10HOE	I-Chemical
140	I-Chemical
in	O
toxic	B-Disease
neuropathy	I-Disease
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Disease
and	I-Disease
toxic	I-Disease
neuropathy	I-Disease
.	O

In	O
streptozotocin	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
,	O
inducible	O
NO	B-Chemical
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	B-Chemical
,	O
whereas	O
in	O
vincristine	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
bradykinin	B-Chemical
seemed	O
to	O
activate	O
neuronal	O
NO	B-Chemical
synthase	O
pathway	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-Chemical
receptor	O
antagonists	O
and	O
NO	B-Chemical
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
,	O
even	O
in	O
hospital	O
care	O
.	O

Confusion	B-Disease
,	O
a	O
rather	O
serious	O
adverse	O
drug	O
reaction	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O

INTRODUCTION	O
:	O
Confusion	B-Disease
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

METHODS	O
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	B-Disease
reported	O
since	O
1985	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B-Disease
were	O
reported	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
153	O
women	O
and	O
119	O
men	O
.	O

Confusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Chemical
acid	I-Chemical
exposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B-Disease
with	O
valproic	B-Chemical
acid	I-Chemical
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	O
drug	O
reaction	O
.	O

Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesion	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazole	B-Chemical
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-Disease
in	O
various	O
organs	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-Chemical
administration	O
.	O

All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B-Disease
lesion	I-Disease
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O

Clinically	O
significant	O
proteinuria	B-Disease
following	O
the	O
administration	O
of	O
sirolimus	B-Chemical
to	O
renal	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B-Disease
than	O
calcineurin	O
inhibitor	O
(	O
CNI	O
)	O
-	O
based	O
regimens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	B-Disease
linked	O
with	O
the	O
use	O
of	O
sirolimus	B-Chemical
.	O

We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	B-Disease
associated	O
with	O
sirolimus	B-Chemical
use	O
.	O

In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	B-Chemical
therapy	O
and	O
proteinuria	B-Disease
implicated	O
sirolimus	B-Chemical
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	B-Disease
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	B-Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O

In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	B-Disease
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	B-Chemical
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	B-Disease
/	O
day	O
.	O

Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	B-Chemical
use	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
eight	O
patients	O
(	O
24	O
%	O
)	O
developed	O
increased	O
proteinuria	B-Disease
from	O
baseline	O
during	O
their	O
post	O
-	O
transplantation	O
course	O
.	O

In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	B-Disease
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	B-Chemical
and	O
the	O
development	O
of	O
nephrotic	B-Disease
-	O
range	O
proteinuria	B-Disease
.	O

Proteinuria	B-Disease
correlated	O
most	O
strongly	O
with	O
sirolimus	B-Chemical
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-Chemical
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-Disease
.	O

CONCLUSIONS	O
:	O
Sirolimus	B-Chemical
induces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuria	B-Disease
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O

Proteinuria	B-Disease
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	B-Chemical
is	O
withdrawn	O
.	O

Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
.	O

The	O
anti	O
-	O
dementia	B-Disease
effects	O
of	O
s	B-Chemical
-	I-Chemical
limonene	I-Chemical
and	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O

These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	B-Disease
impaired	I-Disease
by	O
scopolamine	B-Chemical
;	O
however	O
,	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
relieved	O
the	O
deficit	B-Disease
of	I-Disease
associative	I-Disease
memory	I-Disease
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non	O
-	O
associative	O
memory	O
significantly	O
in	O
OFH	O
.	O

Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	B-Chemical
concentration	O
of	O
the	O
vehicle	O
/	O
scopolamine	B-Chemical
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle	O
/	O
vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s	B-Chemical
-	I-Chemical
limonene	I-Chemical
or	O
s	B-Chemical
-	I-Chemical
perillyl	I-Chemical
alcohol	I-Chemical
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	B-Chemical
.	O

Attentional	O
modulation	O
of	O
perceived	O
pain	B-Disease
intensity	O
in	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
.	O

Perceived	O
pain	B-Disease
intensity	O
is	O
modulated	O
by	O
attention	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B-Disease
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
.	O

Here	O
we	O
show	O
that	O
perceived	O
pain	B-Disease
intensity	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	B-Chemical
-	O
untreated	O
,	O
control	O
condition	O
.	O

Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	B-Chemical
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	B-Chemical
-	O
induced	O
secondary	O
hyperalgesia	B-Disease
and	O
attention	O
might	O
affect	O
mechanical	O
pain	B-Disease
through	O
independent	O
mechanisms	O
.	O

Cardioprotective	O
effect	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Isoproterenol	B-Chemical
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	B-Chemical
dehydrogenase	O
,	O
aspartate	B-Chemical
transaminase	O
,	O
creatine	B-Chemical
kinase	O
and	O
malondialdehyde	B-Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-Chemical
dismutase	O
,	O
catalase	O
and	O
glutathione	B-Chemical
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O

In	O
addition	O
,	O
mitochondrial	O
respiratory	B-Disease
dysfunction	I-Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	O
.	O

Administration	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
myocardial	B-Disease
injury	I-Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O

The	O
protective	O
role	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
.	O

Long	O
-	O
term	O
glutamate	B-Chemical
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
paclitaxel	B-Chemical
.	O

Toxic	O
peripheral	B-Disease
neuropathy	I-Disease
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	B-Chemical
(	O
PAC	B-Chemical
)	O
,	O
although	O
glutamate	B-Chemical
and	O
its	O
closely	O
related	O
amino	B-Chemical
acid	I-Chemical
glutamine	B-Chemical
were	O
claimed	O
to	O
ameliorate	O
PAC	B-Chemical
neurotoxicity	B-Disease
.	O

This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	B-Chemical
supplementation	O
for	O
preventing	O
PAC	B-Chemical
-	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O

Forty	O
-	O
three	O
ovarian	B-Disease
cancer	I-Disease
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	B-Chemical
-	O
containing	O
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	B-Chemical
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	B-Disease
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	B-Disease
sensation	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	B-Chemical
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
PAC	B-Chemical
.	O

Development	O
of	O
ocular	B-Disease
myasthenia	I-Disease
during	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
treatment	O
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O

A	O
63	O
-	O
year	O
-	O
old	O
male	O
experienced	O
sudden	O
diplopia	B-Disease
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	B-Chemical
interferon	I-Chemical
(	I-Chemical
IFN	I-Chemical
)	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O

Ophthalmologic	O
examinations	O
showed	O
ptosis	B-Disease
on	I-Disease
the	I-Disease
right	I-Disease
upper	I-Disease
lid	I-Disease
and	O
restricted	B-Disease
right	I-Disease
eye	I-Disease
movement	I-Disease
without	O
any	O
other	O
neurological	O
signs	O
.	O

The	O
acetylcholine	B-Chemical
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal	O
.	O

The	O
patient	O
'	O
s	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
.	O

The	O
ocular	B-Disease
myasthenia	I-Disease
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
CHC	B-Disease
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	B-Chemical
therapy	O
.	O

Learning	B-Disease
and	I-Disease
memory	I-Disease
deficits	I-Disease
in	O
ecstasy	B-Chemical
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-Chemical
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	B-Chemical
use	O
of	O
the	O
ecstasy	B-Chemical
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	B-Chemical
users	O
(	O
Nestor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Deficits	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
:	O
parahippocampal	O
hyperactivity	B-Disease
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	B-Chemical
users	O
.	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecstasy	B-Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-Chemical
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-Chemical
-	O
specific	O
hyperactivity	B-Disease
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy	B-Chemical
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy	B-Chemical
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O

These	O
ecstasy	B-Chemical
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-Disease
effects	O
of	O
ecstasy	B-Chemical
.	O

Disulfiram	B-Chemical
-	O
like	O
syndrome	O
after	O
hydrogen	B-Chemical
cyanamide	I-Chemical
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O

Hydrogen	B-Chemical
cyanamide	I-Chemical
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O

Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	B-Chemical
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	B-Chemical
syndrome	O
in	O
case	O
of	O
alcohol	B-Chemical
use	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	B-Chemical
-	O
like	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	B-Chemical
cyanamide	I-Chemical
.	O

The	O
first	O
case	O
involved	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
who	O
used	O
Dormex	B-Chemical
,	O
which	O
contains	O
hydrogen	B-Chemical
cyanamide	I-Chemical
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	B-Chemical
during	O
a	O
meal	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	B-Chemical
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-Disease
of	I-Disease
the	I-Disease
face	I-Disease
,	O
tachycardia	B-Disease
,	O
and	O
dyspnea	B-Disease
.	O

The	O
second	O
case	O
occurred	O
in	O
a	O
55	O
-	O
year	O
-	O
old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	B-Chemical
.	O

Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram	B-Chemical
-	O
like	O
syndrome	O
with	O
flushing	B-Disease
,	O
tachycardia	B-Disease
,	O
and	O
arterial	B-Disease
hypotension	I-Disease
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O

These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	B-Chemical
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	B-Chemical
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O

Sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dystonia	I-Disease
.	O

Sulpiride	B-Chemical
is	O
a	O
selective	O
D2	O
-	O
receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	B-Chemical
properties	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dyskinesia	I-Disease
and	O
parkinsonism	B-Disease
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B-Disease
within	O
2	O
months	O
after	O
starting	O
sulpiride	B-Chemical
therapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dystonia	I-Disease
.	O

Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
in	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B-Disease
.	O

Seventy	O
-	O
one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10	O
-	O
mg	O
oxycodone	B-Chemical
)	O
.	O

Plasma	O
oxycodone	B-Chemical
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
pupil	O
size	O
,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Significant	O
declines	B-Disease
in	I-Disease
simple	I-Disease
and	I-Disease
sustained	I-Disease
attention	I-Disease
,	I-Disease
working	I-Disease
memory	I-Disease
,	I-Disease
and	I-Disease
verbal	I-Disease
memory	I-Disease
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O

This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	B-Disease
pain	I-Disease
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-Chemical
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aged	O
adults	O
.	O

PERSPECTIVE	O
:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	B-Chemical
are	O
similar	O
for	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

The	O
glycine	B-Chemical
transporter	O
-	O
1	O
inhibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O

Schizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-Chemical
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-Chemical
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
produce	O
schizophrenic	B-Disease
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	B-Chemical
receptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	B-Chemical
receptor	O
.	O

Among	O
them	O
are	O
glycine	B-Chemical
transporter	O
-	O
1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
indirectly	O
enhance	O
NMDA	B-Chemical
receptor	O
function	O
by	O
increasing	O
the	O
glycine	B-Chemical
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	B-Chemical
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocked	O
hyperactivity	B-Disease
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	B-Chemical
receptor	O
antagonist	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-Disease
of	O
NMDA	B-Chemical
Nr1	O
(	O
neo	O
-	O
/	O
-	O
)	O
mice	O
.	O

In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperactivity	B-Disease
induced	O
by	O
amphetamine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopamine	B-Chemical
transporter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-Chemical
)	O
and	O
atypical	O
(	O
olanzapine	B-Chemical
,	O
clozapine	B-Chemical
and	O
aripiprazole	B-Chemical
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-Disease
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
catalepsy	B-Disease
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O

Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	B-Chemical
status	B-Disease
epilepticus	I-Disease
model	O
.	O

Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa	O
-	O
beta	O
.	O

Both	O
,	O
production	O
of	O
reactive	O
oxygen	B-Chemical
species	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B-Disease
damage	I-Disease
in	O
different	O
sub	O
-	O
regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O

The	O
effect	O
of	O
PDTC	B-Chemical
on	O
status	B-Disease
epilepticus	I-Disease
-	O
associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	B-Chemical
model	O
.	O

Treatment	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	B-Chemical
before	O
and	O
following	O
status	B-Disease
epilepticus	I-Disease
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100	O
%	O
.	O

Administration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	B-Chemical
(	O
low	O
-	O
dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	B-Disease
epilepticus	I-Disease
or	O
the	O
mortality	O
rate	O
.	O

In	O
vehicle	O
-	O
treated	O
rats	O
,	O
status	B-Disease
epilepticus	I-Disease
caused	O
pronounced	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O

Low	O
-	O
dose	O
PDTC	B-Chemical
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O

A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle	O
-	O
and	O
PDTC	B-Chemical
-	O
treated	O
rats	O
following	O
status	B-Disease
epilepticus	I-Disease
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	B-Chemical
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	B-Disease
loss	I-Disease
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-Disease
-	O
associated	O
neuronal	B-Disease
damage	I-Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	B-Chemical
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O

Anaesthetists	O
'	O
nightmare	O
:	O
masseter	B-Disease
spasm	I-Disease
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
.	O

We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
in	O
a	O
24	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	B-Disease
spasm	I-Disease
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	B-Chemical
for	O
induction	O
of	O
anaesthesia	O
.	O

Twin	O
preterm	O
neonates	O
with	O
cardiac	B-Disease
toxicity	I-Disease
related	O
to	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
therapy	O
.	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
infection	I-Disease
.	O

One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-Disease
block	I-Disease
and	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B-Disease
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
in	O
the	O
immediate	O
neonatal	O
period	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
heart	O
transplantation	O
,	O
life	O
-	O
threatening	O
acute	O
right	B-Disease
heart	I-Disease
failure	I-Disease
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O

Increasing	O
doses	O
of	O
catecholamines	B-Chemical
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O

However	O
,	O
a	O
bolus	O
of	O
epinephrine	B-Chemical
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	B-Disease
crisis	O
.	O

The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	B-Chemical
doses	O
.	O

Less	O
frequent	O
lithium	B-Chemical
administration	O
and	O
lower	O
urine	O
volume	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	B-Chemical
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	B-Chemical
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O

Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	B-Chemical
level	O
,	O
creatinine	B-Chemical
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O

RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	B-Chemical
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O

The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	B-Chemical
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	B-Chemical
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	B-Chemical
clearance	O
.	O

CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	B-Chemical
once	O
daily	O
and	O
/	O
or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O

Lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O

Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B-Disease
defects	I-Disease
:	O
National	O
Birth	B-Disease
Defects	I-Disease
Prevention	O
Study	O
.	O

OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population	O
-	O
based	O
,	O
multisite	O
,	O
case	O
-	O
control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B-Disease
defects	I-Disease
identified	O
via	O
birth	B-Disease
defect	I-Disease
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
adjusted	O
for	O
potential	O
confounders	O
.	O

Sulfonamides	B-Chemical
were	O
associated	O
with	O
anencephaly	B-Disease
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	I-Disease
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
choanal	B-Disease
atresia	I-Disease
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
transverse	B-Disease
limb	I-Disease
deficiency	I-Disease
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diaphragmatic	B-Disease
hernia	I-Disease
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitrofurantoins	B-Chemical
were	O
associated	O
with	O
anophthalmia	B-Disease
or	O
microphthalmos	B-Disease
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atrial	B-Disease
septal	I-Disease
defects	I-Disease
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
cleft	B-Disease
lip	I-Disease
with	O
cleft	B-Disease
palate	I-Disease
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	B-Chemical
(	O
2	O
defects	O
)	O
,	O
penicillins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	B-Chemical
(	O
1	O
defect	O
)	O
.	O

CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	B-Chemical
,	O
erythromycins	B-Chemical
,	O
and	O
cephalosporins	B-Chemical
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-Disease
defects	I-Disease
.	O

Sulfonamides	B-Chemical
and	O
nitrofurantoins	B-Chemical
were	O
associated	O
with	O
several	O
birth	B-Disease
defects	I-Disease
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HBeAg	B-Chemical
negativity	O
.	O

Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positive	O
and	O
an	O
HBeAg	B-Chemical
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	B-Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-Chemical
resistance	O
mutations	O
,	O
the	O
nucleotide	B-Chemical
analogues	O
adefovir	B-Chemical
and	O
tenofovir	B-Chemical
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O

Hemolytic	B-Disease
anemia	I-Disease
associated	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
.	O

Omeprazole	B-Chemical
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B-Disease
ulcer	I-Disease
disease	I-Disease
,	O
reflux	B-Disease
esophagitis	I-Disease
,	O
and	O
the	O
Zollinger	B-Disease
-	I-Disease
Ellison	I-Disease
syndrome	I-Disease
.	O

Although	O
clinical	O
experience	O
with	O
omeprazole	B-Chemical
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short	O
-	O
term	O
safety	O
of	O
this	O
drug	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short	O
-	O
term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
:	O
hemolytic	B-Disease
anemia	I-Disease
.	O

The	O
patient	O
developed	O
weakness	O
,	O
lethargy	B-Disease
,	O
and	O
shortness	B-Disease
of	I-Disease
breath	I-Disease
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	B-Chemical
.	O

Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	B-Chemical
.	O

After	O
she	O
discontinued	O
the	O
omeprazole	B-Chemical
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O

The	O
mechanism	O
by	O
which	O
omeprazole	B-Chemical
caused	O
the	O
patient	O
'	O
s	O
hemolytic	B-Disease
anemia	I-Disease
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O

Phenylephrine	B-Chemical
but	O
not	O
ephedrine	B-Chemical
reduces	B-Disease
frontal	I-Disease
lobe	I-Disease
oxygenation	I-Disease
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	B-Chemical
and	O
ephedrine	B-Chemical
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-Disease
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	B-Chemical
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	B-Chemical
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	B-Chemical
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B-Disease
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	B-Disease
decrease	I-Disease
in	I-Disease
MAP	I-Disease
,	I-Disease
HR	I-Disease
,	I-Disease
SV	I-Disease
,	I-Disease
and	I-Disease
CO	I-Disease
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	B-Chemical
,	O
MAP	O
increased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

The	O
administration	O
of	O
ephedrine	B-Chemical
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	B-Chemical
to	O
correct	O
hypotension	B-Disease
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	B-Chemical
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	B-Chemical
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
.	O

BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
or	O
HIT	B-Disease
with	O
thrombosis	B-Disease
(	O
HITT	B-Disease
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
report	O
,	O
a	O
65	O
-	O
year	O
-	O
old	O
critically	B-Disease
ill	I-Disease
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	B-Disease
was	O
administered	O
argatroban	B-Chemical
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O

The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B-Disease
and	I-Disease
postoperative	I-Disease
bleeding	I-Disease
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	B-Chemical
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	B-Chemical
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	B-Chemical
half	O
life	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	B-Disease
impairment	I-Disease
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	B-Chemical
concentration	O
versus	O
the	O
patient	O
'	O
s	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	B-Chemical
may	O
have	O
contributed	O
to	O
the	O
patient	O
'	O
s	O
extended	O
coagulopathy	B-Disease
.	O

This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	B-Chemical
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	B-Disease
.	O

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	B-Chemical
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
and	O
randomized	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	B-Chemical
sustained	O
-	O
release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
(	O
SD	B-Disease
)	O
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
(	O
SSRI	B-Chemical
)	O
,	O
as	O
SD	B-Disease
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
SSRIs	B-Chemical
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	B-Chemical
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-Chemical
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Sexual	O
Function	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-Disease
Dysfunction	I-Disease
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	B-Chemical
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
bupropion	B-Chemical
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
men	O
who	O
received	O
bupropion	B-Chemical
than	O
placebo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EDITS	O
scores	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bupropion	B-Chemical
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
linear	O
regression	O
analyses	O
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	B-Disease
,	O
type	O
of	O
SSRI	B-Chemical
used	O
and	O
age	O
.	O

CONCLUSIONS	O
:	O
Bupropion	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	B-Disease
induced	O
by	O
SSRIs	B-Chemical
.	O

These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	B-Chemical
.	O

Prevention	O
of	O
seizures	B-Disease
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
.	O

BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

Spontaneous	B-Disease
recurrent	I-Disease
seizures	I-Disease
(	O
SRS	B-Disease
)	O
were	O
monitored	O
using	O
Racine	O
'	O
s	O
seizure	B-Disease
severity	O
scale	O
.	O

All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	B-Disease
control	O
group	O
developed	O
SRS	B-Disease
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	B-Disease
control	O
group	O
.	O

At	O
hippocampal	O
Schaeffer	O
collateral	O
-	O
CA1	O
synapses	O
,	O
long	O
-	O
term	O
potentiation	O
was	O
preserved	O
in	O
BMC	O
-	O
transplanted	O
rats	O
compared	O
to	O
epileptic	B-Disease
controls	O
.	O

The	O
donor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	B-Disease
rats	O
.	O

In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	B-Disease
,	O
reduce	O
neuronal	B-Disease
loss	I-Disease
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	B-Chemical
on	O
sleep	O
and	O
daytime	B-Disease
sleepiness	I-Disease
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

METHOD	O
:	O
Twenty	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-Chemical
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
placebo	O
(	O
N	O
=	O
10	O
)	O
every	O
morning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O

RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O

Compared	O
with	O
placebo	O
,	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O

The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O

Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	B-Chemical
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-Chemical
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O

Modafinil	B-Chemical
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Disease
sleepiness	I-Disease
.	O

CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	B-Chemical
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-Disease
sleepiness	I-Disease
in	O
abstinent	O
cocaine	B-Chemical
users	O
.	O

These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O

OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	B-Chemical
(	O
MZ	B-Chemical
)	O
and	O
Flumazenil	B-Chemical
(	O
FL	B-Chemical
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O

METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	B-Chemical
associated	O
to	O
moderate	O
sedation	O
.	O

We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia	O
,	O
with	O
MZ	B-Chemical
use	O
and	O
with	O
the	O
procedure	O
.	O

Uni	O
-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B-Disease
,	O
myocardiopathy	B-Disease
(	O
MP	B-Disease
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-Disease
regurgitation	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	B-Chemical
dose	O
.	O

The	O
mean	O
doses	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

Mild	O
hypoxia	B-Disease
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2	O
%	O
)	O
presented	O
transient	O
hypoxia	B-Disease
due	O
to	O
upper	O
airway	B-Disease
obstruction	I-Disease
by	O
probe	O
introduction	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
hypoxia	B-Disease
caused	O
by	O
MZ	B-Chemical
use	O
.	O

Transient	O
hypotension	B-Disease
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	B-Disease
,	O
MP	B-Disease
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	O
with	O
MP	B-Disease
and	O
44	O
%	O
in	O
the	O
group	O
with	O
severe	O
MR	B-Disease
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O

Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
in	O
patients	O
with	O
and	O
without	O
variant	B-Disease
angina	I-Disease
.	O

The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
and	O
22	O
patients	O
with	O
atypical	O
chest	B-Disease
pain	I-Disease
and	O
in	O
others	O
without	O
angina	B-Disease
pectoris	I-Disease
(	O
control	O
group	O
)	O
.	O

Methylergonovine	B-Chemical
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O

In	O
all	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
,	O
coronary	B-Disease
spasm	I-Disease
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+	O
/	O
-	O
13	O
micrograms	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	B-Disease
occurred	O
.	O

These	O
results	O
suggest	O
that	O
spasm	B-Disease
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	B-Chemical
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B-Disease
angina	I-Disease
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O

Oral	O
manifestations	O
of	O
"	O
meth	B-Disease
mouth	I-Disease
"	O
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	B-Disease
mouth	I-Disease
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

BACKGROUND	O
:	O
Methamphetamine	B-Chemical
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B-Disease
dysrhythmias	I-Disease
,	O
hypertension	B-Disease
,	O
hallucinations	B-Disease
,	O
and	O
violent	B-Disease
behavior	I-Disease
.	O

Dental	O
patients	O
abusing	O
methamphetamine	B-Chemical
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	B-Disease
,	O
rampant	O
caries	B-Disease
(	O
"	O
meth	B-Disease
mouth	I-Disease
"	O
)	O
,	O
and	O
excessive	O
tooth	B-Disease
wear	I-Disease
.	O

Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	B-Chemical
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	B-Disease
,	O
bad	B-Disease
breath	I-Disease
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O

A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B-Disease
lesions	I-Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O

She	O
reported	O
her	O
use	O
of	O
methamphetamine	B-Chemical
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B-Disease
episodes	I-Disease
before	O
she	O
started	O
using	O
the	O
drug	O
.	O

SUMMARY	O
:	O
The	O
patient	O
'	O
s	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
"	O
meth	B-Disease
mouth	I-Disease
.	O
"	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(	O
either	O
conventional	O
or	O
implant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007	O
,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment	O
.	O

CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	B-Disease
mouth	I-Disease
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	B-Chemical
.	O

Antituberculosis	B-Chemical
therapy	O
-	O
induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O

Antituberculosis	B-Chemical
therapy	O
(	O
ATT	O
)	O
-	O
associated	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ATT	O
-	O
ALF	B-Disease
)	O
is	O
the	O
commonest	O
drug	O
-	O
induced	O
ALF	B-Disease
in	O
South	O
Asia	O
.	O

Prospective	O
studies	O
on	O
ATT	O
-	O
ALF	B-Disease
are	O
lacking	O
.	O

The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	B-Disease
.	O

From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	B-Disease
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
patients	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-Disease
virus	I-Disease
infection	I-Disease
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	B-Disease
.	O

ATT	O
-	O
ALF	B-Disease
patients	O
were	O
younger	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	O
.	O

Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	B-Disease
encephalopathy	B-Disease
interval	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
days	O
.	O

The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O

At	O
presentation	O
,	O
advanced	O
encephalopathy	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Gastrointestinal	B-Disease
bleed	I-Disease
,	O
seizures	B-Disease
,	O
infection	B-Disease
,	O
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Compared	O
with	O
hepatitis	B-Disease
E	I-Disease
virus	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
induced	O
ALF	B-Disease
,	O
ATT	O
-	O
ALF	B-Disease
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	B-Disease
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O

In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	B-Chemical
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
grade	O
III	O
/	O
IV	O
encephalopathy	B-Disease
at	O
presentation	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O

Design	O
and	O
analysis	O
of	O
the	O
HYPREN	O
-	O
trial	O
:	O
safety	O
of	O
enalapril	B-Chemical
and	O
prazosin	B-Chemical
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O

Since	O
the	O
introduction	O
of	O
angiotensin	B-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
cases	O
of	O
severe	O
hypotension	B-Disease
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	B-Chemical
inhibitor	I-Chemical
enalapril	B-Chemical
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin	B-Chemical
-	O
controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	B-Disease
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O

Trial	O
medication	O
was	O
2	O
.	O
5	O
mg	O
enalapril	B-Chemical
or	O
0	O
.	O
5	O
prazosin	B-Chemical
.	O

Patients	O
who	O
received	O
enalapril	B-Chemical
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B-Disease
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	B-Chemical
(	O
12	O
.	O
9	O
%	O
)	O
.	O

It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	B-Chemical
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-Chemical
to	O
inpatients	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
in	O
a	O
single	O
pediatric	O
institution	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
childhood	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O

This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B-Disease
complications	I-Disease
during	O
ALL	B-Disease
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O

Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B-Disease
infiltration	I-Disease
at	O
diagnosis	O
,	O
therapy	O
-	O
related	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
late	O
-	O
onset	O
encephalopathy	B-Disease
,	O
or	O
long	O
-	O
term	O
neurocognitive	B-Disease
defects	I-Disease
.	O

During	O
a	O
9	O
-	O
year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	B-Disease
front	O
-	O
line	O
protocol	O
.	O

CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	B-Disease
syndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-Disease
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dose	O
methotrexate	B-Chemical
toxicity	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	B-Disease
antidiuretic	I-Disease
hormone	I-Disease
secretion	I-Disease
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	B-Disease
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O

Cocaine	B-Chemical
causes	O
memory	B-Disease
and	I-Disease
learning	I-Disease
impairments	I-Disease
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	B-Chemical
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-Chemical
toxicity	B-Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-Chemical
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B-Disease
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-Chemical
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Disease
addiction	I-Disease
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
administration	O
in	O
rats	O
.	O

NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-Chemical
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	B-Chemical
concentration	O
and	O
glutathione	B-Chemical
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-Chemical
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-Chemical
.	O

Topiramate	B-Chemical
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O

Efficacy	O
and	O
safety	O
of	O
asenapine	B-Chemical
in	O
a	O
placebo	O
-	O
and	O
haloperidol	B-Chemical
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-Disease
.	O

Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-Disease
or	O
of	O
manic	B-Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
with	O
or	O
without	O
psychotic	B-Disease
features	O
.	O

In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O

With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
15	O
.	O
4	O
)	O
than	O
placebo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Extrapyramidal	B-Disease
symptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O

Salvage	O
therapy	O
with	O
nelarabine	B-Chemical
,	O
etoposide	B-Chemical
,	O
and	O
cyclophosphamide	B-Chemical
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
and	I-Disease
lymphoma	I-Disease
.	O

A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
or	I-Disease
lymphoma	I-Disease
.	O

The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	B-Chemical
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B-Disease
and	O
musculoskeletal	B-Disease
pain	I-Disease
.	O

Haematological	B-Disease
toxicity	I-Disease
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	B-Chemical
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O

All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O

Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	B-Chemical
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-Chemical
and	O
cyclophosphamide	B-Chemical
,	O
although	O
neurological	B-Disease
toxicity	I-Disease
must	O
be	O
closely	O
monitored	O
.	O

Effect	O
of	O
adriamycin	B-Chemical
combined	O
with	O
whole	O
body	O
hyperthermia	B-Disease
on	O
tumor	B-Disease
and	O
normal	O
tissues	O
.	O

Thermal	O
enhancement	O
of	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B-Disease
by	O
whole	O
body	O
hyperthermia	B-Disease
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	B-Disease
growth	O
delay	O
assay	O
.	O

Acute	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
leukopenia	B-Disease
and	O
thrombocytopenia	B-Disease
)	O
and	O
late	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i	O
.	O
e	O
.	O
,	O
myocardial	B-Disease
and	I-Disease
kidney	I-Disease
injury	I-Disease
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O

Whole	O
body	O
hyperthermia	B-Disease
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O

Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
"	O
acute	O
"	O
hematological	O
changes	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimated	O
for	O
"	O
late	O
"	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	B-Disease
and	I-Disease
renal	I-Disease
lesions	I-Disease
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	B-Disease
enhances	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	B-Disease
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O

Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-Disease
starts	O
.	O

Using	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-Disease
,	O
appeared	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

CONCLUSIONS	O
:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-Disease
.	O

A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive	B-Disease
-	I-Disease
compulsive	I-Disease
-	I-Disease
like	I-Disease
behaviors	I-Disease
in	O
animals	O
.	O

BACKGROUND	O
:	O
Current	O
animal	O
models	O
of	O
obsessive	B-Disease
-	I-Disease
compulsive	I-Disease
disorder	I-Disease
(	O
OCD	B-Disease
)	O
typically	O
involve	O
acute	O
,	O
drug	O
-	O
induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	B-Disease
.	O

None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	B-Disease
-	O
like	O
behaviors	O
.	O

METHODS	O
:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	B-Chemical
clomipramine	B-Chemical
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O

RESULTS	O
:	O
Clomipramine	B-Chemical
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	B-Disease
(	O
elevated	O
plus	O
maze	O
and	O
marble	O
burying	O
)	O
,	O
behavioral	B-Disease
inflexibility	I-Disease
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B-Disease
impairment	I-Disease
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
paradigm	O
)	O
,	O
hoarding	B-Disease
,	O
and	O
corticostriatal	B-Disease
dysfunction	I-Disease
.	O

Dopamine	B-Chemical
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	B-Chemical
2C	O
,	O
but	O
not	O
serotonin	B-Chemical
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	B-Disease
-	O
like	O
profile	O
in	O
animals	O
.	O

Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	B-Disease
.	O

This	O
novel	O
model	O
of	O
OCD	B-Disease
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	O
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-Disease
disorders	I-Disease
.	O

Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	B-Chemical
-	O
induced	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
in	O
a	O
rat	O
model	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calcium	B-Chemical
chloride	I-Chemical
(	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
induced	O
arterial	B-Disease
injury	I-Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-Disease
formation	O
.	O

METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
normal	O
saline	O
(	O
NaCl	B-Chemical
)	O
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	B-Chemical
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
non	O
-	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
and	O
NaCl	B-Chemical
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	B-Chemical
-	O
treated	O
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O

CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-Disease
model	O
by	O
periarterial	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O

Suxamethonium	B-Chemical
induced	O
prolonged	O
apnea	B-Disease
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O

Suxamethonium	B-Chemical
causes	O
prolonged	O
apnea	B-Disease
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	B-Chemical
(	I-Chemical
OP	I-Chemical
)	I-Chemical
poisons	I-Chemical
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	B-Disease
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Prolonged	O
apnea	B-Disease
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	B-Chemical
compound	I-Chemical
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

Curcumin	B-Chemical
ameliorates	O
cognitive	B-Disease
dysfunction	I-Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
administered	O
rats	O
.	O

The	O
antiepileptic	O
drugs	O
,	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Disease
impairment	I-Disease
on	O
chronic	O
use	O
.	O

The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Disease
impairment	I-Disease
by	O
antiepileptic	O
drugs	O
.	O

Curcumin	B-Chemical
has	O
shown	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
neuro	O
-	O
protective	O
properties	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-Chemical
administration	O
on	O
phenobarbitone	B-Chemical
-	O
and	O
carbamazepine	B-Chemical
-	O
induced	O
cognitive	B-Disease
impairment	I-Disease
and	O
oxidative	O
stress	O
in	O
rats	O
.	O

Pharmacokinetic	O
interactions	O
of	O
curcumin	B-Chemical
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
were	O
also	O
studied	O
.	O

At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
,	O
whole	O
brain	O
malondialdehyde	B-Chemical
and	O
reduced	O
glutathione	B-Chemical
levels	O
were	O
estimated	O
.	O

The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O

Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O

Curcumin	B-Chemical
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-Chemical
as	O
well	O
as	O
carbamazepine	B-Chemical
.	O

These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Disease
of	I-Disease
cognitive	I-Disease
functions	I-Disease
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O

The	O
findings	O
suggest	O
that	O
curcumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
therapy	O
in	O
preventing	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
these	O
drugs	O
.	O

Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	B-Chemical
associated	O
hemolytic	B-Disease
anemia	I-Disease
?	O

BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirin	B-Chemical
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	B-Chemical
and	O
sorafenib	B-Chemical
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	B-Disease
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	B-Disease
.	O

METHODS	O
:	O
Fourteen	O
patients	O
chronically	B-Disease
infected	I-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
were	O
treated	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
alpha	I-Chemical
2a	I-Chemical
and	O
ribavirin	B-Chemical
.	O

In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
therapy	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	B-Chemical
induced	O
anemia	B-Disease
in	O
patients	O
with	O
hepatitis	B-Disease
C	I-Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	B-Chemical
therapy	O
.	O

Reduction	O
in	O
injection	O
pain	B-Disease
using	O
buffered	O
lidocaine	B-Chemical
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	B-Disease
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	B-Chemical
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B-Disease
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O

Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	B-Disease
after	O
receiving	O
standard	O
lidocaine	B-Chemical
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	B-Chemical
in	O
the	O
opposite	O
femoral	O
area	O
.	O

The	O
mean	O
pain	B-Disease
score	O
for	O
buffered	O
lidocaine	B-Chemical
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	B-Chemical
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-Disease
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Effect	O
of	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
glyceryl	I-Chemical
-	I-Chemical
phosphorylcholine	I-Chemical
on	O
amnesia	B-Disease
caused	O
by	O
scopolamine	B-Chemical
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
glycerylphosphorylcholine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
GFC	I-Chemical
)	O
on	O
memory	B-Disease
impairment	I-Disease
induced	O
by	O
scopolamine	B-Chemical
in	O
man	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
GFC	I-Chemical
or	O
placebo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	B-Chemical
or	O
placebo	O
,	O
i	O
.	O
m	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	B-Disease
of	I-Disease
attention	I-Disease
and	I-Disease
memory	I-Disease
induced	O
by	O
scopolamine	B-Chemical
.	O

Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-Chemical
,	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-Disease
,	O
including	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
,	O
for	O
>	O
40	O
years	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Chemical
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	B-Disease
and	I-Disease
kidney	I-Disease
disease	I-Disease
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Chemical
administration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-Chemical
is	O
an	O
oral	O
prodrug	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
pancreaticobiliary	I-Disease
,	I-Disease
gastric	I-Disease
,	I-Disease
renal	I-Disease
cell	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-Chemical
are	O
diarrhea	B-Disease
,	O
nausea	B-Disease
,	O
vomiting	B-Disease
,	O
stomatitis	B-Disease
and	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
.	O

Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O

Levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O

Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamine	B-Chemical
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	B-Disease
.	O

Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post	O
-	O
receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B-Disease
movements	I-Disease
.	O

Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	B-Chemical
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	B-Chemical
receptors	O
,	O
and	O
non	O
-	O
dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O

Effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
catalepsy	I-Disease
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	B-Chemical
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
symptoms	I-Disease
.	O

RESULTS	O
:	O
Bilateral	O
infusions	O
of	O
neurotensin	B-Chemical
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
catalepsy	I-Disease
in	O
rats	O
.	O

Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	B-Chemical
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	B-Chemical
administration	O
.	O

The	O
neurotensin	B-Chemical
type	I-Chemical
-	I-Chemical
1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
SR48692	B-Chemical
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	B-Chemical
.	O

CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	B-Chemical
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	B-Chemical
-	O
induced	O
antiparkinsonian	O
effects	O
.	O

Carmofur	B-Chemical
-	O
induced	O
organic	B-Disease
mental	I-Disease
disorders	I-Disease
.	O

Organic	B-Disease
mental	I-Disease
disorder	I-Disease
was	O
observed	O
in	O
a	O
29	O
-	O
year	O
-	O
old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	B-Chemical
-	O
induced	O
leukoencephalopathy	B-Disease
.	O

Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
frontal	B-Disease
lobe	I-Disease
syndrome	I-Disease
.	O

Consequently	O
,	O
carmofur	B-Chemical
-	O
induced	O
leukoencephalopathy	B-Disease
may	O
uncommonly	O
result	O
in	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
in	O
the	O
residual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
structural	B-Disease
damage	I-Disease
to	I-Disease
the	I-Disease
frontal	I-Disease
lobe	I-Disease
.	O

Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	B-Disease
after	O
succinylcholine	B-Chemical
for	O
electroconvulsive	O
therapy	O
.	O

BACKGROUND	O
:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	B-Chemical
as	O
part	O
of	O
the	O
anesthetic	O
procedure	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
after	O
ECT	O
.	O

We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	B-Disease
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O

The	O
duration	O
of	O
apnea	B-Disease
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O

The	O
duration	O
of	O
apnea	B-Disease
was	O
5	O
-	O
15	O
min	O
compared	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
literature	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-Disease
.	O

Perhexiline	B-Chemical
maleate	I-Chemical
and	O
peripheral	B-Disease
neuropathy	I-Disease
.	O

Peripheral	B-Disease
neuropathy	I-Disease
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	B-Chemical
maleate	I-Chemical
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B-Disease
pectoris	I-Disease
.	O

In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-Disease
disorder	I-Disease
.	O

The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	B-Disease
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O

A	O
phase	O
I	O
study	O
of	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriamycin	I-Chemical
.	O

A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriamycin	I-Chemical
(	O
Pirarubicin	B-Chemical
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	B-Disease
.	O

Twenty	O
-	O
six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
hepatic	I-Disease
dysfunction	I-Disease
.	O

The	O
dose	O
-	O
limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	B-Disease
.	O

Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	B-Disease
,	O
anemia	B-Disease
,	O
nausea	B-Disease
,	O
mild	O
alopecia	B-Disease
,	O
phlebitis	B-Disease
,	O
and	O
mucositis	B-Disease
.	O

Myelosuppression	B-Disease
was	O
more	O
in	O
patients	O
with	O
hepatic	B-Disease
dysfunction	I-Disease
.	O

Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	B-Chemical
plasma	O
T	O
1	O
/	O
2	O
alpha	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minutes	O
,	O
T	O
beta	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
minutes	O
,	O
and	O
T	O
1	O
/	O
2	O
gamma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

Adriamycinol	B-Chemical
,	O
doxorubicin	B-Chemical
,	O
adriamycinone	B-Chemical
,	O
and	O
tetrahydropyranyladriamycinol	B-Chemical
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-Chemical
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O

Urinary	O
excretion	O
of	O
Pirarubicin	B-Chemical
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
.	O

Activity	O
was	O
noted	O
in	O
mesothelioma	B-Disease
,	O
leiomyosarcoma	B-Disease
,	O
and	O
basal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Ocular	B-Disease
and	I-Disease
auditory	I-Disease
toxicity	I-Disease
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
.	O

During	O
an	O
18	O
-	O
month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B-Disease
toxicity	I-Disease
.	O

6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	B-Disease
or	I-Disease
auditory	I-Disease
toxicity	I-Disease
.	O

Visual	B-Disease
toxicity	I-Disease
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	B-Disease
,	O
sometimes	O
associated	O
with	O
a	B-Disease
loss	I-Disease
of	I-Disease
visual	I-Disease
acuity	I-Disease
and	O
pigmentary	B-Disease
retinal	I-Disease
deposits	I-Disease
.	O

Auditory	B-Disease
toxicity	I-Disease
was	O
characterized	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
frequency	O
neurosensorial	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O

Desferrioxamine	B-Chemical
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B-Disease
loss	I-Disease
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O

This	O
toxicity	B-Disease
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	B-Chemical
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	B-Chemical
serum	O
levels	O
.	O

The	O
data	O
indicate	O
that	O
audiovisual	B-Disease
toxicity	I-Disease
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
.	O

Serial	O
epilepsy	B-Disease
caused	O
by	O
levodopa	B-Chemical
/	I-Chemical
carbidopa	I-Chemical
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O

Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa	B-Chemical
/	I-Chemical
levodopa	I-Chemical
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	B-Disease
and	O
recurrent	O
seizures	B-Disease
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O

The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	B-Chemical
B6	I-Chemical
.	O

Randomized	O
,	O
double	O
-	O
blind	O
trial	O
of	O
mazindol	B-Chemical
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

We	O
conducted	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
of	O
mazindol	B-Chemical
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

Muscle	O
strength	O
,	O
contractures	O
,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	B-Chemical
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placebo	O
.	O

The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
detect	O
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	B-Disease
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Mazindol	B-Chemical
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O

Side	O
effects	O
attributable	O
to	O
mazindol	B-Chemical
included	O
decreased	B-Disease
appetite	I-Disease
(	O
36	O
%	O
)	O
,	O
dry	B-Disease
mouth	I-Disease
(	O
10	O
%	O
)	O
,	O
behavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	B-Disease
symptoms	I-Disease
(	O
18	O
%	O
)	O
;	O
mazindol	B-Chemical
dosage	O
was	O
reduced	O
in	O
43	O
%	O
of	O
patients	O
.	O

The	O
effect	O
of	O
mazindol	B-Chemical
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF	O
-	O
I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	B-Chemical
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O

Although	O
mazindol	B-Chemical
-	O
treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo	O
-	O
treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF	O
-	O
I	O
levels	O
was	O
observed	O
.	O

Mazindol	B-Chemical
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
and	O
its	O
state	O
dependency	O
in	O
the	O
step	O
-	O
through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O

Amnesia	B-Disease
produced	O
by	O
scopolamine	B-Chemical
and	O
cycloheximide	B-Chemical
were	O
reversed	O
by	O
morphine	B-Chemical
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre	O
-	O
test	O
)	O
,	O
and	O
pre	O
-	O
test	O
morphine	B-Chemical
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	B-Chemical
during	O
the	O
training	O
trial	O
.	O

Similarly	O
,	O
pre	O
-	O
test	O
scopolamine	B-Chemical
partially	O
reversed	O
the	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
test	O
cycloheximide	B-Chemical
failed	O
to	O
reverse	O
the	O
cycloheximide	B-Chemical
-	O
induced	O
amnesia	B-Disease
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-Chemical
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

Naloxone	B-Chemical
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	B-Chemical
.	O

In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	B-Chemical
,	O
5	O
to	O
20	O
micrograms	O
/	O
kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	B-Chemical
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypotensive	B-Disease
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
was	O
also	O
partially	O
reversed	O
by	O
naloxone	B-Chemical
.	O

Naloxone	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	B-Disease
rats	O
clonidine	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
naloxone	I-Chemical
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
influence	O
clonidine	B-Chemical
-	O
suppressible	O
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
dihydroergocryptine	I-Chemical
(	O
1	O
nM	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O

As	O
naloxone	B-Chemical
and	O
clonidine	B-Chemical
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	B-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	O
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O

Neurotoxicity	B-Disease
of	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O

An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	B-Disease
reactions	O
to	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
reported	O
from	O
outside	O
Japan	O
.	O

In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	B-Chemical
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	B-Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O

In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	B-Disease
disturbance	I-Disease
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	B-Disease
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	B-Chemical
over	O
a	O
short	O
period	O
.	O

The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B-Disease
atrophy	I-Disease
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	B-Chemical
as	O
treatment	O
for	O
acrodermatitis	B-Disease
enteropathica	I-Disease
.	O

In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	B-Disease
,	O
visual	B-Disease
disturbance	I-Disease
,	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
was	O
the	O
most	O
common	O
manifestation	O
.	O

Isolated	O
myelopathy	B-Disease
or	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O

The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	B-Disease
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O

The	O
full	O
syndrome	O
of	O
subacute	O
myelo	B-Disease
-	I-Disease
optic	I-Disease
neuropathy	I-Disease
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	O
.	O

Prazosin	B-Chemical
-	O
induced	O
stress	B-Disease
incontinence	I-Disease
.	O

A	O
case	O
of	O
genuine	O
stress	B-Disease
incontinence	I-Disease
due	O
to	O
prazosin	B-Chemical
,	O
a	O
common	O
antihypertensive	O
drug	O
,	O
is	O
presented	O
.	O

Prazosin	B-Chemical
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha	O
-	O
1	O
adrenergic	O
receptors	O
.	O

The	O
patient	O
'	O
s	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	B-Chemical
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	B-Chemical
.	O

Her	O
incontinence	B-Disease
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O

Patients	O
who	O
present	O
with	O
stress	B-Disease
incontinence	I-Disease
while	O
taking	O
prazosin	B-Chemical
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B-Disease
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	O
therapy	O
.	O

Myocardial	B-Disease
infarction	I-Disease
following	O
sublingual	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
.	O

A	O
78	O
-	O
year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	B-Disease
suffered	O
a	O
recurrent	O
myocardial	B-Disease
infarction	I-Disease
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
5	O
mg	O
sublingually	O
.	O

After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	B-Disease
and	O
hypotension	B-Disease
-	O
mediated	O
myocardial	B-Disease
ischemia	I-Disease
occurring	O
downstream	O
to	O
significant	O
coronary	B-Disease
arterial	I-Disease
stenosis	I-Disease
in	O
the	O
pathophysiology	O
of	O
acute	B-Disease
coronary	I-Disease
insufficiency	I-Disease
.	O

Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i	O
.	O
v	O
.	O
infusions	O
of	O
morphine	B-Chemical
and	O
regional	O
analgesia	O
by	O
extradural	O
block	O
.	O

The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	B-Disease
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
morphine	B-Chemical
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O

Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	B-Chemical
dioxide	I-Chemical
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O

Both	O
obstructive	B-Disease
(	I-Disease
P	I-Disease
less	I-Disease
than	I-Disease
0	I-Disease
.	I-Disease
05	I-Disease
)	I-Disease
and	I-Disease
central	I-Disease
apnoea	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	B-Chemical
infusion	O
.	O

There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ventricular	B-Disease
ectopic	I-Disease
beats	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
morphine	B-Chemical
infusion	O
group	O
.	O

Effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-Disease
fibrillation	I-Disease
during	O
respiratory	B-Disease
failure	I-Disease
.	O

Cardiac	B-Disease
arrhythmias	I-Disease
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B-Disease
failure	I-Disease
.	O

The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B-Disease
disturbances	I-Disease
in	O
patients	O
with	O
respiratory	B-Disease
failure	I-Disease
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
during	O
normal	O
acid	O
-	O
base	O
conditions	O
and	O
during	O
respiratory	B-Disease
failure	I-Disease
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O

The	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O

During	O
the	O
infusion	O
of	O
aminophylline	B-Chemical
,	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	B-Chemical
(	O
PO2	B-Chemical
)	O
and	O
carbon	B-Chemical
dioxide	I-Chemical
(	O
CO2	B-Chemical
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O

When	O
respiratory	B-Disease
failure	I-Disease
was	O
produced	O
by	O
hypoventilation	B-Disease
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	B-Chemical
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O

These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B-Disease
arrhythmias	I-Disease
in	O
respiratory	B-Disease
failure	I-Disease
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	B-Chemical
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentoxifylline	B-Chemical
(	O
Trental	B-Chemical
)	O
does	O
not	O
inhibit	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
:	O
implications	O
for	O
dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
myocardial	O
imaging	O
.	O

Dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	B-Disease
vascular	I-Disease
disease	I-Disease
.	O

Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	B-Chemical
(	O
Trental	B-Chemical
)	O
,	O
a	O
methylxanthine	B-Chemical
derivative	O
which	O
may	O
improve	O
intermittent	B-Disease
claudication	I-Disease
.	O

Whether	O
pentoxifylline	B-Chemical
inhibits	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
like	O
other	O
methylxanthines	B-Chemical
such	O
as	O
theophylline	B-Chemical
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	B-Chemical
-	O
thallium	B-Chemical
-	O
201	O
imaging	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	B-Chemical
in	O
seven	O
open	O
-	O
chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	B-Chemical
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophylline	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Dipyridamole	B-Chemical
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pentoxifylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
dose	O
of	O
pentoxifylline	B-Chemical
significantly	O
decreased	O
the	O
dipyridamole	B-Chemical
-	O
induced	O
hyperemia	B-Disease
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyifylline	B-Chemical
does	O
not	O
inhibit	O
dipyridamole	B-Chemical
-	O
induced	O
coronary	O
hyperemia	B-Disease
even	O
at	O
high	O
doses	O
.	O

Cause	O
of	O
death	B-Disease
among	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O

Causes	O
of	O
death	B-Disease
,	O
with	O
special	O
reference	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
death	B-Disease
were	O
pneumonia	B-Disease
and	O
bronchitis	B-Disease
(	O
44	O
.	O
1	O
%	O
)	O
,	O
malignant	O
neoplasms	B-Disease
(	O
11	O
.	O
6	O
%	O
)	O
,	O
heart	B-Disease
diseases	I-Disease
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebral	B-Disease
infarction	I-Disease
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemia	B-Disease
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Cerebral	B-Disease
haemorrhage	I-Disease
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	B-Disease
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
deaths	B-Disease
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	B-Disease
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O

The	O
low	O
incidence	O
of	O
cerebral	B-Disease
haemorrhage	I-Disease
as	O
a	O
cause	O
of	O
death	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
may	O
reflect	O
the	O
hypotensive	B-Disease
effect	O
of	O
levodopa	B-Chemical
and	O
a	O
hypotensive	B-Disease
mechanism	O
due	O
to	O
reduced	O
noradrenaline	B-Chemical
levels	O
in	O
the	O
parkinsonian	B-Disease
brain	O
.	O

Possible	O
intramuscular	O
midazolam	B-Chemical
-	O
associated	O
cardiorespiratory	B-Disease
arrest	I-Disease
and	O
death	B-Disease
.	O

Midazolam	B-Chemical
hydrochloride	I-Chemical
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	B-Disease
and	I-Disease
cardiovascular	I-Disease
depression	I-Disease
.	O

This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B-Disease
arrest	I-Disease
and	O
death	B-Disease
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	B-Chemical
.	O

Information	O
regarding	O
midazolam	B-Chemical
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O

Myasthenia	B-Disease
gravis	I-Disease
presenting	O
as	O
weakness	O
after	O
magnesium	B-Chemical
administration	O
.	O

We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B-Disease
disease	I-Disease
who	O
became	O
virtually	O
quadriplegic	B-Disease
after	O
parenteral	O
magnesium	B-Chemical
administration	O
for	O
preeclampsia	B-Disease
.	O

The	O
serum	O
magnesium	B-Chemical
concentration	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O

The	O
magnesium	B-Chemical
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O

While	O
she	O
was	O
weak	O
,	O
2	O
-	O
Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B-Disease
neuromuscular	I-Disease
blockade	I-Disease
.	O

Her	O
acetylcholine	B-Chemical
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O

Although	O
paralysis	B-Disease
after	O
magnesium	B-Chemical
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B-Disease
gravis	I-Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	O
.	O

Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	B-Chemical
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B-Disease
of	I-Disease
neuromuscular	I-Disease
transmission	I-Disease
.	O

No	O
enhancement	O
by	O
phenobarbital	B-Chemical
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
in	O
the	O
rat	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-Chemical
in	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

Groups	O
of	O
5	O
-	O
week	O
old	O
male	O
Fischer	O
-	O
344	O
rats	O
were	O
fed	O
for	O
7	O
-	O
25	O
months	O
semipurified	O
choline	B-Chemical
-	O
devoid	O
or	O
choline	B-Chemical
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenobarbital	B-Chemical
.	O

No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	B-Disease
carcinomas	I-Disease
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-Chemical
-	O
supplemented	O
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B-Disease
carcinoma	I-Disease
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	B-Chemical
.	O

The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B-Disease
carcinomas	I-Disease
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-Chemical
-	O
devoid	O
diet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital	B-Chemical
-	O
containing	O
choline	B-Chemical
-	O
devoid	O
diet	O
.	O

The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	B-Chemical
-	O
devoid	O
diet	O
by	O
phenobarbital	B-Chemical
.	O

On	O
two	O
paradoxical	O
side	O
-	O
effects	O
of	O
prednisolone	B-Chemical
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O

Liver	B-Disease
enlargement	I-Disease
and	O
muscle	B-Disease
wastage	I-Disease
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	B-Chemical
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	B-Chemical
action	O
.	O

Differential	O
effects	O
of	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-Disease
.	O

Gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	B-Chemical
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	B-Disease
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	B-Chemical
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	B-Chemical
-	O
induced	O
seizures	B-Disease
24	O
h	O
after	O
exposure	O
to	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
(	O
Vohland	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	B-Disease
-	O
inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg	O
/	O
kg	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
.	O

One	O
hour	O
after	O
the	O
administration	O
of	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
the	O
activity	O
of	O
seizure	B-Disease
-	O
inducing	O
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
a	O
differential	O
response	O
was	O
observed	O
.	O

Seizure	B-Disease
activity	O
due	O
to	O
PTZ	B-Chemical
and	O
picrotoxin	B-Chemical
(	O
PTX	B-Chemical
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	B-Disease
activity	O
due	O
to	O
3	B-Chemical
-	I-Chemical
mercaptopropionic	I-Chemical
acid	I-Chemical
(	O
MPA	B-Chemical
)	O
,	O
bicuculline	B-Chemical
(	O
BCC	B-Chemical
)	O
,	O
methyl	B-Chemical
6	I-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimethoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
ethyl	I-Chemical
-	I-Chemical
B	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
DMCM	B-Chemical
)	O
,	O
or	O
strychnine	B-Chemical
(	O
STR	B-Chemical
)	O
was	O
not	O
different	O
from	O
control	O
.	O

In	O
vitro	O
,	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pentylenetetrazol	B-Chemical
and	O
picrotoxin	B-Chemical
were	O
shown	O
to	O
inhibit	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	B-Chemical
,	O
BCC	B-Chemical
,	O
DMCM	B-Chemical
,	O
and	O
STR	B-Chemical
showed	O
no	O
inhibition	O
of	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
(	O
t	B-Chemical
-	I-Chemical
butyl	I-Chemical
bicyclo	I-Chemical
-	I-Chemical
orthobenzoate	I-Chemical
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-Disease
activity	O
induced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B-Disease
-	O
inducing	O
agents	O
is	O
decreased	O
.	O

The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	B-Disease
activity	O
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
may	O
be	O
the	O
GABA	B-Chemical
-	O
A	O
receptor	O
-	O
linked	O
chloride	O
channel	O
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
in	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
(	O
AHF	B-Disease
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O

Administration	O
of	O
ribavirin	B-Chemical
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	B-Disease
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O

The	O
average	O
time	O
of	O
death	B-Disease
was	O
delayed	O
.	O

A	O
reversible	O
anemia	B-Disease
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	B-Chemical
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	B-Disease
,	O
and	O
that	O
anemia	B-Disease
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	B-Chemical
during	O
the	O
initial	O
days	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O

Is	O
the	O
treatment	O
of	O
scabies	B-Disease
hazardous	O
?	O

Treatment	O
for	O
scabies	B-Disease
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	B-Chemical
(	O
gamma	B-Chemical
benzene	I-Chemical
hexachloride	I-Chemical
)	O
the	O
treatment	O
of	O
choice	O
.	O

Lindane	B-Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O

Evidence	O
is	O
accumulating	O
that	O
lindane	B-Chemical
can	O
be	O
toxic	B-Disease
to	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
and	O
may	O
be	O
associated	O
with	O
aplastic	B-Disease
anaemia	I-Disease
.	O

Preparations	O
containing	O
lindane	B-Chemical
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O

This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at	O
-	O
risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	B-Disease
.	O

Mouse	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
brain	O
biogenic	O
amines	B-Chemical
.	O

The	O
effect	O
of	O
amantadine	B-Chemical
hydrochloride	I-Chemical
,	O
injected	O
i	O
.	O
p	O
.	O
in	O
6	O
increments	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	B-Chemical
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O

Amantadine	B-Chemical
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O

The	O
initial	O
dose	O
of	O
amantadine	B-Chemical
depressed	B-Disease
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O

Subsequent	O
amantadine	B-Chemical
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O

The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug	O
-	O
free	O
period	O
following	O
the	O
fourth	O
amantadine	B-Chemical
treatment	O
.	O

Readministration	O
of	O
amantadine	B-Chemical
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	B-Disease
of	I-Disease
motility	I-Disease
occurred	O
.	O

Treatment	O
with	O
amantadine	B-Chemical
did	O
not	O
alter	O
whole	O
brain	O
dopamine	B-Chemical
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O

Conversely	O
,	O
brain	O
normetanephrine	B-Chemical
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

The	O
results	O
suggest	O
a	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O

The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	B-Chemical
.	O

The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	B-Chemical
of	O
BALB	O
/	O
C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	B-Chemical
turnover	O
rate	O
and	O
/	O
or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	B-Chemical
which	O
may	O
account	O
for	O
a	O
behavioral	B-Disease
depression	I-Disease
caused	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

Chloroacetaldehyde	B-Chemical
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	B-Chemical
or	O
ifosfamide	B-Chemical
.	O

Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-Chemical
in	O
the	O
development	O
of	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

The	O
data	O
demonstrate	O
that	O
CAA	B-Chemical
after	O
i	O
.	O
v	O
.	O
administration	O
does	O
not	O
contribute	O
to	O
bladder	B-Disease
damage	I-Disease
.	O

When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	B-Chemical
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	B-Chemical
.	O

Source	O
of	O
pain	B-Disease
and	O
primitive	O
dysfunction	O
in	O
migraine	B-Disease
:	O
an	O
identical	O
site	O
?	O

Twenty	O
common	O
migraine	B-Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-Chemical
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

Early	O
onset	O
migraine	B-Disease
attacks	O
were	O
induced	O
by	O
nitroglycerin	B-Chemical
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O

Subsequently	O
20	O
migraine	B-Disease
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	B-Chemical
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O

No	O
early	O
onset	O
migraine	B-Disease
was	O
observed	O
.	O

Thus	O
the	O
migraine	B-Disease
-	O
inducing	O
effect	O
of	O
nitroglycerin	B-Chemical
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	B-Disease
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	B-Disease
crisis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	B-Disease
attack	O
.	O

Hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presenting	O
with	O
a	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
erythroderma	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O

We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presented	O
with	O
generalized	O
erythroderma	B-Disease
,	O
a	O
severe	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
hyponatremia	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	B-Chemical
.	O

Fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

Five	O
patients	O
receiving	O
fluoxetine	B-Chemical
for	O
the	O
treatment	O
of	O
obsessive	B-Disease
compulsive	I-Disease
disorder	I-Disease
or	O
major	B-Disease
depression	I-Disease
developed	O
akathisia	B-Disease
.	O

The	O
typical	O
fluoxetine	B-Chemical
-	O
induced	O
symptoms	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B-Disease
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
.	O

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

Akathisia	B-Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-Chemical
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
propranolol	B-Chemical
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

The	O
authors	O
suggest	O
that	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
and	O
tricyclic	O
antidepressant	B-Chemical
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	O
.	O

Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O

The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	B-Chemical
was	O
assessed	O
in	O
Munich	O
-	O
Wistar	O
rats	O
with	O
established	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O

Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	B-Chemical
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	B-Disease
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O

Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	B-Chemical
.	O

These	O
short	O
-	O
term	O
studies	O
showed	O
that	O
enalapril	B-Chemical
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
group	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
glomerular	O
capillary	O
pressure	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
reducing	O
albuminuria	B-Disease
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O

Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	B-Chemical
on	O
progression	O
of	O
renal	B-Disease
injury	I-Disease
in	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O

Chronic	O
enalapril	B-Chemical
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	B-Disease
in	O
group	O
4	O
.	O

Enalapril	B-Chemical
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
months	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
group	O
3	O
)	O
.	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
both	O
treated	O
and	O
untreated	O
rats	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Clotiazepam	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	B-Disease
with	O
extensive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	B-Chemical
,	O
a	O
thienodiazepine	B-Chemical
derivative	O
.	O

Clotiazepam	B-Chemical
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O

The	O
administration	O
of	O
several	O
benzodiazepines	B-Chemical
,	O
chemically	O
related	O
to	O
clotiazepam	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B-Disease
.	O

This	O
observation	O
shows	O
that	O
clotiazepam	B-Chemical
can	O
induce	O
acute	O
hepatitis	B-Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	B-Disease
between	O
clotiazepam	B-Chemical
and	O
several	O
benzodiazepines	B-Chemical
.	O

5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
potentiates	O
initiation	B-Disease
induced	I-Disease
by	I-Disease
carcinogens	I-Disease
in	O
rat	O
liver	O
.	O

To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	B-Disease
of	I-Disease
carcinogenic	I-Disease
process	I-Disease
,	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pyrene	I-Chemical
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
nitrosourea	I-Chemical
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dimethylhydrazine	I-Chemical
(	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma	O
-	O
glutamyltransferase	O
(	O
gamma	O
-	O
GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2	O
-	O
week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0	O
.	O
02	O
%	O
2	B-Chemical
-	I-Chemical
acetylaminofluorene	I-Chemical
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	B-Chemical
.	O

The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
foci	O
/	O
cm2	O
in	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
and	O
carcinogen	O
-	O
treated	O
rats	O
compared	O
with	O
3	O
-	O
5	O
foci	O
/	O
cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O

Administration	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
azadeoxycytidine	I-Chemical
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cytosine	B-Chemical
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
occurs	O
during	O
repair	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma	O
-	O
GT	O
positive	O
foci	O
.	O

Antihypertensive	O
drugs	O
and	O
depression	B-Disease
:	O
a	O
reappraisal	O
.	O

Eighty	O
-	O
nine	O
new	O
referral	O
hypertensive	B-Disease
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	B-Disease
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O

The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B-Disease
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-Disease
group	O
.	O

Hypertensive	B-Disease
patients	O
with	O
psychiatric	B-Disease
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	B-Disease
than	O
the	O
comparison	O
patients	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B-Disease
occurring	O
in	O
methyl	B-Chemical
dopa	I-Chemical
treated	O
patients	O
with	O
psychiatric	B-Disease
histories	O
.	O

Chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
associated	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
therapy	O
.	O

Diclofenac	B-Chemical
sodium	I-Chemical
(	O
Voltarol	B-Chemical
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-Chemical
acid	I-Chemical
.	O

Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B-Disease
of	I-Disease
liver	I-Disease
function	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B-Disease
induced	O
by	O
diclofenac	B-Chemical
.	O

The	O
patient	O
described	O
developed	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
after	O
six	O
months	O
therapy	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O

Arterial	O
hypertension	B-Disease
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	B-Chemical
treatment	O
.	O

Two	O
of	O
14	O
patients	O
with	O
Cushing	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
treated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazole	B-Chemical
developed	O
sustained	O
hypertension	B-Disease
.	O

In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	B-Chemical
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-Chemical
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B-Disease
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O

In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycortisol	I-Chemical
were	O
elevated	O
.	O

In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycortisol	I-Chemical
levels	O
,	O
plasma	O
aldosterone	B-Chemical
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O

Our	O
findings	O
show	O
that	O
long	O
-	O
term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	B-Chemical
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid	O
-	O
related	O
hypertension	B-Disease
.	O

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
Captopril	B-Chemical
)	O
on	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
due	O
to	O
intravascular	B-Disease
coagulation	I-Disease
in	O
the	O
rat	O
.	O

Induction	O
of	O
intravascular	B-Disease
coagulation	I-Disease
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
AMCA	B-Chemical
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
resembling	O
that	O
occurring	O
after	O
trauma	B-Disease
or	O
sepsis	B-Disease
in	O
man	O
.	O

Injection	O
of	O
Captopril	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
in	O
this	O
rat	O
model	O
.	O

The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	B-Chemical
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O

Renal	B-Disease
damage	I-Disease
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	B-Chemical
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	B-Chemical
.	O

The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	B-Chemical
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	B-Chemical
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	B-Chemical
II	I-Chemical
and	O
an	O
increase	O
in	O
prostacyclin	B-Chemical
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	B-Chemical
)	O
.	O

Captopril	B-Chemical
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B-Disease
damage	I-Disease
will	O
be	O
produced	O
.	O

Stroke	B-Disease
associated	O
with	O
cocaine	B-Chemical
use	O
.	O

We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	B-Chemical
use	O
was	O
related	O
to	O
stroke	B-Disease
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O

Stroke	B-Disease
followed	O
cocaine	B-Chemical
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
or	O
arteriovenous	B-Disease
malformations	I-Disease
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B-Disease
vasculitis	I-Disease
was	O
present	O
in	O
two	O
patients	O
.	O

Cerebral	B-Disease
infarction	I-Disease
occurred	O
in	O
10	O
patients	O
(	O
22	O
%	O
)	O
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B-Disease
hemorrhage	I-Disease
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	B-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine	B-Chemical
-	O
associated	O
stroke	B-Disease
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	B-Disease
may	O
follow	O
any	O
route	O
of	O
cocaine	B-Chemical
administration	O
;	O
(	O
4	O
)	O
stroke	B-Disease
after	O
cocaine	B-Chemical
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B-Disease
aneurysms	I-Disease
and	O
arteriovenous	B-Disease
malformations	I-Disease
;	O
and	O
(	O
5	O
)	O
in	O
cocaine	B-Chemical
-	O
associated	O
stroke	B-Disease
,	O
the	O
frequency	O
of	O
intracranial	B-Disease
hemorrhage	I-Disease
exceeds	O
that	O
of	O
cerebral	B-Disease
infarction	I-Disease
.	O

A	O
randomized	O
comparison	O
of	O
labetalol	B-Chemical
and	O
nitroprusside	B-Chemical
for	O
induced	O
hypotension	B-Disease
.	O

In	O
a	O
randomized	O
study	O
,	O
labetalol	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O

Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	B-Disease
in	I-Disease
mean	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
increase	B-Disease
in	I-Disease
heart	I-Disease
rate	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
;	O
rebound	O
hypertension	B-Disease
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	B-Chemical
.	O

Labetalol	B-Chemical
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O

Arterial	O
PO2	B-Chemical
decreased	O
in	O
both	O
groups	O
.	O

It	O
was	O
concluded	O
that	O
labetalol	B-Chemical
offers	O
advantages	O
over	O
nitroprusside	B-Chemical
.	O

Sodium	B-Chemical
status	O
influences	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
.	O

The	O
nephrotoxic	B-Disease
potential	O
of	O
amphotericin	B-Chemical
B	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
.	O

In	O
salt	O
-	O
depleted	O
rats	O
,	O
amphotericin	B-Chemical
B	I-Chemical
decreased	O
creatinine	B-Chemical
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	O
rats	O
creatinine	B-Chemical
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	O
-	O
loaded	O
rats	O
creatinine	B-Chemical
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

All	O
rats	O
in	O
the	O
sodium	B-Chemical
-	O
depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	O
or	O
salt	O
-	O
loaded	O
rat	O
.	O

Concentrations	O
of	O
amphotericin	B-Chemical
B	I-Chemical
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	B-Chemical
B	I-Chemical
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt	O
-	O
depleted	O
and	O
normal	O
-	O
salt	O
rats	O
than	O
those	O
in	O
salt	O
-	O
loaded	O
rats	O
,	O
with	O
plasma	O
/	O
kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	O
-	O
depleted	O
,	O
normal	O
-	O
salt	O
,	O
and	O
salt	O
-	O
loaded	O
rats	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	B-Chemical
clearance	O
and	O
renal	O
amphotericin	B-Chemical
B	I-Chemical
accumulation	O
after	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	B-Chemical
loading	O
in	O
rats	O
.	O

Flestolol	B-Chemical
:	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Flestolol	B-Chemical
(	O
ACC	B-Chemical
-	I-Chemical
9089	I-Chemical
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	O
.	O

Flestolol	B-Chemical
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half	O
-	O
life	O
of	O
approximately	O
6	O
.	O
5	O
minutes	O
.	O

In	O
long	O
-	O
term	O
infusion	O
studies	O
,	O
flestolol	B-Chemical
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta	O
-	O
blocking	O
dose	O
(	O
5	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O

Flestolol	B-Chemical
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	B-Chemical
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O

Flestolol	B-Chemical
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-Disease
.	O

Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	B-Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O

In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol	B-Chemical
-	O
induced	O
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half	O
-	O
life	O
.	O

Flestolol	B-Chemical
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	B-Disease
tachyarrhythmia	I-Disease
.	O

In	O
patients	O
with	O
unstable	B-Disease
angina	I-Disease
,	O
flestolol	B-Chemical
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B-Disease
pain	I-Disease
.	O

It	O
is	O
concluded	O
that	O
flestolol	B-Chemical
is	O
a	O
potent	O
,	O
well	O
-	O
tolerated	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Use	O
of	O
flestolol	B-Chemical
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O

Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	B-Chemical
-	O
induced	O
rat	O
prolactinomas	B-Disease
after	O
bromocriptine	B-Chemical
treatment	O
.	O

To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	B-Chemical
on	O
prolactinoma	B-Disease
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	B-Chemical
-	O
induced	O
rat	O
prolactinoma	B-Disease
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O

Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B-Disease
cells	O
.	O

These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	B-Chemical
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O

The	O
prolactinoma	B-Disease
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O

Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	B-Disease
cells	O
.	O

However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	B-Chemical
treatment	O
of	O
the	O
adenoma	B-Disease
cells	O
.	O

An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	B-Chemical
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O

Sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
erythematosus	I-Disease
.	O

Pneumonitis	B-Disease
,	O
bilateral	O
pleural	B-Disease
effusions	I-Disease
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-Disease
tamponade	I-Disease
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazine	B-Chemical
therapy	O
for	O
chronic	O
ulcerative	B-Disease
colitis	I-Disease
.	O

After	O
cessation	O
of	O
the	O
sulfasalazine	B-Chemical
and	O
completion	O
of	O
a	O
six	O
-	O
week	O
course	O
of	O
corticosteroids	O
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O

It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
,	O
which	O
manifested	O
with	O
serositis	B-Disease
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O

Physicians	O
who	O
use	O
sulfasalazine	B-Chemical
to	O
treat	O
patients	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	B-Chemical
-	O
induced	O
lupus	B-Disease
syndrome	I-Disease
.	O

Chronic	O
carbamazepine	B-Chemical
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B-Disease
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	B-Chemical
concentrations	O
.	O

Folate	B-Chemical
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O

Carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-Chemical
treatment	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
.	O

In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	B-Chemical
glycol	I-Chemical
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	B-Disease
and	O
inhibited	O
weight	B-Disease
gain	I-Disease
.	O

Seizures	B-Disease
induced	O
by	O
hexafluorodiethyl	B-Chemical
ether	I-Chemical
(	O
HFDE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	B-Chemical
than	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O

Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
treatment	O
.	O

The	O
CBZ	B-Chemical
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatment	O
with	O
CBZ	B-Chemical
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	B-Chemical
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O

Dipyridamole	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O

Angina	B-Disease
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	B-Chemical
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	B-Chemical
therapy	O
,	O
although	O
dipyridamole	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
"	O
steal	O
"	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	B-Chemical
-	O
induced	O
ischemia	B-Disease
observed	O
.	O

In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	B-Chemical
intake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	B-Chemical
and	O
epinephrine	B-Chemical
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
infusions	O
of	O
human	O
alpha	O
-	O
atrial	O
natriuretic	O
factor	O
.	O

Mean	O
arterial	O
pressure	O
(	O
as	O
a	O
percentage	O
of	O
control	O
+	O
/	O
-	O
SEM	O
)	O
during	O
randomized	O
infusions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B-Disease
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	B-Chemical
release	O
rate	O
(	O
up	O
to	O
0	O
.	O
3	O
microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B-Disease
induced	O
by	O
hydralazine	B-Chemical
or	O
nitroglycerin	B-Chemical
.	O

The	O
release	O
rate	O
of	O
epinephrine	B-Chemical
(	O
control	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
declined	O
immediately	O
during	O
infusions	O
of	O
atrial	O
natriuretic	O
factor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
microgram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
microgram	O
/	O
kg	O
/	O
min	O
.	O

Nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systemic	O
corticosterone	B-Chemical
infusion	O
in	O
urethane	B-Chemical
-	O
anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
and	O
oxytocin	B-Chemical
at	O
any	O
corticosterone	B-Chemical
feedback	O
dose	O
tested	O
.	O

Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	B-Chemical
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	B-Chemical
levels	O
of	O
40	O
micrograms	O
/	O
dl	O
.	O

Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	B-Chemical
level	O
between	O
8	O
-	O
12	O
micrograms	O
/	O
dl	O
.	O

Noradrenergic	O
involvement	O
in	O
catalepsy	B-Disease
induced	O
by	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
or	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
THC	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
but	O
not	O
in	O
rats	O
treated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B-Disease
induced	O
by	O
THC	B-Chemical
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O

Reversibility	O
of	O
captopril	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	B-Disease
hypertension	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	B-Disease
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	O
kidney	O
,	O
who	O
developed	O
sudden	B-Disease
deterioration	I-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
following	O
treatment	O
with	O
captopril	B-Chemical
.	O

His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	B-Chemical
but	O
returned	O
to	O
pre	O
-	O
treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	O
.	O

This	O
indicates	O
reversibility	O
in	O
captopril	B-Chemical
-	O
induced	O
renal	B-Disease
failure	I-Disease
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O

Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
the	O
2	O
best	O
-	O
known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Clinical	O
experience	O
with	O
lovastatin	B-Chemical
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	B-Chemical
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O

Lovastatin	B-Chemical
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O

Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	B-Chemical
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholesterol	B-Chemical
of	O
40	O
%	O
in	O
clinical	O
studies	O
.	O

Modest	O
increases	O
in	O
HDL	O
-	O
cholesterol	B-Chemical
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Minor	O
elevations	O
of	O
creatine	B-Chemical
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patients	O
.	O

Myopathy	B-Disease
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	B-Disease
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B-Disease
failure	I-Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	B-Chemical
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	B-Chemical
,	O
gemfibrozil	B-Chemical
or	O
niacin	B-Chemical
.	O

Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
both	O
effective	O
and	O
well	O
-	O
tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	B-Chemical
.	O

As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	B-Disease
and	O
its	O
consequences	O
.	O

Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	B-Chemical
in	O
the	O
United	O
Kingdom	O
.	O

Ketoconazole	B-Chemical
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O

By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	B-Disease
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	B-Disease
.	O

An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	B-Disease
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	O
.	O

The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoxicity	B-Disease
being	O
more	O
common	O
in	O
women	O
.	O

The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	B-Disease
was	O
61	O
days	O
.	O

The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	B-Disease
injury	I-Disease
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O

In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	B-Disease
.	O

Allergic	O
manifestations	O
such	O
as	O
rash	B-Disease
and	O
eosinophilia	B-Disease
were	O
rare	O
.	O

Hepatitis	B-Disease
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3	O
.	O
1	O
months	O
.	O

In	O
two	O
of	O
the	O
three	O
deaths	B-Disease
probably	O
associated	O
with	O
ketoconazole	B-Chemical
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	B-Disease
and	O
other	O
symptoms	O
of	O
hepatitis	B-Disease
.	O

Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	B-Disease
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	B-Chemical
to	O
prevent	O
possible	O
serious	O
hepatic	B-Disease
injury	I-Disease
.	O

Glyburide	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O

Drug	O
-	O
induced	O
hepatotoxicity	B-Disease
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	B-Chemical
.	O

For	O
glyburide	B-Chemical
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	B-Chemical
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	B-Disease
exist	O
.	O

Two	O
patients	O
with	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
mellitus	I-Disease
developed	O
an	O
acute	B-Disease
hepatitis	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
soon	O
after	O
initiation	O
of	O
glyburide	B-Chemical
therapy	O
.	O

There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B-Disease
infection	I-Disease
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
.	O

Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	B-Chemical
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
1	O
year	O
.	O

Glyburide	B-Chemical
can	O
produce	O
an	O
acute	B-Disease
hepatitis	I-Disease
-	I-Disease
like	I-Disease
illness	I-Disease
in	O
some	O
persons	O
.	O

Intracranial	O
pressure	O
increases	O
during	O
alfentanil	B-Chemical
-	O
induced	O
rigidity	B-Disease
.	O

Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil	B-Chemical
-	O
induced	O
rigidity	B-Disease
in	O
rats	O
.	O

Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	B-Chemical
anesthesia	O
.	O

Following	O
instrumentation	O
,	O
halothane	B-Chemical
was	O
discontinued	O
and	O
alfentanil	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-Chemical
anesthesia	O
.	O

In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	B-Disease
rigidity	I-Disease
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	B-Disease
was	O
abolished	O
with	O
metocurine	B-Chemical
.	O

In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	B-Chemical
.	O

These	O
observations	O
suggest	O
that	O
rigidity	B-Disease
should	O
be	O
prevented	O
when	O
alfentanil	B-Chemical
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	O
,	O
are	O
used	O
in	O
the	O
anesthetic	O
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O

Verapamil	B-Chemical
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-Disease
infarction	I-Disease
in	O
a	O
hypertensive	B-Disease
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O

Verapamil	B-Chemical
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertensive	O
drug	O
.	O

Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B-Disease
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B-Disease
infarction	I-Disease
coincided	O
with	O
the	O
introduction	O
of	O
captopril	B-Chemical
and	O
the	O
withdrawal	O
of	O
verapamil	B-Chemical
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	B-Disease
.	O

Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	B-Chemical
-	O
related	O
increase	O
in	O
platelet	O
and	O
/	O
or	O
vascular	O
alpha	O
2	O
-	O
adrenoreceptor	O
affinity	O
for	O
catecholamines	B-Chemical
are	O
discussed	O
.	O

Haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O

This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O

While	O
the	O
involvement	O
of	O
metronidazole	B-Chemical
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	B-Chemical
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	B-Disease
-	I-Disease
uraemic	I-Disease
syndrome	I-Disease
.	O

Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis	B-Chemical
-	I-Chemical
platin	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
.	O

Survival	O
for	O
patients	O
with	O
advanced	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinoma	I-Disease
and	O
esophageal	B-Disease
carcinoma	I-Disease
is	O
poor	O
with	O
radiotherapy	O
and	O
/	O
or	O
surgery	O
.	O

In	O
the	O
present	O
study	O
,	O
cis	B-Chemical
-	I-Chemical
platin	I-Chemical
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O

In	O
the	O
pre	O
-	O
treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
were	O
found	O
in	O
33	O
patients	O
(	O
43	O
%	O
)	O
.	O

The	O
incidence	O
of	O
cardiotoxicity	B-Disease
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O

The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B-Disease
were	O
chest	B-Disease
pain	I-Disease
,	O
ST	O
-	O
T	O
wave	O
changes	O
and	O
atrial	B-Disease
fibrillation	I-Disease
.	O

This	O
was	O
followed	O
by	O
ventricular	B-Disease
fibrillation	I-Disease
in	O
one	O
patient	O
and	O
sudden	B-Disease
death	I-Disease
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patients	O
on	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-Disease
pain	I-Disease
or	O
tachyarrhythmia	B-Disease
is	O
observed	O
.	O

Death	B-Disease
from	O
chemotherapy	O
in	O
gestational	B-Disease
trophoblastic	I-Disease
disease	I-Disease
.	O

Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	B-Disease
.	O

The	O
multiple	O
drug	O
schema	O
consisted	O
of	O
:	O
Etoposide	B-Chemical
16	O
.	O
213	O
,	O
Methotrexate	B-Chemical
,	O
Cyclophosphamide	B-Chemical
,	O
Actomycin	B-Chemical
-	I-Chemical
D	I-Chemical
,	O
and	O
Cisplatin	B-Chemical
.	O

On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	B-Chemical
,	O
Etoposide	B-Chemical
and	O
Cyclophosphamide	B-Chemical
were	O
administered	O
.	O

Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B-Disease
obstruction	I-Disease
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O

Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B-Disease
necrosis	B-Disease
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B-Disease
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B-Disease
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B-Disease
emboli	O
.	O

In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	B-Disease
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	B-Disease
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patients	O
with	O
large	O
pelvic	B-Disease
tumor	I-Disease
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	O
resistance	O
.	O

Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitroprusside	B-Chemical
infusion	O
,	O
5	O
cm	O
H2O	B-Chemical
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	B-Chemical
CPAP	O
before	O
nitroprusside	B-Chemical
infusion	O
produced	O
a	O
further	O
decrease	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-Disease
cardiac	I-Disease
output	I-Disease
and	O
QS	O
/	O
QT	O
.	O

Nitroprusside	B-Chemical
caused	O
significant	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	B-Chemical
CPAP	O
during	O
nitroprusside	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O

However	O
,	O
10	O
cm	O
H2O	B-Chemical
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
data	O
indicate	O
that	O
nitroprusside	B-Chemical
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitroprusside	B-Chemical
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	B-Chemical
)	O
,	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
.	O

Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	B-Disease
than	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
ventilated	O
dogs	O
.	O

The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive	O
-	O
pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	B-Disease
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	B-Disease
-	O
induced	O
hypotension	B-Disease
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
group	O
.	O

The	O
SPV	O
during	O
hypotension	B-Disease
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
group	O
,	O
compared	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
group	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
and	O
SNP	B-Chemical
groups	O
,	O
respectively	O
,	O
during	O
hypotension	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B-Disease
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	B-Disease
than	O
during	O
deliberate	O
hypotension	B-Disease
.	O

Ventricular	B-Disease
tachyarrhythmias	I-Disease
during	O
cesarean	O
section	O
after	O
ritodrine	B-Chemical
therapy	O
:	O
interaction	O
with	O
anesthetics	O
.	O

This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	B-Chemical
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section	O
.	O

Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B-Disease
complications	I-Disease
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	B-Chemical
.	O

Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	B-Chemical
level	O
.	O

Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	B-Chemical
are	O
advised	O
.	O

After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	O
-	O
adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	B-Chemical
to	O
treat	O
hypotensive	B-Disease
patients	O
with	O
tachycardia	B-Disease
.	O

Verapamil	B-Chemical
-	O
induced	O
carbamazepine	B-Chemical
neurotoxicity	B-Disease
.	O

Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	B-Chemical
neurotoxicity	B-Disease
after	O
combined	O
treatment	O
with	O
verapamil	B-Chemical
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	B-Chemical
entry	O
blocker	O
.	O

Use	O
of	O
verapamil	B-Chemical
in	O
combination	O
with	O
carbamazepine	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
by	O
one	O
half	O
)	O
.	O

Paracetamol	B-Chemical
-	O
associated	O
coma	B-Disease
,	O
metabolic	B-Disease
acidosis	I-Disease
,	O
renal	B-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
.	O

A	O
case	O
of	O
metabolic	B-Disease
acidosis	I-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
following	O
paracetamol	B-Chemical
ingestion	O
is	O
presented	O
.	O

Sexual	B-Disease
dysfunction	I-Disease
among	O
patients	O
with	O
arthritis	B-Disease
.	O

The	O
relationship	O
of	O
arthritis	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
osteoarthritis	B-Disease
and	O
spondyloarthropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O

Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-Disease
mood	I-Disease
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O

Sexual	B-Disease
dysfunctions	I-Disease
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O

Impotence	B-Disease
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	B-Chemical
.	O

Depressed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-Disease
.	O

Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-Disease
but	O
was	O
associated	O
with	O
sexual	B-Disease
dysfunction	I-Disease
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O

Does	O
paracetamol	B-Chemical
cause	O
urothelial	B-Disease
cancer	I-Disease
or	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
?	O

The	O
risk	O
of	O
developing	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
,	I-Disease
ureter	I-Disease
or	I-Disease
bladder	I-Disease
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	B-Chemical
or	O
paracetamol	B-Chemical
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

The	O
risk	O
of	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
was	O
increased	O
nearly	O
20	O
-	O
fold	O
by	O
consumption	O
of	O
phenacetin	B-Chemical
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
and	I-Disease
bladder	I-Disease
but	O
not	O
for	O
ureteric	B-Disease
cancer	I-Disease
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	B-Chemical
consumption	O
for	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
any	O
of	O
these	O
cancers	B-Disease
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B-Disease
of	I-Disease
the	I-Disease
ureter	I-Disease
.	O

Dapsone	B-Chemical
-	O
associated	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O

A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-Disease
developed	O
a	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
while	O
taking	O
a	O
dose	O
of	O
dapsone	B-Chemical
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B-Disease
.	O

Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
,	O
and	O
decreased	O
GSH	B-Chemical
stability	O
.	O

The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
dapsone	B-Chemical
-	O
exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	B-Chemical
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	B-Chemical
content	O
and	O
GSH	B-Chemical
stability	O
were	O
normal	O
.	O

The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
non	O
-	O
dapsone	B-Chemical
-	O
exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	B-Chemical
does	O
not	O
cause	O
hemolytic	B-Disease
anemia	I-Disease
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O

Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B-Disease
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E	O
.	O

Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-Chemical
,	O
propafenone	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
sparteine	B-Chemical
.	O

A	O
47	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	B-Disease
with	O
III	O
.	O

AV	B-Disease
block	I-Disease
,	O
severe	O
hypotension	B-Disease
,	O
and	O
impairment	B-Disease
of	I-Disease
ventricular	I-Disease
function	I-Disease
.	O

One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	B-Chemical
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
days	O
before	O
admission	O
diltiazem	B-Chemical
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
prescribed	O
in	O
addition	O
.	O

Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	B-Chemical
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
diltiazem	B-Chemical
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	B-Chemical
,	O
diltiazem	B-Chemical
,	O
propafenone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	B-Chemical
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	B-Chemical
/	O
sparteine	B-Chemical
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
)	O
.	O

Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	O
of	O
sparteine	B-Chemical
/	O
debrisoquine	B-Chemical
polymorphism	O
in	O
drug	O
metabolism	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	O
alone	O
.	O

A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	B-Chemical
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	B-Chemical
as	O
the	O
reference	O
substance	O
.	O

Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B-Disease
concomitant	I-Disease
symptoms	I-Disease
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	B-Chemical
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	B-Disease
syndromes	I-Disease
belonging	I-Disease
predominantly	I-Disease
to	I-Disease
the	I-Disease
schizophrenia	I-Disease
group	I-Disease
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	B-Chemical
.	O

Prolonged	O
cholestasis	B-Disease
after	O
troleandomycin	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	B-Chemical
-	O
induced	O
hepatitis	B-Disease
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
.	O

Jaundice	B-Disease
occurred	O
after	O
administration	O
of	O
troleandomycin	B-Chemical
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	B-Disease
.	O

Jaundice	B-Disease
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
marked	O
by	O
pruritus	B-Disease
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities	O
.	O

Finally	O
,	O
pruritus	B-Disease
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	B-Disease
.	O

This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B-Disease
can	O
follow	O
troleandomycin	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O

Serial	O
studies	O
of	O
auditory	B-Disease
neurotoxicity	I-Disease
in	O
patients	O
receiving	O
deferoxamine	B-Chemical
therapy	O
.	O

Visual	B-Disease
and	I-Disease
auditory	I-Disease
neurotoxicity	I-Disease
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion	O
-	O
dependent	O
anemia	B-Disease
who	O
were	O
receiving	O
iron	B-Chemical
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	B-Chemical
.	O

Twenty	O
-	O
two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	B-Disease
audiograms	I-Disease
with	I-Disease
deficits	I-Disease
mostly	I-Disease
in	I-Disease
the	I-Disease
high	I-Disease
frequency	I-Disease
range	I-Disease
of	I-Disease
4	I-Disease
,	I-Disease
000	I-Disease
to	I-Disease
8	I-Disease
,	I-Disease
000	I-Disease
Hz	I-Disease
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O

When	O
deferoxamine	B-Chemical
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O

Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	B-Disease
disability	I-Disease
.	O

Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	B-Chemical
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	B-Disease
abnormality	I-Disease
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	B-Disease
was	O
demonstrated	O
.	O

Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	B-Chemical
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relation	O
between	O
deferoxamine	B-Chemical
administration	O
and	O
ototoxicity	B-Disease
.	O

Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	B-Chemical
.	O

With	O
mild	O
toxicity	B-Disease
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

In	O
those	O
with	O
symptoms	O
of	O
hearing	B-Disease
loss	I-Disease
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
.	O

Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B-Disease
dysfunction	I-Disease
.	O

Lidocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
asystole	I-Disease
.	O

Intravenous	O
administration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bolus	O
of	O
lidocaine	B-Chemical
in	O
a	O
67	O
-	O
year	O
-	O
old	O
man	O
resulted	O
in	O
profound	O
depression	B-Disease
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-Chemical
.	O

Flurbiprofen	B-Chemical
in	O
the	O
treatment	O
of	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O

Thirty	O
-	O
four	O
patients	O
with	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	B-Chemical
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B-Disease
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	B-Disease
joints	I-Disease
,	O
the	O
severity	O
of	O
swelling	B-Disease
and	O
tenderness	B-Disease
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	B-Disease
stiffness	I-Disease
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B-Disease
occult	I-Disease
blood	I-Disease
(	O
25	O
%	O
of	O
patients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	B-Disease
(	I-Disease
GI	I-Disease
)	I-Disease
bleeding	I-Disease
in	O
these	O
patients	O
.	O

One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B-Disease
and	O
abdominal	B-Disease
pain	I-Disease
.	O

Hyperkalemia	B-Disease
associated	O
with	O
sulindac	B-Chemical
therapy	O
.	O

Hyperkalemia	B-Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	B-Chemical
.	O

Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	B-Chemical
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	B-Chemical
synthesis	O
.	O

We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	B-Disease
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	B-Chemical
administration	O
.	O

In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	B-Chemical
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	B-Chemical
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	B-Chemical
and	O
hyperkalemia	B-Disease
.	O

These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	B-Chemical
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Drug	O
-	O
induced	O
arterial	O
spasm	B-Disease
relieved	O
by	O
lidocaine	B-Chemical
.	O

Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35	O
-	O
year	O
-	O
old	O
man	O
,	O
sodium	B-Chemical
pentothal	I-Chemical
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B-Disease
ischaemia	I-Disease
.	O

Intense	O
vasospasm	B-Disease
with	O
threatened	O
gangrene	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-Chemical
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-Disease
.	O

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
by	O
intracerebral	O
calcitonin	B-Chemical
injections	O
.	O

Calcitonin	B-Chemical
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	B-Chemical
can	O
produce	O
behavioral	O
effects	O
.	O

Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
.	O

In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	B-Chemical
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O

In	O
the	O
present	O
experiment	O
calcitonin	B-Chemical
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O

The	O
areas	O
where	O
calcitonin	B-Chemical
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	B-Chemical
in	O
inhibiting	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
.	O

The	O
hematologic	O
effects	O
of	O
cefonicid	B-Chemical
and	O
cefazedone	B-Chemical
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	B-Chemical
hematotoxicity	B-Disease
in	O
man	O
.	O

Cephalosporin	B-Chemical
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	B-Disease
disturbances	I-Disease
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B-Disease
dyscrasias	I-Disease
can	O
be	O
studied	O
.	O

In	O
four	O
subacute	O
toxicity	B-Disease
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
beagle	O
dogs	O
caused	O
a	O
dose	O
-	O
dependent	O
incidence	O
of	O
anemia	B-Disease
,	O
neutropenia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
after	O
1	O
-	O
3	O
months	O
of	O
treatment	O
.	O

A	O
nonregenerative	O
anemia	B-Disease
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	B-Chemical
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazedone	B-Chemical
.	O

All	O
three	O
cytopenias	B-Disease
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O

Upon	O
rechallenge	O
with	O
either	O
cephalosporin	B-Chemical
,	O
the	O
hematologic	B-Disease
syndrome	I-Disease
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	B-Chemical
(	O
but	O
not	O
cefazedone	B-Chemical
)	O
-	O
treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+	O
/	O
-	O
5	O
days	O
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	O
(	O
61	O
+	O
/	O
-	O
24	O
days	O
)	O
.	O

This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	B-Disease
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	B-Disease
.	O

We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
dogs	O
can	O
induce	O
hematotoxicity	B-Disease
similar	O
to	O
the	O
cephalosporin	B-Chemical
-	O
induced	O
blood	B-Disease
dyscrasias	I-Disease
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O

Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B-Disease
aneurysms	I-Disease
.	O

Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	B-Chemical
were	O
measured	O
during	O
isoflurane	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-Disease
aneurysm	I-Disease
.	O

Flow	O
and	O
metabolism	O
were	O
measured	O
5	O
-	O
13	O
days	O
after	O
the	O
subarachnoid	B-Disease
haemorrhage	I-Disease
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	O
using	O
xenon	B-Chemical
-	O
133	O
i	O
.	O
v	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	B-Chemical
concentration	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	B-Chemical
oxide	I-Chemical
in	O
oxygen	B-Chemical
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaCO2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Controlled	O
hypotension	B-Disease
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	B-Chemical
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

After	O
the	O
clipping	O
of	O
the	O
aneurysm	B-Disease
the	O
isoflurane	B-Chemical
concentration	O
was	O
reduced	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre	O
-	O
hypotensive	B-Disease
values	O
.	O

These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B-Disease
.	O

Triazolam	B-Chemical
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
patient	O
.	O

Large	O
doses	O
of	O
triazolam	B-Chemical
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
elderly	O
woman	O
.	O

Features	O
of	O
organic	B-Disease
mental	I-Disease
disorder	I-Disease
(	O
delirium	B-Disease
)	O
were	O
not	O
present	O
.	O

Manic	B-Disease
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	B-Chemical
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazolo	B-Chemical
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O

The	O
correlation	O
between	O
neurotoxic	B-Disease
esterase	O
inhibition	O
and	O
mipafox	B-Chemical
-	O
induced	O
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
.	O

The	O
correlation	O
between	O
neuropathic	B-Disease
damage	I-Disease
and	O
inhibition	O
of	O
neurotoxic	B-Disease
esterase	O
or	O
neuropathy	B-Disease
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
'	I-Chemical
-	I-Chemical
diisopropylphosphorodiamidofluoridate	I-Chemical
)	O
,	O
a	O
neurotoxic	B-Disease
organophosphate	B-Chemical
.	O

Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long	O
-	O
Evans	O
male	O
rats	O
1	O
hr	O
post	O
-	O
exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B-Disease
damage	I-Disease
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14	O
-	O
21	O
days	O
post	O
-	O
exposure	O
.	O

In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61	O
%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60	O
%	O
produced	O
this	O
degree	O
of	O
cord	B-Disease
damage	I-Disease
in	O
only	O
9	O
%	O
of	O
the	O
animals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	B-Chemical
exposure	O
can	O
predict	O
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
several	O
weeks	O
later	O
.	O

Allergic	B-Disease
reaction	I-Disease
to	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
infusion	O
.	O

An	O
allergic	B-Disease
reaction	I-Disease
consisting	O
of	O
angioneurotic	B-Disease
edema	I-Disease
secondary	O
to	O
continuous	O
infusion	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
oral	I-Disease
cavity	I-Disease
,	O
cirrhosis	B-Disease
,	O
and	O
cisplatin	B-Chemical
-	O
induced	O
impaired	B-Disease
renal	I-Disease
function	I-Disease
.	O

Oral	O
diphenhydramine	B-Chemical
and	O
prednisone	B-Chemical
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B-Disease
reaction	I-Disease
.	O

Myasthenia	B-Disease
gravis	I-Disease
caused	O
by	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose	O
-	O
related	O
myasthenia	B-Disease
gravis	I-Disease
after	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Although	O
acetylcholine	B-Chemical
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O

On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
in	O
rats	O
.	O

The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
was	O
studied	O
in	O
rats	O
.	O

Saline	O
-	O
pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidity	B-Disease
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O

Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	B-Chemical
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	B-Disease
after	O
the	O
test	O
dose	O
of	O
morphine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	B-Disease
(	O
A	O
group	O
)	O
.	O

The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	B-Disease
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and	O
/	O
or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B-Disease
or	O
hyperkinetic	B-Disease
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O

The	O
rigidity	B-Disease
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	B-Disease
without	O
any	O
dopaminergic	O
interference	O
.	O

Haloperidol	B-Chemical
enhanced	O
the	O
rigidity	B-Disease
in	O
the	O
A	O
group	O
.	O

The	O
results	O
suggest	O
that	O
rigidity	B-Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	B-Chemical
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum	O
.	O

The	O
rapid	O
alternations	O
of	O
rigidity	B-Disease
and	O
the	O
signs	O
of	O
dopaminergic	O
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS	O
/	O
KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervated	O
structures	O
.	O

A	O
case	O
of	O
massive	O
rhabdomyolysis	B-Disease
following	O
molindone	B-Chemical
administration	O
.	O

Rhabdomyolysis	B-Disease
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	B-Disease
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O

The	O
clinical	O
signs	O
and	O
symptoms	O
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	O
of	O
rhabdomyolysis	B-Disease
are	O
presented	O
.	O

The	O
case	O
of	O
a	O
schizophrenic	B-Disease
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	B-Disease
and	O
subsequent	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
molindone	B-Chemical
administration	O
.	O

Physicians	O
who	O
prescribe	O
molindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

Compression	B-Disease
neuropathy	I-Disease
of	I-Disease
the	I-Disease
radial	I-Disease
nerve	I-Disease
due	O
to	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-Disease
myopathy	I-Disease
.	O

Fibrous	B-Disease
myopathy	I-Disease
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	B-Chemical
injection	O
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
year	O
-	O
old	O
woman	O
with	O
documented	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-Disease
myopathy	I-Disease
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three	O
-	O
week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B-Disease
myopathy	I-Disease
.	O

Recurrent	O
reversible	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
from	O
amphotericin	B-Chemical
.	O

A	O
patient	O
with	O
cryptogenic	O
cirrhosis	B-Disease
and	O
disseminated	O
sporotrichosis	B-Disease
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	B-Chemical
B	I-Chemical
on	O
four	O
separate	O
occasions	O
.	O

The	O
abruptness	O
of	O
the	O
renal	B-Disease
failure	I-Disease
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B-Disease
dysfunction	I-Disease
.	O

We	O
propose	O
that	O
amphotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Cerebral	B-Disease
infarction	I-Disease
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	B-Chemical
.	O

Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	B-Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O

Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-Disease
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
,	O
neuropsychiatric	B-Disease
symptoms	I-Disease
,	O
and	O
nonhemorrhagic	O
cerebral	B-Disease
infarction	I-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B-Disease
infarction	I-Disease
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	B-Chemical
.	O

Remission	O
induction	O
of	O
meningeal	B-Disease
leukemia	I-Disease
with	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
.	O

Twenty	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
who	O
developed	O
meningeal	B-Disease
disease	I-Disease
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	B-Chemical
concentrations	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing	O
.	O

The	O
methotrexate	B-Chemical
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leucovorin	B-Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	B-Chemical
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
plasma	O
and	O
CSF	O
methotrexate	B-Chemical
concentrations	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

The	O
most	O
common	O
toxicities	B-Disease
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	B-Chemical
elevations	O
,	O
neutropenia	B-Disease
,	O
and	O
mucositis	B-Disease
.	O

One	O
patient	O
had	O
focal	O
seizures	B-Disease
and	O
transient	B-Disease
hemiparesis	I-Disease
but	O
recovered	O
completely	O
.	O

High	O
-	O
dose	O
intravenous	O
methotrexate	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

Interaction	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
with	O
antineoplastic	O
agents	O
.	O

A	O
synergistic	O
effect	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B-Disease
T	I-Disease
-	I-Disease
lymphocytic	I-Disease
leukemia	I-Disease
in	O
relapse	O
.	O

The	O
concomitant	O
administration	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B-Disease
infiltration	I-Disease
of	O
bone	O
marrow	O
.	O

Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	B-Disease
and	O
progressive	O
hyperbilirubinemia	B-Disease
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	B-Disease
in	O
normal	O
tissues	O
.	O

This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T	O
-	O
cell	O
functions	O
.	O

Incidence	O
of	O
neoplasms	B-Disease
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O

Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	B-Chemical
and	O
chlorambucil	B-Chemical
(	O
alkylating	B-Chemical
agents	I-Chemical
)	O
,	O
azathioprine	B-Chemical
(	O
purine	B-Chemical
analogue	O
)	O
,	O
and	O
methotrexate	B-Chemical
(	O
folic	B-Chemical
acid	I-Chemical
analogue	O
)	O
.	O

There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	B-Disease
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O

Patients	O
treated	O
with	O
alkylating	B-Chemical
agents	I-Chemical
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B-Disease
nonlymphocytic	I-Disease
leukemia	I-Disease
,	O
and	O
both	O
alkylating	B-Chemical
agents	I-Chemical
and	O
azathioprine	B-Chemical
are	O
associated	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
lymphoma	I-Disease
.	O

Cyclophosphamide	B-Chemical
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
studies	O
of	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
azathioprine	B-Chemical
and	O
cyclophosphamide	B-Chemical
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	B-Disease
is	O
not	O
increased	O
.	O

Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	B-Disease
in	O
rheumatoid	B-Disease
arthritis	I-Disease
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	O
,	O
particularly	O
alkylating	B-Chemical
agents	I-Chemical
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	B-Disease
arthritis	I-Disease
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	O
or	O
life	O
-	O
threatening	O
complications	O
.	O

Warfarin	B-Chemical
-	O
induced	O
iliopsoas	O
hemorrhage	B-Disease
with	O
subsequent	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
.	O

We	O
present	O
the	O
case	O
of	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
on	O
chronic	O
warfarin	B-Chemical
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	B-Disease
tear	I-Disease
and	O
developed	O
increasing	O
pain	B-Disease
and	O
a	O
flexure	O
contracture	B-Disease
of	O
the	O
right	O
hip	O
.	O

Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B-Disease
and	O
femoral	O
nerve	B-Disease
entrapment	I-Disease
,	O
resulting	O
in	O
a	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
and	O
partial	B-Disease
loss	I-Disease
of	I-Disease
quadriceps	I-Disease
functions	I-Disease
.	O

Anticoagulant	O
-	O
induced	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	B-Chemical
-	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	B-Disease
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	B-Disease
and	I-Disease
sensory	I-Disease
impairment	I-Disease
,	O
and	O
flexure	O
contracture	B-Disease
of	O
the	O
involved	O
extremity	O
.	O

Pneumonitis	O
with	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusion	I-Disease
and	O
neuropathy	B-Disease
during	O
amiodarone	B-Chemical
therapy	O
.	O

A	O
patient	O
with	O
sinuatrial	B-Disease
disease	I-Disease
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	B-Chemical
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B-Disease
tachyarrhythmias	I-Disease
.	O

He	O
developed	O
pneumonitis	B-Disease
,	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusions	I-Disease
,	O
and	O
a	O
predominantly	O
proximal	B-Disease
motor	I-Disease
neuropathy	I-Disease
.	O

Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	B-Chemical
and	O
treatment	O
with	O
prednisolone	B-Chemical
.	O

Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-Chemical
pneumonitis	B-Disease
,	O
immediate	O
withdrawal	O
of	O
amiodarone	B-Chemical
,	O
and	O
prompt	O
but	O
continued	O
steroid	B-Chemical
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O

Amiodarone	B-Chemical
-	O
induced	O
sinoatrial	B-Disease
block	I-Disease
.	O

We	O
observed	O
sinoatrial	B-Disease
block	I-Disease
due	O
to	O
chronic	O
amiodarone	B-Chemical
administration	O
in	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
with	O
primary	B-Disease
cardiomyopathy	I-Disease
,	O
Wolff	B-Disease
-	I-Disease
Parkinson	I-Disease
-	I-Disease
White	I-Disease
syndrome	I-Disease
and	O
supraventricular	B-Disease
tachycardia	I-Disease
.	O

Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	B-Chemical
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-Disease
block	I-Disease
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-Disease
bradycardia	I-Disease
.	O

Desipramine	B-Chemical
-	O
induced	O
delirium	B-Disease
at	O
"	O
subtherapeutic	O
"	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	B-Chemical
developed	O
a	O
delirium	B-Disease
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
"	O
subtherapeutic	O
"	O
range	O
.	O

Delirium	B-Disease
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency	O
.	O

Therapeutic	O
ranges	O
for	O
antidepressants	B-Chemical
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O

Indomethacin	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
:	O
recurrence	O
on	O
rechallenge	O
.	O

We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B-Disease
failure	I-Disease
with	O
hyperkalemia	B-Disease
in	O
a	O
patient	O
with	O
cirrhosis	B-Disease
,	O
ascites	B-Disease
,	O
and	O
cor	B-Disease
pulmonale	I-Disease
after	O
indomethacin	B-Chemical
therapy	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B-Disease
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

Since	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O

Patterns	O
of	O
hepatic	B-Disease
injury	I-Disease
induced	O
by	O
methyldopa	B-Chemical
.	O

Twelve	O
patients	O
with	O
liver	B-Disease
disease	I-Disease
related	O
to	O
methyldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Jaundice	B-Disease
with	O
tender	O
hepatomegaly	B-Disease
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	B-Disease
,	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
and	O
associated	O
with	O
upper	O
abdominal	B-Disease
pain	I-Disease
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O

Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	B-Disease
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	B-Disease
injury	I-Disease
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B-Disease
change	I-Disease
and	O
focal	O
hepatocellular	O
necrosis	B-Disease
to	O
massive	B-Disease
hepatic	I-Disease
necrosis	I-Disease
.	O

Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B-Disease
hepatitis	I-Disease
or	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
with	O
associated	O
cholestasis	B-Disease
.	O

One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	B-Disease
failure	I-Disease
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	B-Chemical
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	B-Disease
hepatitis	I-Disease
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O

In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	B-Chemical
and	O
hepatic	B-Disease
dysfunction	I-Disease
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	B-Disease
within	O
2	O
weeks	O
of	O
re	O
-	O
exposure	O
to	O
the	O
drug	O
.	O

Suxamethonium	B-Chemical
infusion	O
rate	O
and	O
observed	O
fasciculations	B-Disease
.	O

Suxamethonium	B-Chemical
chloride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
administered	O
i	O
.	O
v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	B-Disease
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O

Fasciculations	B-Disease
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B-Disease
score	O
.	O

The	O
times	O
to	O
first	O
fasciculation	B-Disease
,	O
twitch	B-Disease
suppression	O
and	O
tetanus	B-Disease
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O

Fasciculations	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B-Disease
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O

Total	O
fasciculation	B-Disease
scores	O
in	O
the	O
30	O
-	O
mg	O
bolus	O
group	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

Treatment	O
of	O
psoriasis	B-Disease
with	O
azathioprine	B-Chemical
.	O

Azathioprine	B-Chemical
treatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	B-Disease
.	O

Minimal	O
cholestasis	B-Disease
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	B-Disease
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O

Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	B-Chemical
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B-Disease
damage	I-Disease
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O

Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
associated	O
with	O
diethylstilbestrol	B-Chemical
.	O

Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
occurred	O
in	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
with	O
diethylstilbestrol	B-Chemical
for	O
13	O
years	O
.	O

Angiosarcoma	B-Disease
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O

The	O
possibility	O
that	O
the	O
intraarterial	B-Disease
lesions	I-Disease
might	O
represent	O
independent	O
primary	O
tumors	B-Disease
is	O
considered	O
.	O

Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	O
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
Hyoscine	B-Chemical
)	O
.	O

Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
hyoscine	B-Chemical
)	O
overdosage	B-Disease
.	O

It	O
is	O
longer	O
acting	O
than	O
physostigmine	B-Chemical
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non	O
-	O
depolarizing	O
neuromuscular	O
block	O
.	O

However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	B-Chemical
intoxication	O
are	O
indicated	O
.	O

Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i	O
.	O
m	O
.	O
administration	O
of	O
flunitrazepam	B-Chemical
in	O
volunteers	O
.	O

Flunitrazepam	B-Chemical
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i	O
.	O
m	O
.	O
routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared	O
.	O

Dizziness	B-Disease
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O

There	O
was	O
pain	B-Disease
on	O
i	O
.	O
m	O
.	O
injection	O
of	O
flunitrazepam	B-Chemical
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O

Possible	O
teratogenicity	O
of	O
sulphasalazine	B-Chemical
.	O

Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
who	O
received	O
treatment	O
with	O
sulphasalazine	B-Chemical
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-Disease
anomalies	I-Disease
.	O

In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B-Disease
colitis	I-Disease
,	O
and	O
the	O
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	I-Disease
and	O
a	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O

In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter	B-Disease
-	I-Disease
type	I-Disease
IIa	I-Disease
polycystic	I-Disease
kidney	I-Disease
and	O
a	O
rudimentary	B-Disease
left	I-Disease
uterine	I-Disease
cornu	I-Disease
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-Disease
'	I-Disease
s	I-Disease
facies	I-Disease
,	O
hypoplastic	B-Disease
lungs	I-Disease
,	O
absent	B-Disease
kidneys	I-Disease
and	I-Disease
ureters	I-Disease
,	O
and	O
talipes	B-Disease
equinovarus	I-Disease
.	O

Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	B-Chemical
may	O
be	O
teratogenic	O
.	O

Thrombotic	B-Disease
microangiopathy	I-Disease
and	O
renal	B-Disease
failure	I-Disease
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O

Five	O
patients	O
with	O
carcinoma	B-Disease
developed	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
characterized	O
by	O
renal	B-Disease
insufficiency	I-Disease
,	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
usually	O
thrombocytopenia	B-Disease
)	O
after	O
treatment	O
with	O
cisplatin	B-Chemical
,	O
bleomycin	B-Chemical
,	O
and	O
a	O
vinca	B-Chemical
alkaloid	I-Chemical
.	O

One	O
patient	O
had	O
thrombotic	B-Disease
thrombocytopenic	I-Disease
purpura	I-Disease
,	O
three	O
the	O
hemolytic	B-Disease
-	I-Disease
uremic	I-Disease
syndrome	I-Disease
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O

Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	B-Disease
coagulation	I-Disease
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O

Because	O
each	O
patient	O
was	O
tumor	B-Disease
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tumor	B-Disease
at	O
the	O
onset	O
of	O
this	O
syndrome	O
,	O
the	O
thrombotic	B-Disease
microangiopathy	I-Disease
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O

Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B-Disease
failure	I-Disease
may	O
be	O
ascribed	O
to	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
and	O
the	O
anemia	B-Disease
and	O
thrombocytopenia	B-Disease
to	O
drug	O
-	O
induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

International	O
mexiletine	B-Chemical
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I	O
.	O

Report	O
on	O
arrhythmia	B-Disease
and	O
other	O
findings	O
.	O

The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	B-Chemical
(	O
Mexitil	B-Chemical
-	I-Chemical
Perlongets	I-Chemical
)	O
were	O
evaluated	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B-Disease
infarction	I-Disease
.	O

Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	B-Chemical
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O

These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	B-Chemical
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	O
.	O

There	O
were	O
more	O
deaths	B-Disease
in	O
the	O
mexiletine	B-Chemical
group	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B-Disease
and	O
gastrointestinal	B-Disease
problems	I-Disease
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	B-Chemical
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Changes	O
in	O
heart	O
size	O
during	O
long	O
-	O
term	O
timolol	B-Chemical
treatment	O
after	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
effect	O
of	O
long	O
-	O
term	O
timolol	B-Chemical
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-Disease
infarction	I-Disease
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	B-Chemical
115	O
)	O
.	O

The	O
timolol	B-Chemical
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	B-Chemical
-	O
induced	O
bradycardia	B-Disease
and	O
a	O
compensatory	O
increase	O
in	O
end	O
-	O
diastolic	O
volume	O
.	O

The	O
timolol	B-Chemical
-	O
related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O

In	O
patients	O
with	O
cardiomegaly	B-Disease
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O

After	O
re	O
-	O
infarction	B-Disease
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	B-Chemical
group	O
.	O

Vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
in	O
dairy	O
cows	O
.	O

Large	O
parenteral	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitamin	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B-Disease
,	O
hyperphosphatemia	B-Disease
,	O
and	O
large	O
increases	O
of	O
vitamin	B-Chemical
D3	I-Chemical
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O

Calcium	B-Chemical
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
about	O
32	O
days	O
prepartum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
showed	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
this	O
period	O
.	O

Signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
and	O
10	O
of	O
17	O
cows	O
died	O
.	O

Because	O
of	O
the	O
extreme	O
toxicity	B-Disease
of	O
vitamin	B-Chemical
D3	I-Chemical
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
that	O
prevent	O
milk	B-Disease
fever	I-Disease
and	O
doses	O
that	O
induce	O
milk	B-Disease
fever	I-Disease
,	O
we	O
concluded	O
that	O
vitamin	B-Chemical
D3	I-Chemical
cannot	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-Disease
fever	I-Disease
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O

Diseases	B-Disease
of	I-Disease
peripheral	I-Disease
nerves	I-Disease
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O

The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-Disease
nerve	I-Disease
disease	I-Disease
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O

Sensori	B-Disease
-	I-Disease
motor	I-Disease
neuropathy	I-Disease
was	O
the	O
commonest	O
presentation	O
(	O
50	O
%	O
)	O
.	O

Guillain	B-Disease
-	I-Disease
Barr	I-Disease
syndrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Disease
neuropathy	I-Disease
.	O

Peripheral	B-Disease
neuropathy	I-Disease
due	O
to	O
nutritional	B-Disease
deficiency	I-Disease
of	O
thiamine	B-Chemical
and	O
riboflavin	B-Chemical
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori	B-Disease
-	I-Disease
motor	I-Disease
neuropathy	I-Disease
.	O

Diabetes	B-Disease
mellitus	I-Disease
was	O
the	O
major	O
cause	O
of	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

Isoniazid	B-Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B-Disease
.	O

Migraine	B-Disease
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-Disease
neuropathy	I-Disease
although	O
malignancies	B-Disease
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-Disease
was	O
undetermined	O
.	O

Heredofamilial	O
and	O
connective	B-Disease
tissue	I-Disease
disorders	I-Disease
were	O
rare	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease
are	O
briefly	O
discussed	O
.	O

Reduction	O
in	O
caffeine	B-Chemical
toxicity	B-Disease
by	O
acetaminophen	B-Chemical
.	O

A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	B-Chemical
acetylsalicylate	I-Chemical
,	O
caffeine	B-Chemical
,	O
and	O
acetaminophen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	B-Chemical
per	O
mL	O
of	O
serum	O
.	O

Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	B-Chemical
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	B-Chemical
(	O
52	O
micrograms	O
/	O
mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	B-Disease
of	O
caffeine	B-Chemical
.	O

Studies	O
in	O
DBA	O
/	O
2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	B-Chemical
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	B-Disease
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
75	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	B-Disease
produced	O
in	O
the	O
presence	O
of	O
caffeine	B-Chemical
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
frequency	O
of	O
sound	O
-	O
induced	O
seizures	B-Disease
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
caffeine	B-Chemical
was	O
reduced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	B-Chemical
.	O

In	O
the	O
absence	O
of	O
caffeine	B-Chemical
,	O
acetaminophen	B-Chemical
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	B-Chemical
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O

Acetaminophen	B-Chemical
(	O
up	O
to	O
150	O
micrograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	B-Chemical
into	O
ATP	B-Chemical
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O

Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	B-Chemical
antagonizes	O
the	O
actions	O
of	O
caffeine	B-Chemical
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-Chemical
hydrochloride	I-Chemical
in	O
the	O
treatment	O
of	O
major	O
depressive	B-Disease
disorder	I-Disease
.	O

In	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
parallel	O
treatment	O
study	O
,	O
dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	B-Disease
outpatients	O
.	O

Dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-Disease
illness	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O

The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B-Disease
vision	I-Disease
,	O
dry	B-Disease
mouth	I-Disease
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	B-Chemical
than	O
with	O
amitriptyline	B-Chemical
.	O

Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

Dothiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	B-Chemical
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	B-Chemical
in	O
the	O
treatment	O
of	O
depressed	B-Disease
outpatients	O
.	O

Behavioral	O
effects	O
of	O
diazepam	B-Chemical
and	O
propranolol	B-Chemical
in	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
and	O
agoraphobia	B-Disease
.	O

The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	B-Chemical
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	B-Chemical
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B-Disease
disorders	I-Disease
and	O
agoraphobia	B-Disease
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O

Both	O
drugs	O
impaired	B-Disease
immediate	I-Disease
free	I-Disease
recall	I-Disease
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O

Delayed	B-Disease
free	I-Disease
recall	I-Disease
was	I-Disease
also	I-Disease
impaired	I-Disease
but	O
the	O
two	O
drugs	O
did	O
not	O
differ	O
.	O

Patients	O
tapped	O
faster	O
after	O
propranolol	B-Chemical
than	O
diazepam	B-Chemical
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O

Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-Disease
impairment	I-Disease
.	O

Comparison	O
of	O
i	O
.	O
v	O
.	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
in	O
the	O
prevention	O
of	O
bradycardia	B-Disease
and	O
arrhythmias	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
.	O

The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	B-Chemical
5	O
and	O
10	O
micrograms	O
kg	O
-	O
1	O
and	O
atropine	B-Chemical
10	O
and	O
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	B-Disease
and	O
bradycardia	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
,	O
was	O
studied	O
.	O

A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
.	O

A	O
frequency	O
of	O
bradycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O

Bradycardia	B-Disease
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used	O
.	O

It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	B-Chemical
10	O
micrograms	O
kg	O
-	O
1	O
or	O
atropine	B-Chemical
20	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	B-Chemical
is	O
anticipated	O
.	O

Veno	B-Disease
-	I-Disease
occlusive	I-Disease
liver	I-Disease
disease	I-Disease
after	O
dacarbazine	B-Chemical
therapy	O
(	O
DTIC	B-Chemical
)	O
for	O
melanoma	B-Disease
.	O

A	O
case	O
of	O
veno	B-Disease
-	I-Disease
occlusive	I-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
with	O
fatal	O
outcome	O
after	O
dacarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
therapy	O
for	O
melanoma	B-Disease
is	O
reported	O
.	O

There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	B-Disease
.	O

At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-Disease
congestion	I-Disease
.	O

Small	O
-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	B-Disease
.	O

Maternal	O
lithium	B-Chemical
and	O
neonatal	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
:	O
evaluation	O
with	O
cross	O
-	O
sectional	O
echocardiography	O
.	O

Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	B-Chemical
during	O
pregnancy	O
.	O

In	O
one	O
infant	O
,	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O

In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-Disease
'	I-Disease
s	I-Disease
anomaly	I-Disease
.	O

Cross	O
-	O
sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	B-Chemical
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	B-Chemical
-	O
induced	O
cardiac	B-Disease
malformations	I-Disease
.	O

Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B-Disease
infarction	I-Disease
in	O
aging	O
rats	O
.	O

The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
weeks	O
of	O
age	O
.	O

The	O
occurrence	O
of	O
infarcts	B-Disease
were	O
confirmed	O
by	O
histological	O
methods	O
.	O

Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary	O
-	O
isoproterenols	B-Chemical
and	O
minimum	O
in	O
the	O
exercise	O
-	O
controls	O
.	O

Studies	O
dealing	O
with	O
myocardial	B-Disease
infarction	I-Disease
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O

Effect	O
of	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
on	O
adriamycin	B-Chemical
toxicity	B-Disease
in	O
mice	O
.	O

The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
was	O
evaluated	O
in	O
mice	O
.	O

PEG	B-Chemical
400	I-Chemical
impressively	O
decreased	O
both	O
acute	O
high	O
-	O
dose	O
and	O
chronic	O
low	O
-	O
dose	O
-	O
ADR	B-Chemical
-	O
associated	O
lethality	O
.	O

Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	B-Chemical
-	O
induced	O
cardiac	B-Disease
morphological	I-Disease
alterations	I-Disease
.	O

Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antitumor	O
activity	O
in	O
L1210	B-Disease
leukemia	I-Disease
and	O
in	O
Ehrlich	B-Disease
ascites	I-Disease
tumor	I-Disease
.	O

Sublingual	O
absorption	O
of	O
the	O
quaternary	B-Chemical
ammonium	I-Chemical
antiarrhythmic	O
agent	O
,	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
.	O

UM	B-Chemical
-	I-Chemical
272	I-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
-	I-Chemical
dimethylpropranolol	I-Chemical
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	B-Chemical
-	O
induced	O
ventricular	B-Disease
tachycardias	I-Disease
.	O

Sublingual	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
converted	O
ventricular	B-Disease
tachycardia	I-Disease
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O

Early	O
adjuvant	O
adriamycin	B-Chemical
in	O
superficial	O
bladder	B-Disease
carcinoma	I-Disease
.	O

A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O

Adriamycin	B-Chemical
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B-Disease
tumors	I-Disease
.	O

In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	B-Disease
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O

Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	B-Disease
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O

In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	O
tumor	B-Disease
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

The	O
beneficial	O
effect	O
of	O
Adriamycin	B-Chemical
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	O
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
angiopathy	B-Disease
in	O
rats	O
.	O

The	O
effect	O
of	O
high	O
dose	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
(	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
days	O
.	O

TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
-	O
treated	O
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O

The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	B-Chemical
.	O

The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	O
/	O
serum	O
-	O
ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
treatment	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross	O
-	O
linking	O
of	O
collagen	O
and	O
elastin	O
.	O

Effect	O
of	O
aspirin	B-Chemical
on	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formamide	I-Chemical
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
administration	O
of	O
aspirin	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formamide	I-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	B-Chemical
-	O
induced	O
bladder	B-Disease
carcinomas	I-Disease
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B-Disease
tumors	I-Disease
.	O

An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F	O
-	O
344	O
rats	O
fed	O
diet	O
containing	O
FANFT	B-Chemical
at	O
a	O
level	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
aspirin	B-Chemical
at	O
a	O
level	O
of	O
0	O
.	O
5	O
%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	B-Chemical
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
and	O
bladder	O
.	O

FANFT	B-Chemical
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	B-Chemical
co	O
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O

In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	B-Chemical
did	O
not	O
affect	O
the	O
FANFT	B-Chemical
-	O
induced	O
increase	O
in	O
labeling	O
index	O
.	O

The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	B-Chemical
carcinogenesis	B-Disease
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	B-Chemical
'	O
s	O
effect	O
on	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	B-Chemical
.	O

A	O
case	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
caused	O
by	O
metoclopramide	B-Chemical
.	O

Abnormal	B-Disease
involuntary	I-Disease
movements	I-Disease
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	B-Chemical
for	O
gastrointestinal	B-Disease
disorder	I-Disease
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O

When	O
the	O
metoclopramide	B-Chemical
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-Disease
movements	I-Disease
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O

Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-Disease
dyskinesia	I-Disease
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	O
.	O

Intra	O
-	O
arterial	O
BCNU	B-Chemical
chemotherapy	O
for	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
of	O
the	O
central	O
nervous	O
system	O
.	O

Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	B-Chemical
(	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosourea	I-Chemical
)	O
,	O
intra	O
-	O
arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
.	O

Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O

Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	B-Disease
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	B-Disease
without	O
prior	O
radiation	O
therapy	O
.	O

After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	B-Disease
size	O
and	O
surrounding	O
edema	B-Disease
on	O
contrast	O
-	O
enhanced	O
computerized	O
tomography	O
scans	O
.	O

Twenty	O
-	O
four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	B-Disease
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra	O
-	O
arterial	O
BCNU	B-Chemical
therapy	O
.	O

The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	B-Chemical
.	O

A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	B-Disease
of	I-Disease
vision	I-Disease
secondary	O
to	O
a	O
retinal	B-Disease
vasculitis	I-Disease
.	O

The	O
frequency	O
of	O
visual	B-Disease
loss	I-Disease
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	B-Chemical
diluent	O
was	O
lowered	O
.	O

Provocation	O
of	O
postural	O
hypotension	B-Disease
by	O
nitroglycerin	B-Chemical
in	O
diabetic	B-Disease
autonomic	I-Disease
neuropathy	I-Disease
?	O

The	O
effect	O
of	O
nitroglycerin	B-Chemical
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
and	O
5	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	B-Chemical
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	B-Disease
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
in	O
conscious	O
rats	O
.	O

Sodium	B-Chemical
chloride	I-Chemical
solution	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
noradrenaline	B-Chemical
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
infused	O
for	O
five	O
consecutive	O
days	O
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	O
)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed	O
.	O

Intrarenal	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
hypertension	B-Disease
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O

Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
higher	O
plasma	O
noradrenaline	B-Chemical
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	B-Chemical
concentration	O
-	O
blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	B-Chemical
levels	O
.	O

These	O
results	O
suggest	O
that	O
hypertension	B-Disease
after	O
chronic	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	B-Chemical
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O

Characterization	O
of	O
estrogen	B-Chemical
-	O
induced	O
adenohypophyseal	B-Disease
tumors	I-Disease
in	O
the	O
Fischer	O
344	O
rat	O
.	O

Pituitary	B-Disease
tumors	I-Disease
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
,	O
8	O
-	O
10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
days	O
of	O
DES	B-Chemical
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES	B-Chemical
-	O
treated	O
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	O
-	O
cell	O
preparations	O
.	O

The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and	O
/	O
or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	B-Chemical
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O

Total	O
cell	O
yields	O
from	O
DES	B-Chemical
-	O
treated	O
pituitaries	O
increased	O
from	O
1	O
.	O
3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58	O
.	O
9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
content	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
.	O

Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

All	O
these	O
effects	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O

The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	B-Chemical
-	O
induced	O
tumor	B-Disease
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	B-Chemical
.	O

In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	B-Chemical
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	B-Chemical
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	B-Chemical
.	O

Cimetidine	B-Chemical
clearance	O
decreased	O
with	O
age	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	B-Chemical
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O

The	O
ratio	O
of	O
cimetidine	B-Chemical
clearance	O
to	O
creatinine	B-Chemical
clearance	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	B-Chemical
.	O

Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	B-Chemical
is	O
a	O
saturable	O
process	O
.	O

There	O
was	O
only	O
one	O
case	O
of	O
dementia	B-Disease
possibly	O
due	O
to	O
cimetidine	B-Chemical
(	O
with	O
a	O
drug	O
level	O
of	O
1	O
.	O
9	O
microgram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	B-Disease
or	I-Disease
kidney	I-Disease
disease	I-Disease
who	O
had	O
cimetidine	B-Chemical
levels	O
above	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimetidine	B-Chemical
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	B-Disease
.	O

Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	B-Chemical
therapy	O
.	O

A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra	B-Disease
-	I-Disease
Hisian	I-Disease
block	I-Disease
occurring	O
under	O
amiodarone	B-Chemical
treatment	O
for	O
atrial	B-Disease
tachycardia	I-Disease
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B-Disease
conduction	I-Disease
abnormalities	I-Disease
.	O

His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B-Disease
tachycardia	I-Disease
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
days	O
after	O
amiodarone	B-Chemical
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B-Disease
flutter	I-Disease
without	O
intra	O
-	O
Hisian	O
or	O
infra	O
-	O
Hisian	O
delay	O
.	O

Amiodarone	B-Chemical
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O

Development	O
of	O
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
in	O
DES	B-Chemical
-	O
exposed	O
offspring	O
under	O
observation	O
.	O

Two	O
cases	O
of	O
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
of	I-Disease
the	I-Disease
vagina	I-Disease
detected	O
at	O
follow	O
-	O
up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	B-Chemical
are	O
reported	O
.	O

One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	B-Disease
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O

In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	B-Disease
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
bupivacaine	B-Chemical
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
in	O
experimental	O
animals	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	B-Disease
was	O
evaluated	O
.	O

The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	B-Chemical
(	O
N	O
=	O
15	O
)	O
,	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	B-Disease
.	O

None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hind	O
-	O
limb	O
paralysis	B-Disease
.	O

Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
13	O
showed	O
subpial	B-Disease
necrosis	I-Disease
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O

The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O

Procainamide	B-Chemical
-	O
induced	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Seven	O
cases	O
of	O
procainamide	B-Chemical
-	O
induced	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
are	O
presented	O
.	O

In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	B-Chemical
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	B-Chemical
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	B-Disease
ventricular	I-Disease
contractions	I-Disease
or	O
atrial	B-Disease
flutter	I-Disease
.	O

These	O
patients	O
had	O
Q	B-Disease
-	I-Disease
T	I-Disease
prolongation	I-Disease
and	O
recurrent	O
syncope	B-Disease
due	O
to	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

In	O
four	O
patients	O
,	O
the	O
arrhythmia	B-Disease
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	B-Disease
.	O

In	O
two	O
patients	O
,	O
the	O
arrhythmia	B-Disease
degenerated	O
into	O
irreversible	O
ventricular	B-Disease
fibrillation	I-Disease
and	O
both	O
patients	O
died	O
.	O

In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	B-Chemical
therapy	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
did	O
not	O
reoccur	O
.	O

These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	B-Chemical
can	O
produce	O
an	O
acquired	O
prolonged	B-Disease
Q	I-Disease
-	I-Disease
T	I-Disease
syndrome	I-Disease
with	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Phenobarbitone	B-Chemical
-	O
induced	O
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	B-Chemical
tetrachloride	I-Chemical
-	O
induced	O
cirrhosis	B-Disease
.	O

The	O
yield	O
of	O
severe	O
cirrhosis	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	B-Disease
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splenomegaly	B-Disease
2	O
-	O
3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	B-Disease
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
given	O
intragastrically	O
in	O
the	O
phenobarbitone	B-Chemical
-	O
primed	O
rat	O
was	O
increased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	B-Chemical
-	O
induced	O
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450	O
/	O
CCl4	B-Chemical
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O

The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	B-Chemical
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47	O
%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight	O
.	O

The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
was	O
after	O
14	O
days	O
on	O
phenobarbitone	B-Chemical
.	O

Triamterene	B-Chemical
nephrolithiasis	B-Disease
complicating	O
dyazide	B-Chemical
therapy	O
.	O

A	O
case	O
of	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide	B-Chemical
-	I-Chemical
triamterene	I-Chemical
therapy	O
for	O
hypertension	B-Disease
.	O

The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	B-Chemical
metabolite	O
admixed	O
with	O
uric	B-Chemical
acid	I-Chemical
salts	I-Chemical
.	O

Factors	O
affecting	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O

Busulfan	B-Chemical
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

A	O
case	O
of	O
a	O
busulfan	B-Chemical
-	O
induced	O
hemorrhage	B-Disease
cystitis	I-Disease
is	O
reported	O
.	O

The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	B-Chemical
cystitis	B-Disease
and	O
both	O
radiation	O
and	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	B-Chemical
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	B-Disease
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long	O
-	O
term	O
therapy	O
.	O

Variant	O
ventricular	B-Disease
tachycardia	I-Disease
in	O
desipramine	B-Chemical
toxicity	B-Disease
.	O

We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
induced	O
by	O
desipramine	B-Chemical
toxicity	B-Disease
.	O

Unusual	O
features	O
of	O
the	O
arrhythmia	B-Disease
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R	O
-	O
R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O

Recognition	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Rebound	O
hypertensive	B-Disease
after	O
sodium	B-Chemical
nitroprusside	I-Chemical
prevented	O
by	O
saralasin	B-Chemical
in	O
rats	O
.	O

The	O
role	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	B-Chemical
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	B-Chemical
anesthesia	O
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
was	O
evaluated	O
.	O

Control	O
rats	O
received	O
halothane	B-Chemical
anesthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	B-Chemical
infusion	O
,	O
40	O
microgram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recovery	O
period	O
.	O

A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	B-Chemical
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
experimental	O
period	O
.	O

In	O
each	O
group	O
,	O
SNP	B-Chemical
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O

During	O
the	O
SNP	B-Chemical
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	B-Chemical
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuation	O
of	O
SNP	B-Chemical
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	B-Chemical
-	O
treated	O
rats	O
.	O

This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	B-Chemical
anesthesia	O
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	B-Chemical
infusion	O
and	O
the	O
post	O
-	O
SNP	B-Chemical
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	B-Chemical
.	O

This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
-	O
-	O
angiotensin	B-Chemical
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	B-Disease
effects	O
of	O
halothane	B-Chemical
and	O
SNP	B-Chemical
.	O

Clinical	O
nephrotoxicity	B-Disease
of	O
tobramycin	B-Chemical
and	O
gentamicin	B-Chemical
.	O

Nearly	O
3	O
.	O
2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	B-Chemical
antibiotics	O
annually	O
.	O

Gentamicin	B-Chemical
sulfate	I-Chemical
and	O
tobramycin	B-Chemical
sulfate	I-Chemical
continue	O
to	O
demonstrate	O
ototoxicity	B-Disease
and	O
nephrotoxicity	B-Disease
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamicin	B-Chemical
sulfate	I-Chemical
or	O
tobramycin	B-Chemical
sulfate	I-Chemical
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	B-Chemical
-	O
related	O
renal	B-Disease
failure	I-Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	O
function	O
.	O

In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B-Disease
failure	I-Disease
could	O
be	O
identified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin	B-Chemical
-	O
treated	O
patients	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentamicin	B-Chemical
-	O
treated	O
patients	O
had	O
renal	B-Disease
failure	I-Disease
.	O

Thus	O
,	O
gentamicin	B-Chemical
was	O
associated	O
with	O
renal	B-Disease
failure	I-Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	B-Chemical
.	O

Metabolic	O
involvement	O
in	O
adriamycin	B-Chemical
cardiotoxicity	B-Disease
.	O

The	O
cardiotoxic	B-Disease
effects	O
of	O
adriamycin	B-Chemical
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O

Adriamycin	B-Chemical
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O

A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	B-Chemical
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	B-Chemical
-	O
treated	O
cells	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	B-Chemical
mole	O
fraction	O
was	O
unchanged	O
.	O

Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	B-Chemical
phosphokinase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosine	B-Chemical
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	B-Chemical
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	B-Chemical
pool	O
.	O

In	O
the	O
adriamycin	B-Chemical
-	O
treated	O
cells	O
,	O
the	O
addition	O
of	O
adenosine	B-Chemical
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B-Disease
effects	O
of	O
streptomycin	B-Chemical
.	O

Streptomycin	B-Chemical
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O

Abnormal	B-Disease
movements	I-Disease
and	O
deafness	B-Disease
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	B-Chemical
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	B-Disease
.	O

Late	O
,	O
late	O
doxorubicin	B-Chemical
cardiotoxicity	B-Disease
.	O

Cardiac	B-Disease
toxicity	I-Disease
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	B-Chemical
as	O
a	O
chemotherapeutic	O
agent	O
.	O

Cardiomyopathy	B-Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	B-Disease
two	O
and	O
one	O
-	O
half	O
years	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	B-Disease
.	O

Attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
-	I-Disease
insipidus	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
in	O
rats	O
.	O

The	O
effect	O
of	O
amiloride	B-Chemical
on	O
lithium	B-Chemical
-	O
induced	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
and	O
on	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	B-Chemical
.	O

Amiloride	B-Chemical
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O

6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	B-Chemical
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-Chemical
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	B-Chemical
levels	O
.	O

After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	B-Chemical
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O

In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
-	I-Disease
insipidus	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	B-Chemical
level	O
.	O

It	O
is	O
concluded	O
that	O
acute	O
amiloride	B-Chemical
administration	O
to	O
lithium	B-Chemical
-	O
treated	O
patients	O
suffering	O
from	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	B-Chemical
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	B-Chemical
levels	O
and	O
might	O
be	O
hazardous	O
.	O

Cardiovascular	B-Disease
complications	I-Disease
associated	O
with	O
terbutaline	B-Chemical
treatment	O
for	O
preterm	B-Disease
labor	I-Disease
.	O

Severe	O
cardiovascular	B-Disease
complications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
.	O

Toxic	B-Disease
hepatitis	I-Disease
induced	O
by	O
antithyroid	O
drugs	O
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	B-Chemical
and	O
benzylthiouracil	B-Chemical
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	B-Disease
adverse	I-Disease
effects	I-Disease
encountered	O
with	O
antithyroid	O
drugs	O
.	O

METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B-Disease
admitted	O
in	O
our	O
department	O
(	O
in	O
-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RESULTS	O
:	O
Four	O
patients	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identified	O
with	O
toxic	B-Disease
hepatitis	I-Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O

Two	O
patients	O
had	O
a	O
cholestatic	B-Disease
hepatitis	I-Disease
induced	O
by	O
carbimazole	B-Chemical
(	O
N	B-Chemical
omercazole	I-Chemical
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	B-Disease
and	O
cytolytic	O
)	O
hepatitis	B-Disease
following	O
carbimazole	B-Chemical
.	O

One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	B-Disease
which	O
appeared	O
after	O
Benzylthiouracil	B-Chemical
(	O
Basd	B-Chemical
ne	I-Chemical
)	O
had	O
replaced	O
carbimazole	B-Chemical
.	O

Biological	O
features	O
of	O
hepatitis	B-Disease
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O

Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	B-Disease
.	O

CONCLUSION	O
:	O
Toxic	B-Disease
hepatitis	I-Disease
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O

Moreover	O
,	O
hepatotoxicity	B-Disease
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	O
agents	O
.	O

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O

The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
(	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	B-Chemical
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O

Basal	O
frequency	O
(	O
BF	O
)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+	O
/	O
-	O
4	O
beats	O
/	O
min	O
.	O
in	O
control	O
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	O
Na	B-Chemical
and	O
1	O
.	O
35	O
mM	O
Ca	B-Chemical
(	O
N	O
)	O
.	O

It	O
decreased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowering	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lowering	O
simultaneously	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNa	O
+	O
LCa	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
lowering	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O

At	O
normal	O
[	O
Na	B-Chemical
]	O
o	O
,	O
decrease	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
increase	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	B-Chemical
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
normal	O
[	O
Ca	B-Chemical
]	O
o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

Dose	O
-	O
dependent	O
bradycardia	B-Disease
induced	O
by	O
verapamil	B-Chemical
was	O
potentiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil	B-Chemical
]	O
o	O
needed	O
to	O
reduce	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
verapamil	B-Chemical
]	O
o	O
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa	O
+	O
LCa	O
=	O
LNa	O
+	O
HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N	O
.	O

The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na	B-Chemical
]	O
o	O
than	O
on	O
[	O
Ca	B-Chemical
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
normal	O
concentration	O
.	O

Also	O
the	O
enhancement	O
of	O
verapamil	B-Chemical
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pseudo	O
-	O
allergic	B-Disease
reactions	I-Disease
to	O
corticosteroids	B-Chemical
:	O
diagnosis	O
and	O
alternatives	O
.	O

Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	B-Chemical
(	O
Triniol	O
)	O
and	O
dexamethasone	B-Chemical
(	O
Sedionbel	O
)	O
are	O
described	O
.	O

A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	O
,	O
they	O
presented	O
urticaria	B-Disease
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B-Disease
(	O
patient	O
1	O
)	O
.	O

Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	B-Chemical
and	O
ELISA	O
tests	O
were	O
performed	O
.	O

In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	B-Chemical
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	O
.	O

We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	B-Chemical
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O

These	O
results	O
suggest	O
that	O
paramethasone	B-Chemical
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O

Corticosteroids	O
different	O
from	O
paramethasone	B-Chemical
also	O
produced	O
hypersensitivity	B-Disease
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo	O
-	O
allergy	B-Disease
caused	O
by	O
paramethasone	B-Chemical
.	O

Study	O
of	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	B-Disease
of	O
zidovudine	B-Chemical
.	O

A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
zidovudine	B-Chemical
(	O
ZDV	B-Chemical
)	O
-	O
induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

Seventy	O
-	O
five	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
-	I-Disease
infected	I-Disease
patients	O
with	O
CD4	O
+	O
cell	O
counts	O
<	O
500	O
/	O
mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	B-Chemical
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	B-Chemical
acid	I-Chemical
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	B-Chemical
B12	I-Chemical
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	B-Disease
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O

During	O
the	O
study	O
,	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folate	B-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O

Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

There	O
was	O
no	O
correlation	O
between	O
vitamin	B-Chemical
B12	I-Chemical
or	O
folate	B-Chemical
levels	O
and	O
development	O
of	O
myelosuppression	B-Disease
.	O

Vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
of	O
ZDV	B-Chemical
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	B-Chemical
-	O
induced	O
myelotoxicity	B-Disease
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
cannot	O
be	O
excluded	O
.	O

Safety	O
and	O
side	O
-	O
effects	O
of	O
alprazolam	B-Chemical
.	O

Controlled	O
study	O
in	O
agoraphobia	B-Disease
with	O
panic	B-Disease
disorder	I-Disease
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	B-Chemical
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O

The	O
efficacy	O
of	O
alprazolam	B-Chemical
and	O
placebo	O
in	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured	O
.	O

METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
were	O
randomised	O
to	O
alprazolam	B-Chemical
or	O
placebo	O
.	O

RESULTS	O
:	O
Mean	O
alprazolam	B-Chemical
dose	O
was	O
5	O
mg	O
daily	O
.	O

Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	B-Chemical
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
depression	B-Disease
,	O
enuresis	B-Disease
,	O
disinhibition	O
and	O
aggression	B-Disease
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	O
,	O
irritability	B-Disease
,	O
impaired	B-Disease
memory	I-Disease
,	O
weight	B-Disease
loss	I-Disease
and	O
ataxia	B-Disease
.	O

CONCLUSIONS	O
:	O
Alprazolam	B-Chemical
caused	O
side	O
-	O
effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B-Disease
associated	O
with	O
intermittent	O
rifampin	B-Chemical
therapy	O
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
.	O

This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	O
.	O

This	O
patient	O
underwent	O
a	O
10	O
-	O
month	O
regimen	O
of	O
rifampin	B-Chemical
and	O
isoniazid	B-Chemical
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-Disease
failure	I-Disease
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O

Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
were	O
investigated	O
and	O
ruled	O
out	O
.	O

This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O

A	O
61	O
-	O
year	O
-	O
old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	B-Chemical
,	O
etoposide	B-Chemical
,	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
folinic	B-Chemical
acid	I-Chemical
for	O
an	O
inoperable	O
gastric	B-Disease
adenocarcinoma	I-Disease
.	O

He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B-Disease
,	O
disorientation	B-Disease
and	O
irritability	B-Disease
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
.	O

This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given	O
.	O

Because	O
folinic	B-Chemical
acid	I-Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	B-Disease
due	O
to	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
was	O
highly	O
suspected	O
.	O

The	O
pathogenesis	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
neurotoxicity	B-Disease
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	B-Chemical
and	O
fluorocitrate	B-Chemical
,	O
thiamine	B-Chemical
deficiency	O
,	O
or	O
dihydrouracil	B-Chemical
dehydrogenase	O
deficiency	O
.	O

High	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
/	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	B-Disease
.	O

Effect	O
of	O
switching	O
carbamazepine	B-Chemical
to	O
oxcarbazepine	B-Chemical
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O

Carbamazepine	B-Chemical
was	O
switched	O
to	O
its	O
10	O
-	O
keto	O
analogue	O
oxcarbazepine	B-Chemical
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	B-Disease
or	O
organic	B-Disease
psychotic	I-Disease
patients	O
using	O
concomitantly	O
haloperidol	B-Chemical
,	O
chlorpromazine	B-Chemical
or	O
clozapine	B-Chemical
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O

The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	B-Chemical
oxcarbazepine	B-Chemical
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	O
drugs	O
.	O

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O

Reactive	O
oxygen	B-Chemical
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephropathy	B-Disease
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	B-Disease
.	O

The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B-Disease
was	O
examined	O
in	O
this	O
study	O
.	O

Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
,	O
(	O
PAN	B-Chemical
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	O
)	O
.	O

Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
.	O

Proteinuria	B-Disease
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B-Disease
injury	I-Disease
in	O
PAN	B-Chemical
nephropathy	B-Disease
.	O

Composition	O
of	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
associated	O
with	O
octreotide	B-Chemical
:	O
response	O
to	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
.	O

Octreotide	B-Chemical
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B-Disease
,	O
induces	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
in	O
13	O
-	O
60	O
%	O
of	O
patients	O
.	O

Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	B-Chemical
treated	O
acromegalic	B-Disease
patients	O
with	O
gall	B-Disease
stones	I-Disease
.	O

Chemical	O
analysis	O
of	O
gall	B-Disease
stones	I-Disease
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholesterol	B-Chemical
by	O
weight	O
.	O

In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	B-Chemical
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O

All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	B-Chemical
saturation	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	B-Chemical
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	O
contained	O
cholesterol	B-Chemical
microcrystals	O
immediately	O
after	O
sampling	O
.	O

Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
(	O
UDCA	B-Chemical
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	B-Chemical
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O

After	O
one	O
year	O
of	O
treatment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gall	B-Disease
stone	I-Disease
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	B-Chemical
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	B-Disease
stone	I-Disease
dissolution	O
rate	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octreotide	B-Chemical
induced	O
gall	B-Disease
stones	I-Disease
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	B-Chemical
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	B-Disease
stone	I-Disease
disease	I-Disease
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	B-Disease
stones	I-Disease
containing	O
calcium	B-Chemical
.	O

Erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
ampicillin	B-Chemical
and	O
gentamicin	B-Chemical
because	O
of	O
suspected	O
septicemia	B-Disease
.	O

Medications	O
were	O
discontinued	O
when	O
erythema	B-Disease
multiforme	I-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
caused	O
by	O
myocarditis	B-Disease
occurred	O
.	O

The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	B-Chemical
and	O
gradually	O
improved	O
.	O

Macrophage	O
-	O
migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	B-Chemical
was	O
positive	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infections	B-Disease
causing	O
erythema	B-Disease
multiforme	I-Disease
and	O
myocarditis	B-Disease
were	O
ruled	O
out	O
,	O
a	O
drug	B-Disease
-	I-Disease
induced	I-Disease
allergic	I-Disease
reaction	I-Disease
was	O
suspected	O
.	O

Positive	O
MIF	O
test	O
for	O
ampicillin	B-Chemical
showed	O
sensitization	O
of	O
the	O
patient	O
'	O
s	O
lymphocytes	O
to	O
ampicillin	B-Chemical
.	O

CONCLUSIONS	O
:	O
Hypersensitivity	B-Disease
myocarditis	I-Disease
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B-Disease
to	O
penicillins	B-Chemical
.	O

Clomipramine	B-Chemical
-	O
induced	O
sleep	B-Disease
disturbance	I-Disease
does	O
not	O
impair	O
its	O
prolactin	O
-	O
releasing	O
action	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B-Disease
disturbance	I-Disease
,	O
induced	O
by	O
clomipramine	B-Chemical
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O

Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	B-Chemical
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O

During	O
the	O
night	O
clomipramine	B-Chemical
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O

As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-Disease
disturbance	I-Disease
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	O
.	O

The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	B-Chemical
ingestion	O
.	O

Survey	O
of	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
angiography	O
in	O
Japan	O
.	O

PURPOSE	O
:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	B-Chemical
green	I-Chemical
for	O
use	O
in	O
fundus	O
angiography	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	B-Chemical
green	I-Chemical
fundus	O
camera	O
.	O

RESULTS	O
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
indocyanine	B-Chemical
green	I-Chemical
angiograms	O
performed	O
on	O
2	O
,	O
820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O

Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	B-Chemical
green	I-Chemical
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O

The	O
dosage	O
of	O
indocyanine	B-Chemical
green	I-Chemical
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O

There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	B-Disease
,	O
exanthema	B-Disease
,	O
urtication	B-Disease
,	O
itchiness	B-Disease
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O

Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	B-Disease
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	B-Disease
.	O

The	O
two	O
hypotensive	B-Disease
patients	O
required	O
treatment	O
for	O
shock	B-Disease
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Chemical
sodium	I-Chemical
indicated	O
that	O
indocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fluorescein	B-Chemical
for	O
use	O
in	O
angiography	O
.	O

Angioedema	B-Disease
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	B-Chemical
.	O

A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"	O
flash	O
"	O
pulmonary	B-Disease
edema	I-Disease
,	O
preceded	O
by	O
chest	B-Disease
pain	I-Disease
,	O
requiring	O
intubation	O
.	O

Her	O
medical	O
history	O
included	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
with	O
previous	O
myocardial	B-Disease
infarctions	I-Disease
,	O
hypertension	B-Disease
,	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O

A	O
history	O
of	O
angioedema	B-Disease
secondary	O
to	O
lisinopril	B-Chemical
therapy	O
was	O
elicited	O
.	O

Current	O
medications	O
did	O
not	O
include	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	B-Chemical
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	B-Disease
.	O

The	O
angioedema	B-Disease
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	B-Chemical
and	O
diphenhydramine	B-Chemical
hydrochloride	O
.	O

Effect	O
of	O
coniine	B-Chemical
on	O
the	O
developing	O
chick	O
embryo	O
.	O

Coniine	B-Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B-Disease
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O

However	O
,	O
coniine	B-Chemical
has	O
failed	O
to	O
produce	O
arthrogryposis	B-Disease
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
in	O
the	O
developing	O
chick	O
.	O

Concentrations	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
compounds	O
caused	O
deformations	B-Disease
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

All	O
concentrations	O
of	O
nicotine	B-Chemical
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	B-Chemical
lethality	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
deformations	B-Disease
caused	O
by	O
both	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
excessive	B-Disease
flexion	I-Disease
or	I-Disease
extension	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
toes	I-Disease
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nicotine	B-Chemical
sulfate	O
-	O
treated	O
chicks	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O

Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	B-Chemical
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	B-Chemical
-	O
induced	O
arthrogryposis	B-Disease
.	O

Immediate	O
allergic	B-Disease
reactions	I-Disease
to	O
amoxicillin	B-Chemical
.	O

A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-Disease
reactions	I-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
was	O
evaluated	O
.	O

A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	B-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
had	O
selective	O
immediate	O
allergic	B-Disease
responses	O
to	O
amoxicillin	B-Chemical
(	O
AX	B-Chemical
)	O
or	O
were	O
cross	O
-	O
reacting	O
with	O
other	O
penicillin	B-Chemical
derivatives	O
.	O

Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl	B-Chemical
-	I-Chemical
poly	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
lysine	I-Chemical
(	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
)	O
,	O
benzylpenicilloate	B-Chemical
,	O
benzylpenicillin	B-Chemical
(	O
PG	B-Chemical
)	O
,	O
ampicillin	B-Chemical
(	O
AMP	B-Chemical
)	O
,	O
and	O
AX	B-Chemical
.	O

RAST	O
for	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	B-Chemical
were	O
negative	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	B-Chemical
or	O
sensitivity	O
to	O
AX	B-Chemical
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-Disease
to	O
beta	B-Chemical
-	I-Chemical
lactam	I-Chemical
antibiotics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
cases	O
of	O
immediate	O
AX	B-Chemical
allergy	B-Disease
with	O
good	O
tolerance	O
of	O
PG	B-Chemical
.	O

Anaphylaxis	B-Disease
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B-Disease
and	O
/	O
or	O
angioedema	B-Disease
.	O

All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-Chemical
.	O

Skin	O
tests	O
with	O
AX	B-Chemical
were	O
positive	O
in	O
34	O
(	O
63	O
%	O
)	O
patients	O
.	O

RAST	O
was	O
positive	O
for	O
AX	B-Chemical
in	O
22	O
patients	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	B-Chemical
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	B-Chemical
were	O
positive	O
to	O
BPO	B-Chemical
.	O

Challenge	O
tests	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-Disease
reaction	I-Disease
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	B-Chemical
were	O
negative	O
.	O

PG	B-Chemical
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O

We	O
describe	O
the	O
largest	O
group	O
of	O
AX	B-Chemical
-	O
allergic	B-Disease
patients	O
who	O
have	O
tolerated	O
PG	B-Chemical
reported	O
so	O
far	O
.	O

Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	B-Chemical
-	O
related	O
reagents	O
are	O
employed	O
.	O

Reversal	O
by	O
phenylephrine	B-Chemical
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	B-Chemical
in	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

Nitroglycerin	B-Chemical
has	O
been	O
shown	O
to	O
reduce	O
ST	O
-	O
segment	O
elevation	O
during	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O

Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	B-Chemical
and	O
phenylephrine	B-Chemical
therapy	O
.	O

Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	B-Disease
infarctions	I-Disease
received	O
intravenous	O
nitroglycerin	B-Chemical
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minutes	O
.	O

SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravenous	O
nitroglycerin	B-Chemical
.	O

Subsequent	O
addition	O
of	O
phenylephrine	B-Chemical
infusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
minutes	O
,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	B-Chemical
to	O
nitroglycerin	B-Chemical
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

Acetazolamide	B-Chemical
-	O
induced	O
nephrolithiasis	B-Disease
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	B-Disease
disorders	I-Disease
.	O

Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	B-Disease
.	O

We	O
studied	O
20	O
patients	O
receiving	O
long	O
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	B-Disease
and	O
myotonia	B-Disease
.	O

Three	O
patients	O
on	O
acetazolamide	B-Chemical
(	O
15	O
%	O
)	O
developed	O
renal	B-Disease
calculi	I-Disease
.	O

Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B-Disease
calculus	I-Disease
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	B-Disease
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O

Nephrolithiasis	B-Disease
is	O
a	O
complication	O
of	O
acetazolamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effects	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
toxicity	B-Disease
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
acute	O
toxicity	B-Disease
.	O

For	O
each	O
of	O
the	O
three	O
tested	O
calcium	B-Chemical
channel	O
blockers	O
(	O
diltiazem	B-Chemical
,	O
verapamil	B-Chemical
and	O
bepridil	B-Chemical
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
dose	O
of	O
bupivacaine	B-Chemical
.	O

The	O
local	O
anesthetic	O
-	O
induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	B-Chemical
channel	O
blockers	O
.	O

The	O
convulsant	O
activity	O
of	O
bupivacaine	B-Chemical
was	O
not	O
significantly	O
modified	O
but	O
calcium	B-Chemical
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	B-Chemical
.	O

Epidural	O
blood	O
flow	O
during	O
prostaglandin	B-Chemical
E1	I-Chemical
or	O
trimethaphan	B-Chemical
induced	O
hypotension	B-Disease
.	O

To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
or	O
trimethaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
induced	O
hypotension	B-Disease
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	B-Chemical
anaesthesia	O
.	O

An	O
initial	O
dose	O
of	O
0	O
.	O
1	O
microgram	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PGE1	B-Chemical
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	B-Chemical
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypotensive	B-Disease
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O

After	O
starting	O
PGE1	B-Chemical
or	O
TMP	B-Chemical
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	B-Disease
due	O
to	O
PGE1	B-Chemical
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	B-Chemical
infusion	O
whereas	O
in	O
the	O
TMP	B-Chemical
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinfusion	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PGE1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hypotensive	B-Disease
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	B-Chemical
decreased	O
EBF	O
.	O

Dup	B-Chemical
753	I-Chemical
prevents	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
.	O

The	O
appearance	O
of	O
nephrotic	B-Disease
syndromes	I-Disease
such	O
as	O
proteinuria	B-Disease
,	O
hypoalbuminemia	B-Disease
,	O
hypercholesterolemia	B-Disease
and	O
increase	O
in	O
blood	B-Chemical
nitrogen	I-Chemical
urea	I-Chemical
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	B-Chemical
753	I-Chemical
(	O
losartan	B-Chemical
)	O
,	O
a	O
novel	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O

The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
in	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
.	O

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	B-Chemical
and	O
furosemide	B-Chemical
.	O

The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

Sodium	B-Chemical
bicarbonate	I-Chemical
alleviates	O
penile	B-Disease
pain	I-Disease
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B-Disease
dysfunction	I-Disease
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B-Disease
pain	I-Disease
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
to	O
the	O
intracorporeal	O
medications	O
.	O

A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	B-Disease
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combination	O
of	O
3	O
drugs	O
:	O
6	O
mg	O
.	O
papaverine	B-Chemical
,	O
100	O
micrograms	O
.	O
phentolamine	B-Chemical
and	O
10	O
micrograms	O
.	O
prostaglandin	B-Chemical
E1	I-Chemical
with	O
(	O
pH	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patients	O
without	O
sodium	B-Chemical
bicarbonate	I-Chemical
added	O
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B-Disease
pain	I-Disease
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sodium	B-Chemical
bicarbonate	I-Chemical
complained	O
of	O
penile	B-Disease
pain	I-Disease
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O

The	O
use	O
and	O
toxicity	B-Disease
of	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
in	O
HIV	B-Disease
antibody	I-Disease
-	I-Disease
positive	I-Disease
individuals	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
patients	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
received	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
to	O
a	O
maximum	O
dose	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Seventy	O
patients	O
developed	O
major	O
opportunistic	B-Disease
infections	I-Disease
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-Disease
diagnosis	O
in	O
17	O
.	O

Only	O
minor	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	B-Disease
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-Chemical
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrhoea	B-Disease
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O

Peripheral	B-Disease
neuropathy	I-Disease
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	B-Disease
in	O
six	O
.	O

Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	B-Disease
pain	I-Disease
.	O

Seven	O
patients	O
developed	O
glucose	B-Disease
tolerance	I-Disease
curves	I-Disease
characteristic	O
of	O
diabetes	B-Disease
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	B-Chemical
.	O

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-Disease
damage	I-Disease
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O

Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
study	O
axonal	B-Disease
injury	I-Disease
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats	O
.	O

Focal	O
injury	B-Disease
in	I-Disease
the	I-Disease
cortex	I-Disease
was	O
produced	O
by	O
infusion	O
of	O
lactate	B-Chemical
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O

Infarcts	B-Disease
in	I-Disease
substantia	I-Disease
nigra	I-Disease
pars	I-Disease
reticulata	I-Disease
were	O
evoked	O
by	O
prolonged	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O

These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-Disease
damage	I-Disease
in	O
various	O
experimental	O
traumatic	B-Disease
or	O
ischemic	O
lesions	O
.	O

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	B-Chemical
-	O
associated	O
mental	O
confusion	B-Disease
.	O

15	O
cases	O
of	O
cimetidine	B-Chemical
-	O
associated	O
mental	O
confusion	B-Disease
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cimetidine	B-Chemical
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O

These	O
6	O
patients	O
had	O
both	O
renal	B-Disease
and	I-Disease
liver	I-Disease
dysfunction	I-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	B-Chemical
trough	O
-	O
concentrations	O
of	O
more	O
than	O
1	O
.	O
25	O
microgram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	B-Chemical
concentrations	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetidine	B-Chemical
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	B-Chemical
H2	O
-	O
receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentrations	O
and	O
mental	O
confusion	B-Disease
are	O
those	O
with	O
both	O
severe	O
renal	B-Disease
and	I-Disease
hepatic	I-Disease
dysfunction	I-Disease
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	B-Chemical
.	O

Prospective	O
study	O
of	O
the	O
long	O
-	O
term	O
effects	O
of	O
somatostatin	O
analog	O
(	O
octreotide	B-Chemical
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	B-Disease
formation	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O

This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	B-Disease
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	O
analog	O
octreotide	B-Chemical
in	O
dosages	O
of	O
300	O
-	O
1500	O
micrograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
months	O
.	O

During	O
treatment	O
with	O
octreotide	B-Chemical
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B-Disease
,	O
and	O
1	O
developed	O
acute	B-Disease
cholecystitis	I-Disease
requiring	O
surgery	O
.	O

In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	B-Disease
throughout	O
therapy	O
.	O

After	O
withdrawal	O
of	O
octreotide	B-Chemical
in	O
10	O
patients	O
without	O
gallstones	B-Disease
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	B-Disease
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	B-Disease
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	B-Disease
,	O
and	O
cholecystitis	B-Disease
during	O
octreotide	B-Chemical
therapy	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long	O
-	O
term	O
octreotide	B-Chemical
therapy	O
of	O
acromegalic	B-Disease
patients	O
.	O

Increase	O
of	O
Parkinson	B-Disease
disability	I-Disease
after	O
fluoxetine	B-Chemical
medication	O
.	O

Depression	B-Disease
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-Disease
disability	I-Disease
in	O
four	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
after	O
exposure	O
to	O
the	O
antidepressant	B-Chemical
fluoxetine	B-Chemical
.	O

The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	B-Chemical
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	B-Chemical
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
must	O
be	O
considered	O
.	O

Sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
.	O

The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	B-Chemical
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
.	O

A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
leukemia	B-Disease
and	O
no	O
history	O
of	O
cardiac	B-Disease
disease	I-Disease
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-Disease
arrest	I-Disease
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhythmias	B-Disease
were	O
temporally	O
related	O
to	O
cimetidine	B-Chemical
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	B-Chemical
treatment	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
.	O

Phase	O
II	O
trial	O
of	O
vinorelbine	B-Chemical
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O

European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B-Disease
Gastrointestinal	O
Treat	O
Cancer	B-Disease
Cooperative	O
Group	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O

Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	B-Chemical
-	O
based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B-Disease
and	O
response	O
.	O

VNB	B-Chemical
was	O
administered	O
weekly	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
infusion	O
.	O

VNB	B-Chemical
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B-Disease
occurred	O
.	O

At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-Disease
was	O
seen	O
in	O
59	O
%	O
of	O
patients	O
.	O

A	O
grade	O
2	O
or	O
3	O
infection	B-Disease
occurred	O
in	O
16	O
%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	B-Disease
occurred	O
.	O

Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	B-Disease
neurotoxicity	I-Disease
has	O
been	O
minor	O
(	O
26	O
%	O
grade	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	B-Chemical
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	B-Disease
,	O
further	O
evaluation	O
of	O
VNB	B-Chemical
in	O
combination	O
therapy	O
is	O
warranted	O
.	O

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	B-Chemical
hydrochloride	I-Chemical
ophthalmic	O
solution	O
.	O

We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	B-Chemical
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	B-Chemical
in	O
their	O
right	O
eyes	O
.	O

The	O
ocular	B-Disease
hypotensive	I-Disease
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	B-Chemical
-	O
treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1	O
%	O
apraclonidine	B-Chemical
.	O

Decreases	B-Disease
in	I-Disease
systolic	I-Disease
blood	I-Disease
pressure	I-Disease
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O

Conjunctival	B-Disease
blanching	I-Disease
and	O
mydriasis	B-Disease
were	O
commonly	O
found	O
.	O

While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	B-Disease
and	O
marked	O
corneal	B-Disease
abrasion	I-Disease
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O

Thiopentone	B-Chemical
pretreatment	O
for	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
.	O

This	O
study	O
investigated	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	B-Chemical
.	O

Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	B-Chemical
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thiopentone	B-Chemical
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	B-Chemical
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Loss	B-Disease
of	I-Disease
consciousness	I-Disease
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	B-Disease
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Assessing	O
their	O
overall	O
satisfaction	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
propofol	B-Chemical
anaesthesia	O
again	O
.	O

We	O
conclude	O
that	O
lidocaine	B-Chemical
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	B-Chemical
only	O
reduces	O
its	O
severity	O
.	O

Persistent	O
paralysis	B-Disease
after	O
prolonged	O
use	O
of	O
atracurium	B-Chemical
in	O
the	O
absence	O
of	O
corticosteroids	O
.	O

Reports	O
of	O
persistent	O
paralysis	B-Disease
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	B-Chemical
bromide	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O

Atracurium	B-Chemical
besylate	I-Chemical
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolinium	B-Chemical
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	B-Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	O
.	O

We	O
report	O
a	O
case	O
of	O
atracurium	B-Chemical
-	O
related	O
paralysis	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O

A	O
phase	O
I	O
/	O
II	O
study	O
of	O
paclitaxel	B-Chemical
plus	O
cisplatin	B-Chemical
as	O
first	O
-	O
line	O
therapy	O
for	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
:	O
preliminary	O
results	O
.	O

Improved	O
outcomes	O
among	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinomas	I-Disease
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy	O
.	O

Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single	O
-	O
agent	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
response	O
rate	O
in	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
,	O
and	O
the	O
paclitaxel	B-Chemical
/	O
cisplatin	B-Chemical
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	B-Disease
cancer	I-Disease
patients	O
.	O

We	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	B-Disease
of	O
escalating	O
paclitaxel	B-Chemical
doses	O
combined	O
with	O
fixed	O
-	O
dose	O
cisplatin	B-Chemical
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinoma	I-Disease
.	O

Primary	O
tumor	B-Disease
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O

Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	B-Disease
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	O
.	O

Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	B-Chemical
by	O
3	O
-	O
hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	B-Chemical
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	B-Chemical
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	B-Disease
permits	O
.	O

With	O
paclitaxel	B-Chemical
doses	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higher	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
5	O
micrograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O

Alopecia	B-Disease
,	O
paresthesias	B-Disease
,	O
and	O
arthralgias	B-Disease
/	O
myalgias	B-Disease
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	B-Disease
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O

No	O
dose	O
-	O
limiting	O
hematologic	O
toxicity	B-Disease
has	O
been	O
seen	O
.	O

Paclitaxel	B-Chemical
/	O
cisplatin	B-Chemical
is	O
an	O
effective	O
first	O
-	O
line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
and	O
continued	O
study	O
is	O
warranted	O
.	O

Results	O
thus	O
far	O
suggest	O
no	O
dose	O
-	O
response	O
effect	O
for	O
paclitaxel	B-Chemical
doses	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Improvement	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
by	O
propranolol	B-Chemical
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

Seven	O
patients	O
suffering	O
from	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
with	O
severely	O
disabling	O
dyskinesia	B-Disease
received	O
low	O
-	O
dose	O
propranolol	B-Chemical
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B-Disease
score	O
without	O
increase	O
of	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O

Ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B-Disease
was	O
not	O
.	O

This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta	O
-	O
blockers	O
may	O
improve	O
levodopa	B-Chemical
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
in	O
PD	B-Disease
.	O

Habitual	O
use	O
of	O
acetaminophen	B-Chemical
as	O
a	O
risk	O
factor	O
for	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
:	O
a	O
comparison	O
with	O
phenacetin	B-Chemical
.	O

Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-Chemical
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O

However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
is	O
also	O
associated	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
ESRD	B-Disease
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-Chemical
and	O
acetaminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-Disease
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	B-Disease
potential	O
of	O
the	O
drugs	O
themselves	O
.	O

A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	B-Chemical
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O

Thus	O
,	O
acetaminophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	B-Chemical
was	O
available	O
only	O
in	O
combinations	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetaminophen	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

The	O
potential	O
for	O
acetaminophen	B-Chemical
to	O
produce	O
cardiovascular	B-Disease
toxicities	I-Disease
is	O
very	O
low	O
.	O

However	O
,	O
acetaminophen	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B-Disease
,	O
including	O
hypotension	B-Disease
,	O
in	O
sensitive	O
individuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B-Disease
ill	I-Disease
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	B-Disease
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	B-Chemical
.	O

Other	O
symptoms	O
of	O
allergic	B-Disease
reactions	I-Disease
were	O
not	O
clinically	O
detectable	O
.	O

The	O
hypotensive	B-Disease
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O

The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	B-Chemical
in	O
patients	O
with	O
hypotension	B-Disease
of	O
unknown	O
origin	O
.	O

Reduction	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
.	O

Heparan	B-Chemical
sulphate	I-Chemical
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	B-Disease
by	O
streptozotocin	B-Chemical
and	O
in	O
age	O
-	O
adn	O
sex	O
-	O
matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	B-Chemical
blue	I-Chemical
.	O

The	O
heparan	B-Chemical
sulphate	I-Chemical
specificity	O
of	O
the	O
cuprolinic	B-Chemical
blue	I-Chemical
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	B-Chemical
-	O
degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O

The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	B-Disease
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diabetic	B-Disease
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O

Diabetic	B-Disease
rats	O
progressively	O
developed	O
albuminuria	B-Disease
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
in	O
streptozotocin	B-Chemical
-	O
diabetic	B-Disease
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	B-Chemical
sulphate	I-Chemical
charge	O
barrier	O
/	O
density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	B-Disease
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
via	O
central	O
dopamine	B-Chemical
formation	O
in	O
dogs	O
.	O

L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK	B-Chemical
-	I-Chemical
486	I-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anesthetize	O
MAO	B-Chemical
-	O
inhibited	O
dogs	O
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Threo	I-Chemical
-	I-Chemical
dihydroxyphenylserine	I-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

FLA	B-Chemical
-	I-Chemical
63	I-Chemical
,	O
a	O
dopamine	B-Chemical
-	O
beta	O
-	O
oxidase	O
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	B-Disease
,	O
bradycardia	B-Disease
or	O
reflex	O
-	O
enhancing	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
.	O

Pimozide	B-Chemical
did	O
not	O
affect	O
the	O
actions	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O

Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	B-Chemical
.	O

However	O
,	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
restored	O
the	O
bradycardia	B-Disease
caused	O
by	O
norepinephrine	B-Chemical
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

5	B-Chemical
-	I-Chemical
HTP	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	B-Disease
to	O
norepinephrine	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
enhances	O
reflex	O
bradycardia	B-Disease
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O

Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	B-Chemical
rather	O
than	O
norepinephrine	B-Chemical
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O

Microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
complicating	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O

We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
MAHA	B-Disease
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O

In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	B-Chemical
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	B-Chemical
,	O
aspirin	B-Chemical
,	O
and	O
dipyridamole	B-Chemical
led	O
to	O
resolution	O
of	O
MAHA	B-Disease
.	O

In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	B-Chemical
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	B-Disease
.	O

FK506	B-Chemical
-	O
associated	O
MAHA	B-Disease
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O

In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	B-Chemical
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	B-Disease
.	O

Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B-Disease
toxicity	I-Disease
.	O

The	O
nephrotoxic	B-Disease
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	B-Chemical
(	O
NG	B-Chemical
)	O
,	O
methotrexate	B-Chemical
(	O
MTX	B-Chemical
)	O
,	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O

After	O
drug	O
administration	O
,	O
creatinine	B-Chemical
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	B-Chemical
clearance	O
.	O

After	O
MTX	B-Chemical
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plasma	O
creatinine	B-Chemical
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
decrease	O
in	O
creatinine	B-Chemical
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O

After	O
the	O
administration	O
of	O
NG	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
CY	B-Chemical
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	B-Chemical
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	B-Chemical
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O

Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen	O
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
creatinine	B-Chemical
clearance	O
was	O
found	O
,	O
but	O
creatinine	B-Chemical
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O

CY	B-Chemical
caused	O
hemorrhagic	B-Disease
cystitis	I-Disease
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
MTX	B-Chemical
.	O

Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	B-Chemical
,	O
CY	B-Chemical
and	O
NG	B-Chemical
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
joint	O
administration	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
compared	O
to	O
controls	O
.	O

Our	O
studies	O
indicate	O
that	O
nephrotoxicity	B-Disease
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	B-Chemical
'	O
s	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O

Partial	O
lesions	O
were	O
made	O
with	O
kainic	B-Chemical
acid	I-Chemical
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O

Compared	O
with	O
sham	O
-	O
operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomotor	B-Disease
hypoactivity	I-Disease
caused	O
by	O
nicotine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
enhanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicotine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O

Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	B-Chemical
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	B-Chemical
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O

We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	B-Disease
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O

Lithium	B-Chemical
-	O
associated	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
deficits	I-Disease
reduced	O
by	O
a	O
switch	O
to	O
divalproex	B-Chemical
sodium	I-Chemical
:	O
a	O
case	O
series	O
.	O

BACKGROUND	O
:	O
Lithium	B-Chemical
remains	O
a	O
first	O
-	O
line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B-Disease
disorder	I-Disease
.	O

Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	B-Chemical
,	O
such	O
as	O
polyuria	B-Disease
and	O
tremor	B-Disease
,	O
more	O
subtle	O
lithium	B-Chemical
side	O
effects	O
such	O
as	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
remain	O
understudied	O
.	O

This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	B-Disease
patients	O
from	O
lithium	B-Chemical
to	O
divalproex	B-Chemical
sodium	I-Chemical
to	O
alleviate	O
such	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
impairments	I-Disease
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Disease
,	I-Disease
motivational	I-Disease
,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
report	O
,	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
a	O
superior	O
alternative	O
to	O
lithium	B-Chemical
in	O
bipolar	B-Disease
patients	O
experiencing	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
.	O

Effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	B-Chemical
.	O

The	O
effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	B-Chemical
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O

Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	B-Chemical
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	B-Disease
patients	O
who	O
were	O
receiving	O
nifedipine	B-Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	B-Chemical
.	O

Nifedipine	B-Chemical
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	B-Chemical
levels	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
observed	O
positive	O
impact	O
of	O
nifedipine	B-Chemical
on	O
reducing	O
the	O
nephrotoxicity	B-Disease
associated	O
with	O
tacrolimus	B-Chemical
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	B-Disease
in	O
this	O
population	O
.	O

Alpha	O
and	O
beta	O
coma	B-Disease
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	B-Disease
hypoxia	I-Disease
.	O

Four	O
patients	O
who	O
were	O
rendered	O
comatose	B-Disease
or	O
stuporous	B-Disease
by	O
drug	O
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O

Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	B-Chemical
for	O
alcohol	B-Chemical
withdrawal	B-Disease
symptoms	I-Disease
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B-Disease
of	O
nitrazepam	B-Chemical
.	O

The	O
patient	O
with	O
nitrazepam	B-Chemical
overdose	B-Disease
and	O
two	O
of	O
those	O
with	O
chlormethiazole	B-Chemical
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'	O
alpha	O
coma	B-Disease
'	O
,	O
showing	O
non	O
-	O
reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	B-Chemical
administration	O
exhibite	O
generalized	O
non	O
-	O
reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O

All	O
four	O
recovered	O
completely	O
without	O
neurological	B-Disease
sequelae	I-Disease
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O

The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	B-Disease
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	B-Disease
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	B-Disease
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O

Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	B-Disease
patients	O
after	O
phenytoin	B-Chemical
overdosages	B-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	B-Chemical
medication	O
and	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O

Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	B-Disease
duration	O
,	O
elevation	O
of	O
phenytoin	B-Chemical
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O

However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	B-Chemical
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O

We	O
conclude	O
that	O
phenytoin	B-Chemical
overdosage	B-Disease
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-Disease
atrophy	I-Disease
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-Chemical
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
the	O
remaining	O
patients	O
.	O

Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B-Disease
disorders	I-Disease
.	O

Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
HUS	B-Disease
)	O
in	O
a	O
woman	O
taking	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

She	O
was	O
treated	O
with	O
heparin	B-Chemical
,	O
dipyridamole	B-Chemical
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B-Disease
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O

This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B-Disease
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	B-Disease
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	B-Disease
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	B-Disease
and	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morphological	O
features	O
of	O
encephalopathy	B-Disease
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	B-Chemical
to	O
rats	O
.	O

Long	O
-	O
term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	B-Chemical
valproate	I-Chemical
(	O
Vupral	O
"	O
Polfa	O
"	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	B-Disease
disorders	I-Disease
indicating	O
cerebellum	B-Disease
damage	I-Disease
(	O
"	O
valproate	B-Chemical
encephalopathy	B-Disease
"	O
)	O
.	O

Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	B-Disease
of	O
endothelial	O
cells	O
.	O

Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	B-Chemical
protrusions	O
and	O
swollen	O
microvilli	O
.	O

Fragments	O
of	O
necrotic	B-Disease
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O

In	O
electron	O
micrographs	O
both	O
luminal	B-Chemical
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O

The	O
possible	O
influence	O
of	O
the	O
hepatic	B-Disease
damage	I-Disease
,	O
mainly	O
hyperammonemia	B-Disease
,	O
upon	O
the	O
development	O
of	O
valproate	B-Chemical
encephalopathy	B-Disease
is	O
discussed	O
.	O

Fatal	O
intracranial	B-Disease
bleeding	I-Disease
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	B-Chemical
.	O

We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B-Disease
reaction	I-Disease
in	O
a	O
case	O
of	O
pulmonary	B-Disease
edema	I-Disease
with	O
wheezing	B-Disease
.	O

The	O
sudden	O
onset	O
of	O
respiratory	B-Disease
distress	I-Disease
,	O
rash	B-Disease
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	B-Chemical
.	O

Subsequently	O
,	O
acute	O
cardiac	B-Disease
arrest	I-Disease
and	O
fatal	O
subarachnoid	B-Disease
hemorrhage	I-Disease
occurred	O
.	O

Epinephrine	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cardiac	B-Disease
arrest	I-Disease
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-Disease
reaction	I-Disease
and	O
severe	O
hypertension	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
activation	O
of	O
bradykinin	B-Chemical
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O

Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
are	O
not	O
clear	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O

Permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent	O
-	O
labeled	O
dextran	B-Chemical
before	O
and	O
during	O
phenylephrine	B-Chemical
-	O
induced	O
acute	O
hypertension	B-Disease
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe	B-Chemical
-	I-Chemical
140	I-Chemical
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Phenylephrine	B-Chemical
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	B-Chemical
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O

These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
.	O

Risk	O
factors	O
of	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
in	O
preterm	O
infants	O
.	O

Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B-Disease
loss	I-Disease
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications	O
.	O

Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B-Disease
loss	I-Disease
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	O
.	O

Ototoxicity	B-Disease
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	B-Disease
drugs	O
,	O
particularly	O
aminoglycosides	B-Chemical
and	O
furosemide	B-Chemical
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-Disease
loss	I-Disease
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O

Seizure	B-Disease
resulting	O
from	O
a	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O

CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
with	O
major	B-Disease
depression	I-Disease
took	O
an	O
overdose	B-Disease
of	O
venlafaxine	B-Chemical
in	O
an	O
apparent	O
suicide	O
attempt	O
.	O

After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	B-Chemical
50	O
-	O
mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	B-Disease
.	O

She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	B-Chemical
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
that	O
resulted	O
in	O
a	O
generalized	O
seizure	B-Disease
.	O

Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	B-Chemical
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O

CONCLUSIONS	O
:	O
The	O
venlafaxine	B-Chemical
overdose	B-Disease
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	B-Disease
but	O
elicited	O
no	O
further	O
sequelae	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1	I-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
on	O
human	O
hepatic	O
function	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	B-Disease
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	B-Disease
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
.	O

Haemodilution	B-Disease
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	B-Chemical
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O

Controlled	O
hypotension	B-Disease
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	B-Chemical
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto	B-Chemical
-	I-Chemical
acetate	I-Chemical
/	O
3	B-Chemical
-	I-Chemical
hydroxybutyrate	I-Chemical
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O

In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotension	B-Disease
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	B-Chemical
showed	O
significant	O
increases	O
after	O
operation	O
.	O

The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
moderate	O
haemodilution	B-Disease
would	O
cause	O
impairment	B-Disease
of	I-Disease
hepatic	I-Disease
function	I-Disease
.	O

Cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	B-Chemical
channel	O
blockers	O
.	O

Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	B-Chemical
channel	O
blocker	O
,	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
,	O
induced	O
cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	B-Chemical
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	B-Disease
malformations	I-Disease
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O

We	O
studied	O
three	O
calcium	B-Chemical
channel	O
blockers	O
of	O
different	O
structure	O
,	O
nifedipine	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
verapamil	B-Chemical
,	O
along	O
with	O
the	O
new	O
agent	O
.	O

Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	B-Chemical
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B-Disease
malformations	I-Disease
.	O

A	O
low	O
incidence	O
of	O
cardiovascular	B-Disease
malformations	I-Disease
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	B-Chemical
channel	O
blockers	O
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	B-Chemical
and	O
nifedipine	B-Chemical
.	O

All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
and	O
verapamil	B-Chemical
.	O

The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	B-Chemical
.	O

Atypical	B-Disease
sensations	I-Disease
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	B-Chemical
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
with	O
tingling	B-Disease
or	I-Disease
burning	I-Disease
sensations	I-Disease
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	B-Disease
.	O

Macula	O
toxicity	B-Disease
after	O
intravitreal	O
amikacin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	B-Chemical
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B-Disease
,	O
macular	O
infarction	B-Disease
may	O
impair	O
full	O
visual	O
recovery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	B-Chemical
retinal	B-Disease
toxicity	I-Disease
following	O
treatment	O
with	O
amikacin	B-Chemical
and	O
vancomycin	B-Chemical
for	O
alpha	O
-	O
haemolytic	O
streptococcal	B-Disease
endophthalmitis	I-Disease
.	O

RESULTS	O
:	O
Endophthalmitis	B-Disease
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6	O
/	O
24	O
at	O
three	O
months	O
.	O

Fundus	O
fluorescein	B-Chemical
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	B-Disease
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	B-Disease
toxicity	I-Disease
and	O
macular	O
ischaemia	B-Disease
.	O

Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	B-Disease
toxicity	I-Disease
are	O
discussed	O
.	O

The	O
role	O
of	O
nicotine	B-Chemical
in	O
smoking	O
-	O
related	O
cardiovascular	B-Disease
disease	I-Disease
.	O

Nicotine	B-Chemical
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B-Disease
disease	I-Disease
.	O

Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	B-Chemical
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B-Disease
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O

Almost	O
certainly	O
,	O
nicotine	B-Chemical
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	B-Chemical
monoxide	I-Chemical
.	O

Nicotine	B-Chemical
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	B-Disease
among	O
humans	O
.	O

Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	B-Chemical
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	B-Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O

Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	B-Chemical
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	B-Chemical
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
level	O
cigarette	O
exposures	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
after	O
verapamil	B-Chemical
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B-Disease
-	I-Disease
Parkinson	I-Disease
-	I-Disease
White	I-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O

In	O
a	O
patient	O
with	O
WPW	B-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
,	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
(	O
AVRT	B-Disease
)	O
was	O
iatrogenically	O
induced	O
.	O

QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	B-Chemical
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	B-Disease
attack	O
.	O

Epidemic	O
of	O
liver	B-Disease
disease	I-Disease
caused	O
by	O
hydrochlorofluorocarbons	B-Chemical
used	O
as	O
ozone	B-Chemical
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	B-Chemical
.	O

BACKGROUND	O
:	O
Hydrochlorofluorocarbons	B-Chemical
(	O
HCFCs	B-Chemical
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	B-Chemical
-	O
depleting	O
chlorofluorocarbons	B-Chemical
(	O
CFCs	B-Chemical
)	O
.	O

Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	B-Disease
of	O
some	O
of	O
these	O
compounds	O
.	O

We	O
investigated	O
an	O
epidemic	O
of	O
liver	B-Disease
disease	I-Disease
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1	B-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
dichloro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluoroethane	I-Chemical
(	O
HCFC	B-Chemical
123	I-Chemical
)	O
and	O
1	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
tetrafluoroethane	I-Chemical
(	O
HCFC	B-Chemical
124	I-Chemical
)	O
.	O

Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1	B-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluoroethane	I-Chemical
(	O
halothane	B-Chemical
)	O
to	O
form	O
reactive	O
trifluoroacetyl	B-Chemical
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	B-Disease
of	O
halothane	B-Chemical
.	O

We	O
aimed	O
to	O
test	O
whether	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	B-Disease
disease	I-Disease
.	O

METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	B-Chemical
protein	O
adducts	O
were	O
done	O
.	O

FINDINGS	O
:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	B-Disease
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	B-Disease
)	O
.	O

Trifluoroacetyl	B-Chemical
-	O
adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O

Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B-Disease
hepatitis	I-Disease
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O

INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	B-Disease
injury	I-Disease
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O

Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	B-Disease
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	B-Chemical
-	O
altered	O
liver	O
proteins	O
are	O
involved	O
.	O

Bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	B-Chemical
.	O

We	O
report	O
a	O
case	O
of	O
bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazol	B-Chemical
treatment	O
.	O

If	O
the	O
patient	O
develops	O
a	O
liver	B-Disease
mass	I-Disease
,	O
because	O
of	O
non	O
-	O
specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O

Endocrine	O
screening	O
in	O
1	O
,	O
022	O
men	O
with	O
erectile	B-Disease
dysfunction	I-Disease
:	O
clinical	O
significance	O
and	O
cost	O
-	O
effective	O
strategy	O
.	O

PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	B-Chemical
and	O
prolactin	O
determination	O
in	O
1	O
,	O
022	O
patients	O
referred	O
because	O
of	O
erectile	B-Disease
dysfunction	I-Disease
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	B-Chemical
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Every	O
patient	O
was	O
screened	O
for	O
testosterone	B-Chemical
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1	O
,	O
340	O
patients	O
with	O
erectile	B-Disease
dysfunction	I-Disease
and	O
systematic	O
prolactin	O
determination	O
.	O

Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
small	O
testes	O
and	O
gynecomastia	B-Disease
.	O

Endocrine	O
therapy	O
consisted	O
of	O
testosterone	B-Chemical
heptylate	I-Chemical
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	B-Disease
and	O
bromocriptine	B-Chemical
for	O
hyperprolactinemia	B-Disease
.	O

RESULTS	O
:	O
Testosterone	B-Chemical
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O

The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	B-Chemical
increased	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
years	O
and	O
9	O
%	O
50	O
years	O
or	O
older	O
)	O
.	O

Two	O
pituitary	B-Disease
tumors	I-Disease
were	O
discovered	O
after	O
testosterone	B-Chemical
determination	O
.	O

Most	O
of	O
the	O
other	O
low	O
testosterone	B-Chemical
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	B-Disease
dysfunction	I-Disease
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B-Disease
dysfunction	I-Disease
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
testosterone	B-Chemical
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	B-Chemical
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O

Only	O
1	O
prolactinoma	B-Disease
was	O
discovered	O
.	O

These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
patients	O
,	O
prolactinomas	B-Disease
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Bromocriptine	B-Chemical
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

Testosterone	B-Chemical
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSIONS	O
:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	B-Chemical
and	O
high	O
prolactin	O
in	O
erectile	B-Disease
dysfunction	I-Disease
cannot	O
justify	O
their	O
routine	O
determination	O
.	O

However	O
,	O
cost	O
-	O
effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-Disease
tumors	I-Disease
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	B-Chemical
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O

Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
and	O
/	O
or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extrapyramidal	O
side	O
effects	O
with	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O

Risperidone	B-Chemical
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	B-Chemical
D2	O
and	O
serotonin	B-Chemical
5	I-Chemical
-	I-Chemical
HT2	I-Chemical
receptors	O
.	O

Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	B-Chemical
'	O
s	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B-Disease
symptoms	I-Disease
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	O
'	O
neuroleptics	O
.	O

To	O
determine	O
if	O
routine	O
risperidone	B-Chemical
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	B-Chemical
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	B-Chemical
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	B-Chemical
or	O
risperidone	B-Chemical
.	O

Drug	B-Disease
-	I-Disease
induced	I-Disease
parkinsonism	I-Disease
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	B-Chemical
(	O
42	O
%	O
)	O
and	O
haloperidol	B-Chemical
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blockade	O
obtained	O
with	O
risperidone	B-Chemical
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
and	O
48	O
-	O
hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
)	O
:	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	B-Disease
.	O

For	O
previously	O
treated	O
advanced	O
breast	B-Disease
cancer	I-Disease
,	O
there	O
is	O
no	O
standard	O
second	O
-	O
line	O
therapy	O
.	O

Combination	O
chemotherapy	O
with	O
mitoxantrone	B-Chemical
,	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
regimen	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O

From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy	O
-	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovorin	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	B-Chemical
.	O

Median	O
number	O
of	O
courses	O
of	O
MFL	B-Chemical
regimen	I-Chemical
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	B-Chemical
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

Major	O
toxicities	B-Disease
were	O
cardiotoxicity	B-Disease
and	O
leukopenia	B-Disease
.	O

Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	O
-	O
related	O
toxicity	B-Disease
.	O

The	O
MFL	B-Chemical
regimen	I-Chemical
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B-Disease
at	O
a	O
fairly	O
high	O
rate	O
.	O

Administration	O
of	O
this	O
regimen	O
to	O
breast	B-Disease
cancer	I-Disease
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-Disease
heart	I-Disease
function	I-Disease
requires	O
careful	O
attention	O
.	O

Ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O

In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O

Agranulocytosis	B-Disease
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	B-Chemical
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

Treatment	O
for	O
ticlopidine	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	B-Chemical
channel	O
blockers	O
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	O
simultaneously	O
.	O

Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	B-Chemical
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O

The	O
expression	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	B-Chemical
(	O
Li	B-Chemical
)	O
-	O
induced	O
polyuria	B-Disease
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O

The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	B-Chemical
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	B-Disease
.	O

The	O
Li	B-Chemical
-	O
treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O

Plasma	O
sodium	B-Chemical
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O

Plasma	O
concentration	O
of	O
AVP	B-Chemical
and	O
transcripts	O
of	O
AVP	B-Chemical
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
dehydration	B-Disease
and	O
/	O
or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	B-Chemical
and	O
the	O
upregulation	O
of	O
AVP	B-Chemical
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	B-Chemical
-	O
induced	O
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O

Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
antinociceptive	O
effect	O
of	O
3	B-Chemical
alpha	I-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromophenyl	I-Chemical
)	I-Chemical
propionate	I-Chemical
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
micrograms	O
/	O
mouse	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
mice	O
,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot	O
-	O
plate	O
,	O
abdominal	O
-	O
constriction	O
,	O
tail	O
-	O
flick	O
and	O
paw	O
-	O
pressure	O
tests	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinociception	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	B-Chemical
,	O
the	O
M1	O
-	O
selective	O
antagonists	O
pirenzepine	B-Chemical
and	O
dicyclomine	B-Chemical
and	O
the	O
acetylcholine	B-Chemical
depletor	O
hemicholinium	B-Chemical
-	I-Chemical
3	I-Chemical
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	B-Chemical
,	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acidB	I-Chemical
antagonist	O
3	B-Chemical
-	I-Chemical
aminopropyl	I-Chemical
-	I-Chemical
diethoxy	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
phosphinic	I-Chemical
acid	I-Chemical
,	O
the	O
H3	O
agonist	O
R	B-Chemical
-	I-Chemical
(	I-Chemical
alpha	I-Chemical
)	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
,	O
the	O
D2	O
antagonist	O
quinpirole	B-Chemical
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine4	I-Chemical
antagonist	O
2	B-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
chlorobenzoic	I-Chemical
acid	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
diethylamino	I-Chemical
)	I-Chemical
ethyl	I-Chemical
ester	I-Chemical
hydrochloride	O
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamin1A	I-Chemical
antagonist	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxyphenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
phthalimido	I-Chemical
)	I-Chemical
butyl	I-Chemical
]	I-Chemical
piperazine	I-Chemical
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	B-Chemical
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyclomine	B-Chemical
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O

Affinity	O
profiles	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectivity	O
ratio	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti	O
-	O
amnesic	B-Disease
effect	O
induced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
through	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
extracellular	O
levels	O
.	O

In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O

The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B-Disease
loss	I-Disease
following	O
spinal	O
anaesthesia	O
.	O

The	O
cause	O
of	O
hearing	B-Disease
loss	I-Disease
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B-Disease
loss	I-Disease
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B-Disease
loss	I-Disease
.	O

Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	B-Chemical
0	O
.	O
5	O
%	O
.	O

Patients	O
given	O
prilocaine	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
hearing	B-Disease
loss	I-Disease
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	B-Chemical
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
average	O
hearing	B-Disease
loss	I-Disease
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	B-Chemical
and	O
15	O
dB	O
after	O
bupivacaine	B-Chemical
.	O

None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B-Disease
loss	I-Disease
.	O

A	O
transient	O
neurological	B-Disease
deficit	I-Disease
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O

We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	B-Disease
deficit	I-Disease
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
slowly	O
injected	O
through	O
a	O
25	O
-	O
gauge	O
pencil	O
-	O
point	O
spinal	O
needle	O
.	O

The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3	O
-	O
L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B-Disease
of	I-Disease
pinprick	I-Disease
sensation	I-Disease
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil	O
-	O
point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	B-Disease
deficit	I-Disease
.	O

Transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
after	O
spinal	O
anesthesia	O
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	B-Chemical
and	O
bupivacaine	B-Chemical
than	O
with	O
lidocaine	B-Chemical
.	O

BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
(	O
TNSs	B-Disease
)	O
frequently	O
follow	O
lidocaine	B-Chemical
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	B-Chemical
.	O

However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	B-Chemical
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O

Prilocaine	B-Chemical
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	B-Chemical
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double	O
-	O
blind	O
study	O
compares	O
prilocaine	B-Chemical
with	O
lidocaine	B-Chemical
and	O
bupivacaine	B-Chemical
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	B-Disease
.	O

METHODS	O
:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
lidocaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
,	O
2	O
%	O
prilocaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
,	O
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucose	B-Chemical
.	O

In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	B-Disease
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure	O
.	O

RESULTS	O
:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	B-Chemical
experienced	O
TNSs	B-Disease
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	B-Chemical
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	B-Chemical
had	O
TNSs	B-Disease
.	O

Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	B-Chemical
and	O
prilocaine	B-Chemical
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	B-Chemical
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocaine	B-Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-Disease
.	O

Suxamethonium	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrest	I-Disease
and	O
death	B-Disease
following	O
5	O
days	O
of	O
immobilization	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B-Disease
arrest	I-Disease
and	O
subsequent	O
death	B-Disease
as	O
a	O
result	O
of	O
hyperkalaemia	B-Disease
following	O
the	O
use	O
of	O
suxamethonium	B-Chemical
in	O
a	O
23	O
-	O
year	O
-	O
old	O
Malawian	O
woman	O
.	O

Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	B-Disease
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O

Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	B-Chemical
,	O
bradycardia	B-Disease
and	O
cardiac	B-Disease
arrest	I-Disease
occurred	O
.	O

The	O
serum	O
level	O
of	O
potassium	B-Chemical
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
'	O
s	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	B-Disease
following	O
the	O
administration	O
of	O
suxamethonium	B-Chemical
.	O

It	O
is	O
postulated	O
that	O
her	O
death	B-Disease
was	O
caused	O
by	O
hypersensitivity	B-Disease
to	O
suxamethonium	B-Chemical
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immobilization	O
.	O

Acute	O
hepatitis	B-Disease
,	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
erythroblastocytopenia	B-Disease
induced	O
by	O
ceftriaxone	B-Chemical
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
acute	O
hepatitis	B-Disease
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	B-Chemical
.	O

Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	B-Chemical
lactam	I-Chemical
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	B-Chemical
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
and	O
erythroblastocytopenia	B-Disease
.	O

These	O
responded	O
to	O
systemic	O
steroids	B-Chemical
and	O
immunoglobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	B-Chemical
lactam	I-Chemical
antibiotics	O
.	O

Thyroxine	B-Chemical
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	B-Disease
in	O
pregnancy	O
.	O

Eating	B-Disease
disorders	I-Disease
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B-Disease
abuse	I-Disease
are	O
uncommon	O
in	O
pregnancy	O
.	O

This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	O
abuse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B-Disease
remains	O
obscure	O
,	O
thyroxine	B-Chemical
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repeated	O
trimipramine	B-Chemical
induces	O
dopamine	B-Chemical
D2	O
/	O
D3	O
and	O
alpha1	O
-	O
adrenergic	O
up	O
-	O
regulation	O
.	O

Trimipramine	B-Chemical
(	O
TRI	B-Chemical
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	B-Chemical
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	B-Chemical
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
,	O
nor	O
does	O
it	O
induce	O
beta	O
-	O
adrenergic	O
down	O
-	O
regulation	O
.	O

The	O
mechanism	O
of	O
its	O
antidepressant	B-Chemical
activity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	B-Chemical
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1	O
-	O
adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	B-Chemical
.	O

TRI	B-Chemical
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O

In	O
the	O
acute	O
experiment	O
TRI	B-Chemical
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagonize	O
the	O
reserpine	B-Chemical
hypothermia	B-Disease
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
head	O
twitches	O
in	O
rats	O
.	O

TRI	B-Chemical
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
,	O
quinpirole	B-Chemical
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hydroxy	O
-	O
dipropyloaminotetralin	O
(	O
dopamine	B-Chemical
D2	O
and	O
D3	O
effects	O
)	O
.	O

The	O
stereotypies	O
induced	O
by	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
or	O
apomorphine	B-Chemical
are	O
not	O
potentiated	O
by	O
TRI	B-Chemical
.	O

It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	B-Chemical
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	B-Disease
evoked	O
by	O
clonidine	B-Chemical
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1	O
-	O
adrenergic	O
receptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	B-Chemical
studied	O
previously	O
,	O
TRI	B-Chemical
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	B-Chemical
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1	O
-	O
adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	B-Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	B-Chemical
activity	O
.	O

Pethidine	B-Chemical
-	O
associated	O
seizure	B-Disease
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	B-Chemical
for	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-Chemical
via	O
a	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-Disease
.	O

Both	O
plasma	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-Disease
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	B-Chemical
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
.	O

The	O
routine	O
use	O
of	O
pethidine	B-Chemical
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	O
should	O
be	O
reconsidered	O
.	O

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
.	O

An	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
,	O
accompanied	O
by	O
atrial	B-Disease
fibrillation	I-Disease
,	O
agitation	B-Disease
,	O
incomprehensible	B-Disease
shouts	I-Disease
and	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	O
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	B-Chemical
850	O
mg	O
containing	O
adrenaline	B-Chemical
0	O
.	O
225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	B-Disease
'	I-Disease
s	I-Disease
contracture	I-Disease
.	O

After	O
intravenous	O
administration	O
of	O
labetalol	B-Chemical
,	O
metoprolol	B-Chemical
and	O
midazolam	B-Chemical
the	O
patient	O
'	O
s	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
and	O
/	O
or	O
interaction	O
of	O
these	O
drugs	O
with	O
the	O
patient	O
'	O
s	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	O
.	O

Drug	O
-	O
associated	O
acute	O
-	O
onset	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
and	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndromes	I-Disease
in	O
a	O
child	O
.	O

Acute	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	B-Disease
in	O
adults	O
,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O

Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	B-Disease
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	B-Disease
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O

A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
shortly	O
after	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	B-Chemical
use	O
.	O

Despite	O
therapy	O
with	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
,	O
prednisone	B-Chemical
,	O
and	O
then	O
tacrolimus	B-Chemical
,	O
her	O
cholestatic	B-Disease
disease	I-Disease
was	O
unrelenting	O
,	O
with	O
cirrhosis	B-Disease
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O

This	O
case	O
documents	O
acute	O
drug	O
-	O
related	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
and	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
.	O

High	O
incidence	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
associated	O
with	O
appetite	B-Chemical
suppressants	I-Chemical
in	O
Belgium	O
.	O

Primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	B-Chemical
suppressant	I-Chemical
drugs	O
.	O

The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

Thirty	O
-	O
five	O
patients	O
with	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O

Exposure	O
to	O
appetite	B-Chemical
-	I-Chemical
suppressants	I-Chemical
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
,	O
mainly	O
fenfluramines	B-Chemical
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	B-Chemical
suppressants	I-Chemical
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O

A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
.	O

Intake	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
are	O
contraindicated	O
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Disease
jerks	I-Disease
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-Chemical
.	O

Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O

Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Chemical
valproate	I-Chemical
,	O
lamotrigine	B-Chemical
,	O
or	O
ethosuximide	B-Chemical
alone	O
or	O
in	O
combination	O
.	O

Choreoathetoid	B-Disease
movements	I-Disease
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	B-Chemical
.	O

Choreatiform	B-Disease
hyperkinesias	I-Disease
are	O
known	O
to	O
be	O
occasional	O
movement	B-Disease
abnormalities	I-Disease
during	O
intoxications	O
with	O
cocaine	B-Chemical
but	O
not	O
opiates	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	B-Disease
movements	I-Disease
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu	O
-	O
opioid	O
receptor	O
agonist	O
methadone	B-Chemical
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	B-Chemical
and	O
cocaine	B-Chemical
.	O

Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
tardive	B-Disease
dyskinesia	I-Disease
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
and	O
weight	B-Disease
gain	I-Disease
.	O

The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B-Disease
gain	I-Disease
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B-Disease
threshold	O
(	O
primarily	O
clozapine	B-Chemical
)	O
,	O
and	O
agranulocytosis	B-Disease
(	O
clozapine	B-Chemical
only	O
)	O
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
dose	O
-	O
comparison	O
trial	O
of	O
haloperidol	B-Chemical
for	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	B-Chemical
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
patients	O
with	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
random	O
-	O
assignment	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	B-Chemical
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	B-Chemical
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
blind	O
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	B-Chemical
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard	O
-	O
or	O
low	O
-	O
dose	O
haloperidol	B-Chemical
.	O

RESULTS	O
:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard	O
-	O
dose	O
haloperidol	B-Chemical
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dose	O
haloperidol	B-Chemical
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	B-Disease
factor	O
and	O
on	O
psychomotor	B-Disease
agitation	I-Disease
.	O

In	O
phase	O
A	O
,	O
extrapyramidal	B-Disease
signs	I-Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O

Low	O
-	O
dose	O
haloperidol	B-Chemical
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	B-Chemical
in	O
doses	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B-Disease
signs	I-Disease
.	O

The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	B-Chemical
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
with	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
.	O

Effects	O
of	O
acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
on	O
epinephrine	B-Chemical
-	O
induced	O
myocardial	B-Disease
injury	I-Disease
in	O
dogs	O
.	O

A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B-Disease
injury	I-Disease
(	O
epinephrine	B-Chemical
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

Infusions	O
of	O
epinephrine	B-Chemical
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	B-Chemical
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline	O
-	O
infused	O
control	O
animals	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	B-Chemical
also	O
increased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O

Infusions	O
of	O
calcium	B-Chemical
chloride	I-Chemical
sufficient	O
to	O
raise	O
serum	O
calcium	B-Chemical
concentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
increase	O
calcium	B-Chemical
influx	O
into	O
the	O
myocardial	O
cell	O
.	O

Mitochondrial	O
radiocalcium	B-Chemical
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	B-Chemical
acid	I-Chemical
or	O
dipyridamole	B-Chemical
or	O
when	O
hydrocortisone	B-Chemical
was	O
added	O
to	O
the	O
epinephrine	B-Chemical
infusion	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O

Myocardial	O
calcium	B-Chemical
concentrations	O
also	O
were	O
decreased	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	O
groups	O
,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two	O
.	O

Acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
at	O
least	O
one	O
year	O
.	O

BACKGROUND	O
:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
more	O
than	O
1	O
year	O
.	O

RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B-Disease
nephropathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal	O
-	O
type	O
and	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
,	O
respectively	O
.	O

Chronic	O
FK506	B-Chemical
nephropathy	B-Disease
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	B-Disease
fibrosis	I-Disease
(	O
11	O
biopsies	O
)	O
.	O

The	O
serum	O
creatinine	B-Chemical
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506	B-Chemical
-	O
nephropathy	B-Disease
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
is	O
a	O
condition	O
which	O
may	O
lead	O
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O

Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	B-Disease
and	I-Disease
extrahepatic	I-Disease
cholestasis	I-Disease
.	O

Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	B-Disease
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O

We	O
used	O
rat	O
models	O
of	O
intrahepatic	B-Disease
cholestasis	I-Disease
by	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
EE	B-Chemical
)	O
treatment	O
and	O
extrahepatic	B-Disease
cholestasis	I-Disease
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O

After	O
EE	B-Chemical
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	B-Chemical
releaser	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
effects	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromophenyl	I-Chemical
)	I-Chemical
propionate	I-Chemical
)	O
,	O
the	O
acetylcholine	B-Chemical
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O

In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	B-Disease
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	B-Chemical
and	O
the	O
M1	O
-	O
selective	O
antagonist	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
ET	I-Chemical
-	I-Chemical
126	I-Chemical
.	O

In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
5	O
-	O
20	O
microg	O
per	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	B-Disease
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O

At	O
the	O
highest	O
effective	O
doses	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O

PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O

During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O

Therefore	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
could	O
represent	O
a	O
potential	O
useful	O
drug	O
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O

Mechanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O

-	O
Tacrolimus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O

The	O
clinical	O
utility	O
of	O
FK	B-Chemical
506	I-Chemical
is	O
complicated	O
by	O
substantial	O
hypertension	B-Disease
and	O
nephrotoxicity	B-Disease
.	O

To	O
clarify	O
the	O
mechanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	B-Chemical
506	I-Chemical
on	O
the	O
synthesis	O
of	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET	O
-	O
1	O
and	O
endothelin	O
-	O
converting	O
enzyme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endothelial	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
was	O
studied	O
.	O

FK	B-Chemical
506	I-Chemical
,	O
5	O
mg	O
.	O

FK	B-Chemical
506	I-Chemical
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
administration	O
of	O
FR	B-Chemical
139317	I-Chemical
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	B-Chemical
506	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
FK	B-Chemical
506	I-Chemical
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET	O
-	O
1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	O
synthesis	O
in	O
the	O
vasculature	O
.	O
